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Abstract 
The protozoan parasite Trypanosoma brucei is the causative agent of Human African 
Trypanosomiasis (HAT) and Nagana disease in mammals. These diseases present a major socio-
economic burden to large areas of sub-Saharan Africa. Current therapeutics involve complex and 
toxic regimens which can lead to fatal side-effects. In addition, there is evidence for drug resistance 
emerging in the field. Hence, there is a desperate need for novel therapies. Benzoxaboroles are a 
novel class of boron-containing compounds under development for use against a wide spectrum of 
diseases. AN5568 is a lead compound for the treatment of HAT, which has demonstrated effective 
clearance of both early- and late-stage trypanosomiasis in a murine model, and is currently 
undergoing clinical trials. However, the mechanism by which AN5568 kills T. brucei is elusive. In this 
study we sought to use ‘omics’-based techniques to investigate the mode of action of AN5568 in a 
laboratory strain of Trypanosoma brucei brucei. 
Cells treated with the benzoxaborole showed significant perturbations in methionine metabolism. 
In particular, there were increases in S-adenosyl-L-methionine, an essential methyl group donor 
involved in methyltransferase reactions. These changes were similar to those elicited by the non-
specific methyltransferase inhibitor sinefungin. Changes were also observed in lipid metabolism, 
sugar nucleotide metabolism and glycophosphatidylinositol biosynthesis. Further analyses were 
carried out to investigate the effect of AN5568 on cellular stress responses and cell morphology. 
To further probe the mechanics of AN5568-treatment, a drug-resistant cell line was generated. This 
cell line showed cross-resistance with sinefungin, further supporting similar modes of action for 
these two drugs. Interestingly, the AN5568-resistant cell line exhibited upregulation of procyclic 
form-specific genes, as well as downregulation of blood-stream form-specific genes, which led to 
the hypothesis that the cell line had undergone a differentiation event. However, microscopy 
analysis showed that overall morphology of the cells still resembled those of bloodstream forms, 
despite them having acquired a procyclic-like metabolic physiology. 
A secondary aim of this project was to elucidate the metabolic changes that lead to increased 
growth rates in T. brucei cells undergoing loss-of-heterozygosity on chromosome 10. This 
phenomenon, whereby a significant portion of the chromosome is lost, has been observed 
independently on multiple occasions in lab adapted T. brucei strains, yet how this alteration affects 
intracellular metabolism was hitherto unknown. Using two procyclic T. brucei cell lines, this study 
was able to show that the increased growth rates are glucose-dependent with a potential 
intracellular alteration in succinate and acetate production. These data have important implications 
for the field, where LOH has been observed in the clonally expanding T.b. gambiense type I.
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Chapter 1. Introduction 
1.1 General introduction 
1.1.1 Taxonomy 
Trypanosoma brucei is a single-celled protozoan parasite and the causative agent of Human African 
Trypanosomiasis (HAT, also referred to as Sleeping Sickness) as well as Nagana disease (also 
referred to as Animal African Trypanosomiasis, AAT) in mammals (Lejon et al., 2013). This parasite 
is a member of Order Kinetoplastidea, which also includes other human pathogens including 
Trypanosoma cruzi, which causes Chagas’ disease, and Leishmania spp, the parasitic cause of a 
range of diseases collectively referred to as the Leishmaniases, of which the visceral form, or kala 
azar, is fatal (Rassi et al., 2010, Barrett & Croft, 2012). Together, these parasites are responsible for 
a significant socio-economic burden across the globe. Taking into account veterinary parasites 
including T. congolense, T. vivax, T. evansi and T. equiperdum, all subspecies of the Trypanosoma 
genus, widens this burden considerably (Field & Carrington, 2009). The taxonomy of the human-
infective subspecies of African trypanosomes can be broken down into two subspecies of T. brucei: 
T.b. gambiense and T.b. rhodesiense are prevalent in west and central Africa or east and South 
Africa respectively (Koffi et al., 2009). A third T. brucei subspecies, T.b. brucei, is infective to non-
human vertebrates and is distributed across the sub-Saharan African continent (Balmer et al., 
2011). The West African T.b. gambiense can be further divided into two subspecies, type 1 and type 
2 (Tait et al., 1984, Hide et al., 1990). 
Previous analyses of the three aforementioned subspecies of this parasite have found that T.b. 
gambiense is genetically distinct from both T.b. rhodesiense and T.b. brucei (Baker, 1995). T.b. 
rhodesiense and T.b. brucei are morphologically indistinguishable, and are only separated due to 
the human-infective nature of T.b. rhodesiense, which arises due to a single gene, SRA, which 
encodes a protein that defends the parasite against trypanosome lytic factors in human serum, as 
explained in more detail below (Balmer et al., 2011). 
1.1.2 Life Cycle 
The African trypanosomes undergo a complex life cycle involving multiple hosts and extreme 
morphological changes in order to successfully colonise them (fig. 1-1). At least six developmental 
forms have been described with significantly contrasting cell architecture, intracellular transport, 
primary metabolism and gene expression (fig. 1-1). The long slender bloodstream form (BSF) infects 
mammalian hosts, primarily thriving on glucose present in the blood, before penetrating the 
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mammalian blood-brain barrier (Mulenga et al., 2001). These rapidly dividing cells possess a protein 
coat of variable surface glycoproteins (VSGs), which is utilised to evade the host immune system. 
At high densities, BSF cells differentiate into a non-dividing form referred to as short stumpy form 
(SSF) (fig. 1-1) (Matthews et al., 2004). Whilst the mechanisms that initiate differentiation cascades 
are not fully known, they are thought to involve bacterial-like quorum sensing and a secreted 
molecule known as stumpy induction factor (SIF), the molecular identity of which, despite intense 
efforts, remains elusive (Vassella et al., 1997, Fenn & Matthews, 2007). 
SSF parasites are taken up by the definitive host, the tsetse fly, and rapidly differentiate into 
procyclic form (PCF) trypomastigotes. Several significant changes occur in protein expression and 
metabolism at this stage. VSG expression is abolished and the parasites express EP procyclin, and 
at a later stage, GPEET procyclin (Vassella et al., 2001). These are non-variable forms of surface 
proteins, which aid in evasion against the rudimentary tsetse immune system (Richardson et al., 
1988). In addition, central carbon metabolism shifts from glycolysis to a semi-complete TCA cycle 
that utilises proline as a carbon source (Bringaud et al., 2006). 
 
Figure 1-1: Life cycle of Trypanosoma brucei. BSF parasites in the mammalian host reside in the blood, 
lymph, and in later stages of infection, the CNS. Some BSF cells differentiate into SSF cells which are pre-
adapted to life in the tsetse fly vector. Once taken up by feeding tsetse flies, the PCF trypanosomes colonise 
the fly midgut, and continue to divide. PCFs differentiate into the epimastigote stage and travel to the tsetse 
salivary glands where they differentiate once more into a trypomastigote stage that is pre-adapted for 
mammalian infection. Figure is taken from Langousis & Hill (2014). 
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At this stage, cells are again proliferative. PCFs subsequently migrate to the salivary glands, where 
they differentiate once more to an epimastigote, and importantly, sexual recombination has been 
shown to occur in several trypanosome species, with the exception of one class of T.b. gambiense, 
which is thought to be clonal (Koffi et al., 2009, Weir et al., 2016). Cells then differentiate to a 
metacyclic trypomastigote stage, which are non-dividing and infectious to mammalian hosts (Roditi 
& Lehane, 2008). Parasites infect new hosts during tsetse fly feeding, to re-initiate the life cycle. 
All African trypanosome species exhibit a life cycle similar to that described, with the exception of 
the animal-infective T. vivax and T. evansi. These species do not undergo a PCF stage, instead 
colonising the tsetse fly salivary glands as epimastigotes only. In contrast, the other animal infective 
African trypanosome, T. congolense exhibits a life cycle similar to that of T. brucei (Jackson et al., 
2015). 
1.2 Human African Trypanosomiasis 
1.2.1 Historical overview 
Phylogenetic analyses of the trypanosome have concluded that the salivarian trypanosomes 
separated from other trypanosomes around 300 million years ago (Haag et al., 1998). Whilst these 
parasites inhabited the guts of early insects, they were not spread to mammals until the appearance 
of the tsetse fly, some 35 million years ago (Steverding, 2008). 
The first detailed documented report on sleeping sickness was made by naval surgeon Jon Atkins in 
1721 (Cox, 2002).  More than 100 years later, in 1841, the trypanosome was discovered by Gabriel 
Valentin, who observed them during routine observations of salmon blood (Steverding, 2008). 
However, it was not until research carried out by David Bruce that trypanosomes were proven to 
be the cause of Nagana (Cox, 2002). The first trypanosome infection that was isolated from a human 
patient was in 1902, by Robert Michael Ford, who, with the physician Joseph Everett Dutton, named 
the trypanosome Trypanosoma brucei gambiense (Dutton, 1902). Several years later Stephens and 
Fantham described T.b. rhodesiense and further work established the role of the tsetse fly in 
transmission, building on previous studies by David Bruce (Kleine, 1909, Stephens & Fantham, 
1910). 
During the evolution of the trypanosome, most African mammalian wildlife has evolved tolerance 
to the parasite, and these animals show no symptoms. In stark contrast, domesticated mammals 
do not possess mechanisms of trypanotolerance and the majority succumb to Nagana disease 
(Murray et al., 1982). Humans, have evolved mechanisms of resistance to all subspecies of African 
trypanosome, with the exception of T.b. gambiense and T.b. rhodesiense (de Greef & Hamers, 1994, 
Capewell et al., 2013a). 
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1.2.2 Epidemiology 
HAT, as well as the majority of AAT, is restricted to areas where the tsetse fly is prevalent, in sub-
Saharan Africa (fig. 1-2). This area, known as the tsetse belt, comprises some 8 million km2 
(Wertheim et al., 2012). Only T. vivax and T. evansi, which can be transmitted mechanically by other 
biting flies, and T. equiperdum, transmitted venereally in horses, are transmitted outside of this 
area of Africa (Jones & Davila, 2001, Desquesnes et al., 2013). 
 
Figure 1-2: Epidemiology of HAT in the sub-Saharan African continent. This figure, from 2012, shows the 
areas where T.b. gambiense (yellow spots) and T.b. rhodesiense (blue spots), the human-infective 
trypanosomes, are prevalent. In addition, the figure shows how the epidemiology of the disease is restricted 
by the area inhabited by the tsetse fly vector. Taken from Wertheim et al. (2012). 
T.b. gambiense infection is responsible for approximately 98% of HAT cases in 24 countries, with 
many of these (~75%) occurring in the Democratic Republic of the Congo. In contrast, T.b. 
rhodesiense is only responsible for 2% of all HAT cases and affects populations in 13 countries 
(Simarro et al., 2011). In the case of T.b. rhodesiense, Uganda and Malawi carry the highest burden 
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of the disease with the former presenting the only country to report both human variants of the 
parasite (WHO, 2015a). 
Historically, there have been several epidemics of HAT including the most recent occurrence 
between 1970 and 1990 (WHO, 2015b). This was blamed on social insecurity as well as human 
conflicts. However, concentrated efforts by WHO as well as other non-governmental organisations, 
meant that after 38,000 cases were reported in 1998, these numbers dropped to <10,000 in 2009, 
6,314 in 2013 and 3,796 in 2014 (fig. 1-3) (WHO, 2015a). T. gambiense HAT was targeted for 
elimination by 2020 under the WHO Roadmap on NTDs (WHO, 2012), although this date has since 
been revised to 2030 (WHO, 2013). Evidence suggests significant underreporting of the disease 
across sub-Saharan Africa and there are approximately 65 million individuals at risk across the 
continent (WHO, 2015b). 
 
Figure 1-3: Deaths resulting from T.b. gambiense (Tbg) and T.b. rhodesiense (Tbr) infections between 
1990 and 2014. Data taken from a WHO report (WHO, 2015a). Whilst the 1990s saw a resurgence of deaths 
as a result of T.b. gambiense infection (likely due to increased reporting), in general, there has been a 
decreasing trend in human deaths caused by African trypanosomes. 
Restricting the distribution of the fly is one method of disease control (Tirados et al., 2015). The 
main genus of the vector is Glossina spp., which survive at specific temperatures (16°C–38°C) and 
humidity (50%–80%) (Franco et al., 2014). It is due to these factors that HAT has not spread further 
north past the Sahara. Furthermore, wild mammals provide a significant reservoir, in particular for 
T.b. rhodesiense, and to a lesser extent, T.b. gambiense (Welburn et al., 2001, Njiokou et al., 2010). 
1.2.3 Clinical manifestations & diagnosis 
Whilst HAT is commonly referred to as Sleeping Sickness, this only partially describes the clinical 
symptoms of T. brucei infections (Kennedy, 2013). Clinically, HAT infection can be broken into two 
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stages. During the early stage (stage 1), also known as the haemolymphatic stage, the parasite 
infects the bloodstream and lymphatic vessels, where it thrives on glucose present in mammalian 
blood (Brun et al., 2010). This is followed by the late stage (stage 2), the CNS stage, where the 
parasite penetrates the blood-brain barrier (Masocha et al., 2007). 
The clinical manifestations arising from HAT exposure can vary significantly between the two 
human-infective variants (Kennedy, 2004). Whilst T.b. gambiense is responsible for a chronic 
infection, often lasting months or years, T.b. rhodesiense infection is acute and severe, and can lead 
to fatalities in a matter of weeks to months (Kennedy, 2004). However, in both cases, early stage 
symptoms can be non-specific such as headaches, weight loss, fatigue and intermittent fevers 
(Kennedy, 2013). As the infection progresses, symptoms gradually become more severe and can 
include, but are not limited to, lymphadenopathy, cardiac complications, conjunctivitis, endocrine 
dysfunction, alopecia, hepatomegaly and splenomegaly (Lejon et al., 2013). 
During the late stage of the disease, symptoms become increasingly severe. This can mainly be 
attributed to neurological complications as a result of the parasite spreading to the CNS (Reviewed 
by (Kennedy, 2004)). These manifestations include mental or motor system disturbances as well as 
the typical sleep disturbances for which the disease in named, although the latter does not occur 
in every case (Blum et al., 2006).  
Rapid diagnosis is crucial to ensure patient recovery. However, because the early stage symptoms 
are not specific to trypanosome infection, early diagnosis is challenging and other tropical diseases 
such as malaria, leishmaniasis, TB and others, must also be excluded (Kennedy, 2004). The most 
commonly used assay for diagnosis is a card agglutination test for trypanosomiasis (CATT) (Magnus 
et al., 1978). However, this assay has several disadvantages. In particular, the test does not apply 
to T.b. rhodesiense as it uses T.b. gambiense-specific antigens, and there is limited sensitivity (Dukes 
et al., 1992). In addition, false positive results are often reported (Chappuis et al., 2005, Brun et al., 
2010). For these reasons, microscopic identification of parasites in patient blood or lymph is often 
required for diagnosis (Mitashi et al., 2012, Mukadi et al., 2013), but low parasitaemias, especially 
in the case of T.b. gambiense, can confound this (Kennedy, 2004).  Other diagnostic tools such as 
PCR have also been utilised, although their practicality in the field remains debatable (Mugasa et 
al., 2012). Rapid tests, using lateral flow devices, are showing increasing promise, although 
parasitological identification post serology still seems necessary (Sternberg et al., 2014). 
Different therapeutic regimens exist depending on the subspecies that is responsible for a HAT case, 
as described below. This makes accurate diagnosis crucial, especially in areas such as Uganda, 
where both variants of the human-infective trypanosomes are prevalent (Kennedy, 2013). In 
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addition, differential diagnosis of early and late stage HAT is equally important, as different 
therapies exist for both, as described in section 1.3 (Lejon et al., 2013). 
1.2.4 Human mechanisms of resistance 
The mechanisms of resistance to human serum-mediated lysis for both human-infective strains 
have been elucidated (de Greef & Hamers, 1994, Capewell et al., 2013a). African trypanosome 
species such as T.b. brucei succumb to the effects of a human serum component called 
trypanosome lytic factor (TLF) (Raper et al., 1999). To date, two of these factors have been 
described, termed TLF-1 and TLF-2. The mechanism of TLF-1 mediated trypanosome killing is 
understood to a better extent than TLF-2. TLF-1 is taken up via endosomes through the 
trypanosome haptoglobin haemoglobin receptor (TbHpHbR), and trafficked to the lysosome (Drain 
et al., 2001, Vanhollebeke et al., 2008). Here, TLF is activated by acidic pH, which leads to lysosomal 
membrane destabilisation and degradation. It is thought that apolipoprotein L-1 (apoL-1), one of 
the components of TLF-1, forms pores in the lysosomal membrane, allowing the contents to leak 
into the cytoplasm (Vanhamme et al., 2003, Perez-Morga et al., 2005). Ultimately, this leads to 
trypanosome cell death. 
Interestingly, resistance to this killing mechanism has arisen on three independent occasions, in T.b. 
rhodesiense and T.b. gambiense (Stephens et al., 2012). In the case of the former, it was shown that 
this species possesses a VSG-like molecule, termed the serum resistance (SRA) gene (de Greef & 
Hamers, 1994, Xong et al., 1998). Current hypotheses suggest that whilst TLF-1 uptake still occurs, 
the molecule does not localise to the lysosome, a process that is likely inhibited by the binding of 
SRA to apoL-1 (Vanhamme et al., 2003). The mechanism for T.b. gambiense resistance to human 
serum is not as clear, although it has been shown that another VSG-like molecule called TgsGP 
confers serum resistance (Capewell et al., 2013a, Uzureau et al., 2013). In addition, a study also 
reported downregulation of the TbHpHbR gene in human serum resistant T.b. gambiense, which 
could lead to a reduction in TLF-1 uptake (Kieft et al., 2010). T.b. brucei does not possess either of 
the human serum resistance genes, which explains why this subspecies does not infect humans 
(Xong et al., 1998). 
1.3 Therapeutics/chemotherapy against HAT/AAT 
1.3.1 Human African Trypanosomiasis (HAT) 
HAT was until recently considered to be fatal in close to 100% of untreated cases, although recent 
evidence in the case of T.b. gambiense has challenged this theory (Kabore et al., 2011, Jamonneau 
et al., 2012, Ilboudo et al., 2014). In any case, this fact underlies the desperate need for therapeutics 
to combat the disease. The majority of current therapies target the mammalian stage of the 
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parasite, although some work has also focused on blocking the transmission cycle of T. brucei as a 
form of preventative medicine (Tirados et al., 2015, Vale et al., 2015). 
Current regimens used to treat HAT consist of species- and stage-dependent chemotherapeutics 
which are outlined in figure 1-4. Treatments for early stage HAT usually involve pentamidine and 
suramin for T.b. gambiense and T.b. rhodesiense respectively (Kennedy, 2013). Pentamidine is a 
diamidine administered intramuscularly, with good efficacy (cure rate ~93-98%) (Balasegaram et 
al., 2006). However, treatment with pentamidine can lead to potential cardiac malfunctions as well 
as hypotension and hypoglycaemia amongst other side-effects (Babokhov et al., 2013). Similarly, 
side effects to suramin treatment, which is administered by intravenous injection, have been 
described in the form of renal failure, anaphylactic shock and neuronal complications (Babokhov et 
al., 2013). Both these therapies involve strict regimens of at least seven days, thereby requiring 
patients to remain in a clinical setting for the duration of the therapy. This is challenging to achieve 
in a rural environment (Mwanakasale et al., 2013). 
 
Figure 1-4: A timeline of drugs used against HAT, and when they were first brought to market. Eflornithine 
and nifurtimox, both for the treatment of T.b. gambiense late-stage infection, are newest drugs currently 
available. Red boxes indicate reports of resistance in the field. Dotted border indicates drugs currently in 
clinical trials. Figure taken from Horn & Duraisingh (2014). 
Late stage HAT presents an even greater challenge to combat, given that drugs developed against 
this particular stage must cross the blood-brain barrier. The most recent drug brought to market 
for late-stage T.b. gambiense infection is eflornithine, an analogue of ornithine, which targets the 
ornithine decarboxylase enzyme (Phillips & Wang, 1987, Vincent et al., 2012). Developed initially 
as an anti-tumor drug as well as a therapy against facial hirsutism, eflornithine is thought to have 
an efficacy of up to 95% , although it has only limited potency against late-stage T.b. rhodesiense 
infection (Babokhov et al., 2013). 
The only front-line therapeutic specifically against late-stage T.b. rhodesiense is melarsoprol, a 
trivalent arsenical (Friedheim, 1949). This drug can elicit significant toxicities, leading to fatal side 
effects such as encephalopathy. It is estimated that up to 10% of patients succumb not to the 
parasite, but rather the treatment (Pepin & Milord, 1994). Melarsoprol is a relatively old drug 
compared with eflornithine, having been introduced in 1949, and resistance to this compound has 
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been reported in the field, with some T.b. gambiense endemic areas showing almost 30% treatment 
failure (Lejon et al., 2013). 
More recently, eflornithine has been used in combination with nifurtimox, a 5-nitrofuran drug that 
can be administered orally (Legros et al., 2002). Whilst nifurtimox is not effective as a monotherapy, 
patients can be treated with a lower dose of eflornithine, whilst maintaining a similar efficacy and 
cure rate, if nifurtimox is used simultaneously (Priotto et al., 2009). 
As shown in fig 1-4, the majority of drugs used to treat HAT were introduced almost half a century 
ago, with no significant improvements since. As several reviewers have argued, this can be 
attributed to underinvestment by governments and pharmaceuticals, given the weak prospect of 
financial gain (Kennedy, 2013). However, the turn of the 21st century has brought changes, due in 
large parts to the efforts of many non-governmental organisations such as the Drugs for Neglected 
Tropical Disease initiative (DNDi) and the Bill and Melinda Gates foundation, as well as academic 
partnerships with significant input from several pharmaceutical companies (Barrett, 2010). Indeed, 
as mentioned previously, these efforts are helping to lower the number of annual cases, and with 
two new drugs in clinical trials for HAT, the future is looking brighter. 
1.3.2 Drugs currently in clinical trials 
1.3.2.1 Fexinidazole 
Fexinidazole (1-methyl-2-((p-(methylthio)phenoxy)methyl)-5-nitroimidazole) (fig. 1-5) was 
previously under preclinical development in the early 1980s as a broad-spectrum antimicrobial 
agent (Torreele et al., 2010). At this time, this drug was reported to exhibit anti-trypanosomal 
activity, but its development as a therapeutic against HAT was not pursued (Jennings & Urquhart, 
1983). Currently, the drug is in phase III trials in the Democratic Republic of the Congo, as well as 
Central African Republic, and close to registration (Tarral et al., 2014). Whilst the target of 
fexinidazole is not currently known, it is thought that the compound acts in a similar fashion to 
other nitro prodrugs like nifurtimox, which requires activation in the cell via a trypanosomal 
mitochondrial nitroreductase (Sokolova et al., 2010, Wyllie et al., 2015). Several studies have looked 
in detail at the potency of fexinidazole, as well as its sulfoxide and sulfone derivatives which are 
rapidly produced upon administration of the parent compound in vivo (Torreele et al., 2010, Kaiser 
et al., 2011, Tarral et al., 2014). Doses of the compound up to 3,600 mg are safe and well tolerated, 
and also shows activity against visceral leishmaniasis and Chagas disease (Tarral et al., 2014). One 
potential disadvantage of the drug is that generation of cross-resistance to nifurtimox in the field 
could have a knock-on effect leading to decreased efficacy of fexinidazole (Sokolova et al., 2010). 
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Figure 1-5: Two-dimensional chemical structures of drugs commonly used against HAT. 
1.3.2.2 Benzoxaboroles – a unique scaffold with great potential 
Benzoxaboroles have only recently come to wider attention, although this class of compounds was 
first synthesised more than half a century ago (Baker et al., 2011, Liu et al., 2014). These compounds 
possess a unique chemistry offered by the presence of boron in their structure (Nare et al., 2010). 
The structural motif has been used in a wide range of applications including, but not limited to, 
antivirals (Mahalingam et al., 2011), antifungals (Markham, 2014), antibacterials (Goldstein et al., 
2013, Hernandez et al., 2013), kinase inhibitors (Akama et al., 2013b, George et al., 2015), anti-
inflammatories (Akama et al., 2013a, Dong et al., 2013), and antiparasitics (Ding et al., 2010, Zhang 
et al., 2015). In many cases, there are few toxicity or instability problems related to the in the 
compounds in vivo. The use of benzoxaboroles is by no means limited to the development of novel 
therapeutics, as is reviewed by Liu and colleagues (Liu et al., 2014). Indeed, the high affinity for 
sugars and diols that benzoxaboroles possess has led to their application in materials science for 
chromatographic separation-based work (Li et al., 2012). 
In many cases there is only a basic knowledge regarding the SAR of these compounds in a 
therapeutic setting, and there is much less known about the exact mechanisms of drug action on 
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pathogens. Several studies have looked at boronic acids, from which benzoxaboroles are derived, 
but to date, only one benzoxaborole target has been validated (Rock et al., 2007). Tavaborole, 
(AN2690), is used as a treatment against onychomycosis, a fungal infection affecting the toenail, 
and has recently been approved by the FDA (FDA, 2014). Through the generation and 
characterisation of AN2690-resistant yeast mutants as well as the resolution of crystallography 
structures, Rock and colleagues were able to show that AN2690 inhibits the cytoplasmic leucyl-
tRNA synthetase by formation of a stable tRNALEU-AN2690 adduct localised in the editing site of the 
enzyme (Rock et al., 2007). This adduct was mediated by the boron from the oxaborole ring which 
bound to the diol group of the 3’-terminal adenosine (Rock et al., 2007), thus highlighting the 
importance of the boron group within the structure, as well as the high affinity benzoxaboroles 
exhibit for diol groups. However, the group did not discuss what led to the attachment of AN2690 
to tRNALEU rather than other molecular structures exhibiting exposed diol groups. 
1.3.2.3 Benzoxaboroles for neglected tropical diseases 
Anacor Pharmaceuticals has been developing drugs against neglected tropical diseases (NTDs) 
based on the benzoxaborole scaffold, in collaboration with the DNDi as well as the Gates 
foundation. Recent publications highlighted potential new scaffolds with great potency against 
Plasmodium falciparum, the causative agent of the most virulent strain of malaria (Zhang et al., 
2011b). Working with the Medicines for Malaria Venture (MMV), two benzoxaboroles were 
selected for pre-clinical screening. Further efforts to develop therapeutics against leishmaniasis and 
Chagas disease, as well as tuberculosis, river blindness and shigellosis, are also underway (Anacor, 
2015). In addition, drugs against NTDs in animals, such as T. congolense and T. vivax, are under 
development, and leads have been selected for pre-clinical screening (Barrett, personal 
communication).  
Of the compounds in the Anacor NTD portfolio, the most promising lead for NTDs so far is a 
benzoxaborole currently awaiting phase II clinical trials as a therapeutic against HAT. This 
compound, AN5568 (formerly known as SCYX-7158) (fig. 1-5), exhibits low levels of host toxicity, 
and readily clears both T.b. gambiense and T.b. rhodesiense infections in mouse models (Jacobs et 
al., 2011). More importantly, it is able to clear parasites in both early and late stage HAT. Further in 
vivo studies concentrating on reproductive toxicology have also determined there are no adverse 
effects on male and female fertility, mating behaviour or peri/postnatal development (Giannotti et 
al., 2014). Whilst the drug appears to be secreted in maternal milk, Giannotti and colleagues found 
no adverse symptoms in F1 progeny (Giannotti et al., 2014). These data, in addition to those 
published previously, demonstrate that AN5568 possesses a good safety profile (Jacobs et al., 2011, 
Giannotti et al., 2014).  In addition, unlike current therapies, AN5568 is orally bioavailable (Jacobs 
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et al., 2011). These factors make the benzoxaborole a very exciting candidate as a therapeutic 
against HAT. 
1.3.3 Animal African Trypanosomiasis (AAT) 
The outlook for therapeutics against AAT, or Nagana, is much poorer compared to HAT. The two 
drugs currently used for the majority of cattle cases are diminazene aceturate and isometamidium 
chloride. The latter was introduced in 1961, but remains the most recent novel therapy against AAT 
(Berg et al., 1961). In some cases, ethidium bromide, marketed as homidium, is also used, although 
widespread resistance has been reported (Scott & Pegram, 1974). Treatment failure, presumably 
due to emerging resistance, has been increasingly reported in recent years for all drugs (Geerts et 
al., 2001). Due to differences between trypanosome species, the drugs commonly used against HAT 
have little effect against Nagana (Auty et al., 2015). Clearly, there is also a critical need for novel 
therapeutics against the animal trypanosomes. 
1.4 Trypanocides and their mechanisms of action 
Drug target deconvolution (also referred to as drug target identification, or mechanism of action 
[MoA] studies) has become increasingly important with regards to the development of novel 
therapies. Understanding the mechanisms by which drugs acts to kill pathogens leads to a greater 
understanding of the biology of the organism, which in turn can lead to the development of more 
potent therapies with increased efficacy and reduced side- and off-target effects (Hughes et al., 
2011). In the study of trypanosomatids, there is a severe lack of knowledge regarding drug MoAs. 
This is in part due to the lack of optimised techniques for investigating drug MoAs in the 
kinetoplastids, and also due to lack of research specifically aimed at identifying detailed 
mechanisms. 
1.4.1 Eflornithine (α-difluoromethylornithine, DFMO) 
As mentioned previously, eflornithine is the current front-line therapy against T.b. gambiense and 
targets ornithine decarboxylase (ODC) (Li et al., 1998). This compound is an analogue of ornithine, 
a precursor for polyamine and subsequently, trypanothione biosynthesis in the parasite. Recent 
metabolomics analyses by the Barrett lab have confirmed the effect of eflornithine on this pathway, 
leading to a build-up of putrescine and a decrease in spermidine (Vincent et al., 2012). Earlier work 
by Wang and colleagues demonstrated that an ODC-null mutant, whilst unable to establish an in 
vivo infection in mice, was desensitised to eflornithine (Li et al., 1998). In a separate study, Wang 
showed that eflornithine-resistant cells retained ODC activity, but exhibited significantly reduced 
uptake of the drug (Phillips & Wang, 1987). These data were supported by more recent work carried 
out by Vincent and colleagues (Vincent et al., 2010, Vincent et al., 2012). 
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1.4.2 Pentamidine 
Pentamidine is a diamidine that has been used in both HAT and AAT. However, the mode of action 
of this drug is still not fully known (Berger et al., 1993, Barrett et al., 2007). Uptake is carrier-
mediated through the P2 amino purine transporter, the high-affinity pentamidine transporter 
(TbHAPT1) (now known to be encoded by the TbAQP2 gene), and the low-affinity pentamidine 
transporter (TbLAPT1) (De Koning, 2001, de Koning & Jarvis, 2001, Munday et al., 2014). Published 
data indicates that diamidines are nucleic-acid binding drugs that localise to the mitochondrion, 
where they destroy the kinetoplast, and the mitochondrial DNA (Ludewig et al., 1994). Whilst this 
drug remains effective in the field, loss of the kinetoplast in trypanosomes, which has been 
observed in vitro and in other trypanosome species like T. evansi (Lai et al., 2008), could lead to 
widespread resistance (Horn & Duraisingh, 2014). In reality, loss of transporters have played a more 
significant role in generating resistance (Graf et al., 2013). 
1.4.3 Melarsoprol 
Melarsoprol has multiple modes of action in both host and parasite (Alsford et al., 2012). In 
trypanosomes, melarsoprol is metabolised to melarsen oxide, which binds to trypanothione, 
forming a stable adduct which competitively inhibits the enzyme trypanothione reductase, an 
essential protein involved in the regulation of the thiol/disulphide redox balance in 
trypanosomatids (Fairlamb et al., 1989). In addition, the oxide derivative of melarsoprol also binds 
other thiol groups, thereby inhibiting many enzymes in both the host and the parasite, leading to 
the widespread side effects seen in HAT patients treated with the drug (Fairlamb et al., 1992). 
1.4.4 Suramin 
Whilst several potential MoAs have been proposed for suramin, none of these have been proven 
experimentally (Barrett et al., 2007). The drug possesses significant points of negative charge, 
leading to electrostatic interactions with many enzymes (Barrett et al., 2007). In addition, the drug 
is not able to enter the cell by passive diffusion, and endocytosis was proposed as a route of entry 
(Vansterkenburg et al., 1993). A recent study investigating drug MoA using the RIT-seq approach 
implicated the invariant surface glycoprotein, ISG75, as a major receptor for suramin uptake. In 
addition, drug resistance was observed in cells lacking components of the endocytosis pathway 
(Alsford et al., 2012). 
Previous work indicates that suramin is far more potent against BSF trypanosomes, compared with 
PCF parasites (Scott et al., 1996). This led to the hypothesis that glycolysis could be targeted, as 
glycolytic metabolism is essential to BSF trypanosomes only (Fairlamb & Bowman, 1977, Besteiro 
et al., 2005). However, suramin has been shown to inhibit a wide range of enzymes, and it is 
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unknown whether inhibition of glycolysis is the primary mechanism resulting in trypanosome death 
(Alsford et al., 2012). 
1.5 Cell biology 
1.5.1 Antigenic variation 
Trypanosomes live in an extracellular environment and are continuously exposed to the host 
immune system. To counter this, the parasite has evolved a unique and effective method to evade 
host immunity, using a switchable array of cell surface proteins called variable surface glycoproteins 
(VSGs), which were first discovered in 1969 (Vickerman & Luckins, 1969). Approximately 10 million 
copies of these 60 kDa homodimeric proteins cover the cell surface of the parasite at any one time, 
and the protein accounts for up to 20% of the entire cell proteome (Horn, 2014). VSGs are not 
transmembrane proteins but instead, are anchored to the cell surface membrane by 
glycosylphosphatidylinositol (GPI) moieties (Ferguson et al., 1988). The host immune system 
recognises VSGs as a foreign antigen, which it combats with high levels of B-cell derived antibodies 
(Campbell et al., 1977, de Gee et al., 1983, Reinitz & Mansfield, 1990). However, trypanosomes 
possess many hundreds of genes coding for VSGs. These, in addition, can undergo recombination, 
leading to further variation (Marcello & Barry, 2007, Hall et al., 2013). By predominantly expressing 
only one VSG at a time, the host immune response remains concentrated against one VSG structure. 
This results in the killing of high numbers of trypanosomes, whilst those expressing different VSGs 
survive to re-initiate infection (Horn, 2014). The VSG coat is highly immunogenic, but it also serves 
to protect non-variant surface proteins from immune effectors by physically obstructing access to 
these proteins (Horn, 2014). It is the continuous switching of dominantly expressed VSGs and the 
subsequent host immune responses generated against each VSG structure that are responsible for 
the intermittent parasitaemia often observed in the clinic (Black et al., 1985, Vickerman, 1985, 
Emmer et al., 2010). 
Interestingly, whilst the human immune system does not possess antibodies capable of recognising 
epitopes of trypanosome molecules other than VSG, cattle have been shown to possess antibodies 
with an exceptionally long CDR H3 loop, the most diverse portion of a classical antibody (Wang et 
al., 2013). It is thought these could potentially bypass the VSG coat and recognise other molecules 
on the trypanosome cell surface, making them important in the context of novel therapeutics and, 
potentially, vaccines (L. Morrison, personal communication). 
1.5.2 Overview of T. brucei cell biology and organelles 
The majority of the T. brucei forms are spindle-shaped, with a polarized microtubule cytoskeleton 
(fig. 1-6), and possess a single elongated flagellum, which emerges through a flagellar pocket 
(Matthews, 2005, Field & Carrington, 2009). This pocket is a small plasma membrane invagination 
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close to the basal body and is the only site for endo- and exo-cytosis (Overath & Engstler, 2004) (fig. 
1-6). The motility of the parasite is driven by a flagellar wave that initiates at the tip of the flagellum 
and moves towards the base (Weisse et al., 2012). It has recently been shown that BSF trypanosome 
locomotion is adapted to the density of blood (Heddergott et al., 2012). Interestingly, Heddergott 
and colleagues used high-speed video microscopy to show that the presence of blood cells is 
required for the parasite to achieve maximum velocity in the bloodstream (Heddergott et al., 2012). 
Thus, motility is not solely due to flagellar motion. The flagellum itself is made up of a conventional 
axonemal structure along with a paraflagellar rod (Vaughan & Gull, 2003).  
Whilst T. brucei possesses a conventional nucleus, endoplasmic reticulum and Golgi body, the cell 
has an elongated single mitochondrion, rather than multiple smaller mitochondria as observed in 
yeast and mammalian cells (Acestor et al., 2009) (fig. 1-6). In BSF trypanosomes, the mitochondrion 
does not contain cristae, although the organelle is much more active in PCF cells, and here it 
contains an extensive electron transport chain (Matthews, 2005). 
T. brucei, along with the other kinetoplastids T. cruzi and Leishmania spp., possess several unique 
organelles. A major part of glycolysis is contained in the glycosome, described in more detail below. 
In addition, the complex network of mitochondrial DNA is encompassed by the kinetoplast, from 
which this group of organisms takes its name (Shlomai, 2004). Finally, trypanosomatids also possess 
acidocalcisomes, which are organelles rich in orthophosphate (Pi), PPi and PolyP, complexed with 
cations and basic amino acids (Docampo et al., 2005). 
 
Figure 1-6: Cell biology of T. brucei. A simplified diagram showing the locations of the major organelles and 
structural features of T. brucei. Taken from Matthews (2005). 
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1.5.3 Comparing bloodstream form and procyclic form cells 
Compared to BSF cells, PCFs are larger and longer, and the mechanics of cell division differ between 
the two life cycle stages (Wheeler et al., 2013). There are also extreme metabolic differences 
between BSF and PCF forms. In particular, whilst BSF parasites rely primarily on glycolysis for the 
generation of ATP, PCFs utilise proline, generating ATP via oxidative phosphorylation (Besteiro et 
al., 2005). 
The localisation of organelles also differs between life cycle stages. In BSF cells, the kinetoplast is 
localised at the posterior end of the parasite. In contrast, the kinetoplast moves inwards in PCF cells 
and is localised midway between the nucleus and the posterior end (Matthews, 2005). Another well 
characterised event during differentiation, is the downregulation of the VSG surface coat, as this is 
replaced by EP procyclin, and later on, by GPEET procyclin (Butikofer et al., 1997, Vassella et al., 
2001). 
1.5.4 The glycosome 
BSF trypanosomes rely heavily on glucose as a primary carbon source (Mazet et al., 2013). To enable 
high flux through the glycolytic pathway, the parasite has evolved a unique and essential organelle 
which compartmentalises the first seven steps of glycolysis (Visser et al., 1981). This peroxisome-
like organelle, known as the glycosome, contains primarily (~90%) glycolytic enzymes including 
hexokinases, phosphofructokinase, fructose-bisphosphate aldolase and glyceraldehyde-3-
phosphate dehydrogenase (Misset et al., 1986). Previous studies have shown that glucose is toxic 
to glycosome-deficient trypanosomes (Furuya et al., 2002, Guerra-Giraldez et al., 2002). A T. brucei 
cell typically contains approximately 65 glycosomes in its BSF stage (Tetley & Vickerman, 1991). This 
number is drastically reduced in PCF stage parasites, reflecting the BSF stage parasite’s dependency 
on this organelle for central metabolism (Haanstra et al., 2015). In addition to glycolysis, the 
glycosome also contains a number of other pathways including lipid synthesis, the pentose 
phosphate pathway (PPP), purine salvage and pyrimidine synthesis (Michels et al., 2006). 
1.5.5 Kinetoplasts and the trypanosome mitochondrion 
T. brucei possess a large, complex mitochondrial DNA compartment called the kinetoplast. This DNA 
(referred to as kDNA) consists of two types of circular DNAs termed minicircles and maxicircles 
(Hines & Ray, 2010). Whilst maxicircles encode ribosomal RNA and mitochondrial-specific genes, 
similar to other eukaryotes, minicircles code for a myriad of small RNAs referred to as guide RNAs, 
and number to approximately 5,000 (Carpenter & Englund, 1995, Lukes et al., 2005). These guide 
RNAs act as templates in the RNA editing of maxicircle transcripts, primarily in the form of uridine 
additions/deletions (Feagin et al., 1988, Sturm & Simpson, 1990).  
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In addition to the kDNA, the kinetoplast also contains a variety of house-keeping proteins unique 
to trypanosomatids. For example, there are four histone-like molecules called kinetoplast 
associated proteins 1-4 (Xu et al., 1996). More recent work has also identified the key players 
involved in the unique mechanisms of RNA editing (Ammerman et al., 2013). These kinetoplastid-
specific phenomena could arguably become an important therapeutic target in the near future. 
1.6 Genome and gene regulation in T. brucei 
1.6.1 Genome structure and arrangement 
T. brucei possesses a diploid genome divided into 11 pairs of classical chromosomes of varying size 
(0.9 – 5.7 Mb) (Berriman et al., 2005). The genome is thought to code for approximately 10,000 
genes, many of them multiple copies (Berriman et al., 2005). In addition, T. brucei contains varying 
numbers of intermediate and mini chromosomes made up of approximately 0.3-0.9 Mb and 0.05-
0.1 Mb respectively (Berriman et al., 2005). These chromosomes contain the VSG gene repositories, 
and genes here are usually transcribed by RNA polymerase (Pol) I (Shea et al., 1987, Zomerdijk et 
al., 1991). In contrast, all other genes are transcribed by RNA polymerase (Pol) II. Pol I initiation can 
be regulated epigenetically, enabling stage-specific expression, and more importantly in the case 
of VSGs, exclusive expression of one gene at a time (Clayton, 2014). 
Gene arrangement in African trypanosomes differs from mammalian cells, as well as other 
protozoans. This is due to two phenomena. Firstly, almost all genes are arranged in poly-cistronic 
arrays that can contain tens to hundreds of genes (Imboden et al., 1987, Berriman et al., 2005). 
These genes are constitutively transcribed and their expression is regulated at the post-
transcriptional level through complex interplay of RNA transcription and degradation (De Gaudenzi 
et al., 2011). Secondly, trypanosomes do not appear to possess introns, and trans-splicing only 
occurs during addition of a short 39-nucleotide spliced leader (described below) to the 5’ ends of 
mature mRNAs (Perry et al., 1987). This process occurs simultaneous to polyadenylation of the 3’ 
ends (Huang & van der Ploeg, 1991). To date, only two genes have been discovered that harbour 
introns: poly(A) polymerase (PAP) and RNA helicase, which are both cis-spliced (Mair et al., 2000, 
Berriman et al., 2005). 
In many ways, the arrangement of the T. brucei genome is linked to the significant differential 
expression that occurs in the various extracellular environments the parasite encounters in its 
different life cycle stages. Several studies have investigated the transcriptomes of BSF and PCF 
trypanosomes by microarray (Brems et al., 2005, Koumandou et al., 2008, Jensen et al., 2009), as 
well as RNA-seq (Kolev et al., 2010, Siegel et al., 2010, Hamidou Soumana et al., 2015). These data 
have shown that most transcripts are present at 1-10 copies per cell, although some are present at 
much higher quantities (>200) (Kolev et al., 2010). One of the advantages of genes arranged in poly-
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cistronic arrays is that expression of stage specific genes can be altered rapidly (Roditi et al., 1989, 
Archer et al., 2011). 
The genomes of several T. brucei strains have been sequenced, including T.b. brucei isolates, with 
TREU 927 being the gold standard reference (Berriman et al., 2005). In addition, sequencing has 
been carried out on T.b. gambiense (DAL972) (Jackson et al., 2010). However, the majority of 
protein coding regions are known, there is a lack of annotation, with almost 50% of genes annotated 
as “putative” or “unknown” (Salavati & Najafabadi, 2010, Shateri Najafabadi & Salavati, 2010). It is 
also thought there are non-coding RNAs in the T. brucei genome, but these have not been 
characterised experimentally (Zheng et al., 2013). 
1.6.2 Post-transcriptional regulation of gene expression 
Due to the constitutive and poly-cistronic nature of T. brucei transription, there is a lack of 
regulation of gene expression at the transcription level (Clayton, 2014). Instead, regulation occurs 
on the post-transcriptional level and can include trans-splicing, polyadenylation and mRNA 
degradation, amongst others (Clayton, 2014). In addition, it is thought that sequence elements in 
the 5’ and 3’-untranslated regions (UTRs) play an important role in mRNA stability and degradation 
(Irmer & Clayton, 2001, Robles & Clayton, 2008). This hypothesis is supported by the fact that the 
trypanosome genome encodes a large number of RNA-binding proteins (RBPs) (Wurst et al., 2009). 
1.6.3 The trypanosome spliced leader  
In 1982, researchers discovered that all trypanosome VSG mRNAs possessed an identical short 
nucleotide sequence on the 5’ end (Boothroyd & Cross, 1982). This 39-nucleotide sequence was 
termed the spliced leader (SL) and further work showed it was present on all mature mRNAs 
(Parsons et al., 1984). Whilst SL splicing has since been shown to be present in other eukaryotes 
such as nematodes, it has not been observed in higher eukaryotes such as vertebrates, including 
humans (Douris et al., 2010, Gunzl, 2010). This makes the SL splicing pathway an attractive target 
for HAT therapy and much work has revolved around attempting to identify the enzymes and 
spliceosome factors that trypanosomes possess, and how they differ from their mammalian 
counterparts (Gunzl, 2010). 
Published data indicates that trypanosomes possess all 5 conserved U spliceosomal snRNAs (U1, 
U2, U4, U5 and U6), which are involved in the generation of mature mRNAs (Gunzl, 2010). Humans 
possess up to 170 protein factors often associated with spliceosomes, but it is not known how many 
of these are present in T. brucei, mainly due to lack of annotation and significant sequence 
divergence (Gunzl, 2010). 
The trypanosome SL sequence itself has been shown to possess a highly conserved and complex 
pattern of methylation on the first 4 bases (Perry et al., 1987, Bangs et al., 1992). This capping 
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process is crucial as it protects the mRNA from degradation, and it is also implicated in translation 
initiation (Zeiner et al., 2003). The first base, an inverted guanosine bound to the rest of the SL via 
a 5’-5’ triphosphate linkage, is termed cap0 (m7G), and is modified by TbCet1, an RNA 
triphosphatase, as well as a bifunctional guanylyltransferase-methyltransferase, TbCgm1 (Hall & 
Ho, 2006a, Ruan et al., 2007a, Takagi et al., 2007). Cap0 formation and methylation is essential 
(Takagi et al., 2007). However, RNAi knock-down of TbCgm1 in PCF trypanosomes does not lead to 
an observed growth defect (Monnerat et al., 2009). A further methyltransferase (MTase) called 
TbCmt1 has also been described, and is closely related to TbCgm1, although it does not possess 
guanylyltransferase capabilities (Hall & Ho, 2006a). 
The cap1, cap2, cap3 and cap4 positions immediately after the cap0 m7G are also methylated and 
to date, three 2’-O-ribose MTases have been identified (Zamudio et al., 2009). TbMtr1 methylates 
the cap1 position and is distantly related to MTase families also found in humans, although it acts 
specifically on T. brucei SL (Zamudio et al., 2007, Mittra et al., 2008). TbMtr2 methylates the cap2 
nucleotide (Arhin et al., 2006b). TbMtr3 methylates the third nucleotide and in addition, is thought 
to methylate the cap4 position, as TbMtr3 KOs lack 2’-O-ribose methylation on cap4 (Arhin et al., 
2006a, Zamudio et al., 2009). However, this could be because the cap4 position is only methylated 
after methylation of cap3. Whilst enzymes acting on cap0 are essential, data indicates that the 2’-
O-ribose MTases are not (Zamudio et al., 2006, Zamudio et al., 2009). For example, TbMtr2 dKOs 
are viable, albeit with a lack of cap2 modifications (Arhin et al., 2006b). 
One recent study discovered an mRNA decapping and recapping pathway that has important 
implications for the functional reactivation of mRNA, as well as mRNA stability and turnover 
(Ignatochkina et al., 2015). Specifically, this study characterised a cytoplasmic capping enzyme 
called TbCe1. Ignatochkina and colleagues showed that TbCe1 possesses 5’-monophosphate RNA 
(pRNA) kinase activity, enabling it to recap uncapped SL RNA (Ignatochkina et al., 2015). In the same 
study, the authors discovered an SL decapping enzyme called TbDcp2, which also localised to the 
cytoplasm and is involved in the 5’-3’ exonuclease-mediated degradation of mature mRNA 
(Ignatochkina et al., 2015). 
African trypanosomes have been shown to possess an SL silencing (SLS) pathway that is related to 
the highly conserved unfolding protein response (UPR) pathway found in other eukaryotes 
(Goldshmidt et al., 2010, Michaeli, 2012, Michaeli, 2015). In response to persistent ER stress, which 
can occur due to several acute intracellular changes leading to protein un- or mis-folding, an 
apoptotic cascade is activated that leads to programmed cell death through the inhibition of SL 
trans-splicing. This process leads to significant degradation of, and reduction in all RNAs 
(Goldshmidt et al., 2010). Several other intracellular changes also occur during this process 
including increase in cytoplasmic Ca2+, and DNA fragmentation (Goldshmidt et al., 2010). 
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1.7 Genetic diversity in the trypanosome 
The generation and maintenance of genetic diversity is key to survival. In parasites like T. brucei, 
the genome is shaped by the requirement to constantly evolve in order to survive in the various 
hosts in which the parasite lives (Stephens et al., 2012). Leigh Van Valen’s Red Queen hypothesis 
(Van Valen, 1973), covered in detail elsewhere (Liow et al., 2011), states that this constant evolution 
is necessary to overcome the host immune responses, which themselves evolve to destroy the 
parasite (Stephens et al., 2012). The evolutionary mechanisms of human serum resistance 
described in section 1.2.4 are a good example of this theory. Our understanding of genetic diversity 
of T. brucei in the field is crucial in order to target the parasite (Tait et al., 2011). For example, 
varying genetics could in theory explain the differing efficacies of drugs, eflornithine in particular, 
against T.b. gambiense and T.b. rhodesiense (Iten et al., 1997). Furthermore, genetic diversity has 
been implicated in differing pathologies such as splenomegaly and hepatomegaly (Morrison et al., 
2009, Capewell et al., 2015b). 
Several years ago it was demonstrated that T. brucei undergoes sexual recombination during the 
epimastigote stage in the salivary glands of the tsetse fly, prior to the development of metacyclic 
parasites (Gibson & Stevens, 1999, Tait et al., 2002, Tait et al., 2007). In addition, genetic diversity 
in the field has been measured using genotyping markers (Tait et al., 2011). Whilst T. brucei have 
been shown to exhibit high levels of genetic diversity, T.b. rhodesiense is mixed, depending on 
geographical location, and T.b. gambiense shows low levels of diversity. The latter, however, has 
been shown to possess distinct genetic traits in different geographical foci (Tait et al., 2011). 
Whilst meiotic recombination does aid in generating diversity, there are mechanisms involving 
mitotic recombination that may also contribute to this phenomenon. Examples include, but are not 
limited to, multiple ploidy states, which havs been reported in C. albicans and C. neoformans 
(Bennett et al., 2014), and loss-of-heterozygosity (LOH). 
1.7.1 Loss-of-heterozygosity: a potential key to genetic diversity 
Loss of heterozygosity is a previously reported genetic phenomenon where heterozygous loci are 
rendered homozygous either due to loss of one allelic variant, or by mitotic recombination (Ryland 
et al., 2015). Generation of genetic diversity can occur in heterozygous diploids as a result of 
homozygosis of short genomic regions, or large portions of a chromosome (Bennett et al., 2014). 
This can be due to recombination, double chromosome cross-overs or break-induced replication 
(BIR) involving strand invasion (Llorente et al., 2008). In the case of the latter, break events that 
occur in a chromosome can result in LOH from the break-point all the way to the telomeric regions 
of the chromosome (Bennett et al., 2014). Double-strand breaks and their repair in T. brucei have 
been studied in depth, especially in the context of driving antigenic variation (Alsford et al., 2009). 
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This phenomenon has been reported in several organisms, including C. albicans (Diogo et al., 2009) 
and S. cerevisiae (Andersen et al., 2008). One recent publication provided evidence to show that 
environmental perturbations that induce cellular stress can also lead to LOH (Forche et al., 2011). 
Interestingly, LOH has been observed in an in vitro setting in several independent cell lines including 
two TREU 927 T.b. brucei isolates, a melarsoprol-resistant STIB 247 T.b. brucei line and a STIB 386 
T.b. gambiense line (A. Cooper, personal communication). In the three T.b. brucei isolates, a 
significant increase in growth rate was also observed (A. Cooper, personal communication). 
Genotyping experiments as well as genomics analyses of two TREU 927 LOH lines showed the 
occurrence of LOH on chromosome 10 (fig. 1-7). In the laboratory strains, up to 50% of the 
chromosome had mutated to a homozygous genotype, and the current hypothesis that an 
underlying genetic alteration is responsible for increased growth rates is currently under 
investigation by the MacLeod group.  
 
Figure 1-7: Map of PCR microsatellite analysis of chromosome 10 in a wild-type TREU 927 PCF line, and 
two LOH lines. All sites selected were those that usually display heterozygosity in TREU 927, as indicated by 
blue and yellow circles. In both LOH lines, a large portion of the chromosome showed the presence of only 
one allele, thus indicating homozygosity in these loci. Figure taken from Cooper (2009). 
LOH was recently shown to be one of the major factors influencing genetic diversity in the asexual 
T.b. gambiense type 1 (Weir et al., 2016). Genomics analyses by Weir and colleagues showed that 
type 1 strains exhibit low levels of intra group diversity and geographically restricted sub-
populations. Inspection of SNP distributions showed large areas of chromosomes to be devoid of 
SNPs, confirming that LOH played a role in the genomic evolution of these parasites (Weir et al., 
2016). Furthermore, the authors hypothesise that LOH is intimately linked to the Meselson Effect, 
whereby chromosome homologues in asexual organisms evolve and diverge independently (Weir 
et al., 2016). Thus, whilst LOH removes heterozygosity, independent evolution re-introduces SNPs, 
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thereby driving genetic diversity. It is currently not known whether these events also lead to 
phenotypic advantages such as the increased growth rates seen in the laboratory strains. 
1.8 Metabolism in T. brucei 
1.8.1 General metabolism 
As an ancient eukaryote, metabolism in T. brucei is biologically relevant not only due to its ability 
to cause disease, but also to those attempting to understand the evolution of metabolism. The 
parasite’s metabolism has evolved to exploit the host for many nutrients, including amino acids, 
fatty acids, sterols, sugars and purines (Bringaud et al., 2006, Smith & Butikofer, 2010). The key 
differences between the mammalian infective and insect forms have been studied for many years, 
and it is known that whilst BSF parasites carry out metabolism streamlined towards acquiring 
energy through glycolysis, PCF cells readily use various sugars and amino acids from their 
extracellular environment for energy production, with an emphasis on mitochondrial metabolism 
(Besteiro et al., 2005, Bringaud et al., 2006, Bringaud et al., 2012). 
Lipids constitute 8-11% of the T. brucei dry weight (Richmond et al., 2010), and lipid metabolism in 
the trypanosomatids bears some key differences compared to more conventional eukaryotes 
(Reviewed by (Smith & Butikofer, 2010). Historically, research on T. brucei lipids focused on 
glycosylphosphatidylinositol (GPI) biosynthesis, as these form the structures that anchor VSGs to 
the trypanosome surface (Smith & Butikofer, 2010). In particular, myristate formation and turnover 
was of high interest as a potential therapeutic target (Buxbaum et al., 1996, Werbovetz & Englund, 
1997). However, focus has recently shifted to other areas of lipid metabolism that are unique to 
the parasite (Richmond et al., 2010). T. brucei possesses all major phospholipid classes present in 
other eukaryotes, and whilst eukaryotic cells typically utilise type I or type II synthases to generate 
fatty acids, T. brucei uses a system of 4 elongases to generate fatty acids, including myristate in the 
BSF stage (Patnaik et al., 1993, Smith & Butikofer, 2010).  
The glycerophospholipids phosphatidylcholine (PC) and phosphatidylethanolamine (PE) comprise 
45-60% and 10-20% of the total T. brucei phospholipid content respectively (Richmond et al., 2010). 
Choline and ethanolamine, which are taken up from the extracellular environment, form the head 
groups of these phospholipids and these are incorporated into the Kennedy pathway to generate 
PC and PE (Smith & Butikofer, 2010).  
T. brucei was thought to possess a large complement of nutrient transporters, which was confirmed 
upon the completion of the sequencing of its genome (Berriman et al., 2005), as well as that of the 
human-infective T.b. gambiense (Jackson et al., 2010) and T. congolense and T. vivax (Jackson et al., 
2013). This reflects the parasite’s dependency on its extracellular environment for many metabolic 
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factors such as amino acids and vitamins. Indeed, T. brucei has the largest number of transporters 
of the three TriTryps, probably due to the fact that unlike both Leishmania spp. and T. cruzi, it 
remains extracellular and thus, has greater access to these nutrients (Berriman et al., 2005).  
1.8.2 Energy metabolism: glycolysis and the incomplete citric acid cycle 
BSF trypanosomes rely primarily on glycolysis for ATP production (Michels et al., 2006). As 
mentioned previously, several of the glycolytic steps proceed in a peroxisome-like organelle called 
the glycosome (Visser et al., 1981). However, in this organelle, net production of ATP is zero, and 
ATP production though the action of pyruvate kinase using phosphoenolpyruvate (PEP) is the main 
generator of ATP-derived energy (Michels et al., 2006). The majority of pyruvate is shuttled out of 
the cell as a waste product (fig. 1-8). 
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Figure 1-8: Energy metabolism in T. brucei. BSF trypanosomes rely on glucose for ATP production, carrying 
out enzymatic reactions 1-12. In contrast, PCF trypanosomes preferentially utilise proline to generate 
succinate, although they are known to utilise glucose through glycolysis in the presence of the sugar. 
Abbreviations: AA, amino acid; 1,3BPGA, 1,3-bisphosphoglycerate; CoA-SH, coenzyme A; DHAP, 
dihydroxyacetone phosphate; G-3-P, glyceraldehyde-3-phosphate; Gly-3P, glycerol 3-phosphate; OA, 2-
oxoacid; PEP, phosphoenolpyruvate; 3-PGA, 3-phosphoglycerate; Pi, inorganic phosphate; PPi, inorganic 
pyrophosphate;  Suc-CoA, succinyl-CoA. Enzymes: 1, hexokinase; 2, glucose 6-phosphate isomerase; 3, 
phosphofructokinase ; 4, aldolase; 5, triose-phosphate isomerase; 6, glycerol 3-phosphate dehydrogenase; 7, 
glycerol kinase; 8, glyceraldehyde 3-phosphate dehydrogenase; 9, phosphoglycerate kinase; 10, 
phosphoglycerate mutase; 11, enolase; 12, pyruvate kinase; 13, phosphoenolpyruvate carboxykinase; 14, 
glycosomal malate dehydrogenase; 15, fumarase; 16, NADH-dependent fumarate reductase; 17, pyruvate 
phosphate dikinase; 18, malic enzyme; 19, alanine aminotransferase; 20, pyruvate dehydrogenase; 21, 
unknown; 22, acetate:succinate CoA transferase; 23, citrate synthase; 24, aconitase; 25, isocitrate 
dehydrogenase; 26, ketoglutarate dehydrogenase; 27, succinyl-CoA synthase; 28, NADH-dependent fumarate 
reductase; 29, fumarase; 30, malate dehydrogenase; 31, L-proline dehydrogenase; 32, pyrroline-5 
carboxylate dehydrogenase; 33, L-glutamine deaminase; 34, glutamate dehydrogenase; 35, glutamate 
aminotransferase. 
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Whilst the paradigm of BSF T. brucei central carbon metabolism has historically been based around 
the uptake of glucose and excretion of the main glycolytic waste product, pyruvate, recent data has 
emerged that questions the accuracy of this theory (Mazet et al., 2013). Mazet and colleagues 
demonstrated that inhibition of acetate production from pyruvate was lethal to the parasite, 
suggesting that pyruvate is not only excreted from the cell, but rather like PCF metabolism, is also 
used for mitochondrial metabolism in the form of succinate and acetate production (Mazet et al., 
2013). In addition, the mitochondrion is the location of the trypanosome alternative oxidase 
(TbAOX) that aids in the maintenance of redox balance in the glycosome through the action of a 
glycerol 3-phosphate, dihydroxyacetone shunt (Opperdoes et al., 1977, Creek et al., 2015). 
Work was recently published by the Barrett group showing the distribution of heavy carbon 
isotopes (13C) derived from glucose, in the BSF parasite (Creek et al., 2015). By culturing T. brucei in 
the presence of universally (U)-13C-labeled glucose as well as (U)-12C-glucose in a 50:50 ratio, and 
subsequently analysing the cell pellets by liquid chromatography mass spectrometry (LC-MS), Creek 
and colleagues observed glucose-derived carbon labelling in over 150 metabolites ranging from 
pentose phosphate pathway components to sugar phosphates and nucleotides (Creek et al., 2015). 
In addition to 50% labelling seen in pyruvate, carbon isotopes were also incorporated into 
succinate, alanine and acetyl-CoA, thereby supporting the previous findings by Mazet and 
colleagues (Creek et al., 2015). 
The glycosome also harbours the pentose phosphate pathway (PPP) (Kerkhoven et al., 2013). This 
pathway, although less active compared to glycolysis, plays an important role in producing NADPH, 
protecting the parasite from oxidative stress. The link between glycolysis and PPP metabolism in 
trypanosomatids was highlighted by a study which showed that Leishmania mexicana cells lacking 
glucose transporters were more sensitive to oxidative stress (Rodriguez-Contreras et al., 2007). 
In PCF trypanosomes, energy metabolism occurs primarily in the mitochondrion, which houses a 
semi-complete citric acid cycle (tricarboxylic acid [TCA] cycle) (Besteiro et al., 2005, van Hellemond 
et al., 2005) (fig. 1-8). In addition, pyruvate is further metabolised by the pyruvate dehydrogenase 
complex into acetyl-CoA, before being converted to acetate. PCFs also utilise threonine, which is 
taken up from the extracellular environment, to produce acetate (Millerioux et al., 2013).  
In addition to TCA metabolism, PCFs are also able to switch to glucose catabolism for energy 
generation, akin to their mammalian infective counterparts (Bringaud et al., 2006). In laboratory 
culture, PCFs are routinely cultured in high levels (>5 mM) of glucose, and proline metabolism is 
down-regulated under these conditions (Lamour et al., 2005). Therefore, by regulating the proline 
and glucose levels, different areas of central carbon metabolism are activated in this life cycle stage 
(Lamour et al., 2005). Importantly, tsetse fly haemolymph contains negligible amounts of glucose, 
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although this depends on the fly taking bloodmeals, and parasites using proline as the main carbon 
source are thought to more accurately reflect PCF metabolism in the field (Besteiro et al., 2005) 
1.8.3 L- methionine and the Yang cycle 
L-methionine is a highly-important sulfur-containing amino acid involved in many key processes in 
T. brucei, akin to all eukaryotes (Hasne & Barrett, 2000). It is the first residue in all proteins and in 
plants and prokaryotes and also forms an integral part of the Yang cycle (fig. 1-9). This cycle involves 
the degradation of L-methionine through S-adenosyl-L-methionine (AdoMet), S-methyl-5’-
thioadenosine (5’-methylthioadenosine, 5’-MTA) and S-methyl-5-thio-D-ribose (5’-MTR) (Adams & 
Yang, 1977, Yung et al., 1982). In plants and bacteria, this cycle proceeds with further degradation 
of 5’-MTR to 2-oxo-4-methylthiobutanoate through 6 steps (fig. 1-9), before L-methionine is 
regenerated (Yung et al., 1982). Thus, in these organisms, the cycle is maintained through the 
continuous biosynthesis and degradation of L-methionine. L-methionine degradation is essential in 
trypanosomatids, as has been shown through the use of 5’-alkyl-substituted analogues of 5’-MTA 
(Bacchi et al., 1991). 
In contrast to other eukaryotes, evidence suggests that T. brucei lacks the ability to synthesise L-
methionine de novo, and instead, this amino acid is taken up from its extracellular surroundings (F. 
Achcar, personal communication). Ongoing work using (U)-13C-L-methionine has shown that the 
Yang cycle is incomplete in T. brucei, and 5’-MTR can be observed in spent medium samples, 
suggesting that L-methionine degradation only proceeds up to this point (F. Achcar & K. Johnston, 
personal communication) (fig. 1-9). Whilst there were previous suggestions that the full methionine 
recycling pathway exists in T. brucei, the stable-isotope labelling observations do not support this 
hypothesis (F. Achcar, personal communication). 
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Figure 1-9: The Yang cycle. Components indicated in red are those that are known to be present in T. 
brucei. Enzymes: 1, S-adenosyl-L-methionine synthase; 2, S-adenosyl-L-methionine decarboxylase; 3, 
spermidine synthase; 4, S-methyl-5’-thioadenosine nucleosidase; 5, S-methyl-5-thio-D-ribose kinase; 6, S-
methyl-5-thio-D-ribose 1-phosphate isomerase; 7, 5-methylthioribulose 1-phosphate dehydratase; 8, 5-
(methylthio)-2,3-dioxopentyl phosphate enolase; 9, 2-hydroxy-5-(methylthio)-3-oxopent-1-enyl phosphate 
phosphatase; 10, acireductone dioxygenase; 11, 2-oxo-4-methylthiobutanoate aminotransferase. Letters 
correspond to the following pathways: A. Methyltransferase reaction, B. Polyamine synthesis pathway and 
trypanothione biosynthesis, C. Excretion of S-methyl-5-thio-D-ribose (F. Achcar, personal communication). 
There are a number of important metabolic pathways that branch from the L-methionine 
degradation pathway where its components play an integral role. Firstly, as described in section 
1.8.6, decarboxylated AdoMet (dcAdoMet) is fed into the polyamine pathway, where it is a 
substrate for spermidine synthase (Bitonti et al., 1984, Willert & Phillips, 2012). Secondly, AdoMet 
itself is a crucial substrate involved in methyltransferase (MTase) reactions, where it acts as a 
methyl group donor. MTase reactions are found in all living organisms, yet whilst the process of 
methyl transfer is conserved, enzymes regulating these reactions are remarkably divergent 
(Schubert et al., 2003). 
1.8.4 The role of S-adenosyl-L-methionine in global metabolism 
As mentioned, AdoMet is a crucial substrate in MTase reactions, where it provides a methyl group. 
Methylation is an essential process involved in many areas of biology such as gene expression, 
signal transduction, protein sorting, protein activation and nucleic acid processing (Fontecave et al., 
2004). In more complex eukaryotic systems, methylation also plays an important role in regulation 
of hormones and neurotransmitters (Hunter et al., 2009, Nugent et al., 2015). Characterised 
examples of MTases in T. brucei include protein arginine MTases as well as histone MTases in the 
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context of gene regulation (Janzen et al., 2006, Fisk et al., 2010, Frederiks et al., 2010, Lott et al., 
2014). Substrates of methylation are varied and include nucleic acids and proteins. Many of these 
processes are essential, and this has been shown through the use of sinefungin, an analogue of 
AdoMet containing an amino methylene group in place of the methylated sulfonium group that 
usually acts as the methyl donor (Devkota et al., 2014). Most eukaryotes are highly sensitive to this 
compound, reflecting the deep conservation of methyl transfer reactions (Borchardt et al., 1979, 
Ferrante et al., 1984, Ferrante et al., 1988, Chrebet et al., 2005, Yadav et al., 2014). 
 
Figure 1-10: Comparison of structures of AdoMet and sinefungin. In AdoMet, the methyl group that is 
donated to the substrate in MTase reactions, forms parts of the methylated sulfonium group in the AdoMet 
structure. In contrast, sinefungin possesses an amino methylene group in this position and thereby 
competitively inhibits AdoMet-dependent MTases. 
Whilst the key role of AdoMet appears to be its use in MTase reactions, it is important in many 
other metabolic processes. AdoMet is utilised as a source of methylene groups (Grogan & Cronan, 
1997), ribosyl groups (Van Lanen et al., 2003), and 5’-deoxyadenosyl radicals (Jarrett, 2003). As 
mentioned previously, AdoMet is also an important source of aminopropyl groups in the polyamine 
synthesis pathway (Willert & Phillips, 2012). Indeed, AdoMet is one of the most commonly utilised 
substrates in eukaryotic cells, second only to ATP (Fontecave et al., 2004). 
1.8.5 Methyltransferases 
Methyltransferases (MTases) catalyse methyl transfer reactions. Whilst they all catalyse similar 
reactions, MTases are structurally divergent and, amino acid sequence identity can be as low as 
10% (Schubert et al., 2003). The majority of MTases are AdoMet-dependent, although other methyl 
donors including methyl tetrahydrofolate, methylamines, methanethiol and chloromethane have 
been described (Coulter et al., 1993, Ragsdale, 2008).  
Several years ago, researchers classified MTases based on structure (Schubert et al., 2003). 
AdoMet-dependent-MTases were subsequently classified further based on substrate specificity 
and the atom targeted for methylation (Martin & McMillan, 2002). Protein methylation is the 
second most common posttranslational modification in eukaryotic biology, after phosphorylation 
(Fontecave et al., 2004). In addition, methylation of nucleic acids, tRNA in particular, are essential 
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modification processes in structure maintenance and stabilisation (Swinehart & Jackman, 2015). 
Given their structural divergence and importance, MTases are important therapeutic targets, as 
exemplified in the field of oncology (reviewed by (Subramaniam et al., 2014, Hamamoto & 
Nakamura, 2016)). 
To date, two genome-wide MTase analyses have been carried out, one in humans (Petrossian & 
Clarke, 2011), and the other in Saccharomyces cerevisiae (Wlodarski et al., 2011). Both studies 
highlighted the diversity of MTases. In T. brucei, MTases described in the literature are 
concentrated around several specific processes. Firstly, histone modifications, where both DOT 
homologues have been characterised (Janzen et al., 2006, Figueiredo et al., 2008, Frederiks et al., 
2010). MTases involved in SL methylation have also been described in detail, although the T. brucei 
genome contains further uncharacterised capping enzymes, the annotations of which can be 
visualised on the TriTrypDB project website (Aslett et al., 2010). Another area of MTase biology that 
has been described are the protein arginine MTases, of which there are several that exhibit 
homology to their mammalian counterparts (Pelletier et al., 2005, Goulah et al., 2006, Pasternack 
et al., 2007, Fisk et al., 2009, Fisk et al., 2010, Lott et al., 2014, Wang et al., 2014a). However, there 
are likely to be many more MTases encoded in the T. brucei genome, which can be found through 
bioinformatical means, in order to collate a “methyltransferome”, similar to the work done by the 
Mottram group on the T. brucei “kinome” (Parsons et al., 2005, Jones et al., 2014a). 
1.8.6 Polyamine pathway and oxidative stress 
Polyamines are positively charged amino hydrocarbons essential to most eukaryotes. Whilst most 
eukaryotic species synthesize putrescine, spermidine and spermine, all components of the 
polyamine synthesis pathway, trypanosomatids do not synthesize the latter (Willert & Phillips, 
2012). Putrescine is synthesised by the decarboxylation of ornithine, catalysed by ODC (Vincent et 
al., 2012). Putrescine is then converted to spermidine by the addition of an aminopropyl group 
transferred from decarboxylated AdoMet (dcAdoMet) (Bitonti et al., 1984). This reaction is 
catalysed by spermidine synthase (fig. 1-9) (Willert & Phillips, 2012).  
Trypanosomatids have evolved an unusual end product of the polyamine pathway, where 
spermidine fuses with two glutathione molecules to generate trypanothione (N1,N8-
bis(glutathionyl)spermidine), a redox factor that is essential in maintaining redox balance and is 
used in oxidative stress responses (Fairlamb et al., 1985). The first step is carried out by 
glutathionylspermidine synthetase (GSS) and the second reaction that conjugates a second 
glutathione molecule to the structure is catalysed by trypanothione synthetase (TrypSyn) 
(Henderson et al., 1990).  
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Almost every enzyme involved in the synthesis of trypanothione has been characterised in the 
context of gene deletion studies (Huynh et al., 2003, Xiao et al., 2009, Pratt et al., 2014). In addition, 
inhibitors of AdoMet decarboxylase (AdoMetDC) have proven potent against the parasite in both 
in vitro and in vivo experiments (Barker et al., 2009, Hirth et al., 2009). AdoMetDC in particular has 
attracted interest as a drug target, because it possesses key structural differences compared to 
mammalian AdoMetDC (Willert et al., 2007). Upon the publication of the T. brucei genome, an 
AdoMetDC-like gene, now called prozyme, was discovered (El-Sayed et al., 2005b). This protein was 
shown to form a heterodimer with AdoMetDC (Willert et al., 2007). This type of AdoMetDC protein 
has so far only been identified in T. brucei and T. cruzi, making it an intriguing therapeutic target, 
as it catalyses the production of a precursor involved in the essential polyamine synthesis pathway 
(Willert & Phillips, 2012). 
Regulation at the mRNA and translation level is crucial for the function of the polyamine synthesis 
pathway (Clayton, 2014). AdoMetDC and ODC in particular have been shown to exhibit long half-
lives, when compared to the eukaryotic counterparts (Phillips et al., 1987, Willert & Phillips, 2008). 
It is thought that this plays a role in the selective nature of eflornithine action in vivo. The half-life 
of ODC in T.b. rhodesiense is much shorter compared to that in T.b. gambiense, and this could 
explain why eflornithine is less potent against the former (Iten et al., 1997). 
1.8.7 Metabolism during differentiation 
Differentiation from BSF to SSF trypanosomes is initiated by an external signal termed SIF (Vassella 
et al., 1997). Response to this factor generates several intracellular signalling cascades that bring 
around a significant remodelling in morphology as well as intracellular metabolism, involving 
several kinases and the cAMP pathway (Jones et al., 2014a, Tagoe et al., 2015). 
Glycolysis is a key process in BSF parasites and interestingly, silencing of the glycosomal enzymes 
of glycolysis leads to changes in surface protein expression, which suggests that the downregulation 
of glycolysis and the differential expression of stage-dependent surface proteins are intrinsically 
linked (Morris et al., 2002). Glycosomal turnover is also altered in differentiating trypanosomes, 
ultimately leading to a reduction in number of these organelles (Herman et al., 2008, Bauer et al., 
2013). GPEET procyclin, the major procyclic surface molecule, exhibits differential expression 
depending on mitochondrial activity and is directly related to expression of key mitochondrial 
enzymes such as the acetate, succinate CoA transferase/succinyl-CoA synthetase (ASCT) (Vassella 
et al., 2004). 
The Barrett group has carried out metabolomics analyses of a pleomorphic T. brucei line, to 
investigate metabolic changes in differentiating cells (J. Anderson et al., unpublished). As expected, 
a general downward trend was seen in metabolites involved in BSF-specific metabolism, including 
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in phenylpyruvate, a pyruvate derivative resulting from a phenylalanine transaminase reaction, 
which is commonly found in the serum of trypanosome-infected hosts (Li et al., 2011). Sphingolipid 
metabolism also exhibited a decreasing trend. In contrast, several metabolic components of PCF-
specific metabolism, such as mitochondrial metabolites, were found to increase during 
differentiation (J. Anderson et al., unpublished). There were also unexpected, and so-far 
unexplained, changes observed in differentiating cells. For example, L-cystathionine was found to 
increase, as well as 5’-MTA, several modified lysines such as acetyl-L-lysine and trimethyl-L-lysine, 
sn-glycero-3-phosphocholine and other phospholipids (J. Anderson et al., unpublished). 
1.9 Omics technologies 
Investigations into T. brucei metabolism have benefited from the use of ‘omics’ technologies. 
Modernisation of computer science and experimental techniques have been exploited by many 
areas of science, especially with regards to the deconvolution of large, memory-intensive datasets. 
This has enabled large-scale studies of entire cells, organisms and systems (Berger et al., 2013). 
Through the analysis of biological processes in their entirety, a much more accurate and detailed 
picture of the process or system in question can be obtained, at a higher resolution than previously 
possible. The term ‘omics’, is often used to refer to these types of datasets, and the four classical 
omics technologies are summarised below. 
1.9.1 Genomics, transcriptomics and proteomics 
Analysis of full genomes, is now an integral part of biological research. Since the completion of the 
Human Genome Project, thousands of genomes from a wide range of species have been sequenced, 
improving our understanding of organisms including prokaryotes, eukaryotes and archaea has been 
gained. One of the key parts of genomics analyses is the accurate and detailed annotations of 
genomes, including protein coding genes, regulatory regions, regulator binding sites, UTRs, introns 
and exons and non-coding RNA regions. 
The abundance of mRNA transcripts can provide important insights into differential expression, and 
is often, but not always, correlated with the levels of protein expression (Zhang et al., 2010). Given 
that the transcriptome can vary dynamically in response to external stimuli, it is often a better 
indicator of intracellular dynamics, compared to the relatively static genome (Zhang et al., 2010). 
Historically, transcriptomics analyses were based on understanding differential expression of mRNA 
transcripts, using techniques such as microarrays (Kagnoff & Eckmann, 2001). However, 
transcriptomics data is frequently carried out through sequencing technologies, allowing the 
analysis of both transcript abundance and sequence (Ozsolak et al., 2009). Importantly, RNA-seq 
thereby provides a very detailed overview of splicing variants in organisms that possess introns as 
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well as exons (Trapnell et al., 2013). In the case of T. brucei, this is less important as they only 
possess two known introns (Mair et al., 2000). 
The entire complement of proteins in a cell or system is referred to as the proteome. As mentioned 
above, the transcriptome does not always reflect the proteome. For example, T. brucei RNA 
undergoes significant posttranscriptional regulation. Therefore, not all mRNA is translated to 
protein (Clayton, 2014). The main strategy for proteomics investigations is the use of 2-dimensional 
PAGE (2D-PAGE) or 2-dimensional difference gel electrophoresis (2D-DIGE) (Timms & Cramer, 
2008). These experiments separate proteins according to the isoelectric point as well as mass 
(Timms & Cramer, 2008). Protein identification is generally done by mass spectrometry (Ummanni 
et al., 2011). Whilst the principle of studying proteomics shows significant potential, there are still 
some disadvantages, the main one being that only a small portion of the proteome is usually 
identified (Mirza et al., 2007). In addition, insoluble proteins are often unwittingly removed during 
the generation of a protein lysate (Mirza et al., 2007). Recently, proteomics analyses have been 
aided by several technological developments that allow for quantification of relative protein 
abundances in multiple samples: Examples are stable isotope labelling-based isotope coded affinity 
tags (ICAT) and isobaric tag for relative and absolute quantification (iTRAQ) (Haqqani et al., 2008, 
Yan et al., 2008). 
1.9.2 Metabolomics 
The field of metabolomics aims to investigate the complex interplay of metabolic pathways 
occurring in a biological system, and to understand how external environments and pressures such 
as drug treatment can impact this system (Creek & Barrett, 2014). The metabolome is defined as 
all small molecules (<1,500 Da) in a cell or system (Dunn et al., 2013). This can include a large variety 
of molecules including, but not limited to, peptides, sugars, oligonucleotides, organic acids, 
ketones, amines, amino acids, drugs, xenobiotics, lipids and steroids. 
Historically, the concept of metabolomic studies dates back as far as 2,000 B.C., where evidence 
suggests that Chinese doctors used patient urine to diagnose diabetes (Eknoyan & Nagy, 2005). In 
the 17th century, Santorio Santorio, regarded by many as the founding father of metabolism 
research, published a study on “insensible perspiration of the body” (Eknoyan, 1999). However, 
many early studies were based on investigating individual components of metabolism. It was not 
until the early 20th century, after the assembly of the first mass spectrometer at the University of 
Cambridge, that multiple metabolites could be studied. The first mention of the word 
“metabolome” was a publication by Oliver and colleagues in 1998 (Oliver et al., 1998). Since then, 
rapid modernisation of the technologies required to study the metabolome have allowed 
researchers to study them in their entirety, culminating in the publication of the first draft of the 
human metabolome in 2007 (Wishart et al., 2007). 
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Currently, several methods exist to study the metabolome, primarily involving either mass 
spectrometry (MS) or nuclear magnetic resonance (NMR) spectroscopy (Bringaud et al., 2015). The 
most common NMR platform analyses 1H nuclei within sampled metabolites (termed 1H-NMR) by 
detecting the spin properties of the nuclei (Creek et al., 2012a). Whilst reproducibility of 
experimental data, as well as easy of sample preparation without sample loss, are advantages to 
this technique, it offers poorer resolution compared to mass spectrometry. 
Mass spectrometry involves mass measurements through the ionisation of metabolites and 
subsequent detection of the molecule mass-charge ratios (m/z) (Creek et al., 2012a). Generally, 
mass spectrometers consist of an ion source, a mass analyser and a detector. More modern MS 
systems incorporate an orbitrap analyser to increase resolution, with mass accuracies less than 1 
ppm (Kamleh et al., 2008). To further resolve complex mixtures of cellular metabolites, MS systems 
are generally coupled to liquid- or gas-chromatography (LC & GC respectively) columns which 
further separate metabolites and aid in the reduction of ion suppression. Peaks of similar m/z ratios 
can then be separated by retention time (Misra & van der Hooft, 2016).  
The methodology used for metabolomics studies often depends on the biological questions and 
system under investigation. Neither platform offers 100% coverage (Creek et al., 2012a). There are 
two commonly used approaches to metabolomics experiments. An untargeted approach is 
hypothesis generating, often comparing a biological system under two different conditions, such as 
drug- and vehicle-treated (Creek & Barrett, 2014). In contrast, a targeted approach is aimed at 
investigating a particular pathway, often with the use of stable isotope (e.g. 13C, 15N) labelling of 
particular metabolites in order to investigate pathway interactions and isotope distribution 
throughout a system (Chokkathukalam et al., 2014). Important considerations must also be made 
with regards to data analysis, for which many different pipelines exist (Misra & van der Hooft, 2016). 
1.9.3 Other ‘omics 
Whilst the four main ‘omics’ described above are considered to be the classical omics fields, the 
last few years have seen a rapid increase in the use of ‘–omics’-related terms in the literature. Some 
estimates suggest there are in excess of 100 individual omics fields described (Baker, 2013). 
Whether these new -omes will be taken seriously over time remains to be seen. There lies some 
sense in coining ‘-omics’ terms for subsets of proteins, or as in another example, describing all 
known genome modifications (i.e. epigenomics). However, several novel ‘omics’ describe very 
specific fields of biology, and whether these are valid, stand alone omics areas is debateable. The 
rapid expansion of ‘omics’ research has prompted one evolutionary biologist to say: “it [omics] is a 
language parasite” (Hotz, 2012). To that extent, Eisen also outlined a theory of “badomics”, even 
going so far as to develop approaches to distinguish “badomes” from “goodomes” (Eisen, 2012). In 
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this publication, Eisen argues that, in order for newer omics fields to be recognised and taken 
seriously, they must be a valid effort to further an area of science hitherto scarcely studied, rather 
than revisiting old hypotheses (Eisen, 2012).  
The term ‘Omics’ itself could in theory be applied to any sort of “totality”. As Prof. Barrett mentions 
in an opinion piece for the New Statesman, the total scientific literature could be called a 
“bibliome”, and continuing in a similar vein, a collection of portraits, such as those at the National 
Gallery, is a “National Portraitome” (Barrett, 2015). Expanding further still, if all opinions on a 
particular topic were to be taken into account, would that be an “opiniome” (Watson, 2015)? 
Whilst these interpretations highlight the absurdity of some recently emerging ‘omics’ topics, it is 
also important to realise that perhaps this term reflects the universal aim of modern science, to 
generate large amounts of finely detailed information on a whole cell or organism, and more 
importantly, to integrate these datasets in order to further our understanding of the system in 
question. Whether this ultimate aim is achieved could define the success or failure of the ‘omics’ 
era of biology. In the context of NTDs, systems biology and omics analyses have concentrated on 
genome, transcriptome, proteome and metabolome, with the odd mention of ‘kinome’ (Parsons et 
al., 2005, Jones et al., 2014a). Importantly, all have been utilised with great success, especially in 
the area of drug discovery. 
1.10 Techniques in drug target identification and validation 
As mentioned in section 1.4, drug target deconvolution is crucial for the development of novel 
therapeutics. Discovery of novel therapeutic compounds is typically carried out in several different, 
but complementary, approaches. Structure-based drug design involves the validation of an 
essential protein drug target in a pathogen, and the subsequent development of small molecules 
aimed at that target (Khalaf et al., 2014). This process is cyclical, involving many rounds of 
optimisation of the small molecule structure and observations of its interactions with the protein 
target, often through the use of 3-dimensional X-ray structures (Deschamps, 2005). This approach 
is greatly aided by bioinformatics analyses that can predict drug:protein interactions, as well as 
genome sequencing to identify novel therapeutic targets (Reguera et al., 2014). The latter has been 
achieved for several trypanosomatids (Berriman et al., 2005, El-Sayed et al., 2005a, Ivens et al., 
2005, Jackson et al., 2010), meaning that target-based approaches are now feasible for many NTDs 
(Reguera et al., 2014). The second approach is termed phenotypic screening. This involves making 
observations of phenotypic effects that are induced by compounds, and further optimising 
compounds showing significant selectivity for further structure optimisation. Gene modification in 
the pathogen can be used to validate essential targets. Phenotypic screening is more commonly 
applied in an in vitro setting, as in vivo screens do not offer high throughput (Reguera et al., 2014). 
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Both the aforementioned methods carry advantages and disadvantages. For example, whilst target-
based approaches allow the refinement of the interaction between drug and target, many of the 
compounds often present low selectivity against the pathogen (Reguera et al., 2014). In addition, a 
target-based approach does not take into account the cell membrane the compound must cross to 
get to the pathogen target. Similarly, neither approach can predict further biological barriers, such 
as the blood-brain barrier in late-stage HAT. One of the major disadvantages of phenotypic screens 
is that they do not directly identify the MoA of lead compounds (Lee & Bogyo, 2013). 
To this extent, many techniques are now available to aid in drug target identification and many 
more are currently under development, providing an ever-improving field with many 
complementary techniques to aid in this challenging, but exciting field of biology. The main 
techniques currently available are summarised here. 
1.10.1 Affinity chromatography 
Affinity chromatography remains one of the most widely used techniques for the purposes of drug 
target identification (Lomenick et al., 2011b). The technique involves the immobilisation of the 
active compound to an affinity tag, often through the action of biotin attachment to streptavidin, 
and is carried out in a similar fashion to immunoprecipitation assays (Annis et al., 2007). Subsequent 
to drug immobilisation, a protein isolate pull down is carried out using a lysate from the pathogen 
required. This is followed by several wash steps to remove unbound protein and an elution step 
using excess drug or denaturing agents. The development of mass-spectrometry-based 
chromatography assays has greatly aided in the identification process, which is normally coupled 
to a protein gel assay (Slon-Usakiewicz et al., 2005, Annis et al., 2007).  
There are many examples where affinity chromatography has been utilised successfully for drug 
target deconvolution. One T. brucei study used this technique to identify an interaction between 
the trypanocidal cymelarsan and glycerol 3-phosphate dehydrogenase (Denise et al., 1999). A more 
recent Anacor study on a benzoxaborole, SCYX-5070, described an affinity chromatography 
approach using drug immobilised on sepharose beads to reveal interactions between the 
compound and mitogen-activated protein kinases (MAPKs) as well as cdc2-related kinases (CRKs) 
(Mercer et al., 2011). 
The main, and perhaps obvious, disadvantage of affinity chromatography, given that the drug is 
immobilised prior to the ligand binding step, is that a certain degree of SAR knowledge is required. 
In cases where the wrong functional group is used to bind an affinity tag, the chances of false 
negatives as well as false positives are significantly increased due to either non-specific protein 
binding, or lack of ligand-protein binding due to steric hindrance caused by the immobilisation. 
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Therefore, this method is less effective in drug discovery approaches in cases where no SAR 
knowledge exists (Lomenick et al., 2011a).  
1.10.2 Generation of resistant cell lines 
Another commonly used method for drug target identification is the generation of resistance in a 
lab-adapted pathogen, followed by comparative analyses of the wild-type and resistant lines. 
Resistance can be generated in one of two ways: the first (and more common) method involves 
incubation of the pathogen in vitro with very low dose of the drug or compound. Small increments 
in drug concentrations over time, mimic selection pressure, and resistance is generated in the cell 
line through alterations in the genome or protein expression (Nzila & Mwai, 2010). The second 
method involves induced mutagenesis through the addition of powerful chemical mutagens to in 
vitro cultures. The live cells recovered from this treatment are then subject to the drug or 
compound, and resistant mutants are recovered for downstream analysis (Vincent et al., 2010). 
Several other techniques including RIT-seq and CRISPR (both explained below) have refined this 
approach. 
Mechanisms of resistance in the trypanosomatids (Leishmania spp, T. cruzi and the African 
trypanosomes) can involve reduced drug uptake, increased drug efflux, reduced metabolism in the 
drug activation process, biochemical inactivation of drug, target mutation, target overexpression, 
metabolic compensatory pathways and increased uptake of downstream metabolites, amongst 
others (Horn & Duraisingh, 2014). The advent of omics techniques discussed previously, have 
greatly enhanced the study of resistant cell lines by allowing a detailed overview of both wild-type 
and resistant cell lines on multiple levels (Canuto et al., 2014, Wyllie et al., 2015). To exhibit 
resistant phenotypes, pathogens often undergo point mutations, gene deletions, or significant 
changes in expression of the target protein (Graf et al., 2013, Ranade et al., 2013). In cases where 
these mutations affect protein:drug binding, subsequent analyses often incorporate structural 
biology approaches to determine the underlying mechanisms or resistance, as was done by Rock 
and colleagues to elucidate the MoA of Tavaborole, an anti-fungal benzoxaborole (Rock et al., 
2007). Whilst the main findings of these studies are often more relevant to resistance mechanisms, 
they can lead to the identification of target proteins that are otherwise unknown (Rock et al., 2007). 
One disadvantage of this method of drug target identification is that the mechanism of resistance 
can mask the genuine mode of action of the drug. For example, loss of expression of a specific 
transporter or subsets thereof is often sufficient to generate drug resistance in trypanosomes in 
vitro. Indeed, there are several examples of this phenomenon involving an amino acid transporter 
(TbAAT6) in eflornithine resistance (Vincent et al., 2010), loss of the P2 (TbAT1) transporter in 
diminazene resistance (de Koning et al., 2004, Teka et al., 2011), and both the TbAT1 and the 
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TbAQP2 transporter in pentamidine resistance (Baker et al., 2012, Graf et al., 2013, Munday et al., 
2014). 
1.10.3 RNAi-target sequencing (RIT-seq) 
RIT-seq was developed specifically as a gene knock-down tool for T. brucei (Alsford et al., 2011, 
Alsford et al., 2012). It is based on genome wide knock-down of functional genes using RNA 
interference (RNAi). A genome-wide knock-down is easier to achieve as RNAi targeting does not 
require full coding sequences. Instead, an RNAi plasmid library was generated, containing randomly 
sheared genomic fragments (Alsford et al., 2011).   
This assay has been used successfully to unravel pathways involved in drug action for several drugs 
with previously unknown mechanisms (Alsford et al., 2012). Importantly, with a genome-wide 
approach, multiple genes involved in the drug mode of action can be elucidated. However, one 
caveat of this approach is that it exclusively identifies non-essential genes (Alsford et al., 2011). This 
is due to the fact that knock-down of essential genes will kill the parasite regardless of drug 
treatment, whereas non-essential gene knock-downs that confer drug resistance do survive 
(Alsford et al., 2012). A more desirable approach based on a genome-wide study would be to create 
an overexpression library, as overexpression of target proteins can confer resistance in the 
pathogen (Begolo et al., 2014). Surviving parasites could then be analysed regardless of the 
essentiality of the overexpressed gene. This approach is challenging, however, as plasmids 
containing full open reading frames for each of the >8,000 genes must be generated, compared to 
the RIT-seq approach requiring only gene fragments. 
Another disadvantage associated with this approach is that more than 50% of genes found to be 
essential by knock-down experiment, carry an unknown function (Shateri Najafabadi & Salavati, 
2010). Therefore, in many cases, candidates have to be selected and characterised before their role 
can be elucidated. 
1.10.4 Metabolomics 
As discussed above, metabolomics provides perhaps the most dynamic and accurate observation 
of a cellular system compared to other omics technologies. Metabolites change in abundance in 
response to many external as well as internal stimuli (Creek & Barrett, 2014). Metabolomics is 
ideally suited to investigating the mode of action of novel drugs by allowing the examination of 
these changes. Indeed, in the study of tropical diseases, the MOAs of several drugs have been 
elucidated through the application of this tool (table 1-1). It should be noted, however, that the 
application of metabolomics is well suited to a great variety of organisms for the study of drug 
modes of action (Reviewed in (Keun & Athersuch, 2007, Rabinowitz et al., 2011, Russell et al., 2013) 
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Organism Compound/drug Target identified Reference 
T. brucei Eflornithine Ornithine decarboxylase (Vincent et al., 2012) 
T. brucei Nifurtimox 
Involves nucleotide and oxidative 
stress metabolism 
(Vincent et al., 2012) 
T. brucei 5-fluoro-2'-deoxyuridine Thymidine synthase inhibition (Ali et al., 2013) 
T. brucei 
5-fluoroorotate & 5-
fluorouracil 
RNA modification (Ali et al., 2013) 
T. cruzi Benznidazole Thiol metabolism (Trochine et al., 2014) 
T. cruzi Bestatin Leucine aminopeptidase (Trochine et al., 2015) 
L. infantum Antimony (III) Oxidative stress 
(Canuto et al., 2012, 
Rojo et al., 2015) 
L. donovani Milefosine Polyamine pathway (Canuto et al., 2014) 
P. falciparum Atovaquone & CK-2-68 Dihydroorotate dehydrogenase (Biagini et al., 2012) 
P. falciparum Fosmidomycin 
Methylerythritol phosphate 
cytidyltransferase (IspD) and 
deoxyxylulose phosphate 
(Zhang et al., 2011a) 
P. falciparum 
Eflornithine & 
MDL73811 
Polyamine synthesis 
(van Brummelen et al., 
2009) 
P. falciparum Pyrimethamine Dihydrofolate reductase 
A. Srivastava et al, 
unpublished 
P. falciparum Dihydroartemisinin Haemoglobin catabolism (Cobbold et al., 2015) 
Table 1-1: Example of drug MoA studies using metabolomics. Adapted from Creek & Barrett (2014). 
There are various methodologies employed for metabolomics-based approaches, which are 
outlined in section 1.9.2. Individual experiments can therefore be altered to suit the requirements 
of the investigation. In trypanosome biology in particular, metabolomics was successfully employed 
by Vincent and colleagues to confirm the target of eflornithine, a drug used in combination with 
nifurtimox in the treatment of late-stage T.b. gambiense infection (Vincent et al., 2012) (table 1-1). 
In addition to confirming the preconceived hypotheses of drug treatment, metabolomics analysis 
also led to the discovery of further perturbations occurring in treated cells, that were hitherto 
unknown (Vincent et al., 2012). This highlights one of the main advantages of metabolomics as a 
tool for drug target deconvolution. 
Furthermore, metabolomics-based approaches carry the advantage that mechanisms involving 
both protein targets as well as non-protein targets, such as nucleic acids, can be identified. One 
study investigating treatment of T. brucei in vitro with 5-fluoroorotate and 5-fluorouracil showed 
the presence of fluorinated uracil residues in the treatment groups, confirming the mechanism of 
action of these two compounds (Ali et al., 2013). These phenomena cannot be detected using 
techniques such as the recently developed DARTS and thermal profiling, as discussed below. 
Whilst mass spectrometry data often contains a significant amount of background noise, recent 
work has gone to great lengths to counter this issue with the development of minimal media for 
the culture of T. brucei (Creek et al., 2013). Indeed, similar work is currently underway for in vitro 
culture of L. mexicana as well as T. congolense (M. Barrett, personal communication). Interestingly, 
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by mimicking the extracellular environment more accurately, drug sensitivity was shown to be more 
akin to that reported in vivo (Creek et al., 2013). In addition, it is theorised that a minimal essential 
medium restricts the ability of the parasite to activate many compensatory mechanisms, potentially 
masking drug efficacy. 
1.10.5 Systems biology 
As mentioned previously, systems biology aims to integrate omics data on multiple levels in order 
to produce an in silico overview of a cell or system. These models can be used to predict metabolic 
networks, and in the context of drug discovery, predict pathways that are essential to the system 
in question. Systems biology is mainly used to identify novel drug targets in a target-based drug 
discovery approach. Many methods in drug discovery are limited exclusively to unique proteins and 
pathways in the pathogen, which leads to several disadvantages including limited number of targets 
if the pathogen is similar to the host (e.g. cancer), as well as the disqualification of potentially valid 
targets (Haanstra & Bakker, 2015). 
Genome-wide metabolic models now exist for several organisms, including T. brucei (Achcar et al., 
2014a, Achcar et al., 2014b), and some pathways in this organism that the host also possesses have 
been shown have been predicted to be more essential in the pathogen, when compared to the host 
(Haanstra et al., 2011). In the aforementioned paper, Haanstra and colleagues showed that a 50% 
inhibition of glycolysis was sufficient to kill T. brucei, as this is the sole source of ATP. Whilst the 
host system also possesses the glycolytic pathway, 50% inhibition is not enough to affect host cells 
to the same degree. This validates glycolysis as a potential drug target that would not be identified 
by other approaches, highlighting the role systems biology could play in drug discovery (Haanstra 
et al., 2011). One complication of this approach is the complexity of the mammalian host, where 
differing cell types react in varied ways to signals such as hormones and chemokines. These factors 
must be taken into account to further enhance the model accuracy, but this has proven challenging 
(Haanstra & Bakker, 2015). 
Another method by which computer predictions aid drug discovery, is predicting the effect of 
multiple targets being inhibited by combining drugs (Kandoi et al., 2015). The phenotype-based 
approaches for target identification often utilise gene knock-outs or knock-downs, as previously 
mentioned. Crucially, gene knock-downs are primarily carried out for one gene/protein at a time, 
due to the fact that targeting more genes increases the complexity of the cloning approaches used 
in the lab. In contrast, metabolic models can easily investigate the effect of multiple target 
inhibition in silico (Haanstra et al., 2011). This is important, because whilst one gene might not 
appear to be essential in a pathogen, inhibiting multiple proteins in the same pathway could affect 
the cell to a much greater degree (Haanstra & Bakker, 2015). 
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An important consideration for the use of systems biology in drug discovery is that there is a 
requirement for in depth knowledge concerning the pathogen under investigation. Significantly 
improved predictions are calculated when enzyme kinetics and metabolic networks are understood 
to a very high degree (Haanstra & Bakker, 2015). Metabolism, and glycolysis in particular, in T. 
brucei has received much attention for a long time, and in silico modelling taking into account 
uncertain enzyme kinetics and parameters has allowed a much more accurate depiction of 
glycolytic metabolism in the parasite (Achcar et al., 2012), as well as other important pathways 
(Kerkhoven et al., 2013). These models can then be validated experimentally, which was done in 
both of the aforementioned cases (Achcar et al., 2012, Kerkhoven et al., 2013). 
1.10.6 Drug affinity responsive target stability (DARTS) 
One of the major disadvantages of structure-based approaches in drug discovery is that techniques 
such as affinity chromatography often require immobilisation of the compound under investigation 
(Lomenick et al., 2009). For this reason, there is increasing interest in the development of assays 
that are effective in the absence of drug immobilisation.  
One of these assays was developed by Lomenick and colleagues and is termed Drug Affinity 
Responsive Target Stability (DARTS) (Lomenick et al., 2009). This concept is based on the theory 
that binding of ligands to targets results in a thermodynamic shift, whereby the conformation of 
protein and ligand exhibits higher stability and resistance to proteolytic attack compared to 
unbound conformations (Lomenick et al., 2011b). The DARTS technique has already shown promise 
in multiple publications, either elucidating novel drug targets, or confirming known targets as a 
proof-of-principle (Gao et al., 2015, Kost et al., 2015). In addition, the same assay was used to show 
that α-ketoglutarate inhibits ATP synthase in C. elegans, thereby extending the organism’s lifespan 
(Chin et al., 2014). 
Whilst the assay shows good potential, it still carries numerous disadvantages, the majority of 
which can be linked to the mechanisms of ligand-protein binding. First and foremost, the amount 
of proteinases used must be carefully optimised. Excessive amounts can cause widespread 
proteolysis of proteins including the drug target. In contrast, insufficient amounts can lead to a high 
number of undigested proteins (Lomenick et al., 2011a). In T. brucei, VSGs are by far the most 
abundant proteins in the proteome, and this could lead to bias in the resulting protein gel. 
Furthermore, the T. brucei proteome, under normal conditions, possesses a great variation of 
stabilities, one example of which is fructose bisphosphate aldolase, which exhibits a high level of 
proteolytic resistance (Clayton, 1988). 
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1.10.7 Stable isotope labelling by amino acids in cell culture (SILAC) 
The use of stable isotopes in complex biochemical or protein mixtures, coupled to mass 
spectrometry, have generally allowed for high resolution identification of both proteins and 
metabolites. One method that takes advantage of this technology is termed stable isotope labelling 
by amino acids in cell culture (SILAC), and was first described more than a decade ago (Ong et al., 
2002). 
SILAC was not originally developed for drug discovery specifically. In the case of trypanosomatid 
biology, this method was used to great success to investigate changes in the proteome between 
different life cycle stages of T. brucei (Gunasekera et al., 2012, Urbaniak et al., 2012a). However, 
more recent adaptations of SILAC include the comparative analyses of drug-treated and negative 
control cell cultures in order to dissect the mechanisms of drug action. One recent example of the 
use of SILAC involved studies on a compound called Withaferin A, which is isolated from a medicinal 
plant (Narayan et al., 2015). Another SILAC-based method was pioneered by researchers at the 
Board Institute (Ong et al., 2009). In this case, SILAC was combined with affinity enrichment, where 
lysates were pulled down over beads containing small molecule drugs. Quantitative proteomics was 
then used to probe for drug target enrichment (Ong et al., 2009). As a proof of concept, drug targets 
of numerous kinase inhibitors and immunoliphin binders were investigated, with a high success 
rate. Indeed, in addition to previously known targets, several new drug targets were also identified 
(Ong et al., 2009). 
1.10.8 The cellular thermal shift assay and thermal profiling 
The cellular thermal shift assay (CETSA) was developed by Jafari and colleagues as a method to 
investigate drug-ligand interaction without requiring immobilised drugs (Martinez Molina et al., 
2013, Jafari et al., 2014). In a similar approach to the DARTS method outlined above, CETSA is based 
on the principle of increased thermodynamic stability during drug-ligand interactions (Jafari et al., 
2014). However, whilst the DARTS assay uses a proteolysis approach, the CETSA method relies of 
protein aggregation at high temperatures. Protein aggregation causes the molecules to become 
insoluble, and they are removed from the proteome during the experiment. By generating a melting 
curves of proteins of interest either in the presence or absence of drug, the group observed 
increased melting temperatures for proteins interacting with a drug (Jafari et al., 2014). As proof-
of-principle, the group investigated melting curves for the targets of methotrexate and raltitrexed, 
which are dihydrofolate reductase and thymidylate synthase inhibitors, respectively (Martinez 
Molina et al., 2013). Protein lysates were heated at varying temperatures and the proteins of 
interest were subsequently probed by western blot. The band intensities were quantified relative 
to the lowest temperature of the experiment, in order to generate a melting curve for each protein 
of interest. 
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Building on this approach to drug target identification, a collaborative group of researchers based 
at GSK in Germany and the Karolinska Institutet in Sweden, developed a high-throughput method 
based on CETSA, in order to visualise the entire proteome (Savitski et al., 2014). For this experiment, 
entire protein lysates, rather one protein of interest, were assayed by mass spectrometry. Samples 
in the presence or absence of a drug were incubated at 10 different temperatures and labelled 
using TMT10 isotope tags. Relative protein quantification could then be carried out with just 2 mass 
spectrometry runs (Savitski et al., 2014). This process was, as shown by several studies, carried out 
with great success. In addition to altered thermodynamic stability of target proteins, the 
experiments were also able to identify off-targets in the lysates (Savitski et al., 2014). However, one 
significant criticism of this study was the lack of replicates and it is likely that this expensive assay 
would require lengthy optimisation for new systems such as protozoan pathogens. 
The authors discussed several other areas where improvement is required. Most importantly, the 
assay has only been used on soluble protein isolates. This disregards proteins such as 
transmembrane proteins that might be targeted. Transporters form an important subset of these 
proteins, and the assay requires significant improvement to enable incorporation of this subset of 
proteins for investigation. In addition, and much like the DARTS assay, only compounds that target 
one or multiple proteins can be studied, whereas the assay is rendered useless for those that target, 
for example, nucleic acids (Savitski et al., 2014). 
1.10.9 CRISPR – the new kid on the block 
The RNA guided nuclease CRISPR-Cas9 was recently shown to be a very useful tool for gene editing 
and its use in genetic manipulation of a wide variety of host organisms has been highly publicised 
(Cong et al., 2013, Mali et al., 2013), with 661 publications on this topic in 2015 alone. The system 
involves the bacterial clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 
nuclease, which is part of the prokaryote adaptive immune response (Moore, 2015). This nuclease 
can be targeted using a guide RNA with very high specificity to edit genes in other cell types such 
as mammalian cells, or protozoans (Sollelis et al., 2015). 
The CRISP-Cas9 system shows great promise as a phenotypic screening method to validate new 
therapeutic targets, especially on a whole genome, high-throughput scale (Koike-Yusa et al., 2014). 
Indeed, the advantages of this system compared to, for example, the RIT-seq approach are evident 
as it allows the genome-wide targeting of both essential and non-essential genes (Moore, 2015). It 
remains to be seen whether CRISP-Cas9 causes a similar revolution in the study of trypanosomatids, 
although the early indications are very positive (Lander et al., 2015, Peng et al., 2015, Sollelis et al., 
2015, Zhang & Matlashewski, 2015). 
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1.10.10 Summary of drug target identification 
Taken together, it is clear new techniques have recently emerged that can be applied to drug 
discovery, both in target- and structure-based approaches. Whilst the techniques discussed above 
are perhaps most applicable to the study of the trypanosomatid drugs, the list is by no means finite 
and other published methods used in drug target deconvolution studies include the yeast three-
hybrid system (Rezwan & Auerbach, 2012), mammalian three-hybrid system (Caligiuri et al., 2006), 
phage display (Omidfar & Daneshpour, 2015), mRNA display (Josephson et al., 2014), protein 
microarrays (Schax et al., 2014), biochemical fractionation/suppression (Peterson et al., 2006), 
genome-wide association studies (GWAS) (Grover et al., 2014), drug-induced haploinsufficient 
profiling (HIP) (Giaever et al., 1999), kinobeads (Kim & Sim, 2010) and further chemoproteomics 
systems aside from affinity chromatography (Urbaniak et al., 2012b). With this newfound wealth of 
complementary techniques, the future of drug target and mode of action elucidation looks positive. 
However, for NTD research, it is of utmost importance that some of these techniques are adapted 
to relevant organisms. This will have the knock-on effect of generating new therapeutic targets and 
mechanistic understandings, which will significantly aid in the fight again these debilitating 
diseases.  
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1.11 Aims & Objectives for this project 
With the advent of omics technologies coupled to more classical molecular biology approaches, 
there is a great opportunity to gain detailed insights into the biology of the African trypanosome, 
in a hypothesis generating manner. This opportunity coincides with the emergence of several new 
therapeutic leads in fexinidazole and the benzoxaborole AN5568. Both of these have so far shown 
little to no adverse effects in mammalian cells, show good clearance in murine models for both 
human-infective T. brucei subspecies, and importantly, are orally bioavailable (Torreele et al., 2010, 
Jacobs et al., 2011). Whilst the mode of action of fexinidazole has been reported in terms of its 
metabolism and effect on the trypanosome (Jennings & Urquhart, 1983, Kaiser et al., 2011), no 
MoA has been described for AN5568. This knowledge is crucial, as it could aid in understanding the 
SAR of the drug, which in turn could lead to improved small molecule inhibitors that bind the target 
with higher potency and minimise resistance. 
Similarly, given the occurrence of LOH in the field, its discovery in a laboratory environment 
presents a great opportunity to develop an understanding of the mechanisms involved in the 
metabolic alterations leading to increased growth rates in cell lines exhibiting LOH. This 
understanding could lead to new hypothesis about the generation and evolution of genetic diversity 
in the African trypanosomes. Metabolomics analysis tools provide enhanced methods that could 
aid in the understanding of these mechanisms. 
With the above in mind, the main aims of this study were as follows: 
1. To elucidate the MoA of AN5568 using a combination of omics and molecular biology 
approaches. 
 
2. To generate and characterise an AN5568-resistant cell line with a view to complementing 
the first aim, as well as develop an understanding of the mechanisms that could lead to 
benzoxaborole resistance. 
 
3. To investigate the changes in metabolism underlying differential growth in trypanosomes 
possessing LOH on chromosome 10. 
4.  
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Chapter 2. Methods 
2.1 Trypanosome tissue culture 
2.1.1 Bloodstream form culture 
Bloodstream form (BSF) culture was carried out using the 427 Lister strain, a monomorphic strain 
of T.b. brucei well adapted to in vitro conditions. Lister 427 express VSG221 with a relatively low 
switch rate (between 10-6–10-7 switches per generation) (Lamont et al., 1986). For RNAi 
experiments, the 2T1 cell line, derived from Lister 427, was used (Alsford et al., 2011). 
Cells were cultured at a density between 2 × 104 cells/mL and 2 × 106 cells/mL, and incubated at 
37°C in a humidified incubator with 5% CO2. Densities were routinely assessed using a 2-cell 
counting chamber (Hawksley). To maintain stable cultures, cell lines were typically discarded after 
a maximum of 30 passages, and substituted for a new isolate from the same stabilate batch. Cells 
were passaged, on average, every two days and maximum three. This approach limits a build-up of 
genetic abnormalities that can occur as a result of in vitro culture. 
BSF parasites were cultured in HMI-9, a medium supplied in powder form (Gibco). The media was 
supplemented with 10% foetal bovine serum (FBS). For targeted metabolomics experiments, 
Creek’s Minimal Media (CMM) was used. This medium is based on HMI-9, but contains fewer 
components, without reducing cellular growth. CMM thereby reduces background noise in 
experiments such as mass spectrometry (Creek et al., 2013). In addition, this medium allows for the 
addition of isotope-labeled components in place of their standard counterparts. CMM was 
supplemented with gold standard FBS (10%) (PAA). 
2.1.2 Procyclic form culture 
The procyclic form (PCF) trypanosomes used in this study were either Lister 427 (also identified as 
29-13), or Trypanosomiasis Research Edinburgh University (TREU) 927, the strain used for the 
reference genome of T. brucei (Berriman et al., 2005). PCFs were typically cultured in SDM-79, 
supplemented with 10% FBS and 7.5 µg/mL hemin. In some cases, a more defined medium, SDM-
80 was used (Appendix B). SDM-80 allows more control over the concentrations of proline and 
glucose, the main carbon sources used by the parasite, added to media. PCF cell density was kept 
between 5 × 105 cells/mL and 1 × 107 cells/mL and grown at 27°C. PCFs do not require artificial 
levels of CO2 or humidified incubators. 
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2.1.3 Differentiation of bloodstream forms to procyclic forms 
In some experiments, attempts were made to differentiate BSF cells into PCF cells in vitro. In these 
experiments, cells were cultured in differentiating trypanosome medium (DTM) containing 3 mM 
cis-aconitate (Overath et al., 1986) (Appendix A). These cells were incubated at 27°C, under 
conditions similar to PCF trypanosomes. Cell lines that survived subsequent passages were kept in 
DTM lacking cis-aconitate. 
2.1.4 Stabilate preparation and retrieval 
Where novel cell lines were made, these were subsequently stabilated in order to maintain a cell 
line library. Cell cultures in mid-log phase of growth were diluted in a 1:1 ratio with medium 
containing 20% glycerol, resulting in a cell culture aliquot of 10% glycerol. Up to ten 1 mL aliquots 
were then made in 2 mL cryovials (Alpha Laboratories, UK). These were kept in wool at -80°C for 24 
hours to slowly freeze the cells, and subsequently they were transferred to liquid nitrogen for long-
term storage. In order to revive stabilated cell lines, 1 mL cell aliquots were quickly thawed and 
transferred to 9 mL culture medium warmed to the required temperatures. Drugs and selective 
antibiotics were added after the first passage. 
2.1.5 Alamar blue assay 
To obtain in vitro EC50 values for specific compounds targeting T. brucei, the alamar blue assay was 
applied (adapted from(Raz et al., 1997)). This colorimetric assay was carried out in solid white flat-
bottomed 96-well plates. Compounds were added starting with the highest concentration (typically 
100 µM) and serially diluted over either 23, or 11 wells, leaving one negative control. Subsequently, 
100 µL cells at a density of 4 × 104 cells/mL was added to each well, resulting in a final density of 
2 × 104 cells/mL. Bloodstream form parasites were incubated for 48 hours at 37°C, 5% CO2. 
Subsequently, 20 µL of alamar blue reagent (resazurin sodium salt, 0.49 mM  in 1× PBS, pH 7.4) was 
added to each well, and the plate incubated for another 24 hours. When carried out on slower 
growing PCF parasites, plates were incubated for 72 hours prior to addition of alamar blue reagent, 
and then incubated for another 48 hours. 
Reduction of the alamar blue reagent was measured as a function of cell viability on a BMG 
FLUOstar OPTIMA microplate reader (BMG Labtech GmbH, Germany) with λexcitation = 544 nm and 
λemission = 590 nm. The raw values were plotted against the log value of each concentration of drug 
or compound, and EC50 values were calculated using a non-linear sigmoidal dose-response curve. 
Each assay was performed in duplicate, and the final EC50 values presented represent a mean of 
three or four independent experiments. 
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2.1.6 Isobologram assay 
To investigate drug-drug interactions, isobolograms were carried out using a fixed-ratio protocol 
previously described (Fivelman et al., 2004). This assay uses the same principles as an alamar blue 
assay to test for cell viability over a range of drug concentrations but test two drugs simultaneously. 
For both drugs, the top concentrations used were chosen for the EC50 to fall near the midpoint of a 
12-part two-fold dilution series. We typically started with 16× EC50 and concentrations are indicated 
where applicable. Once drug stocks were prepared in parasite medium, fixed ratio solutions of 
drugs were made as follows: 10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, 0:10. These stocks were 
then added to the first column of 3 solid white flat-bottomed 96-well plates in duplicate. The 
compounds were then serially diluted with the final well of each row left blank as a negative control. 
Finally, cells were added at a final concentration of 2 × 104 cells/mL. Plates were then incubated for 
48 hours and alamar blue reagent added as described above. The plates were read after another 
24 hour incubation on a BMG FLUOstar OPTIMA microplate reader (BMG Labtech GmbH, Germany) 
with λexcitation = 544 nm and λemission = 590 nm. 
For each fixed ratio, one EC50 value was generated for each drug. These values were then used to 
obtain fractional inhibitory concentration (FICs) indices, which are defined as the EC50 values of drug 
in combination, divided by the EC50 values of those drugs acting alone (Hall et al., 1983). The 
isobologram was then made by plotting the FICs of one drug against the other. An overall mean 
ΣFIC was calculated for each combination by adding the values of each individual FIC of either drug 
and taking an average. Interactions were then defined as described by Seifert and colleagues 
(Seifert et al., 2011): 
• ΣFIC ≤ 0.5 = synergy 
• ΣFIC between > 0.5 and ≤ 4 = indifference 
• ΣFIC >4 = antagonism 
2.1.7 Transfection of trypanosomes 
To transfect trypanosomes with genetic constructs in vitro, a previously described method was used 
(Schumann Burkard et al., 2011). Up to 4 × 107 cells in mid-log growth were centrifuged at 1,500 × 
g for 10 minutes, and resuspended in 100 µL transfection buffer (Appendix D) (Schumann Burkard 
et al., 2011). Cells were then transferred to a transfection cuvette along with 10 µL H2O, containing 
10 µg linearised plasmid DNA. Cells were electroporated using an Amaxa Nucleofector II (Lonza), 
set to the programme X-001. After electroporation, cells were transferred by Pasteur pipette to 30 
mL warm HMI-9. After a 10 minute incubation at 37°C, 5% CO2, cells were cloned by dilution in 24-
well plates at 1:20 and 1:40 dilutions, and left at 37°C, 5% CO2. Selective antibiotics were added at 
the required concentration after 24 hours. Successfully transfected cells were harvested after 7 
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days. When <30% of wells contained cells, these were assumed to be clonal. If not, another round 
of cloning by dilution was carried out. For each transfection, two different clones were used in 
downstream experiments, unless mentioned otherwise. All resulting cell lines were given 
nomenclature in accordance with classifications suggested by Clayton and colleagues (Clayton et 
al., 1998). 
2.1.8 Generation and selection of AN5568-resistant T. brucei 
To generate in vitro resistance to the benzoxaborole AN5568, the 427 Lister cell line was used in 
HMI-9. First, RNA was extracted from the parental line, to store for downstream analyses. 
Resistance generation was initiated by growing cells in 170 nM of the compound. Once a cell line 
was established in this concentration, cells were then transferred to 6 wells of a 24-well plate at a 
density of 1 × 105 cells/mL. Six incrementing concentrations of AN5568 were then added, to obtain 
six 2 mL cultures. Typically, increments of 0.2 µM were used, and cells were incubated at 37°C and 
5% CO2. Cells were routinely observed under a microscope and after 2 weeks, live cells in the highest 
concentration of AN5568 were taken and cultured for 2 passages in the same concentration of the 
benzoxaborole, before transfer to 6 wells in a 24-well plate, from which point the process was 
repeated using the new AN5568 concentration as the lowest. A wild-type cell line was grown in the 
absence of drug as a “highly-passaged” control, in order to detect transcriptome changes related 
to in vitro culture adaptation. Once sufficient resistance was deemed to have been generated, cells 
were cloned by dilution and 4 isolates were recovered. Drug resistance was measured by alamar 
blue.  
2.2 Isolation of biological components from trypanosomes 
2.2.1 DNA Extraction 
Genomic DNA extractions from trypanosomes were carried out to use in PCR reactions, to genotype 
and to verify construct integration. Between 1 × 107 and 2 × 107 cells were centrifuged at 1,500 × g 
for 10 minutes and DNA was extracted from pellets using a commercially available kit (Nucleospin® 
Tissue, Macherey-Nagel GmbH), according to the manufacturer’s instructions.  
For experiments that required highly purified and concentrated DNA, an ethanol precipitation was 
carried out on DNA samples purified using the aforementioned approach. Firstly, 1/10× volume of 
3 M sodium acetate (pH 5.2) was added, followed by 2.5× volumes 100% ethanol. After a brief 
vortex, this mixture was left at room temperature for at least one hour. Subsequently, the sample 
was centrifuged for 10 minutes at 16,060 × g, 4ºC. Supernatant was removed and the DNA pellet 
was washed with 70% ethanol before centrifugation for another 2 minutes under the 
aforementioned conditions. After removal of the supernatant, the DNA pellet was left to dry in a 
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laminar flow hood. The desired volume of filter-sterilised ddH2O was then added to resuspend the 
DNA. Concentration was confirmed using a NanoDrop (Thermo Scientific). 
2.2.2 RNA extraction 
For RNA extractions, between 4 × 107 and 5 × 107 cells were centrifuged for 10 minutes at 
1,500 × g. After removal of the supernatant, cells were resuspended in remaining medium, 
transferred to a 1.5 mL eppendorf tube and spun again for 5 minutes. Cell pellets were then 
resuspended in 1 mL TRIzol® (Life Technologies, Thermo Fischer Scientific). Samples were stored at 
-80ºC until extractions were carried out according to the kit instructions. Briefly, 200 µL chloroform 
was added, before tubes were vigorously shaken and centrifuged to separate the aqueous phase 
containing RNA. This RNA was further purified, treated with DNase, and extracted into RNase-free 
H2O using a commercially available kit (Nucleospin® RNA, Macherey-Nagel GmbH). RNA 
concentration was assessed with a NanoDrop (Thermo Scientific). 
2.2.3 Protein extraction 
Proteome isolation from trypanosomes was carried out in differing buffers, dependent on the 
downstream applications. Typically, 1 × 108 cells in mid-log phase were centrifuged for 10 minutes 
at 1,500 × g, 4ºC. Supernatant was removed and cells transferred to an eppendorf tubes before 
they were washed twice with ice-cold 1× phosphate buffered saline (PBS) (Appendix D). After 
removing the supernatant, cell lysates were resuspended in protein extraction lysis buffer 
(Appendix D), and left on ice for 30 minutes with intermittent vortexing. If required, samples were 
broken up by sonication. Otherwise, the protein concentration was measured using a Bradford 
assay (Bio-Rad Laboratories Inc), according to the kit instructions. 
Fractionation of the proteome was achieved using a hypotonic lysis buffer (Appendix D). Cells were 
resuspended in this buffer after the PBS wash, and incubated on ice for 5 minutes, prior to 
centrifugation at 20,000 × g for 10 minutes. The soluble fraction was removed and stored at -20ºC. 
The pellet was then resuspended in more hypotonic lysis buffer and spun down again to obtain the 
wash fraction. Finally, the remaining pellet, containing the membrane fraction, was resuspended in 
ice-cold protein extraction lysis buffer. All samples were stored at -20ºC. 
For 2D DIGE experiments, cell lysates were washed and resuspended in DIGE lysis buffer (Appendix 
D) supplemented with a cOmpleteTM ULTRA protease inhibitor cocktail (Roche, Switzerland). These 
samples were then sonicated in three 1-second cycles followed by incubations on ice to avoid 
overheating of the sample. After a 10-minute incubation at room temperature, samples were 
centrifuged for 10 minutes at 13,000 × g and supernatant was transferred to a fresh eppendorf 
tube. 
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To hyperconcentrate and clean the protein lysates for 2D DIGE, an acetone precipitation was 
performed. Four volumes of ice-cold 100% acetone were added to the protein samples, which were 
then incubated at -20ºC overnight to allow protein to precipitate. Samples were centrifuged at 
13,000 × g for 10 minutes at 4ºC. The supernatant was removed and pellets were washed with 80% 
ice-cold acetone before being centrifuged again under the same conditions. This washing step was 
repeated twice to remove contaminants. After the supernatant was removed for the final time, 
pellets were left to air-dry in a laminar flow hood. Finally, the pellets were resuspended in the 
desired volume of DIGE lysis buffer and protein content was evaluated using a Bradford assay (Bio-
Rad Laboratories Inc.), according to the manufacturer’s instructions. 
2.3 Electrophoresis 
2.3.1 DNA gel electrophoresis 
DNA gel electrophoresis was typically performed on 1% UltraPureTM agarose gels (Life Technologies) 
that were made with 1× TAE (Appendix D) containing a 1:10,000 dilution of SYBRsafe (Invitrogen, 
Life Technologies). Gels were run in tanks filled with 1× TAE at 110 V. In the first and last lanes, a 
commercial 1 kb or 100 bp DNA ladder was added (Promega). Gels were visualised by fluorescence, 
using a BioDoc-It® imaging system (UVP). 
2.3.2 Protein gel electrophoresis 
Protein samples were mixed in a 1:4 ratio with SDS loading buffer (Appendix D) and then boiled at 
100ºC for 10 minutes. 20 µL of each sample was then loaded onto a NuPAGE® Novex® 4-12% Bis-
Tris protein gel (Life Technologies), set up in an Xcell SureLock® Mini tank system with 1× SDS 
running buffer (Appendix D). The outer lanes of the gel contained dual colour protein standard 
ladders (Bio-Rad Laboratories Inc.). Electrophoresis was run at 200 V for approximately 40 minutes. 
This allowed an expected current of 110–125 mA. Subsequent to electrophoresis, gels were either 
used for Western blots (section 2.9), or proteins were visualised by Coomassie. 
For Coomassie staining, gels were incubated at room temperature on a shaker in Coomassie 
staining solution (Appendix D) for at least 4 hours, or overnight. The gel was then destained in 
destaining solution (Appendix D), which was replaced every 30 minutes for 2-3 hours. Gels were 
visualised using a myECLTM Imager system (Thermo Fischer Scientific). 
2.3.3 Two-dimensional difference gel electrophoresis (2D DIGE) 
For the 2D DIGE experiment, protein lysates were prepared using the aforementioned protocols 
(section 2.2.3). This experiment was carried out with a control sample and a treatment sample. The 
protein concentration of each sample was measured using a Bradford assay (Bio-Rad Laboratories 
Inc), and adjusted to 5 mg/mL. For each sample, a 10 µL aliquot was prepared (50 µg). The pH was 
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checked using pH strips (Macherey-Nagel GmbH), and if pH was judged to be between 8 and 9, 
either CyDye Fluor Cy5 or CyDye Fluor Cy3 (both GE Healthcare) were added to each aliquot at a 
final concentration of 400 pmol. Sample and dye were mixed by pipetting and incubated in the dark, 
on ice, for 30 minutes, before the reaction was stopped by addition of 1 µL 10 mM lysine. The 
aliquots were then combined together and diluted with rehydration buffer (Appendix D). This 
sample, containing both control and treatment lysates bound to different fluorescent markers, was 
pipetted onto an immobilised pH gradient (IPG) gel (Bio-Rad Laboratories Inc.). Once rehydration 
of the strip was complete, isoelectric focusing was set up with an IPGphor isoelectric focusing 
system (GE Healthcare) and run overnight (Cycling conditions: Appendix F). Upon IEF completion, 
the strip was equilibrated with strip equilibration buffer, and washed twice, before laying on top of 
an SDS-page gel (Appendix D) which was run at 1 W overnight. Spots were analysed by fluorescence 
using a Typhoon 9410 Variable Mode Imager (GE Healthcare). If gel extraction was required, 
another gel was run using pooled samples of 250 µg of each sample. This gel was run alongside the 
gel containing CyDyes, but stained with colloidal Coomassie (Appendix D) upon completion of gel 
electrophoresis, spots of interest were first found using DeCyder 2-D Differential Analysis Software 
(GE Healthcare), and then excised under sterile conditions. Excised parts were placed in wells of a 
sterile 96 well plate. Isolation of protein samples from gel as well as mass spectrometry, was carried 
out by Richard Burchmore at Glasgow Polyomics. 
2.4 Molecular biology  
2.4.1 PCR 
Polymerase chain reaction set up was dependent on the application. For the amplification of genes 
for the generation of expression or knock-down constructs, a high-fidelity proofreading polymerase 
(New England Biolabs Ltd) was used in 50 µL reactions. The cycling conditions for HF polymerase 
PCRs are shown in Appendix F. For routine PCR assays throughout molecular cloning experiments, 
such as colony screens and construct integration confirmations, GoTaq polymerase (Promega) was 
used in 20 µL reactions using cycling conditions in Appendix F. Primers are listed in Appendix E. 
2.4.2 Genotyping 
Genotyping was routinely carried out on chromosome 10 of the TREU 927 PCF lines and its LOH 
derivatives. This was done to confirm cultures were labelled correctly and no further genetic 
changes had occurred. Two genotyping primer-sets, 3778 and CRAM, were used for this. The PCR 
conditions are summarised in Appendix F. Each PCR reaction contained the following: 45 mM Tris-
HCl (pH 8.0), 11 mM (NH4)2SO4, 4.5 mM MgCl2, 6.7 mM 2-mercaptoethanol, 4.4 µM EDTA, 
113 µg/mL BSA, 1 mM dATP, 1 mM dGTP, 1 mM dTTP, 1 mM dCTP (Custom PCR MasterMix), 1 µM 
of each primer (Appendix E), 0.5 units Taq DNA polymerase and 1 µL DNA template at a 
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concentration of 2 ng/µL. The 3778 and CRAM PCR products were run on 3% and 1% agarose gels 
respectively and gels were visualised by fluorescence, using a BioDoc-It® imaging system (UVP).  
2.4.3 Plasmids 
The various plasmids used in this study are outlined in Appendix E. In all cases the gene of interest 
was amplified by PCR, before adding A-overhangs and ligation into the intermediate vector pGEM-
T easy (Promega). Insertion of fragments into this plasmid disrupts a LacZ gene, allowing for blue-
white screening of bacterial colonies. Plasmids were transformed under standard conditions and 
plated onto LB agar plates containing 150 µg/mL ampicillin. Colony screens were carried out by PCR 
and single positive colonies were grown overnight at 37ºC in LB broth supplemented with 
100 µg/mL ampicillin. Extraction of plasmid DNA from overnight cultures was carried out using a 
commercial kit, without protocol modification (Nucleospin® Plasmid, Macherey-Nagel, GmbH). 
Purified plasmid was eluted with 50 µL elution buffer.  
To ligate the PCR products into their final plasmid, they were extracted from pGEM-T easy through 
a restriction digest followed by an agarose gel extraction. Final vectors were treated with Antarctic 
phosphatase (New England BioLabs) for 1 hour at 37ºC, to avoid self-ligation. PCR products were 
then ligated into the corresponding vector using T4 DNA ligase (Promega). 
2.4.4 RNA interference constructs 
RNA interference was carried out using published methods developed by Alsford et al (Alsford et 
al., 2011). The system is based on the pHellsgate4 plasmid, and is termed pGL2084 (Helliwell et al., 
2002). It contains two sets of opposing AttP1 and AttP2 recombination sites flanking counter-
selectable markers. A single PCR product with flanking AttB1/2 sites was recombined in opposing 
directions into pGL2084, to generate a stem loop RNAi construct. Successful integration of PCR-
products into the vector remove counter-selectable markers, allowing the vector to be amplified in 
DH5α E. coli cultures. Confirmation of successful integration was determined through restriction 
digests, and the vector was linearised using AscI. Finally, linearised DNA was concentrated with an 
ethanol precipitation and resuspension in sterile distilled H2O (500 ng/µL). 
RNAi constructs in pGL2084 were transfected into the 2T1 cell line (Alsford et al., 2011). Under 
normal conditions, this cell line contains puromycin and phleomycin resistant cassettes, and is 
grown in 0.2 µg/mL and 0.5 µg/mL of these antibiotics respectively. Upon successful transfection 
and integration of the RNAi construct, puromycin resistance is removed, and cells become 
hygromycin resistant (2.5 µg/mL), and puromycin sensitive, whilst maintaining phleomycin 
resistance. RNAi-mediated knockdown was induced by the addition of 1 µg/mL tetracycline from a 
1 mg/mL stock. During induction experiments, tetracycline was added to cultures every 24 hours.  
 
 
53 
To confirm successful gene knock-downs, RNA was extracted from cells in the presence or absence 
of tetracycline over a period of 5 days. RNA was reverse-transcribed and qPCRs were carried out 
using the cDNA as described in section 2.5. 
2.4.5 Overexpression & re-expression constructs 
Two plasmids were used to overexpress T. brucei proteins. The primary plasmid utilised in this study 
was pURAN, a ribosomal array-targeting plasmid. This vector was a gift from the Stephen Hajduk 
group in Georgia, USA. The vector contained one EcoRI restriction site into which genes of interest 
were cloned with T4 DNA ligase. Colonies containing the pURAN::GOI construct were screened by 
PCR using one gene-specific and one construct-specific primer. The plasmid was linearised with 
BstXI or AvaI before transfection into T. brucei. Successful transfectants were screened using a G418 
selectable marker at a concentration of 2.5 µg/mL. Integration of the construct was then assessed 
by PCR using one gene-specific primer and one rRNA-targeting primer. Increases in GOI transcript 
abundance was assessed by qPCR. 
In some cases, pURAN-mediated overexpression was detrimental to T. brucei cells, as judged by 
inability to grow. In these cases, the pRM482 plasmid was used (Trenaman et al., 2013). This 
construct is targeted to the tubulin array of the T. brucei genome. Promoters here lead to 
constitutive expression of genes encoded in the construct, but to a much lesser degree than that 
ribosomal locus integration. 
2.5 Real-time qPCR 
2.5.1 Reverse transcription 
To confirm successful knock-down, over-expression or re-expression of genetic constructs 
transfected into T. brucei cells, real-time quantitative PCR (qPCR) was used. This process involves 
reverse transcription of total cellular RNA to cDNA, followed by qPCR analysis of genes of interest 
alongside an endogenous control. 
All experiments involving RNA were carried out in RNase-free conditions, using certified RNase-free 
or DEPC-treated H2O as well as RNase-free components (Appendix D). RNA was extracted from cells 
as described in section 2.2.2. Reverse transcription was initiated by adding 250 ng random primers 
(Invitrogen), 1 µL of 10 mM dNTPs (Roche) and H2O to 1 µg RNA in a 14 µL reaction in a PCR tube. 
This mixture was heated to 65ºC for 5 minutes to allow denaturing of RNA and binding of random 
primers, and was then incubated on ice for 1 minute. For the reverse transcription, a commercial 
kit, Superscript III®, was used (Invitrogen). The RT reaction was supplemented with 4 µL first strand 
buffer, 1 µL 0.1 M DTT and 1 µL Superscript III®. A negative control lacking the reverse transcriptase 
was also set up for each sample. All reactions were then incubated at room temperature for 5 
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minutes before a 60 minute incubation at 50ºC. The reaction was subsequently inactivated by 
heating it to 70ºC for 15 minutes. Finally, template RNA was removed by the addition of 2U E. coli 
RNase H (Life Technologies) and incubation at 37ºC for 20 minutes. Samples were stored at -20ºC 
and cDNA prepared in this way was used directly in qPCR reactions. 
2.5.2 Primers and primer efficiency 
To guarantee accurate data interpretation, each newly acquired primer-set for qPCRs was assessed 
for their efficiency. Primers were designed using the Primer Express software, version 3.0 (Life 
Technologies, USA), and were supplied by Eurofins Genomics (Germany). All qPCR primers used in 
this study are described in table E-2 (Appendix E). Wild-type T. brucei Lister 427 DNA was used as 
template for primer efficiency analysis. 
Primers were diluted to 3 µM stock, and 25 µL reactions were set up on 96-well MicroAmp® optical 
96-well qPCR reaction plates (Applied Biosystems) with 12.5 µL SYBR® Green master-mix (Life 
Technologies), 2.5 µL of each primer, 6.5 µL H2O and 1 µL template DNA. For each primer set, 8 
reactions were set up in triplicates with the following amounts template DNA (from 2 ng/µL stock): 
2 ng, 1 ng, 500 pg, 250 pg, 125 pg, 62.5 pg, 31.25 pg and negative control. The qPCR was run using 
an Applied Biosystems 7500 RT PCR system with cycling conditions described in (Appendix F). 
Results were downloaded in .csv files containing the Ct values for each reaction well. These Ct 
values were then plotted against Log10 of the corresponding DNA concentration in order to obtain 
an efficiency slope. The following equations were then used to calculate the primer efficiency: 
 
 
 
The theoretical maximum of 100%, using the aforementioned calculations, would indicate doubling 
of the amount of product with each cycle, during the logarithmic phase of the reaction (Bustin et 
al., 2009). However, it is not uncommon for primer efficiency to be higher than 100% (Bustin et al., 
2009). Using these calculations, primer sets were judged to be accurate if efficiency was >90%. 
Otherwise they were discarded and new sets designed.  
2.5.3 Real-time PCR 
Real-time PCRs were set up in triplicate with the following reaction in each well: 12.5 µL SYBR® 
Green Master Mix (Life Technologies), 2.5 µL forward primer, 2.5 µL reverse primer, 5 µL RNase-
free H2O and 2.5 µL cDNA. RT-PCR was carried out using an Applied Biosystems 7500 RT PCR system 
with cycling conditions described in (Appendix F). 
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2.6 Metabolomics 
2.6.1 Metabolite extraction from T. brucei cultures for LC-MS 
Samples for metabolomics analysis were acquired by rapidly quenching 8 × 107 cells in log phase in 
a dry-ice/ethanol bath, to ~4°C. For each sample group, four replicates were grown independently. 
In experiments involving stable isotope labelling, three replicates were used and isotope-labeled 
compounds (13C-(U)-L-methionine, enrichment 99%, Cambridge Isotope Laboratory Inc., cat: CLM-
893-H-0.1) were added at the moment the time course was initiated. After quenching, samples 
were centrifuged for 10 minutes at 1,500 × g, 4°C, and all experimental steps hereafter were done 
on ice to keep the samples cold. Subsequently, 5 µL supernatant was transferred to an eppendorf 
containing 200 µL extraction solvent (Appendix D), and the rest removed. Cells were resuspended 
in the remaining supernatant and transferred to an eppendorf so that they could be centrifuged at 
1,500 × g for another 5 minutes. Remaining supernatant was carefully removed, and the cells 
resuspended in 200 µL extraction solvent. All samples, including a blank and fresh medium control, 
were then left in a shaker at 4°C for one hour. Subsequently, samples were spun down at 16,060 × 
g for 10 minutes, and the supernatant was transferred to a 2 mL screw-top tube. From each sample, 
10 µL was transferred to an empty tube to produce a quality control sample. Finally, air in the tubes 
was displaced with argon gas to prevent oxidation of metabolites, and samples were stored at -
80°C until they were analysed by liquid chromatograph-mass spectrometry. 
2.6.2 Liquid chromatography-mass spectrometry 
All mass spectrometry of metabolite samples was carried out by Glasgow Polyomics. Metabolomics 
samples were separated by HPLC using a ZIC-pHILIC (polymer-based hydrophilic interaction liquid 
chromatography) column (Merck). Two solvents were used in the column. Solvent A was 20 mM 
ammonium carbonate in H2O and solvent B was 100% acetonitrile. Mass detection was carried out 
using an Exactive Orbitrap mass spectrometer (Thermo). The mass spectrometer was run in positive 
and negative mode with an injection volume of 10 µL and a flow rate of 100 µL/minute.  
2.6.3 LC-MS Data analysis 
Raw data produced by the mass spectrometer was converted to the mzXML format using msconvert 
(Chambers et al., 2012). This step also split the polarity of the data. Files were then converted to 
peakML files with XCMS, which uses the Centwave function to pick peaks, converting every 
individual file to the peakML output. Data was combined across replicate samples and related peaks 
were annotated using mzMatch, an R-based analysis package. mzMatch output was processed 
using Ideom (Scheltema et al., 2011, Creek et al., 2012b), an excel-based annotation tool, which 
uses known standards to assign putative annotations to the filtered peaks. 
 
 
56 
In experiments where 13C-isotope labelling was used, mzXML files were analysed using mzMatch-
ISO (Chokkathukalam et al., 2013). This R-based tool requires a tab-delimited file containing 
metabolites of interest and their corresponding formulae, which was obtained from the KEGG 
database (Okuda et al., 2008). This list is then used by mzMatch-ISO to look for labelled metabolites 
which possess identical retention times, but differ in their mass. Peaks were subsequently manually 
filtered based on noise and intensity. 
2.7 Proteomics 
2.7.1 Drug affinity responsive target stability (DARTS) 
The DARTS assay was recently described by Lomenick and colleagues (Lomenick et al., 2009, 
Lomenick et al., 2011a, Pai et al., 2015), who used it to successfully validate several small molecule 
drug targets in both mammalian and yeast cells. The protocol outlined by the group was adapted 
for use with T. brucei cells.  
In this study, 1 × 108 Lister 427 T. brucei cells were used for one experiment. Cells were centrifuged 
at 1,500 × g for 10 minutes. Supernatant was removed and cells were washed twice in ice-cold 1× 
PBS, before resuspension in DARTS lysis buffer (Appendix D). After an hour-long incubation at 4ºC 
with intermittent vortexing, the sample was centrifuged at 16,060 × g for 30 minutes at 4ºC, to 
remove cellular debris. The protein content was then measured with a Bradford assay (Bio-Rad 
Laboratories Inc), and adjusted to 1 mg/mL by adding additional buffer. 
The sample was then split into three aliquots of 297 µL in 1.5 mL eppendorf tubes (the remaining 
sample was discarded). To one of each aliquot was added either the AN5568 benzoxaborole at 
varying concentration, or the drug vehicle (i.e. DMSO). Samples were mixed, briefly centrifuged, 
and incubated at 37ºC for one hour.  
Each aliquot was subsequently split into 6 aliquots of 50 µL. Pronase (Sigma-Aldrich), which was 
kept as a 10 mg/mL stock, was added at the following final concentrations to 5 of the 6 samples for 
each sample group: 50 µg/mL, 10 µg/mL, 5 µg/mL, 1 µg/mL and 0.5 µg/mL. One sample from each 
sample group was left as a negative control. Samples were incubated with pronase for exactly 30 
minutes at room temperature. In order for this to be carried out successfully, a timer was started 
after pronase was added to the first sample. The next pronase digest was then set up 30 seconds 
later and this was repeated until all digests had been set up. After 30 minutes, protease inhibitor 
(Roche) was added to the first sample. Protease inhibitor was then added to each subsequent 
sample every 30 seconds in the same order as the digests had been initiated. Samples were then 
left on ice until the experiment was complete.  
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To visualise the DARTS experiment results, 9 µL from each sample was added to 3 µL SDS loading 
buffer and boiled at 100ºC for 10 minutes. All samples were then run on a NuPAGE® Novex® 4-12% 
Bis-Tris protein gel (Life Technologies, USA). Sample to which the same concentration of pronase 
has been added, were run next to each other (for example, DMSO and benzoxaborole samples 
digested with 5 µg/mL were separated in parallel, so they could be directly compared). Protein gels 
were run and stained with Coomassie as described in section 2.3.2.  
2.7.2 Protein mass spectrometry and analysis 
Protein gel extractions, trypsin digests and mass spectrometry was carried out by Glasgow 
Polyomics. Submitted gel pieces from either protein gels or 2D-DiGE gels were washed twice with 
100 mM ammonium bicarbonate (ABC), followed by destaining using 50% acetonitrile/100 mM 
ABC. Gels were incubated in acetonitrile for 10 minutes and subsequently dried in a speed vac. 
Samples were then re-hydrated using 25 mM ABC and incubated overnight. 
Digested proteins were dried and analysed by LC-MS/MS. An UltiMate 3000 Rapid Separation LC 
system (Thermo) was used to separate samples and this was coupled to an electrospray ionization 
tandem mass spectrometer (AmaZon ETD, Bruker Daltonics). Raw MS/MS data was analysed using 
the MASCOT server (Hirosawa et al., 1993) and protein sequences were identified using the TREU 
927 (v5.0) T. brucei reference proteome. 
2.8 Transcriptomics 
2.8.1 Sample preparation 
RNA was extracted from samples as described in section 2.2.2, using approximately 108 cells to 
ensure the isolation of surplus RNA. The total RNA was purified using a commercial kit (Nucleospin® 
RNA, Macherey-Nagel). A DNase treatment step was included in the kit protocol. RNA was stored 
at -80ºC and transported to Glasgow Polyomics on dry ice. 
2.8.2 RNA-seq 
Purified RNA was first subjected to a quality control by NanoDrop (Thermo Fischer), and then 
sequenced by Glasgow Polyomics. The RNA library was prepared using PolyA selection using the 
TruSeq stranded mRNA sample prep kit (Illumina®). Sequencing was carried out using Illumina 
NextSeq500 sequencing apparatus. 
2.8.3 Transcriptomics data analysis 
Raw sequencing files, in .file format, were processed using a pipeline as follows: Raw reads were 
trimmed using cutadapt to trim adapter sequences (Martin, 2011). The read quality and coverage 
was then assessed using FastQC (Andrews, 2010). Once all sequencing data was judged to be of 
 
 
58 
good quality, the reads were then aligned to the TREU927 genome (TriTrypDB, v9.0) using the 
TopHat RNAseq data processing pipeline (Trapnell et al., 2009, Trapnell et al., 2012, Ghosh & Chan, 
2016), which incorporates Bowtie2 to align reads and Samtools to remove duplicates (Li et al., 
2009). For sequencing analysis, the data was further processed using the genome analysis tool-kit 
(GATK) (McKenna et al., 2010), and SNPs as well as indels were filtered using the SnpEff/SnpSift 
package (Cingolani et al., 2012). To analyse transcript abundance the cufflinks package was used 
(Trapnell et al., 2012, Ghosh & Chan, 2016). 
2.9 Blotting 
2.9.1 Sample preparation 
Protein samples for Western blots were prepared as described in section 2.3.2. Protein was 
extracted either in protein extraction lysis buffer, or in hypotonic lysis buffer for fractionation. 
Samples were diluted in 4x sample loading buffer (Appendix D) and boiled at 100ºC for 10 minutes, 
with one exception; For Western blots to study the cross-reactive determinant (CRD), samples were 
not boiled to avoid membrane protein aggregation in the membrane fractions. Protein gel 
electrophoresis was carried out as described above. 
2.9.2 Transfer & blotting 
Protein was transferred to a nitrocellulose membrane (Amersham Hybond ECL, GE Healthcare Life 
Sciences) that was equilibrated in transfer buffer (Appendix D). Transfer was achieved using a XCell 
IITM blot module (Invitrogen) in an Xcell SureLock® Mini tank (Invitrogen). The blot was kept at 30 V 
for ~2 hours. Once protein was transferred, the gel was discarded and blot was placed in a 50 mL 
falcon tube and blocked overnight at 4ºC on a roller mixer containing 5 mL western blot blocking 
solution (Appendix D). The blot was then incubated with a primary antibody (α-VSG221, a gift from 
the Mottram group) for 1 hour at room temperature. This was followed by three 10-minute washes 
in PBS-T and another hour incubation containing the secondary antibody conjugated to HRP. The 
blot was then washed three times in PBS-T and treated with the developing reagent (Thermo 
Fischer Scientific). Chemiluminescence was detected using a myECLTM Imager system (Thermo 
Fischer Scientific), with an exposure time between 1 and 15 minutes depending on the target. 
Typically, α-enolase was used for the loading control as previously described (Hannaert et al., 2003). 
2.10 Microscopy 
2.10.1 Mitotracker staining 
For some experiments, mitochondria were stained using Mitotracker Red (Invitrogen) prior to 
fixation and mounting. To achieve this, cells (typically 1 mL at ~5 x 105 cells/mL) were incubated for 
5 minutes at 37ºC, 5% CO2, with a final concentration of 100 nM Mitotracker. Upon completion, 
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cells were centrifuged for 5 minutes at 1,500 × g and washed twice in fresh medium before cells 
were fixed as described below. 
2.10.2 Preparation and fixation of cells 
Trypanosomes were grown to mid-log phase before control and treatment cultures were started at 
a density of 2 × 105 cells/mL. For each time-point, at least 3 mL culture was transferred to a falcon 
tube, centrifuged at 1,500 × g and resuspended in 1 mL fresh, warm, HMI-9. Subsequently, cells 
were spun down again, washed twice with sterile 1× PBS, and finally resuspended in 500 µL PBS.  
Samples were fixed by adding a final concentration of 2% formaldehyde, and incubated for 15 
minutes at room temperature. Next, another 500 µL PBS was added to dilute fixative, and samples 
were washed once with sterile PBS. Cells were then resuspended in 50 µL PBS and transferred onto 
a poly-L-lysine-coated slide, which was left to air-dry in a safety cabinet. 
Dried slides were rehydrated and washed in PBS, and a counterstain consisting of 1× PBS with 3 µM 
4,6-diamidino-2-phenylindole (DAPI) was applied to the slide, before mounting with a coverslip that 
was sealed with clear nail varnish. 
Slides were kept at 4°C for up to a week until analysis was carried out using a Zeiss axioscope 
(Scope.A1, Zeiss). 
2.10.3 Cell cycle and morphology analyses 
To ascertain whether compounds affected the T. brucei cell cycle, cells were prepared for 
microscopy analysis as described above. Cells were then counterstained with DAPI and classified 
according to the numbers of nuclei and kinetoplasts they had, as a direct correlation to phases of 
the cell cycle, as described in several publications (Woodward & Gull, 1990, McKean, 2003, Siegel 
et al., 2008). Cells in G1 phase have one nucleus and one kinetoplast (1N1K). Kinetoplast replication 
(S-phase) then initiates (1N2K) prior to nuclear division (2N2K). Finally, completion of the cell cycle 
leads to two cells in G1 phase.  
To analyse any potential changes in cell cycle, >300 cells were counted in multiple samples and the 
number of cells in different cell cycle stages, as well as those in 2N1K and MNMK (‘M’ defined as 
‘multiple’ organelles) phase, were calculated as percentages of the total number of counted cells. 
To measure the distance between nucleus and kinetoplast, images were obtained from DAPI 
stained samples and imported into the Fiji software (Schindelin et al., 2012). Distances were 
measured after the scale was set using the “measure” tool. For each sample group, 30 
measurements were taken from three independent microscopy experiments. 
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2.10.4 Analysis of kinetoplast localisation 
To measure the mean distance between nucleus and kinetoplast, DAPI-stained slides were 
prepared for the relevant cell lines, as described above. For each sample, images were under a DAPI 
filter and DC, at 10× magnification. These were imported into the Fiji software (Schindelin et al., 
2012). Distances between nucleus and kinetoplast were measured in ~300 cells per sample, using 
the Analyse  Measure function. Mean and error was then calculated in Microsoft Excel. 
2.11 Chemicals 
This study used several experimental compounds. The benzoxaborole AN5568, previous identifier 
SCYX-7158, was supplied by Anacor Pharmaceuticals Inc., and was stored at -20°C in DMSO at a 
stock concentration of 100 mM. Ornidyl was supplied by Sanofi Aventis. Unless described 
specifically, all powder reagents were obtained from Sigma-Aldrich. 
2.12 Computational methods 
2.12.1 Data analysis and presentation 
Graphical representation of data was created using the Graphpad Prism software (v6.0, GraphPad 
Software, www.graphpad.com). Statistical analyses were carried out using Graphpad Prism, SPSS 
and Microsoft Excel. Further computational analysis was carried out using R (R Core Team, 2013). 
Analysis of microscopy images was carried out using the Fiji software (Schindelin et al., 2012), an 
ImageJ package containing all available extensions. This software was also used for further 
processing of protein gels and blots. 
Metabolite identification was done using Ideom (Scheltema et al., 2011, Creek et al., 2012b). Where 
targeted metabolomics using stable isotopes was carried out, mzMatch-ISO (Chokkathukalam et 
al., 2013) was used for metabolite identification, and all hits were then confirmed using Ideom. 
Putatively identified metabolites were also analysed using the Metacyc (Caspi et al., 2006, Caspi et 
al., 2015), Kegg (Okuda et al., 2008), and HMDB (Wishart et al., 2007) databases. Further 
metabolomics figures, including heat maps and PCA plots, were either created using Metaboanalyst 
(Xia et al., 2015) Microsoft Excel, R or GraphPad Prism. 
Genomic and transcriptomic analysis was visualised with IGV (Robinson et al., 2011). For sequence 
alignments, the CLC Genomics Workbench software v7.0 (QIAgen) was used. 
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Chapter 3. The mode of action of AN5568 
3.1 Introduction 
3.1.1 AN5568 brings hope for HAT 
AN5568 was identified as an effective inhibitor of T. brucei infection from a library screen involving 
benzoxaborole 6-carboxamides. The compound is based on another benzoxaborole called SCYX-
6759, which exhibited only partial inhibition of stage 2 trypanosomiasis (Nare et al., 2010). Both in 
vitro as well as in vivo assays have shown AN5568 to be highly potent against T.b. gambiense and 
T.b. rhodesiense (Wring et al., 2010, Jacobs et al., 2011, Giannotti et al., 2014). Importantly, 
pharmacokinetic characterisation of the drug showed that brain exposure was high, with a Cmax of 
>10 µg/mL and AUC0-24 hr >100 µg*h/mL (Jacobs et al., 2011). Further in vitro analysis showed that 
AN5568 exhibited high CNS permeability in the MDCK-MDR1 CNS transport assay (414.8 nm/s) 
(Wring et al., 2014), an important consideration with regards to development of drugs for stage 2 
HAT. In addition, CNS concentrations of the compound were maintained above the MIC for 20 
hours, meaning the benzoxaborole could be administered orally once or twice daily (Wring et al., 
2014). This is consistent with in vivo studies, which have shown 100% cure rates only after 3 or 
more days of dosing (Jacobs et al., 2011, Wring et al., 2014). 
Whilst the pharmacokinetics of AN5568 are well understood, little work has been carried out to 
understand its mode of action, which is currently not known. This understanding is crucial, as it will 
give novel insights into trypanosome biology, as well as indicating any potential structure 
alterations that could lead to higher drug efficacy as well as reduce the possibility of drug resistance 
arising. Previous work in the Barrett group has suggested that AN5568 causes several major and 
highly specific perturbations in the metabolome of T. brucei cells in vitro (D. Creek, unpublished). 
In particular, significant increases were seen in S-adenosyl-L-methionine, an important methyl-
group donor in methyltransferase reactions. Its breakdown product, 5’-methylthioadenosine was 
also increased in drug-treated cells. These results led to the hypothesis that AN5568 might interfere 
with methyltransferase reactions.  
In this chapter we investigated the putative mode of action of AN5568. Firstly, we repeated the 
preliminary metabolomics analyses resulting in similar findings to those previously seen. We further 
probed this data set, with an emphasis on understanding the underlying determinants leading to 
changes in methionine metabolism. Initial characterisation of drug-treated cells in vitro showed 
signs of cell cycle inhibition, and through utilising a combination of omics-based approaches we 
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were able to show how the drug impacts various metabolic pathways. In addition, we performed 
an in silico study of the trypanosome “methyltransferome” to gain a better understanding of the 
methyltransferase complement of the parasite.  
3.2 In vitro activity of AN5568 on T. brucei 
To investigate AN5568 efficacy in vitro, an alamar blue assay was carried out to determine the EC50 
(the concentration necessary to kill 50% of cells) for AN5568 in Lister 427 T. brucei. The EC50 for BSF 
cells was 193 ± 48 nM. In contrast, the EC50 of AN5568 in PCF cells was 1,500 ± 90 nM (fig. 3-1). This 
suggests the compound exhibits a far higher efficacy against BSF trypanosomes. Whilst this could 
mean the benzoxaborole targets a protein or pathway that is more active in BSF cells, it may also 
reflect slower uptake and metabolism, both of which are decreased in PCF cells compared to BSF. 
Previous work showed that a daily dose of 5 mg/kg/day for 4 days was sufficient for a 100% cure-
rate in vivo (Jacobs et al., 2011).  
 
Figure 3-1: Sigmoidal dose-response curves carried out on AN5568-treated T. brucei. Alamar blue plates 
were set up as described in the methods section, and the EC50 of AN5568 was calculated in both BSF and PCF 
parasites in vitro. Whilst procyclic cells have an EC50 of 1,500 nM, BSFs were found to be almost ten-fold more 
sensitive, with an EC50 of 190 nM. 
The drug was also tested on the other trypanosomatids (table 3-1). Alamar blue assays were carried 
out on Leishmania mexicana promastigotes, a kinetoplastid parasite closely related to T. brucei, but 
kept in culture in its vector life cycle stage. Here, we found the EC50 to be far higher, at 37.8 ± 3.7 µM 
(table 3-1). Further work was done on this parasite in section 3.6.  
The EC50 concentrations are important to know because further in vitro studies would be based on 
the use of consistent concentrations of the benzoxaborole. The next step was to analyse the impact 
of drug treatment on cellular growth. Cultures were set up in triplicate for both BSF and PCF Lister 
427 cell lines. For both cell lines, incubations with AN5568 were set up at concentrations of ½× EC50, 
1× EC50, 2× EC50, 5× C50 and 10× EC50, along with a control containing DMSO only. Cells were cultured 
BSF T. brucei Lister 427 PCF T. brucei Lister 427 
A B 
 
 
63 
at a density of 2 × 105 cells/mL, so that a 10-fold decrease in density could be seen using a cell 
counting chamber. Cell growth was assessed by haemocytometer for up to 30 hours. 
Organism Approximate EC50 Origin of data 
T. brucei – BSF 190 nM This study 
T. brucei – PCF 1,500 nM This study 
T. congolense – BSF 500 nM F. Giordani 
T. cruzi  7.5 µM R. Jacobs (Anacor) 
L. mexicana - promastigote 38 µM This study 
Table 3-1: EC50 of AN5568 in various kinetoplastids. Where the value was not obtained by this study, it was 
instead given by the named individual in a personal communication. 
BSF trypanosomes were particularly susceptible to higher concentrations of AN5568, with cell 
growth halted by 12 hours in concentrations of 2× EC50 and above (fig. 3-2A). Indeed, cells incubated 
with 950 nM AN5568, or higher, show growth phenotypes by the 6-hr time-point. In addition, there 
were no viable cells observed at 24 hours when cells were treated with ≥5× EC50. This suggests that 
BSF cells in these concentrations of the benzoxaborole are killed before 24 hours. 
In contrast, PCF cells were less affected by benzoxaborole exposure. Despite a noticeable decrease 
in growth in high concentrations, live cells were observed after 30 hours exposure to 10× EC50 (fig. 
3-2B). It appeared that cell populations treated with ≤5× EC50 recovered from AN5568 exposure 
after 24 hours. 
These data indicate that AN5568 is trypanocidal in BSF cells, but its effect on PCF cells is largely 
trypanostatic, even at high doses. PCFs are therefore less sensitive to the compound, which 
supports the alamar blue results. 
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Figure 3-2: Growth of BSF and PCF T. brucei during AN5568 treatment in vitro. Growth curves were set 
up, and cultures observed over a period of 30 hours, to assess parasite growth in the presence of various 
concentrations of the benzoxaborole drug. Cell viability was calculated as a percentage of a DMSO control. 
In both cases, colours correspond to the following relative concentrations: red: ½× EC50, green: 1× EC50, 
black: 2× EC50, grey: 5× EC50, purple: 10× EC50. A) Concentrations of 5× EC50 and above abolished all growth 
within 24 hours in BSF T. brucei. Growth cultures were rendered static in concentrations above EC50, whilst 
there was no difference in parasite growth when cells were treated with ½× EC50 concentration of AN5568. 
B) Whilst parasite growth was limited upon treatment with high concentrations of AN5568, live cells were 
still observed after 30 hours, even in cultures given the highest dose of the drug. 
3.3 Morphological changes in AN5568-treated cells 
To analyse morphological changes in BSF parasites after AN5568 treatment, fluorescent microscopy 
was employed. Cell cycle analysis was carried out as described in the methods, using DAPI staining 
as well as bright field microscopy. In addition, mitochondrial staining was carried out using a 
commercial antibody (Mitotracker Red, Invitrogen), to assess further changes to this organelle. The 
use of ER tracker (Life technologies) was also attempted, however, this was unsuccessful in fixed 
cells. Analysis was done with AN5568 concentrations of 2× EC50 and 10× EC50, (380 nM & 1,900 nM 
respectively) and a negative control was supplemented with an equal volume of DMSO. Microscopy 
analyses were carried out at time points of 6 hours, 12 hours and 24 hours post-treatment. 
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At 2× EC50 concentration of AN5568, no significant changes in morphology were observed at the 6 
hour time-point (fig 3-3). Cells were comparable to the control under visualisation of both DAPI and 
mito-tracker. However, by 12 hours, many cells under this dosage exhibited a rounded shape. 
Under DIC, these cells appeared to have a compromised plasma membrane. Whilst DAPI showed 
the location and morphology of both nuclei and kinetoplasts to be normal, the mitochondrial shape 
differed to the wild-type mitochondria. These phenotypes were more extreme at 24 hours post-
treatment (fig. 3-3). In addition, many cells exhibited multiple nuclei, but not multiple kinetoplasts, 
at this time-point. A similar phenomenon has been reported after depletion of mitochondrial acyl 
carrier protein (Clayton et al., 2011). However, in this case, there were a variety of defects in the 
kinetoplast, including organelle enlargement, which was not observed here. In addition, RNAi of a 
mitochondrial DNA helicase, TbPIF1, resulted in the complete loss of kinetoplast DNA (Liu et al., 
2010). Again, this was not a phenomenon that occurred after AN5568-treatment. Cells with 
multiple flagella were also seen, albeit low in number. DIC microscopy showed disintegration of the 
plasma membrane, although we could not confirm whether this was as a direct result of the 
benzoxaborole action, or rather, a general cell death phenotype. There were many cells showing 
abnormal mitochondria after 24 hours (fig. 3-3). Rather than the linear mitochondrion seen in WT 
cells, the cells here exhibited patches of high intensity stain, which could suggest breaking up, or 
leakage, of the mitochondrial matter (fig. 3-3). 
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Figure 3-3: The effect of 2× EC50 AN5568 on cellular morphology. T. brucei cells were incubated with 
2× EC50 concentration of AN5568 and cells were isolated for analysis by microscopy at specific time-points. 
Under normal conditions, cells show 1 nucleus and 1 kinetoplast, or other conformations depending on the 
stage of cellular division. In addition, the mitochondrion appears as a thin line along the long axis of the cell 
when stained by Mitotracker Red. After 6 hours of drug exposure, both DIC and DAPI staining showed the cells 
to appear normal. However, the mitochondrion appeared to be swelling at this time-point. At the 12-hour 
time-point, cells were observed to be swelling under direct light. This is a common morphological phenotype 
in response to trypanocidal compounds. In addition, whilst the nuclei and kinetoplast still appeared to be 
mostly normal in both number and morphology, the mitochondria were showing abnormal phenotypes. In 
particular, the organelles seemed to be breaking up and become ‘patchy’. This phenotype was also apparent 
24 hours after AN5568 exposure. Here, cells were also showing significant rounding and compromised 
membranes. Moreover, DAPI staining indicated a build-up of nuclei, but not kinetoplasts, in a significant 
number of cells, suggesting a cellular division defect. Scale bar represents 5 µm. 
Work was also undertaken to analyse the morphological changes to the parasite when treated with 
10× EC50 (~2 µM). Cells were analysed at the same time-points as mentioned above. DIC analysis 
showed that the cells exhibited the same rounding of the cell body after 12 hours, as seen after 
treatment with 2× EC50 for the same amount of time (fig. 3-4). By 24 hours, it was challenging to 
find any live cells resembling BSF T. brucei. Much of the culture was reduced to numerous flagella 
and cellular debris, making this time-point challenging to analyse at this concentration of 
benzoxaborole. DAPI staining did not reveal the same phenotypes as those seen at 2× EC50. Live 
cells contained either one or two nuclei, as well as one or two kinetoplasts, suggesting that at this 
concentration, cells were killed before a significant cell division phenotype was visible. 
Mitochondrial morphology appears to undergo similar changes to those seen at lower drug 
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concentrations (fig. 3-4). By 12 hours there appears to more mitochondrial leakage, although this 
could also occur as a result of organelle replication before cytokinesis. After 24 hours of drug 
treatment, the mitochondria appeared ‘patchy’ as seen in figure 3-3 as well.  
In addition to visual analysis of drug-treated cells, the nuclei and kinetoplasts in untreated and 
treated cells were quantified. This type of analysis, termed ‘NK analysis’, allows the assessment of 
changes in the cell division cycle (Woodward & Gull, 1990). For each sample, up to 300 cells were 
counted in triplicate. Cells with 1 nucleus and 1 kinetoplast (1N1K) were deemed not to be 
undergoing cell division. Cells with one nucleus but 2 kinetoplasts (1N2K) had replicated 
kinetoplasts, but not nuclei. Cells containing two nuclei as well as two kinetoplasts (2N2K) were 
towards the end of the DNA replication cycle and were undergoing cytokinesis. In some cases two 
flagella could be seen at the 2N2K stage. We also noted cells that contained a conformation of 
either 2N1K, or multiple DNA-containing organelles (MNMK), which suggests a defect in cytokinesis 
or DNA replication (Woodward & Gull, 1990). 
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Figure 3-4: Effect of 10x EC50 AN5568 treatment on T. brucei morphology. Microscopy analysis was also 
carried out on cells treated with 10× EC50 AN5568, at similar time-points to those observed with 2× EC50. 
Similarly, cells were observed to show wild-type morphology after 6 hours of drug exposure. DAPI and 
Mitotracker staining did not raise any phenotypes of interest. By 12 hours, cells were very rounded and 
showing staining phenotypes similar to those observed after 24 hours of incubation with 2× EC50. In the 
representative image shown, cells did show normal replication of nuclei, kinetoplasts and mitochondria, 
suggesting the cell division defects were not as severe. Analysis of the 24 hour time-point proved challenging 
by the lack of cells left in the sample. When they were seen, there was significant swelling and rounding of 
the cell body. Whilst DAPI staining still did not show severe phenotypes, the mitochondrial stain exhibited 
leakage throughout the cell, indicating that the mitochondrial membrane had been compromised, most likely 
as a result of cell death. Scale bar represents 5 µm. 
Treatment with benzoxaborole does not cause any visible changes until at least 12-hours post-
treatment (fig. 3-3 & 3-4). Similarly, changes in NK distribution were also observed after 12 hours, 
when treated with 2× EC50 AN5568 (fig. 3-5A). This phenotype was more apparent after 24-hours, 
where an increase was also observed in MNMK cells. Indeed, up to 20% of cells exhibited multiple 
nuclei and/or kinetoplasts at this time-point. 
When treated with 10× EC50, a similar increase in 2N1K cells was observed by 12 hours. There was 
also a 10% reduction in 1N2K cells at this time-point. Unfortunately, there were so few cells left by 
24 hours that NK analyses were not possible. 
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The microscopy analysis suggests that AN5568 has a significant impact on the parasite’s ability to 
divide. In particular, there are indications that cytokinesis is impaired, leading to cells containing 
multiple nuclei as seen in figures 3-3 and 3-4. Interestingly, increases in 2N1K, and MNMK cells, 
suggests that whilst replication of the nucleus occurs, there could be further complications in 
kinetoplast division as a direct result of drug-treatment. 
 
Figure 3-5: Cell cycle analysis of AN5568-treated cells. For both microscopy experiments, DAPI staining was 
analysed in more detail to identify potential defects in cell division as a result of AN5568 treatment. A) 
Exposure to 2× EC50 AN5568 caused a build-up of 2N2K cells by 12 hours. In addition, there were increases in 
2N1K and MNMK (M represent multiple) cells by 24 hours, along with a corresponding decrease of cells in the 
1N1K state, compared to WT cells. B) These phenotypes were less obvious in cells treated with 10× EC50 
concentration of the benzoxaborole. Whilst there were increases in 2N2K and 2N1K cells, the changes were 
not as high as those seen in cells treated with a lower dose of the drug. Unfortunately, not enough cells were 
seen after 24 hours of 10× EC50 exposure, making cell cycle analysis at this time-point all but impossible. 
3.4 Untargeted metabolomics analysis of AN5568-treated 
bloodstream form trypanosomes 
As described previously, there are several methods that can be utilised to investigate and validate 
drug targets. Recent advances in metabolomics allow us to observe all small molecule metabolites 
in a cell/system. This gives a distinct advantage over the use of genomics or transcriptomics because 
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the metabolome is much more dynamic, allowing the observation of significant perturbations very 
quickly (Veenstra, 2012). Given the advantages and potential of this method, we chose to apply it 
to the investigation of the mode of action of AN5568. 
Growth analysis of drug-treated cells indicated that effects might be visible by 6 hours post-
treatment, as cell growth is static by this point at a drug concentration of 10× EC50, even if 
morphology remains rather unchanged. This is because the proteome is less dynamic than the 
metabolome, and changes in the metabolome will occur much faster upon drug treatment. 
Preliminary metabolomics analysis by the Barrett group indicated perturbations in S-adenosyl-L-
methionine (AdoMet) metabolism (Darren Creek, personal communication). Therefore, mass 
spectrometry analysis was carried out on cells treated with AN5568 as well as a sample group 
treated with sinefungin, an AdoMet. Sinefungin is a non-specific inhibitor of MTase reactions, and 
would therefore show similarities with AN5568 should our hypotheses be correct. Both drug-
treated samples were incubated for 6 hours with a drug concentration of 10x EC50, alongside a 
DMSO control. Samples were prepared as described in the methods and analysed by liquid 
chromatography mass spectrometry (LC-MS). The resulting data was processed using the 
mzMatch/Ideom pipeline. 
Processing of data using Ideom led to the identification of 840 putative metabolites. Of these, 50 
were deemed to show significant changes (Log2 fold-change = <-1, >1, P<0.05 [t-test]), as shown in 
figure 3-6. Amongst the significantly altered metabolites, we noticed an enrichment of the 
methionine degradation pathway (fig. 3-6-3-8). There were also several significant increases found 
in amino acid, as well as nucleotide metabolism, which were analysed in depth below. 
In addition, several lipids were significantly decreased after drug-treatment (fig. 3-6). This could 
suggest either degradation of cell surface membrane, or an organelle membrane. This result was 
especially interesting in the context of possible mitochondrial damage, and is covered in detail in 
section 3.4.3. The majority of metabolites were, however, unchanged. This suggests that the 
benzoxaborole possesses a highly specific target, or mode of action, bypassing many metabolic 
pathways present in the parasite. In addition, it indicates a high level of robustness in the T. brucei 
metabolome. Components of glycolysis and carbohydrate metabolism in general, were no different 
than in wild-type samples. 
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Figure 3-6: Volcano plot of metabolic changes in T. brucei after 6-hour treatment with 10× EC50 AN5568. 
Metabolite samples were prepared from drug-treated as well as DMSO control samples, as described in the 
methods. Analysis was carried out using the mzMatch/Ideom pipeline. A volcano plot was generated where 
all red dots indicate metabolites undergoing significant increases as assessed by a combination of a Student’s 
t-test (P<0.05), and a fold change higher than 2× (Log2(fold-change)= >1). Blue dots indicate significant 
decreases as calculated by the same t-test and a fold change lower than -2× (Log2(fold-change)= <-1). 
Numbers at red dots correspond to the following metabolites that were significantly increased: 1) S-adenosyl-
L-methionine (m/z: 398.1374, RT: 18.02 mins, 7.67-fold), 2) 1,2-Dihydroxy-5-(methylthio)pent-1-en-3-one 
(m/z: 162.0350, RT: 17.24 mins, 46.33-fold), 3) 5’-methylthioadenosine (m/z: 297.0896, RT: 7.75 mins, 6.17-
fold), 4) N6-acetyl-L-lysine (m/z: 188.1162, RT: 14.70 mins, 2.83-fold), 5) adenine (m/z: 135.0546, RT: 7.71 
mins, 12.55-fold), 6) 4-hydroxy-4-methylglutamate (m/z: 177.0637, RT: 15.3 mins, 3.46-fold), 7) N6,N6,N6-
trimethyl-L-lysine (m/z: 188.1524, RT: 23.54 mins, 7.4-fold), 8) cyclic ADP-ribose (m/z: 541.0608, RT: 16.90 
mins, 43.78-fold), 9) aminoacetone (m/z: 73.0528, RT: 7.67 mins, 12.06-fold), 10) 8-amino-7-oxononanoate 
(m/z: 187.1208, RT: 13.75 mins, 8.43-fold). Numbers at blue dots correspond to the following metabolites 
that were significantly decreased: 1) [PC(14:0)] 1-tetradecanoyl-sn-glycero-3-phosphocholine (m/z: 
467.3014, RT: 4.75 mins, 0.35-fold), 2) sn-glycerol 3-phosphate (m/z: 172.0136, RT: 16.44 mins, 0.4-fold), 3) 
D-glucosamine 6-phosphate (m/z: 259.0457, RT: 17.68 mins, 0.47-fold), 4) 2-deoxy-D-ribose 5-phosphate 
(m/z: 214.0242, RT: 16.45 mins, 0.39-fold), 5) Asp-Asp-Cys-Pro (peptide) (m/z: 448.1256, RT: 17.64 mins, 
0.22-fold). 
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Figure 3-7: Heat map showing the changes in metabolism occurring in T. brucei as a result of AN5568-
treatment. Black arrow: AN5568. Whilst both increases and decreases were shown to occur in the majority 
of areas of metabolism, there were few increases in lipid metabolism. In addition, 206 metabolites were 
purported not to be definitively involved in a particular metabolic pathway (shown as ‘no annotated 
pathway’). Red colours indicate increased metabolite peak intensities in drug-treated cells. Blue indicates 
peak intensity decreases whilst yellow indicates no difference. 
3.4.1 Methionine metabolism 
After 6 hours, there were significant changes in methionine metabolism in response to AN5568 
treatment (fig 3-7 & 3-8). The largest changes were seen in L-methionine (m/w: 149.0510, RT: 18.05 
mins), S-adenosyl-L-methionine (AdoMet, m/z: 398.1374, RT: 18.01 mins) and 5’-
methylthioadenosine (5’-MTA, m/z: 297.0896, RT: 7.75 mins). In addition, there was also a 
significant increase in adenine, a molecule produced during the hydrolysis of 5’-MTA. These 
molecules are all part of the methionine degradation pathway in T. brucei, which is thought to 
progress from L-methionine to 5’-methylthio-D-ribose (fig. 3-9). 5’-methylthio-D-ribose is thought 
to be excreted by the parasite, albeit at very small quantities (F. Achcar, personal communication), 
and was not detected in this experiment. Importantly, methionine is required for the biosynthesis 
of AdoMet, which plays a significant role in MTase reactions by supplying methyl groups in these 
reactions. In addition, decarboxylation of AdoMet results in the formation of decarboxylated 
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AdoMet (dcAdoMet), which feeds the polyamine pathway, a crucial and essential stress response 
pathway for the parasite (Olin-Sandoval et al., 2012). Again, dcAdoMet was not detected by mass 
spectrometry. However, the product of the aminopropyl transfer reaction that consumes 
dcAdoMet is 5’-MTA, which was significantly increased in AN5568-treated cells, most likely due to 
the breakdown of accumulating AdoMet. 
 
Figure 3-8: Changes in methylation metabolism after AN5568 treatment. A major pattern was observed 
with regards to the methionine degradation pathway. Several metabolites with significant changes were all 
found to be associated with methionine and methylation metabolism. AdoMet (A) had been seen to increase 
previously and this result was repeated here. L-methionine (B) 5’-MTA (D) and adenine (E) levels showed a 
similar increase, suggesting a build-up of these metabolites all belonging to the same pathway. Both AdoHcy 
(F) and Hcy (C) were found to increase, which at first, did not appear to support our MTase inhibition 
hypothesis. However, both the peaks for these metabolites were noisy and the wild-type samples showed 
significant variation. Finally, L-serine (G), utilised in the conversion of L-homocysteine to L-cystathionine, 
showed a decrease after AN5568-treatment, suggesting it was being used at a higher rate compared to wild-
type cells. However, levels of L-cystathionine (H) were not found to be altered in AN5568-treated cells, 
although there was a high amount of variation in this peak, for the drug-treated samples. 
Previous work investigating the mode of action of eflornithine also looked at the methionine 
degradation pathway (Vincent et al., 2012). However, the metabolomics results of that study did 
not find similar metabolic alterations in AdoMet, even though 5’-MTA did show increases. Data 
from eflornithine studies led to the hypothesis that the benzoxaborole does not target the 
polyamine pathway directly. Indeed, most of the components in the trypanothione synthesis 
 
 
74 
pathway were actually increased after AN5568 treatment (fig. 3-14C). In contrast, many of these 
metabolites are decreased in abundance after eflornithine treatment (Vincent et al., 2012). 
 
Figure 3-9: Metabolites involved in methyltransferase reaction pathways. The uptake of L-methionine is 
crucial for T. brucei, as its breakdown product, 5’-MTA, is involved in the polyamine synthesis pathway. In 
addition, L-methionine is converted to AdoMet, which is an important methyl group donor in MTase reactions. 
The results generated by the metabolite extraction of AN5568-treated cells indicated that a specific MTase 
reaction could be inhibited (red cross). However, the particular reaction might not be observed in 
metabolomics datasets, should the methylation occur on proteins or nucleic acids. In addition, it is unknown 
what effect this could have on the downstream metabolites such as AdoHcy, Hcy, L-cystathionine and L-
cysteine. 
Instead, given the high levels of AdoMet, one possible target could be an MTase reaction. 
Methylation and demethylation of DNA, RNA and proteins is an important regulatory modification 
across all organisms (Fontecave et al., 2004). AdoMet is crucial in these reactions, as it provides a 
methyl group that is transferred to the target substrate. In fact, there are very few instances where 
AdoMet is not the donor for an MTase reaction (Coulter et al., 1993, Ragsdale, 2008). MTases are 
also highly specific, meaning the inhibition can occur of one MTase only.  
Interestingly, we did not see many abundance changes in the metabolites found after the 
methyltransferase reaction (fig. 3-8). AdoMet is converted to AdoHcy, which did not show a 
corresponding drop in peak intensity. Similarly, both L-homocysteine (m/z: 135.0354, RT: 19.12 
mins) and L-cystathionine (m/z: 222.0674, RT: 19.12 mins) did not decrease after AN5568 
treatment, with the former slightly increased compared to the WT control. 
 
3.4.2 Effect of AN5568-treatment on VSG biosynthesis 
Further analysis of the metabolomics dataset also showed increased peak intensities for several 
components of the glycoprotein synthesis pathway upon benzoxaborole treatment (fig. 3-10). 
Glycoprotein synthesis in T. brucei is crucial to the parasite, which requires the GPI-anchored 
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glycoproteins for the expression of VSGs on its cell surface, in addition to a wide variety of other 
cell surface proteins (Crossman et al., 2002). Indeed, several recent studies have highlighted that 
inhibition of glycoprotein synthesis can lead to a general arrest in translation initiation as well as a 
spliced leader silencing response pathway, similar to the mammalian unfolding protein response 
(Smith et al., 2009, Goldshmidt et al., 2010)  
Upon exposure to AN5568, we found increased abundance of 3 important metabolites involved in 
glycoprotein biosynthesis (fig. 3-10A). GDP-mannose (m/w: 605.0774, RT: 20.59 mins) is formed by 
a side-branch of glycolysis from mannose 6-phosphate (Smith et al., 1996). The mannose molecules 
are then bound to N-acetyl-glucosamine (GlcNAc, m/w: 221.0899, RT: 15.29 mins), with the loss of 
GDP in the reaction (Kuettel et al., 2012). Both of these metabolites were increased after AN5568 
treatment, which led us to believe there might be changes in glycoprotein synthesis. To further 
confirm changes in glycoprotein synthesis, we also found a putative UDP-glucose (m/z: 566.0551, 
RT: 18.71 mins) to be increased in drug-treated cells (fig. 3-10A). Whilst this metabolite was 
predicted to be UDP-glucose, it carries the same mass as UDP-galactose, and these two metabolites 
are impossible to differentiate using LC-MS. UDP glucose is utilised in T. brucei by a UDP-
glucose:glycoprotein glucosyltransferase, in a reaction that helps to protect the parasite against 
stress (Izquierdo et al., 2009). UDP-glucose is also converted to UDP-galactose, which is used for 
the galactosylation of glycoproteins (Urbaniak et al., 2006). In any case, increased intensity of this 
peak suggests the parasite is undergoing significant perturbations in glycoprotein biosynthesis. 
To determine whether VSG biosynthesis was disrupted by AN5568 treatment, several western blots 
were carried out to assess their expression over a 6-hour period in various concentrations of the 
drug (fig. 3-10B & 3-10C). The Lister 427 laboratory strain of T. b. brucei is known to express VSG221, 
with a very low VSG switching rate (Lamont et al., 1986). Interestingly, VSG expression was not 
found to change over a period of 6 hours post-treatment, even at 20× EC50 concentrations of the 
benzoxaborole (fig. 3-10B). By altering contrast significantly, an extra band was seen in samples 
treated with 2× EC50 AN5568, but this was dismissed as background noise, or non-specific binding 
(fig. 3-10B). One interesting finding was that the loading control used for VSG blots, α-enolase, 
seemed to be less abundant in cells treated with high concentrations of AN5568 (fig. 3-10B). Indeed, 
when the metabolome data was analysed to specifically look for 2-phospho-D-glycerate and 
phosphoenolpyurvate, the substrate and product of enolase respectively, both were found to be 
decreased in AN5568-treated cells (Supplementary [S]-1). 
In addition, further blots were analysed for the cross-reactive determinant (CRD) epitope. This 
marker corresponds to the glycosyl-phosphatidylinositol (GPI) membrane protein that anchors 
VSGs to the cell membrane (Shak et al., 1988). In this experiment, T. brucei cells were fractionated 
to look for differences between the soluble fraction and the membrane fraction, which normally 
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contains the highest levels of CRD. We hypothesised that, should GPI biosynthesis be inhibited, we 
would see a less intense band for CRD in the membrane fraction. However, we found this not to be 
the case (fig. 3-10C). In all 3 fractions that were observed, there were no unexpected differences in 
CRD expression between the two sample groups. In both groups there was weaker expression in 
the membrane fraction. These results suggest that neither VSG expression, nor glycoprotein 
biosynthesis are affected by AN5568. However, it would be worthwhile to analyse protein lysates 
from cells incubated for longer time-points as expression might change more significantly over 
time. 
 
Figure 3-10: Metabolites involved in glycoprotein synthesis are upregulated after AN5568 treatment, but 
VSG expression is not impaired. A) Three metabolites, all known to be involved in glycoprotein biosynthesis, 
were found to be upregulated in AN5568-treated cells. The majority of glycoproteins expressed on the T. 
brucei cell membrane are glycosyl-phosphatidylinositol moieties which anchor the VSG, leading us to 
hypothesise that VSG expression could be impaired post-treatment. B) Western blots carried out on protein 
lysates taken from AN5568-treated cells at a 6-hour time-point showed no significant changes in VSG 
expression at this time-point. When the contrast of the resulting blot was increased, an extra band was seen 
in the 2× EC50-treated sample. However, this was dismissed as background noise, as this band was not seen 
in the other two drug-treated conditions. C) In addition to VSG expression, blots were probed for the cross-
reacting determinant of the GPI anchor. For this experiment, protein lysates were fractionated to isolate the 
membrane fraction and separate it from the soluble fraction. Most of the cellular GPI is found in the 
membrane, and no changes in expression could be seen in cells treated with 10× EC50 for 6 hours. 
3.4.3 Lipid metabolism 
The analysis of lipids and long-chain fatty acids using pHILIC columns are not optimal due to high 
amounts of background noise and poor mass peaks (Richmond et al., 2010). In addition, accurate 
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identification of these molecules is difficult in comparison to the identification of nucleotides and 
amino acids, as they can undergo a wide variety of modifications. Nevertheless, attempts were 
made to find any patterns of change in these metabolites.  
Firstly, we aimed to analyse possible changes in the mitochondria, given the microscopy analysis 
that had been carried out before. This organelle is an important compartment for the β-oxidation 
of fatty acids in all eukaryotes, in order to generate acetyl-CoA. (Millerioux et al., 2012). Whilst in 
T. brucei this catabolic process is more important in the procyclic form, it is still required for the 
generation of GPI synthesis in BSF cells. Therefore, to further probe the hypothesis that 
mitochondrial metabolism is targeted by AN5568, we set out to identify any changes in lipids often 
associated with the mitochondria.  
Fatty acids were seen on the mass spectrometer, although several of the putative metabolites had 
many isomers (fig. 3-11 & 3-12). Interestingly, these fatty acids all appeared to have a decreased 
abundance in AN5568-treated cells. However, it is impossible to confirm with these data whether 
this is due to mitochondrial disintegration or cell death in general. 
 
Figure 3-11: Fatty acid metabolism in cells treated with AN5568 for 6 hours at 10× EC50. In general, long 
chain fatty acids showed decreased abundance, although there were putative fatty acids showing increased 
abundance, such as eicosanoic acid (A). However, identification of these metabolites was complex, and many 
showed high numbers of isomers. Therefore, the identification of [FA (20:0)] eicosanoic acid (A, 11 isomers), 
decanoic acid (B, 9 isomers) and tetradecanoic acid (C, 15 isomers) is putative at best. Interestingly, glycerol-
3-phosphate, a precursor of cardiolipin synthesis, was significantly decreased in benzoxaborole-treated cells 
(D). In addition, L-carnitine, an important molecule for the transport of fatty acyl chains into mitochondria, 
was also significantly decreased in abundance (E), thereby supporting the microscopy observations regarding 
damage in the mitochondria upon AN5568 treatment. 
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Another result of possible intrigue was a sharp decrease seen in L-carnitine abundance (fig. 3-11E). 
This molecule is crucial for the transport of acyl groups from fatty acids into the mitochondrial 
matrix for β-oxidation (Gilbert & Klein, 1982, Klein et al., 1982). Therefore, its decrease suggests 
this process has been downregulated either intentionally, or as a result of drug treatment. We were 
unsuccessful in finding carnitine derivatives such as acylcarnitines in this experiment. However, 
several acylcarnitines were identified putatively in further experiments involving Leishmania 
mexicana promastigotes (section 3-6). Perhaps the most interesting type of lipid to further 
investigate in the context of mitochondrial biology, would be cardiolipins (IUPAC name: 1,3-bis(sn-
3’-phosphatidyl)-sn-glycerol), as these usually constitute approximately 20% of the inner 
mitochondrial membrane, a higher concentration than in any other organelle membrane 
(Serricchio & Butikofer, 2012). However, its size (monoisotopic mass: >1,000) makes it difficult to 
detect by pHILIC mass spectrometry due to the possibility of complex fragmentations as well as 
lipids possessing a decreased ionising capability, and it was not found in this study. However, 
glycerol-3-phosphate, a precursor of the cardiolipin synthesis pathway, was found at decreased 
levels in AN5568-treated cells (fig. 3-11D). Whilst this could be indicative of decreased 
mitochondrial lipids, it is clear that glycerol-3-phosphate has diverse roles in the cell including as a 
component of glycolysis, and caution must be taken before reaching any conclusions with regards 
to this particular metabolite. 
A trend of general decrease was seen in phosphatidylcholine (PC) and phosphatidylethanolamine 
(PE) metabolism (fig. 3-12). These molecules are all important components of membranes of both 
the whole cell, as well as individual organelles, and are the largest class of phospholipids in T. brucei 
(Smith & Butikofer, 2010). Whilst there was a clear pattern, we were unsure whether this was a 
direct result of the benzoxaborole, or perhaps a general result of cell death. Ongoing work in the 
Barrett group is currently observing the metabolic signatures of trypanosome cell death (D. Kim, 
personal communication), and the outcome of these analyses should be analysed in the context of 
drug treatment as well. Furthermore, the rounding of cells seen after 12 hours of AN5568 treatment 
at 10× EC50 (fig. 3-4) could suggest that the outer membrane of the cell becomes severely 
compromised after drug treatment, which might explain the general loss of lipids in the drug-
treated samples as they diffuse into the extracellular environment. 
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Figure 3-12: AN5568 causes decreased abundances in lipids derived from phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE). These lipids are amongst the most abundant phospholipids found in T. 
brucei and are synthesised in the ER and on the ER membrane. These lowered abundances suggest reduced 
ER activity, but could also indicate loss of lipids due to cell death. The number of isomers predicted by the 
Ideom software are given in square brackets. 
3.4.4 Further changes of interest 
An untargeted metabolomics approach allowed us to look at all results in a hypothesis generating 
manner, rather than with preconceived ideas. Using this approach, we isolated several metabolic 
perturbations of interest, other than those mentioned previously. These are shown in table 3-2. 
Importantly, we were able to identify the benzoxaborole in metabolite extracts from AN5568-
treated parasites (m/z: 367.1005, RT: 4.63 mins). A further isotope of the drug, corresponding to 
an 11B isotope, was also found. Using the known isotope distribution of the common boron isotopes 
10B and 11B, we attempted to mine the metabolomics data to find other metabolites with a similar 
isotope distribution, as this could give an insight into potential metabolic activation of the drug. 
Whilst the mzMatch output data showed several possible molecules, the peak intensities were low 
and they were dismissed as background noise after analysis of the raw data. We were therefore 
unable to confirm whether the drug requires metabolic activation. 
There were several further perturbations in amino acid metabolism. Several acetylated or 
hydroxylated amino acids, such as N6-acetyl-L-lysine, were increased, perhaps indicating increased 
post-translational modifications occurring as a response to benzoxaborole treatment. Modification 
on lysine residues are often found in proteins such as histones, although it is unclear what could 
cause increases in free acetyl-L-lysine. There was also increased (R)-2-hydroxyglutarate (m/z: 
148.0371, RT: 17.51 mins) present in AN5568-treated cells. 
 
 
 
80 
Measured 
Mass R
e
te
n
ti
o
n
 t
im
e
 
Predicted 
formula N
o
. 
is
o
m
e
rs
 
Putative metabolite ID F
o
ld
 c
h
a
n
g
e
 i
n
 
A
N
5
5
6
8
-t
re
a
te
d
 
ce
ll
s 
FDR 
73.05280 7.67 C3H7NO 6 Aminoacetone 12.06 0.01213 
188.11619 14.70 C8H16N2O3 7 N6-Acetyl-L-lysine 2.83 0.00056 
148.03710 17.51 C5H8O5 18 (R)-2-Hydroxyglutarate 2.18 0.02035 
173.08010 16.17 C6H11N3O3 1 5-Guanidino-2-oxopentanoate 2.01 0.00020 
129.07899 7.76 C6H11NO2 9 N4-Acetylaminobutanal 1.71 0.00156 
187.12085 13.75 C9H17NO3 3 8-Amino-7-oxononanoate 8.43 0.03460 
244.08837 7.71 C10H16N2O3S 1 Biotin 0.66 0.10260 
177.06370 15.30 C6H11NO5 1 4-Hydroxy-4-methylglutamate 3.46 0.00207 
194.07902 15.07 C7H14O6 18 1-O-Methyl-myo-inositol 0.73 0.01799 
230.01903 18.15 C5H11O8P 16 D-Ribose 5-phosphate 0.60 0.00100 
161.06868 18.75 C6H11NO4 10 N-Methyl-L-glutamate 0.75 0.01297 
367.10048 4.63 C17H14BF4NO3 1 AN5568 246.02 0.03408 
252.13595 3.91 C14H20O4 1 ubiquinol-1 1.63 0.00513 
165.06522 10.61 C6H7N5O 5 7-Methylguanine 0.78 0.01211 
111.04324 13.34 C4H5N3O 1 Cytosine 0.62 0.00002 
138.03168 18.75 C7H6O3 7 4-Hydroxybenzoate 1.76 0.00653 
Table 3-2: Further changes in T. brucei metabolism after AN5568 treatment, that were not associated 
with one particular pathway. Additional analysis of the Ideom results file showed several other metabolites 
that were significantly changed in AN5568-treated cells. Whilst these metabolites could not be linked to one 
particular pathway, they could offer further clues of specific changes occurring in the T. brucei metabolome 
as a result of drug treatment. 
The analyses also showed a large increase in putatively identified aminoacetone. This compound, 
also known as 1-amino-2-propanone, is a secondary amino ketone and is a product of 
aminoacetone synthase (glycine C-acetyltransferase) (Linstead et al., 1977). A older study showed 
that the activity of this enzyme is tightly coupled to L-threonine dehydrogenase in vertebrates, and 
is involved in L-threonine catabolism (Aoyama & Motokawa, 1981), an important mitochondrial 
metabolic network in PCF trypanosomes, that has also recently been found to be essential in BSF 
parasites (Mazet et al., 2013). Linstead and colleagues discussed in their study that L-threonine 
breakdown proceeds via 2-amino-3-oxobutyric acid, which spontaneously decarboxylates to 
aminoacetone in a pathway that ultimately generates glycine and acetate (Linstead et al., 1977). 
Several studies have more recently identified aminoacetone as a source of methylglyoxal in 
diabetes patients, where it increases in cases of nutritional deprivation (Sartori et al., 2008). In the 
context of AN5568-treatment, increase in aminoacetone could suggest perturbations in 
mitochondrial metabolism, or in acetate production, which could be consistent with the general 
downward trend in lipid abundance. 
Carbohydrate metabolism was largely unchanged. Glycolysis components were not significantly 
different in drug-treated samples. However, we found metabolites in the pentose phosphate 
pathway to be decreased, with a putatively identified ribose 5-phosphate (m/z: 230.0190, RT: 18.15 
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mins) a good example of this. However, it must be noted that ribose 5-phosphate could be a 
fragment of a larger structure. In addition, it is impossible to distinguish ribose from other pentose 
sugars which are not involved in the PPP. 
3.4.5 Comparison of AN5568 & sinefungin metabolotypes 
Previous data generated by the Barrett group using AN5568 support the data presented here. In 
particular, high levels of S-adenosyl-L-methionine and 5’-MTA were seen during preliminary 
experiments (Creek & Barrett, unpublished). The prevailing theory that a methyltransferase 
reaction might be the drug target led to the comparative analysis of the metabolic profile of 
AN5568-treated and sinefungin-treated parasites. Sinefungin is a naturally occurring AdoMet 
analogue (fig. 3-13A). Whilst structurally related to AdoMet, it contains an amino methylene group 
in place of the methylated sulfonium group that usually acts as the methyl donor (Devkota et al., 
2014). Thus, the molecule inhibits AdoMet-dependent methyltransferase reactions in a non-
specific/non-selective manner (Vedel et al., 1978). 
After calculating the EC50 of sinefungin to be approximately 1.0 nM in Lister 427 trypanosomes, we 
looked at the possibility of AN5568-sinefungin interactions by carrying out an isobologram (fig. 3-
13B). Isobolograms show whether there are synergistic, antagonistic, or additive effects between 
two drugs. This experiment suggests an antagonistic drug-drug interaction because the addition of 
one drug causes the overall efficacy of the other to diminish. Further analyses of these data showed 
that the ΣFIC for AN5568 and sinefungin were 5.28 and 8.02 respectively. The mean ΣFIC was 
therefore 6.65, which indicates significant antagonism between the 2 drugs (Seifert et al., 2011). 
This result indicates that the two drugs might act on similar protein targets or metabolic pathways. 
Another possibility is that the two drugs are transported through the same routes. Sinefungin is 
non-specific, affecting the AdoMet binding pocket on MTases, and affects most organisms to a 
similar degree. Thus, the mode of action of this drug probably differs from that of AN5568. 
Furthermore, given the contrasting structures, should these two drugs target similar classes of 
proteins, one would assume they do so with different mechanisms, especially since the 
benzoxaborole maintains a strong affinity for diols, which has not been shown for sinefungin. 
 
 
82 
 
Figure 3-13: Comparative analysis of metabolic profiles of AN5568-treated and sinefungin-treated T. 
brucei. A) The structure of sinefungin. This compound is an AdoMet analogue, and therefore binds strongly 
to the AdoMet-dependent MTase domain of MTases and inhibits them. B) A fixed-ratio isobologram was carried 
out using sinefungin and AN5568. Data showed that there is significant antagonism between the two drugs, 
suggesting they could act on the same pathway, or interfere with each other’s mechanisms of drug action. 
C) Comparative metabolomics analysis was carried out to assess any similarities between the metabolomes 
of sinefungin-treated and AN5568-treated cells. Whilst the wild-type samples separated well, both drug-
treated samples showed overlap, thereby supporting the results obtained from isobologram experiments. 
Having established a potential link between the two drugs, we next looked at the metabolic profile 
of sinefungin-treated cells and compared them to both a wild-type, DMSO-treated control and an 
AN5568-treated sample group. Interestingly, a PCA plot of the 9 samples suggested an overlap 
between the two drug-treated samples, again highlighting potential similarities between the modes 
of action of AN5568 and sinefungin (fig. 3-13C). We further analysed this by looking at single 
metabolites in detail (fig. 3-14). 
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Given the metabolic changes occurring in AN5568-treated cells, and the hypothesis that 
methyltransferase inhibition should give rise to changes in methionine metabolism, the changes in 
these pathways were investigated first (fig. 3-14A). As expected, both AdoMet and 5’-MTA were 
significantly increased in comparison to a DMSO control, in both drug-treated sample groups. 
However, the fold change in sinefungin-treated cells was overall lower than that in AN5568-treated 
cells. For AdoMet, there was a 4.10-fold increase in sinefungin-treated cells, whilst the increase was 
7.67-fold in AN5568-treated cells. Similarly, 5’-MTA was increased 3.66-fold and 6.17-fold in 
sinefungin-treated and AN5568-treated samples respectively. Whilst both sample groups were 
treated at 10× EC50 for 6 hours, the absolute concentrations of the drugs contrasted significantly, 
which could lead to more extreme perturbations for some metabolites. 
Somewhat interestingly, there was no apparent change in S-adenosyl-L-homocysteine (AdoHcy, 
m/z: 384.1216, RT: 15.32 mins) levels after sinefungin treatment (fig. 3-14A). Given the high levels 
of AdoMet and 5’-MTA resulting from methyltransferase inhibition after sinefungin treatment, we 
hypothesised there would be a corresponding decrease in AdoHcy and downstream metabolites 
such as L-homocysteine (Hcy) and L-cystathionine. However, sinefungin treatment does not lead to 
these expected changes. It is possible that the balance of the hydrolysis reaction between AdoHcy 
and Hcy is highly regulated, potentially by lysine acetylation on S-adenosyl-L-homocysteine 
hydrolase (AdoHcyH), the enzyme that catalyses this reaction (Wang et al., 2014b). Therefore, 
MTase inhibition could leave the AdoHcy pool only moderately changed, whilst causing the high 
levels of AdoMet and its degradation products, as seen in these data. Interestingly, acetylated free 
L-lysine was found to increase in AN5568-treated samples, but we could not deduce whether this 
was linked to AdoHcyH. Nonetheless, given the metabolic profile of sinefungin-treated cells, it is 
likely that methyltransferase inhibition, albeit with a different mechanism, could be a target of 
AN5568. Methyltransferases are a highly divergent class of proteins with very small sequences 
conserved across the group, such as the binding sites of the AdoMet substrate (Wlodarski et al., 
2011). However, members of this class can possess similar domains depending on the methylation 
target. For example, most lysine MTases possess a SET domain (Schubert et al., 2003). Should this 
domain be targeted, it is likely that many lysine MTases would be inhibited. 
Importantly, there were also marked differences between the metabolic profiles of AN5568- and 
sinefungin-treated cells. Sinefungin, unlike AN5568, is a non-specific inhibitor of AdoMet-
dependent MTases, thereby affecting a high number of metabolic pathways. One example is the 
biosynthesis of ovothiol (fig. 3-14B). This metabolite is through to be synthesized in situ through 
AdoMet-dependent methylation of mercaptohistidine (Ariyanayagam & Fairlamb, 2001). Whilst we 
could only see a putatively labelled mercaptohistidine with low confidence, putative peaks 
predicted to correspond to Ovothiol A (m/z: 201.0572, RT: 17.55 mins) as well as ovothiol disulfide 
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(m/z: 400.0987, RT: 17.38 mins), the reduced form of the metabolite, were found in the datasets 
(fig. 3-14B). Our data showed a large reduction in this metabolite after sinefungin-treatment, 
suggesting inhibition of the corresponding methyltransferase by the compound. 
In addition, sinefungin left the polyamine pathway largely unchanged (fig. 3-14C). This was in stark 
contrast to AN5568, which appeared to cause upregulation of this pathway, possibly due to the 
stress-inducing effects of the benzoxaborole. This pathway is upregulated in response to oxidative 
stress with the end product, trypanothione, being a highly potent reducing agent (Fairlamb et al., 
1985). These data would indicate that the cells are undergoing significant amount of oxidative 
stress, supported by the production of both trypanothione disulfide and ovothiol disulfide. 
These data also showed increased levels of ornithine (m/z: 132.0898, RT: 18.04 mins) in the 
AN5568-treated sample group. It is currently thought that ornithine is not synthesised in situ, but 
is transported from the extracellular environment (M. Barrett, personal communication), 
suggesting increased ornithine transport upon drug treatment (fig. 3-14C). We hypothesise the 
reason for this is increased polyamine synthesis in response to drug treatment. This pathway is 
involved in the oxidative stress response, and is unique in T. brucei, in particular due to the 
generation of trypanothione (Fairlamb et al., 1985, Henderson et al., 1990). One theory could be 
that mitochondrial defects, such as those observed by microscopy (fig. 3-3 & 3-4), cause leakage of 
mitochondrial material including reactive oxygen species generated by oxidative phosphorylation. 
This phenomenon could indeed lead to a strong oxidative stress response, and this might be worth 
investigating further. 
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Figure 3-14: Further analysis of metabolic changes in AN5568- and sinefungin-treated T. brucei. A) The metabolic phenotypes observed in methionine 
metabolism were consistent between both sample groups when compared to wild-type cells. However, AN5568 treatment led to much higher fold changes. 
Interestingly, AdoHcy did not decrease as expected in sinefungin-treated cells, suggesting AdoHcy is a poor marker for MTase inhibition. Abbreviations: AdoMet 
– S-adenosyl-L-methionine, AdoHcy – S-adenosyl-L-homocysteine, 5’-MTA – 5’methylthioadenosine, Lys(Me3) – N6,N6,N6-trimethyl-L-lysine, Lys(Me2) – N6,N6-
dimethyl-L-lysine, Lys(Me) – N6-methyl-L-lysine, Met – L-methionine. B) Sinefungin is a non-specific MTase inhibitor which led to defects in a wide range of 
MTase reactions. Ovothiol is a metabolite utilised in oxidative stress responses, and is generate by the methylation of mercapto-histidine. Whilst AN5568 caused 
increases in ovothiol, and its reduced form ovothiol disulphide, sinefungin treatment caused significant decreases in both metabolites, indicating that the 
MTase reaction had been severely affected by the drug. C) AN5568 also seemed to cause an upregulation of the trypanothione biosynthesis pathway, indicating 
a response to oxidative stress. This was not seen in sinefungin-treated cells. 
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3.5 Metabolism in AN5568-treated procyclic cells 
Metabolomics analyses of AN5568-treated PCF T. brucei were also carried out, in order to 
ascertain whether the benzoxaborole caused similar effects in parasites at this point in the T. 
brucei life cycle. For this study, PCF 427 Lister cells were used, in order to maintain consistency 
with the trypanosome strain, allowing comparisons between BSF and PCF cells. As shown by 
the initial in vitro study, this experiment required a significantly higher concentration of the 
benzoxaborole due to a high EC50. Therefore, 15 µM, equal to 10× EC50, was used for drug 
treatment, and cultures were incubated for 8 hours before metabolite extractions were carried 
out, as this was deemed to be an optimal time point given the preliminary in vitro data. Two 
sample groups were studied: A drug treated sample group of 4 independent replicates and a 
sample group consisting of 4 replicates treated with an equal volume of DMSO. 
Interestingly, the metabolic profiles of AN5568-treated PCF cells showed similar trends to those 
seen in BSF parasites. Again, AdoMet (m/z: 398.1386, RT: 13.88 mins) and 5’-MTA (m/z: 
297.0898, RT: 7.69 mins) were highly increased after drug treatment. In addition, methylated 
lysines were found in higher abundance than in control samples (fig. 3-15). Also comparable 
with BSF drug treatment were the lack of changes in methylated arginine, in contrast to lysine. 
Indeed, acetylated lysine was also increased in AN5568-treated PCF cells, as they were in BSF 
cells (fig. 3-15). GDP-mannose, which was found to increase in BSF parasites treated with 
AN5568, was not detected in this experiment. However, UDP-N-acetyl-D-glucosamine, which is 
also involved in GPI biosynthesis, was increased in a similar manner as that seen in AN5568-
treated BSF cells (fig. 3-15). Finally, an increase in L-cystathionine (m/z: 222.0677, RT: 14.25 
mins) was again seen (fig. 3-15) in this dataset. 
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Figure 3-15: Metabolic changes occurring after AN5568 treatment of PCF T. brucei. Many of the 
changes seen in BSF cells subsequent to treatment with AN5568 were also observed in PCF cells. Increases 
were seen in AdoMet (m/z: 398.1386, RT: 13.88 mins), 5’-MTA (m/z: 297.0898, RT: 7.69 mins) and 
adenine (m/z: 135.0544, RT: 10.01 mins), as well as a slight increase in L-methionine (m/z: 149.0511, 
RT: 11.34 mins). Another similarity was widespread increases in abundance of modified lysine residues 
such as N6-methyl-L-lysine (m/z: 160.1211, RT: 18.59 mins), N6,N6,N6-trimethyl-L-lysine (m/z: 
188.1227, RT: 17.69 mins) and N6-acetyl-L-lysine (m/z: 188.1160, RT: 12.05 mins). There was an increase 
in L-cystathionine (m/z: 222.0677, RT: 14.25 mins), which is generated downstream from the MTase 
reaction. There were similar changes in carbohydrate metabolism, with increases seen in N-acetyl-D-
glucosamine (m/z: 221.0901, RT: 11.54 mins) and UDP-glucose (m/z: 566.0551, RT: 13.61 mins), and 
finally, an increase in 8-amino-7-oxononanoate (m/z: 187.1210, RT: 11.65 mins), the role of which is 
unknown in T. brucei. 
The PCF dataset was also analysed for key differences between BSF and PCF AN5568-treated 
cells (fig.3-16). An increase was observed in a metabolite predicted to be 3-demethylubiquinol, 
which is found in the ubiquinol biosynthesis pathway (Chaudhuri et al., 2006). Interestingly, this 
metabolite undergoes an MTase reaction with AdoMet as donor, leading to the formation of 
ubiqionol-9, which is a substrate for the trypanosome alternative oxidase (TbAOX), an 
important component of the mitochondrial electron chain (Chaudhuri et al., 1995, Fang & 
Beattie, 2003). An increase in 3-demethylubiquinol could suggest inhibition of the 3-
demethylubiquinol 3-O-methyltransferase. 
Other differences included high levels of thiamin in PCF cells treated with AN5568, which was 
not observed in BSF cells. Thiamin is an important component in energy metabolism, and it is 
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thought that the metabolite is synthesized by the parasite, as uptake has not been observed 
(Stoffel et al., 2006). Another interesting change was 4-hydroxy-4-methylglutamate (fig. 3-16). 
During metabolomics analysis with BSF parasites, this metabolite, derived from glutamate, was 
found to increase subsequent to AN5568-treatment. In contrast, it was decreased following 
AN5568-treatment in PCF cells. There is no literature on this metabolite in protozoan parasites, 
although it has been found to accumulate in plants (Kakule et al., 2015). Here, it is proposed 
that the metabolite is generated using pyruvate as a precursor, in a reaction catalysed by an 
aldolase (Kakule et al., 2015). Pyruvate is produced at high levels as a glycolytic waste product 
in BSF T. brucei. In PCF cells pyruvate is used in pathways synthesising either succinate or 
acetate. This has also recently been shown to occur in BSF cells (Mazet et al., 2013). Whilst 
acetate was not detected in this experiment, both succinate and pyruvate were found not to 
undergo any significant changes following treatment with AN5568 (fig.3-16). 
 
Figure 3-16: Further metabolic changes in AN5568-treated PCF T. brucei parasites. Much like BSF T. 
brucei, 8-amino-7-oxononanoate was increased in AN5568-treated cells. In contrast, 4-hydroxy-4-
methylglutamate was decreased in AN5568-treated PCFs. Another change not observed in BSF cells was 
increased levels of thiamin. Finally, components of energy metabolism such as pyruvate and succinate 
appeared unchanged in drug-treated cells, as seen in BSFs. 
The results presented here indicate that similar changes occur in PCF cells, in addition to a 
couple of key differences that should be analysed further. Unfortunately, these differences 
occur with metabolites whose roles are not understood well in trypanosomatids. As mentioned 
above, the concentration of drug required to elicit the same metabolic responses are 
significantly higher for PCF cells, suggesting that the target is either less essential in procyclics, 
or it is present in higher abundance. There is also a chance that high concentrations of the 
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benzoxaborole lead to lethal non-specific effects on the cell, although the metabolomics data 
does not support this hypothesis. Finally, another difference between BSF and PCF cells that 
could influence the efficacy of the drug is the differential expression of transporters between 
the two life cycle stages. However, as mentioned previously, SAR knowledge on this 
benzoxaborole is scarce, and the uptake mechanisms are currently unknown. 
3.6 AN5568 elicits a similar metabolic response in L. mexicana 
Trypanosoma brucei is a member of the kinetoplastidea, which also includes Trypanosoma 
cruzi, the causative agent of Chagas disease in South America, and Leishmania spp., parasites 
responsible for the Leishmaniases. To determine whether AN5568 is active against these other 
protozoans, collectively called the TriTryps, we sought to analyse the metabolome of AN5568-
treated leishmania cells. L. mexicana promastigotes are easily cultivated in laboratory culture, 
and a drug-treatment incubation was set-up after the EC50 was calculated to be 37.8 ± 3.7 µM. 
Firstly, growth of cells was measure in various concentrations of the benzoxaborole (fig. 3-17). 
As was observed with PCF T. brucei cells, the benzoxaborole did not completely kill L. mexicana 
parasites, even after 24 hours (fig. 3-17). Whilst cell division seemed to have been abolished, 
live cells were seen even at the highest concentration of benzoxaborole used in both growth 
curves. Furthermore, growth was static even at 10× EC50 AN5568 (fig. 3-17B).  
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Figure 3-17: Effect of AN5568 on in vitro growth of L. mexicana promastigotes. Cells were grown in 
the presence of varying concentrations of the benzoxaborole. A) In the first experiments, concentrations 
were replicated from a previous publication by Jacobs and colleagues (Jacobs et al., 2011). This showed 
that concentrations as low as 0.08 µg/mL were sufficient to cause a decrease in growth rate after 24 
hours. The extent of cellular growth decreased with every doubling of the AN5568 concentration. 
However, at 40 µg/mL, there were still live cells visible in the cultures. B) The EC50 of AN5568 in L. 
mexicana was calculated to be ~38 µM, which corresponds to 14 µg/mL. Interestingly, cells treated with 
this concentration were equally resilient as those treated with 10× EC50 (140 µg/mL). In both cases, cell 
density was stationary, although live cells were observed 24 hours after drug treatment. 
Metabolite extracts were prepared after a 6-hour incubation with 10× EC50 concentration of the 
benzoxaborole. Mass spectrometry analysis was carried out by Glasgow Polyomics, and data 
was processed using the same mzMatch/Ideom pipeline as described in the methods. 
Interestingly, the metabolic changes post-treatment were very similar to those observed in T. 
brucei (fig.3-18). AdoMet (m/z: 398.1372, RT: 111.14 mins), 5’-MTA (m/z: 297.0896, RT: 6.97 
mins) and adenine (m/z: 135.0545, RT: 8.30 mins), were again found at high levels in drug-
treated samples (fig. 3-18). In addition, there was a similar increase in modified lysines in drug-
treated cells, although dimethyl-L-lysine (m/z: 174.1368, RT: 15.11 mins) was not found to 
increase in this experiment (fig. 3-18). 
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Figure 3-18: AN5568 causes metabolic perturbations in L. mexicana that are similar to those 
observed in T. brucei. The most significant metabolic phenotypes in BSF and PCF T. brucei treated with 
AN5568 were increased levels of AdoMet, 5’-MTA and adenine. These metabolites, along with L-
methionine, were again increased in L. mexicana promastigote samples after 10× EC50 (380 µM) drug 
treatment (A). Whilst N6,N6-dimethyl-L-lysine did not show variation between the two sample groups, 
N6,N6,N6-trimethyl-L-lysine was increased after drug treatment, similar to T. brucei cells. Interestingly, 
NG,NG-dimethyl-L-arginine was found to increase subsequent to AN5568-treatment, in contrast to T. 
brucei, where no increase was detected. Further changes were seen in (S)-3-methyl-2-oxopentanoic acid, 
pyruvate and GDP-mannose. 
Again, key differences were observed between AN5568-treated T. brucei and L. mexicana (fig. 
3-19). One of the most intriguing results in this dataset was high levels of putative carnitine 
derivatives, which were not seen in the control group (fig. 3-19).  These derivatives were also 
not seen in other metabolomics experiment and could appear due to defects in lipid transport 
across the mitochondrial membranes. In addition, there were increases in putative lipid 
metabolites (fig. 3-19). This was in stark contrast to the T. brucei results, which indicated 
decreased lipids (fig. 3-11-3-12). There are several reasons this phenomenon could have 
occurred. L. mexicana are a different species of kinetoplastid, and thus exhibit differences in 
the overall “lipidome”, as reviewed by Smith and Butikofer (Smith & Butikofer, 2010). In 
addition, significant metabolic changes occur throughout the differential life cycles of 
trypanosomatids. In the case of Leishmania, promastigotes colonise the insect vector, whilst 
amastigotes are mammalian infective. Therefore, the parasites used in this study are more 
 
 
92 
similar to PCF T. brucei, and comparisons would be predicted to be weaker between L. mexicana 
promastigotes and T. brucei BSF parasites. 
 
Figure 3-19: Changes in lipid metabolism after AN5568-treatment of L. mexicana promastigotes. 
There were significant perturbations in carnitine metabolism, with several derivatives observed only in 
AN5568-treated cells. L-carnitine itself was increased in abundance in drug-treated cells, as well as 
linoelaidylcarnitine, heptadecanoylcarnitine, elaidiccarnitine, tetradecanoylcarnitine, O-palmitoyl-R-
carnitine and stearoylcarnitine. This might reflect increased mitochondrial metabolism in AN5568-treated 
cells.  
With regards to key differences in lipid biosynthesis, one interesting features of Leishmania is 
their ability to synthesize phosphatidylcholine (PC) from phosphatidylethanolamine (PE). This is 
a conserved process in eukaryotic cells that forms part of the Kennedy pathway (Gibellini et al., 
2009). In Leishmania, PE can be methylated to PC, but the enzyme for this reaction, PE N-MTase, 
has not been found in the trypanosome genome (Smith & Butikofer, 2010). PE itself is a product 
of the Kennedy pathway that involves conversion of ethanolamine to CDP-ethanolamine. In 
addition, a similar pathway converts choline to CDP-choline, before PC is generated (Farine et 
al., 2015). Of the metabolites that were found in AN5568-treated T. brucei, the majority were 
found in lower abundance (fig. 3-12). However, they were all increased in L. mexicana cells, 
which could indicate that the benzoxaborole targets different pathways in each organism. On 
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the other hand, this result in particular could also suggest that the benzoxaborole possesses 
several targets including, for example, the PE N-MTase in Leishmania. 
3.7 Targeting methionine metabolism  
Currently, it is not thought that T. brucei recycles, or synthesises, L-methionine (Hasne & 
Barrett, 2000). It must therefore transport L-methionine into the cytoplasm from its 
extracellular environment. This methionine is then incorporated into AdoMet, as discussed in 
chapter 1. As we were able to observe several significant changes in methionine metabolism, 
we hypothesized that the benzoxaborole might affect methylation. To further investigate this 
hypothesis, we pursued a targeted metabolomics experiment utilizing methionine universally 
labelled with stable carbon isotopes (13C). This way, AdoMet becomes labelled with 5 carbon 
isotopes which can be traced throughout the metabolome to search for changes between 
control and AN5568-treated sample groups.  
For this experiment, cells were grown in Creek’s minimal medium (CMM), a semi-defined 
medium containing far less components when compared to standard culturing media such as 
HMI-9 (Hirumi & Hirumi, 1989, Creek et al., 2013). In addition, this medium allowed us to add 
100% 13C-(U)-methionine at a final concentration of 200 µM. This methionine was added and 
cell pellets, as well as spent medium, were analysed after 6 hours, in addition to a non-labelled 
control at 0 hours. Labelling patterns were analysed using mzMatch-ISO, an R-based package 
that calculates isotope labelling distributions (Chokkathukalam et al., 2013). The results were 
analysed in the context of methionine metabolism, using metabolic pathways from Kegg and 
Metacyc (Caspi et al., 2006, Okuda et al., 2008, Caspi et al., 2015). 
Using this pipeline, several hundred metabolites were identified by mzMatch-ISO after scanning 
the data for each metabolite in the KEGG database (Okuda et al., 2008).  However, a surprisingly 
small number of these showed any isotope labelling from L-methionine, suggesting that 
carbons from this source are only used by the parasite for very specific pathways, or that further 
labelling is a slow process and thus, requires longer than 6 hours before isotope labels are 
incorporated. There were 17 labeled metabolites detected in positive mode, whilst a further 8 
were identified in negative mode. These data are presented in the supplementary data (S2). 
The mzMatch-ISO output data was subsequently manually filtered to remove peaks with high 
amounts of background noise. 
Whilst AdoMet is a widely used methyl donor, it is mainly used as a substrate for nucleic acid 
or protein methylation, which could explain the low number of 13C-labelled metabolites. In 
addition, the experimental data presented here was generated from a 6 hour time-course, 
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which might not have been sufficient for some methylation pathways to incorporate 13C 
isotopes. For example, we could not detect arginine methylation (S2).  
 
Figure 3-20: Heat plot showing metabolic changes upon AN5568 treatment in both intracellular 
metabolism and spent medium. Both intracellular metabolites and spent medium metabolites were 
analysed in this experiment. There was a significant difference in metabolic profile between cell pellets 
and spent medium, which was expected, given the difference between the two sample groups. The heat 
map shows large amounts of variation within sample groups (for example, the first replicate taken from 
the AN5568-treated 6-hour time-point), which was important to consider for downstream analyses. Heat 
map was generated by Euclidian distance measures using the Ward clustering algorithm, in the 
Metaboanalyst tool (Xia et al., 2015). 
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3.7.1 Changes in 13C labeling patterns across the metabolome 
We first looked at methionine metabolism in detail (fig. 3-21). After 6 hours post-treatment, we 
saw similar changes to those in previous metabolomics experiments. In particular, the high 
increases seen in AdoMet (m/z: 298.1370, RT: 13.49 mins) and 5’-MTA (m/z: 297.0892, RT: 
13.50 mins) were apparent. This highlighted the reproducibility of the results, and helped to 
confirm these changes are real, and significant. However, L-methionine itself (m/z: 149.0512, 
RT: 10.92 mins) was not increased in the same manner as recorded previously (fig. 3-21). This 
could be due to the change in culture mediums, although at 200 µM, HMI-9 contains similar 
amounts of L-methionine as CMM, excluding the serum contents. The other result that was 
highly reproducible was the decrease observed in AdoHcy (m/z: 384.1222, RT: 12.08 mins). 
Using the mzMatch-ISO package (Chokkathukalam et al., 2013), we next analysed the patterns 
of 13C distribution, and how these isotopes disseminated through the metabolome after 
addition of 13C-(U)-L-methionine (fig. 3-21). After 6 hours, there were no changes in labelling 
distribution in metabolites involved in methionine degradation. In addition, whilst the culture 
medium contained 100% 13C-(U)-L-methionine, intracellular L-methionine was not 100% 
labelled after 6 hours (fig. 3-21), suggesting uptake is slow compared to, for example, glucose, 
which shows 100% labelling within minutes post-incubation (Creek et al., 2015). 
Both AdoMet and 5’-MTA showed approximately 75% labelling in the presence and absence of 
AN5568 (fig. 3-21), whilst AdoHcy and L-cystathionine were approximately 50% labelled. 13C 
isotopes were also used in the methylation reactions of L-lysine, an important post-translational 
modification, discussed in detail below. In contrast, we could not find any labelling of arginine 
after 6 hours in the presence, or absence of AN5568, suggesting the methylation of this amino 
acid is a much slower process compared to lysine methylation. Arginine methylation has been 
shown to originate from AdoMet and thus, L-methionine (F. Achcar, personal communication).  
The labelling data presented here indicate that there is no specific point in the metabolome 
where carbon distribution originating from L-methionine is perturbed. In particular, AdoHcy is 
still labelled after AN5568-treatment, which suggests that methyltransferase reactions are still 
occurring, albeit at a potentially lower overall rate. Indeed, this could highlight the specificity of 
the AN5568 protein target. This is supported by the observation of methylated lysines. An in 
depth study of methylation patterns in the proteome could potentially indicate more specific 
changes, should a particular enzyme be inhibited. This type of study has recently been 
completed for the S. cerevisiae proteome, where a significant number of previously 
unannotated methylation events were uncovered (Wang et al., 2015). 
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Figure 3-21: Tracing 13C distribution in cells incubated with 13C-(U)-L-methionine and treated with AN5568. Cells were incubated with 200 µM 13C-(U)-L-methionine for 6 
hours. In addition, one sample group was incubated with 10× EC50 AN5568. Firstly, methionine metabolism was analysed. After 6 hours, there were still significant increases in 
the metabolites previously seen to increase. In addition, intracellular L-methionine was not 100% labelled, suggesting that uptake is relatively slow compared to, for example, 
glucose uptake. Interestingly, whilst only small amounts of AdoMet and 5’-MTA were detected in WT samples, they showed almost 100% labelling, suggesting these metabolites 
all originate from L-methionine. In contrast, these metabolites were only ~75% labelled in drug-treated samples, suggesting they might be recycled, or the build-up initiates very 
quickly after drug treatment. AdoHcy was also detected, with 4 13C labels, as expected. In addition, L-cystathionine had 4 13C labels, and was found to increase, as seen previously. 
This means that MTase reactions are still occurring, but perhaps only very specific reactions are being affected. This would be masked in these data. Arrows indicate metabolites 
that were found to change in abundance, but were not labelled. Where no arrow or graph is shown, the metabolite was not detected. 
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3.7.2 Lysine is methylated in an AdoMet-dependent fashion, but is not 
involved in carnitine biosynthesis 
An interesting result regarding lysine methylation was uncovered from the dataset (fig. 3-22). 
Lysine methylation plays an important biological role in all living organisms, including T. brucei 
as a post-translational modification (Janzen et al., 2006). In the metabolomics dataset, both 
mono-methylated lysine and tri-methylated lysine were found to be highly increased after 
AN5568 treatment. Furthermore, a large percentage of these metabolites were labelled with 
heavy carbon isotopes, suggesting that the methylation is AdoMet dependent (fig. 3-22). 
In mammalian cells, methylation of lysine is part of the carnitine biosynthesis pathway, which 
is also referred to as the L-lysine degradation pathway (Hoppel et al., 1980). Carnitine is an 
important molecule used to transport fatty acids across the mitochondrial membrane (Klein et 
al., 1982). Therefore, we looked at L-carnitine and its derivatives in AN5568-treated parasites. 
Interestingly, we did not find the same methylation pattern in L-carnitine (fig. 3-22). This 
suggests that the L-carnitine biosynthesis pathway does not exist in T. brucei. Indeed, previous 
studies have suggested that the parasite obtains this metabolite exclusively from its external 
environment (Gilbert & Klein, 1982, Klein et al., 1982). The results shown here support these 
previous conclusions. 
Given these results, it is important to understand the reasons behind the increased levels of 
free methylated lysine residues. These modifications are crucial in the activation of proteins, 
for example, on histones (Janzen et al., 2006, Gassen et al., 2012). It is also possible that these 
lysines are involved in the synthesis of tRNA, which is known to involve many complex PTMs 
(Swinehart & Jackman, 2015). To understand the origin of these methylated lysines, it would be 
necessary to look at PTMs on a proteomic level, allowing the analysis of methylation changes 
across the proteome. This is possible using mass spectrometry technologies as well as SILAC 
based approaches (Olsen et al., 2016). Another method that could be used to look at lysine 
methylation patterns are to use commercial antibodies and carry out a Western blot. Whilst 
this was attempted during this study, we were not able to optimise these in time for the 
completion of the project. This would be an interesting starting-point to analyse changes in 
lysine methylation upon AN5568-treatment. 
Interestingly, whilst L-carnitine does not seem to originate from lysine methylation in T. brucei, 
there was a decrease in the abundance of this metabolite after AN5568 treatment (0.66-fold 
change relative to untreated). This is an important point of discussion because L-carnitine is 
crucial in aiding the transport of long chain acyl groups from fatty acids into the mitochondrial 
matrix (Gilbert & Klein, 1982). Given the data mentioned above, the decreased levels of L-
carnitine support the theory that there are significant changes in the mitochondrion upon 
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AN5568 treatment. In addition, the observed decreases in lipid metabolism in general also 
correlate with L-carnitine downregulation. 
 
 
Figure 3-22: AN5568 causes significant changes in methylated lysine metabolism. AN5568-treated 
cells were observed to have highly increased levels of both mono-methylated and tri-methylated L-lysine. 
This is a common, and highly conserved, posttranslational modification that has been shown to play roles 
in a myriad of cellular processes. Interestingly, it was also observed that much of the methylation 
originated from L-methionine in MTase reactions. In mammalian cells, methyl-L-lysine degradation leads 
to the formation of L-carnitine, which was previously found to decrease after AN5568 treatment. 
However, we could not find any evidence of 13C-labeled L-carnitine, nor its derivatives. Indeed, previous 
studies have suggested that L-carnitine is solely obtained through uptake in T. brucei, and the results 
presented here support this theory. 
3.8 Knock-down of TbCgm1, a splice-leader methyltransferase 
An intense literature search for important and unique mechanisms of methylation in the 
trypanosomatids, led to the hypothesis that spliced leader methylation might be targeted by 
the benzoxaborole. As described in the introduction, spliced leader methylation is uniquely 
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complex in the tri-tryps, in comparison to other eukaryotes (Gunzl, 2010). A 39-nucleotide 
sequence is spliced to every mRNA transcribed, and we hypothesised that this process requires 
a significant quantity of AdoMet as the methyl-group supplying substrate. Indeed, this has led 
to previous discussions that the spliced leader complex machinery could be targeted by 
therapeutics against the parasite (Takagi et al., 2007). 
Previous studies have identified four MTases involved in methylation of the spliced leader cap. 
TbCgm1 (Tb927.7.2080) methylates the inverted guanosine cap, and is thought to be essential 
in BSF trypanosomes (Hall & Ho, 2006a, Ruan et al., 2007a, Takagi et al., 2007). TbMtr1, TbMtr2 
and TbMtr3 (Tb927.10.7940, Tb927.11.4890 and Tb927.9.12.040 respectively) are 2’-O-ribose 
MTases that methylate the first 4 bases of the spliced leader cap (Zamudio et al., 2007, Mittra 
et al., 2008, Zamudio et al., 2009). Importantly, several studies have found these to be non-
essential. Whilst methylation on the corresponding bases is abolished, there are no growth 
phenotypes associated with the knock-down of these 2’-O-ribose MTases (Zamudio et al., 
2006). 
Given the aforementioned findings, we chose to attempt an RNAi-mediated knock-down of the 
TbCgm1 MTase, and comparatively analyse the metabolic profile of this knock-down to that of 
AN5568-treated cells. For this experiment, the 2T1 cell line was used (Alsford et al., 2011), and 
a construct targeting this enzyme was made using the pGL2084 plasmids as described in section 
2.4.4. Integration of the construct into the vector was confirmed by a series of restriction digests 
(fig. 3-23A).  
A successful transfectant was isolated and characterised. qPCR analysis showed a 50% 
reduction in TbCgm1 transcript abundance by 24 hours (fig 3-23B). Consecutive days of 
tetracycline-mediated RNAi induction showed that 50% knock down was the highest amount 
possible (3-23B). In addition, growth analysis of the RNAi-induced cell line, compared to a 
culture grown in the absence of tetracycline, showed the appearance of a growth phenotype 
by 48 hours, with a significant inhibition of cellular growth (fig. 3-23C). Thus, we concluded that 
TbCgm1 protein to be essential in BSF T. brucei parasites. 
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Figure 3-23: Generation of a TbCgmRNAi cell line. An RNAi knock-down was generated using the 2T1 cell 
line (Alsford et al., 2011). A) A combination of restriction digests confirmed the insertion of two identical 
gene constructs into the pGL2084 plasmid. B) RNA was isolated every 24 hours over a period of 3 days 
post-induction. qPCRs were carried out on both uninduced and induced TbCgm1RNAi cells, which confirmed 
a 50% knock-down of the TbCgm1 gene. C) Comparative growth analysis of induced and uninduced cells 
showed a significant growth defect in the presence of tetracycline, thereby proving that the TbCgm1 
gene was indeed essential to BSF trypanosomes. 
The next step was to carry out untargeted metabolomics of the TbCgm1RNAi line and compare 
the RNAi induction metabolic phenotype to that of AN5568 cells. Tetracycline-mediated RNAi-
induction was done for 36 hours, before an uninduced culture was treated with 10× EC50 
benzoxaborole for 6 hours. In addition, an uninduced sample containing DMSO, as well as an 
RNAi-induced sample treated with AN5568 were also prepared. Samples were then extracted 
and run on a mass spectrometer as described in the methods. Data was processed using the 
mzMatch/Ideom pipeline. 
The triplicate samples in the dataset were compared first by analysis of variance using a PCA 
plot (fig. 3-24A). As expected, both drug-treated samples correlated closely. This also suggests 
that the effect of the drug is much stronger than the phenotype produced by RNAi-mediated 
knock-down of TbCgm1. However, the RNAi-induced cell line by itself did not correlate very well 
with either drug-treated sample, suggesting that the overall metabolotypes were different.  
 
 
101 
 
Figure 3-24: Metabolomics analysis of the TbCgmRNAi T. brucei cell line. Metabolite extractions were 
carried out on uninduced and induced cells, both in the presence and absence of 10× EC50 concentrations 
of AN5568 (6 hour incubation). Interference was induced for a total of 36 hours before extractions were 
carried out. A) A PCA plot of the four sample groups showed that both the drug-treated sample groups 
localised closely together, whilst good separation was achieved from the uninduced cell line. There was 
no significant overlap of the induced RNAi line in the absence of drug with any drug treated samples, 
suggesting that the metabolic phenotypes of these cells were somewhat different from those treated 
with AN5568. Moreover, this indicated that the drug treatment caused a much stronger phenotype than 
RNAi-mediated knock-down of TbCgm1. Legend: WT: TbCgm1RNAi in the absence of tetracycline; AN: 
AN5568-treated TbCgm1RNAi cells in the absence of tetracycline; TbCgm1: TbCgm1RNAi in the presence of 
tetracycline; TbCgm1_AN: AN5568-treated TbCgm1RNAi cells in the presence of tetracycline. B) Some of 
the candidate metabolites were analysed using the mzMatch/Ideom pipeline. Both AdoMet and 5’-MTA 
were not found to be altered in RNAi-induced cells, indicating that the TbCgm1 protein was most likely 
not the target. However, TbCgm1 knock-down did lead to increased levels of L-methionine and adenine, 
most likely due to perturbations in nucleotide metabolism, as well as ablation of protein synthesis, both 
of which are known to occur as a result of spliced leader methylation inhibition. 
We next analysed metabolites independently, to assess the metabolic changes occurring during 
TbCgm1 knock-down, and compare these changes to those occurring in drug-treated cells. 
Specifically, we targeted the changes that were known to occur during AN5568 treatment (fig. 
3-24B). There were no significant changes in either AdoMet levels, or 5’MTA levels, in the 
TbCgm1 knock-down (fig. 3-24B). However, interestingly, there was a large increase in L-
methionine, as well as adenine, both of which were seen to increase in AN5568-treated cells as 
well. 
The reason for these changes might well vary from why they occur in AN5568-treated cells. 
Inhibition of the TbCgm1 MTase is known to abolish the formation of mature mRNAs, and 
therefore, protein translation (Hall & Ho, 2006a, Takagi et al., 2007). This has several knock-on 
effects in the metabolome. Firstly, inhibition of protein synthesis could explain high levels of L-
methionine, which is no longer incorporation into peptide chains. Hypothetically, there would 
be significant changes in nucleotide metabolism in general, should both transcription and 
translation cease to function. 
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Indeed, when we looked closer at nucleotide metabolism in the TbCgm1RNAi line and compared 
it to AN5568-treated cells, we found large increases in almost every purine and pyrimidine that 
could be detected (fig. 3-25). The majority of these do not change in AN5568-treated cells, and 
therefore, this led to the conclusion that the MTase TbCgm1 cannot be the protein target of 
the benzoxaborole. However, the metabolic perturbations that result from spliced leader 
methylation inhibition are intriguing in their own right, and should be studied further. 
 
Figure 3-25: Comparative analysis of changes in nucleotide metabolism in the TbCgmRNAi cell line and 
AN5568-treated cells. The TbCgm1RNAi cells showed high increases in several metabolites associated with 
nucleotide metabolism, especially in comparison with cell treated with AN5568 alone. 
The data from the TbCgm1 knock-down were important to analyse, especially because it 
allowed us to understand whether the changes seen in AN5568-treated cells are indicative of 
spliced leader methylation inhibition. Given the data, we concluded that spliced leader 
methylation is not the target of the benzoxaborole. In particular, the lack of AdoMet and 5’-
MTA increase in TbCgm1RNAi is intriguing, because we had hypothesised these pathways would 
have been severely affected.  
There were other candidates under consideration for RNAi experiments. Recent publications 
have given further insight into the activation pathways associated with spliced leader function 
(Zamudio et al., 2009). In addition, there were other MTases that could have been worth 
knocking-down to observe metabolic changes. However, given the technical demands of 
developing these lines, and the costs associated with repeated mass spectrometry experiments, 
it was decided to search for other methods that could probe the possible mode of action of 
AN5568 further. 
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3.9 ER stress leads to metabolic perturbations also seen in AN5568 
treatment 
Further literature searches with the metabolomics results in mind led to another hypothesis 
centred on ER stress induction. As discussed previously, ER stress and protein unfolding 
predominantly leads to a conserved unfolding protein response (Smith et al., 2009, Goldshmidt 
et al., 2010). We hypothesised that ablation of transcription could lead to increased levels of 
AdoMet, due to the absence of spliced leader formation, and therefore, methylation. To 
observe the metabolic changes occurring as a result of ER stress, and more importantly, to 
compare these changes to those occurring in AN5568-treated cells, another metabolomics 
experiment was set-up, using the ER stress inducer dithiothreitol (DTT). This compound 
contains two S-H groups. It is a very strong reducing agent that acts by attacking disulphide 
bridges in two sequential thiol-disulphide exchange reactions which leave a 6-membered ring 
(Tiengwe et al., 2015). By attacking disulphide bridges, DTT disrupts protein folding, leading to 
the conserved response described above. 
3.9.1 ER stress results in upregulation of the trypanothione 
biosynthesis pathway 
Analyses of the dataset revealed that several components of the trypanothione biosynthesis 
pathway, which is involved in the oxidative stress response, were upregulated in DTT-treated 
cells. Both ornithine and glutathione were increased in similar fashion to AN5568-treated cells, 
suggesting this response was not specific to benzoxaborole treatment (fig. 3-26). In addition, 
trypanothione disulphide, which consists of two trypanothione molecules bound by a 
disulphide bridge, was decreased in DTT-treated cells, to a much greater extent than in those 
treated with AN5568 (fig. 3-26). This was most likely due to the effect of DTT in disulphide bridge 
disruption. 
Whilst lower levels of trypanothione disulphide were unsurprising, upregulation of the 
oxidative stress response pathway in the presence of a reducing agent was unexpected. It is 
possible that this upregulation was due to the need for the parasite to synthesise trypanothione 
disulphide, to counter the effect of the stress inducer. 
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Figure 3-26: Metabolic changes in the trypanothione biosynthesis pathway. There were similar perturbations observed between AN5568- and DTT-
treated cells. L-ornithine, an important precursor for the generation of spermidine, was increased in both sample groups, compared to untreated cells, 
as was glutathione. Trypanothione disulfide did not show much change in AN5568-treated cells. However, this metabolite was significantly reduced in 
DTT-treated cells, most likely due to the reducing nature of the compound, which breaks disulfide bonds in a non-specific manner. 
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increased in AN5568-treated cells, did not show changes in DTT-treated parasites (fig. 3-26). 
This suggests that the changes occurring in methionine metabolism are not due to the 
conserved SLS pathway response. 
However, other changes first observed in cells treated with the benzoxaborole were shown to 
occur in DTT-treated cells as well (fig. 3-27). In addition to the aforementioned upregulation of 
the trypanothione biosynthesis pathway, modified lysine residues were also sharply increased 
in DTT-treated cells (fig. 3-27) 
 
Figure 3-27: Changes seen in methionine metabolism are specific to AN5568-treatment, but modified 
lysine residues are not. The increases in AdoMet (A), 5’-MTA (B) and adenine (C) which are the most 
significant metabolic phenotypes in AN5568-treated cells, do not occur after DTT treatment, suggesting 
these changes are specific to the MoA of the benzoxaborole. Conversely, modified lysine residues such as 
N6-acetyl-L-lysine (D), N6-methyl-L-lysine (E) and N6,N6,N6-tri-methyl-L-lysine (F) were also found to 
increase in abundance after DTT treatment. This implies that these changes could be related to cellular 
stress responses. 
The results certainly help to understand how conserved the metabolic changes are in response 
to the benzoxaborole. It would appear as though lysine modifications are not related to the 
AN5568 mode of action in particular, but could form part of a more generalised cellular stress 
response. Indeed, this posttranslational modification has been implicated in many cellular 
functions including protein degradation, gene expression, protein activation and regulation of 
protein-protein interactions. This is reflected by the significant number of lysine MTases that 
have been characterised in both humans and yeast. 
Whilst these data provided a useful insight into the non-specific changes occurring in AN5568-
treatment, the DTT dataset is also crucial to our understanding of trypanosome biology in its 
own right. Further analyses will be carried out to unravel the metabolic changes associated with 
ER stress. 
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3.10 Using DARTS to probe the putative mode of action of AN5568 
A vital area of NTD research is drug target identification and validation. As discussed in chapter 
1, investigations in this field often take one of two approaches: target-based approaches and 
phenotype screening approaches (Reguera et al., 2014). For reasons described in details in 
chapter 1, the approach taken by Anacor in the context of HAT drug discovery was phenotypic 
screen based on the benzoxaborole 6-carboxamides class of boron-containing compounds. 
Whilst this led to the identification of AN5568 as a lead compound, the screen did not identify 
the protein target of the parasite.  
There are a variety of methods currently used to investigate drug mode of action, and more 
specifically, for drug target identification, as described in section 1.10. The most commonly used 
method is affinity chromatography. This method involves immobilization of the drug to beads. 
These beads are added to a column through which a protein lysate pull-down can be carried 
out, thereby allowing the protein target to bind to the compound of interest (Annis et al., 2007). 
However, immobilisation of drugs becomes problematic if there is a lack of knowledge 
concerning the compound structure-activity relationship (SAR) (Lomenick et al., 2009). Novel 
experimental approaches, published recently, have attempted to utilise compounds without 
the necessity of immobilising them. One example published by Lomenick and colleagues, is 
based on the theory that proteins have an increased thermodynamic stability when bound to 
ligands (Lomenick et al., 2009, Pai et al., 2015). By subjecting a control protein lysate as well as 
a drug treated lysate to the same amount of proteolysis, Lomenick and colleagues argue that 
target proteins would show a lesser degree of disintegration in the drug-treated sample 
(Lomenick et al., 2009). 
This process has been shown to work by the group themselves, and several other publications 
have shown a moderate success rate (Lomenick et al., 2011b, Chin et al., 2014). We therefore 
attempted to use this assay in T. brucei to see if it would be possible to find any proteins of 
interest with AN5568. Optimisation was required for the final concentration of the 
benzoxaborole, as well as the protease concentrations added to the samples and their 
incubation time. The final conditions that were chosen are outlined in the methods section 
(section 2.7.1) 
Subsequent to optimisation, the DARTS experiment was run using final concentrations of both 
1 mM and 10 mM AN5568. The protein lysates were extracted using trypanosome lysis buffer, 
rather than M-PER lysis buffer as suggested by the original publications (Pai et al., 2015). 
Samples were incubated for 1 hour and pronase concentrations were added as described in 
section 2.7.1. The pronase-treated lysates were then run on a protein gel, and a Coomassie 
stain showed a band of increased intensity in the 1 mM AN5568 sample (fig. 3-28). This band, 
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as well as the corresponding band in the DMSO control, were extracted from the gel and gel 
extraction, as well as mass spectrometry, was carried out by Glasgow Polyomics. 
Interestingly, we did not see the same enrichment when cells were treated with 10 mM 
AN5568, though this was probably because the drug precipitated at this concentration, 
removing a large number of proteins from the sample. When concentrations of pronase lower 
than 25 µg/mL were used, there were many more bands detected (data not shown), and 
therefore, we determined both 50 µg/mL and 25 µg/mL to be optimal for the DARTS assay. 
 
Figure 3-28: Protein samples subjected to DARTS assay. The soluble protein content was isolated from 
T. brucei cells and divided into three samples. These were incubated with either AN5568 or DMSO alone 
and subsequently divided into further sample groups for pronase degradation. Samples were subsequently 
analysed on a protein gel, and an enriched band was seen at approximately 37 kDa, in the sample treated 
with 1 mM AN5568 (red star). This band was excised from the gel, along with the corresponding control 
band, and sent for proteomics analysis at Glasgow Polyomics. 
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Sample GeneID Description 
Sequence  
coverage 
Peptide Delta E-value 
DMSO 
Tb.927.10.5620 
Fructose-bisphosphate 
aldolase (ALD) 
13.70% 
TGETFPQYLR -0.1888 0.0054 
ATAEQVAEYTVK -0.1247 0.6000 
GEQMTAGLDGYIK -0.2622 0.0260 
Tb10.v4.0241 
Variant surface glycoprotein 
(VSG), putative 
2.70% 
DGRQHLR -0.2273 0.7300 
DGRQHLR -0.2113 0.1100 
DGRQHLR -0.1653 0.0470 
Tb927.2.4590 Branched-chain amino acid 
aminotransferase, putative 
21.50% DSILSLVR -0.1578 0.0500 
LHVEEER -0.1754 0.1000 
Tb927.6.3150 Hydin 0.50% MPMTIDVPAKQK -0.2372 0.2800 
Tb11.16.0004 Variant surface glycoprotein 
(VSG, pseudogene), putative 
3.50% RIAEALAPK -0.3600 0.3700 
Tb927.6.1000 Cysteine peptidase, clan A, 
family C1, cathepsin L-like 
1.80% APAAVDWR -0.1090 0.4500 
Tb927.4.3470 Hypothetical protein, 
conserved 
1.00% GSLHCR 0.0047 0.5700 
Tb927.1.3910 TPR repeat 0.90% AMKQCMQR -0.0620 0.4700 
AN5568 
Tb.927.10.5620 Fructose-bisphosphate 
aldolase (ALD) 
16.70% 
TGETFPQYLR -0.0868 0.2000 
GLLAADESTGSCSK -0.0393 0.0005 
GEQMTAGLDGYIK -0.1182 0.1900 
Tb927.2.4590 Branched-chain amino acid 
aminotransferase, putative 
16.10% DSILSLVR -0.3018 0.0049 
LHVEEER -0.1734 0.1900 
Tb927.11.5570 
DNA replication licensing 
factor MCM5, putative 
0.90% 
TYINGGR -0.1751 0.4500 
TYINGGR -0.1411 0.2600 
TYINGGR -0.1291 0.0150 
Tb927.1.4010 Primase 2 0.60% CPQKYSR -0.3205 0.3400 
Tb927.6.550 Hypothetical protein 7.00% MLTTSFMAVVEPK 0.0740 0.7000 
Tb927.10.3080 Methionine biosynthetic 
protein, putative 
3.00% STLDEATTSLMR 0.3465 0.9500 
Table 3-3: Proteomics analysis of the enriched band observed in the DARTS assay. Several peptides 
were identified in both the control sample and the drug-treated sample. Several of these are known to 
be highly abundant in the T. brucei proteome. 
Proteomics analysis of both gel bands showed several protein hits, with several being unique to 
either the drug-treated, or control band (table 3-3).  Both bands contained several sequences 
that were mapped to a fructose-bisphosphate aldolase (ALD) (ID: Tb927.10.5620). The 
appearance of ALD in both protein samples is interesting, because one previous study showed 
this enzyme to be partially protease resistant (Clayton, 1987). This could explain why it does not 
disappear from the protein lysate after pronase treatment. In addition, studies in A. thaliana, a 
plant model organism, have shown that a chloroplastic homologue of this enzyme is methylated 
by lysine MTases (Mininno et al., 2012). Whether the same occurs with ALD in T. brucei is 
currently unknown, but the appearance of this protein in both sample groups led us to discard 
it. 
Peptides belonging to branched-chain amino acid aminotransferase (ID: Tb927.2.4590) were 
also seen in both gel extracts, and therefore not deemed to be of interest. In addition, the 
control band contained peptides mapped to two different VSGs, as well as a peptide 
corresponding to a cysteine peptidase (table 3-3). Again, these results were disregarded as the 
peptides identified in the drug-treated gel extract were the main concern, and result of interest. 
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Here, there were several uniquely mapped peptides that were not seen in the control sample. 
Firstly, a DNA replication factor, MCM5 (Tb927.11.5570). The product of this gene has 
previously been shown to be part of the MCM complex (Kim et al., 2013). This complex is 
involved in many DNA-specific roles including replication initiation, damage response, 
transcription and chromatin structure, and is highly conserved across all eukaryotes (reviewed 
by (Forsburg, 2004). Due to this conservation, it is unlikely that MCM5 is the benzoxaborole 
target, and this peptide was disregarded. Another protein identified in the drug-treated gel 
extract was primase 2 (ID: Tb927.1.4010). One previous study was found regarding this protein 
and in it, the authors showed this protein is targeted to the mitochondrion (Hines & Ray, 2010). 
In addition, Hines and Ray found that knock-down by RNAi resulted in a loss of kinetoplast 
(k)DNA (Hines & Ray, 2011). This is certainly interesting, because microscopy analysis presented 
here indicates ablation of kinetoplast replication in response to AN5568 treatment. In addition, 
the mitochondria appear to lose their normal linear shape. However, there was no evidence of 
complete loss of kinetoplast DNA during, or after, AN5568 treatment. Furthermore, the low 
percentage coverage seen in the DARTS assay could signify that this identification was an 
artefact and this protein was not investigated further. Another protein identified in the drug-
treated sample was a hypothetical protein (Tb927.6.550). No further information could be 
found regarding this protein, even after running the full sequence through databases such as 
pfam, interpro, SMART and SCOP. For this reason, this protein was not followed up. 
Finally, and by far most interesting was the appearance of a protein thought to be involved in 
methionine metabolism in the drug-treated band. This gene (ID: Tb927.10.3080) showed 3% 
sequence coverage in the dataset, but importantly, was not detected in the corresponding 
control band. We therefore chose to investigate this further through in vitro overexpression 
experiments, which were carried out as shown in section 3.13.   
3.11 Lysates of treated parasites show enrichment of a protein 
subset 
Whilst carrying out the DARTS experiment, it was subsequently discovered that incubation of 
parasites with the benzoxaborole caused a significant change in the protein lysate, when run 
directly on a protein gel (fig. 3-29A). This phenotype was not seen when extracted lysates were 
incubated with AN5568 and then run on a protein gel, suggesting that the drug could require 
activation before causing the metabolic phenotypes seen in earlier experiments. 
The gel band that was enriched in the drug-treated protein lysate was found to localise at a 
molecular weight of just over 37 kDa (fig. 3-29A). Interestingly, this matched the mass of 
VSG221 in the absence of any glycosylation (Aitcheson et al., 2005). However, as western blots 
found in previous experiments, there was no detectable change in VSG expression after drug 
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treatment (fig. 3-10). In order to better understand this change in the proteome, new protein 
lysates were prepared by isolating the soluble and membrane fractions in separate samples. 
Included with these samples was a further wash fraction containing soluble protein. These 
samples were then run on a protein gel in similar fashion to previous experiments (fig. 3-29B). 
In this experiment, results showed the presence of an enrichment of proteins at the same 
molecular weight as found previously (fig. 3-29). Interestingly, this enrichment was only seen in 
the soluble fraction, and to a greater extreme in the wash fraction. As well as concluding that 
proteomic changes were occurring upon drug-treatment, this experiment also highlighted the 
reproducibility of this phenomenon in drug-treated protein lysates. To attempt to identify the 
proteins present in this band, both the drug-treated gel band (red star in fig. 3-29) and the 
corresponding control band were cut out of the gel. These bands were then sent to Glasgow 
Polyomics for protein extraction and subsequent proteomics analysis. 
 
 
Figure 3-29: Protein lysates from AN5568-treated parasites visualised on protein gels show 
differences with wild-type lysates. A) Cultures of T. brucei Lister 427 were treated with varying 
concentrations of the benzoxaborole for 6 hours. The soluble proteome was then isolated and prepared 
for protein gel analysis as described in methods (section 2.7.2). Gels were visualised with Coomassie to 
show an enrichment of proteins in the treated samples at a molecular weight of just above 37 kDa. B) 
Further analysis of fractionated lysates confirmed the presence of this enriched subset of proteins in both 
the soluble and wash fractions. It did not appear to be present in the membrane fraction of the lysates. 
For both bands, over 60 different proteins were identified from the wash fraction. These results 
are shown in the supplementary data (S3). This was a much larger dataset than anticipated. 
Given the nature of proteomics analysis, which allows identification of peptides, but not their 
amounts, it was also very difficult to assess whether any proteins had changes in their 
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abundance compared to the control sample. Therefore, rather than filter through this large 
dataset, analyse individual proteins and select candidates, it was decided to attempt a 2-
dimensional difference gel electrophoresis (DiGE) experiment, in order to produce greater 
separation with the aim of pinpointing the proteins causing visible changes to a higher 
resolution. This experiment was set up as described in the methods. A control and drug-treated 
lysate were labelled with Cy5 and Cy3 respectively, and subsequently separated by isoelectric 
point (IEP). One gel was used for initial analysis of protein shifts, and was visualised using a 
Typhoon laser scanner (fig. 3-30).  
The gel images were next analysed using commercial software, to pick out significant changes 
between the two conditions. Ten point of interest were chosen, and manually extracted from a 
second gel containing a combination of lysates from both the control and drug-treated samples, 
and these were sent once more to Glasgow Polyomics for extraction and mass spectrometry 
analysis. 
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Figure 3-30: Comparative analysis of the soluble proteome from WT and AN5568-treated T. brucei 
cells. Two protein lysates from a DMSO and AN5568-treated cell culture were tagged with Cy5 and Cy3 
respectively and combined on to an IEP separation column. The lysates were then separate by size on an 
SDS protein gel. A) A merged composite of the DMSO-control (green) and AN5568-treated (red) lysates. 
Yellow points are those where no change is judged to have occurred post-treatment. In contrast, red and 
green spots represent proteins that are more abundant in the AN5568-treated sample and the DMSO-
control respectively. B) A commercially available software, DeCyder, was used to pick out spots of 
interest that showed a minimum of two-fold change between control and AN5568-treated lysates. Red 
contours indicate spots with a higher volume in AN5568-treated cells, whilst blue contours are of higher 
volume in the control lysate. Ten spots (indicated by number) were eventually extracted from the gel 
and analysed by mass spectrometry at Glasgow Polyomics. The line of blue contours in the top-right of 
the gel was judged to be a smear and thus, disregarded in the analysis. 
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Several peptides were identified in each spot, and the top hits, along with their fold changes, 
are summarised in table 3-4. Several of the spots were found to contain peptides originating 
from multiple proteins. In particular, spot numbers 7, 8 and 9 matched several peptides. This is 
most likely due to the fact they were extracted from a portion of the gel that was heavily 
stained, indicating that the majority of the soluble proteome migrated to this area of the gel 
based on pI and size. However, for the majority of spots analysed by mass spectrometry, only 
one or two significant hits were identified. 
Most strikingly was the enrichment of both serine and cysteine peptidase precursors in AN5568-
treated cells (table 3-4). Spot 1 was identified as a serine peptidase, an enzyme that cleaves 
peptide bonds, which contains a serine as the nucleophilic amino acid in its active site (Moss et 
al., 2015). In T. brucei, this serine peptidase is part of a tandem array of at least 3 peptidases 
that have been linked to suramin efficacy (Alsford et al., 2012). Recent analyses of the entire 
complement of serine peptidases has identified these genes as serine carboxypeptidase III 
precursors (Moss et al., 2015). 
Spots 2, 3 and 4 were all identified as cysteine peptidases, of which there is an array totalling 
some 11 near-identical genes (Moss et al., 2015). The differences in the spots indicate that they 
were separated based on pI, which could be due to posttranslational modifications such as 
phosphorylation or acetylation (Zhu et al., 2005). Current literature on T. brucei, as well as other 
fields of biology, have not linked any of the metabolic phenotypes seen after AN5568 treatment 
to inhibition of cysteine/serine peptidase activation, and therefore, it is unknown whether 
these phenomena could be linked. 
Amongst the proteins that decreased in abundance after AN5568 was a nascent polypeptide 
associated complex subunit, which was found at two different molecular weights (spots 5 & 6, 
table 3-4). This chaperone complex is one of the first cytosolic proteins to contact new 
polypeptide chains as they emerge from the ribosome and it aids in prevention of inappropriate 
interactions with signal recognition peptides (Funfschilling & Rospert, 1999). Whilst the 
complex is not thought to be essential in yeast, there is evidence to suggest in may aid in the 
targeting of proteins to the mitochondria (Funfschilling & Rospert, 1999). There is scarce 
literature to explain the potential reasons for downregulation of this complex, although it could 
be due to reduced protein synthesis in the nucleus requiring targeting to the mitochondria. One 
study, again carried out in yeast, showed that one of the sub-units is downregulated in response 
to ubiquitin ligase (Rsp5) under stress conditions (Hiraishi et al., 2009). With this in mind, it is 
probable that similar mechanisms occur in the kinetoplastids, and the large amounts of cellular 
stress caused by AN5568 leads to a downregulation of machinery involved with protein 
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translation. Indeed, given the conclusions by Hiraishi and colleagues, one could suggest that the 
difference between spots 5 and 6 could be related to ubiquitination. 
There was also downregulation of a heat shock protein (Hsp)-70 in response to AN5568-
treatment. Interestingly, this particular Hsp has been identified as a glycosomal Hsp (Guther et 
al., 2014). Whilst Hsps are generally upregulated in response to environmental stress (Bringaud 
et al., 1995), downregulation of this Hsp70 could suggest decreased metabolism, or 
deterioration of the glycosome as a result of benzoxaborole treatment. This could be confirmed 
with western blotting.  
S
p
o
t 
n
u
m
b
e
r fold change 
(AN5568/ctrl) 
Significant ID's Description Score 
1 1.91 Tb927.10.1040 Serine peptidase, Clan SC, family S10 (CBP1) 138 
2 3.15 Tb927.6.1000 
Cysteine peptidase, Clan CA, family C1, Cathepsin 
L-like (CP) 
132 
3 3.47 Tb927.6.1000 
Cysteine peptidase, Clan CA, family C1, Cathepsin 
L-like (CP) 
460 
4 3.85 
Tb927.6.1000 
Cysteine peptidase, Clan CA, family C1, Cathepsin 
L-like (CP) 
55 
Tb927.3.5050 60S ribosomal protein L4 46 
5 -2.13 Tb927.9.8100 Nascent polypeptide associated complex subunit 315 
6 -2.11 
Tb927.9.8100 Nascent polypeptide associated complex subunit 49 
Tb927.11.550 Hypothetical protein SCD6.10 (P-body formation) 40 
7 -2.19 
Tb927.8.4140 Hypothetical protein 38 
Tb927.4.3470 Hypothetical protein 36 
8 -2.12 
Tb927.11.11330 Heat shock protein (Hsp) 70 1397 
Tb927.11.11290 Heat shock protein (Hsp) 70 423 
Tb927.11.13500 paraflagellar rod component 1 213 
9 2.21 
Tb927.10.6510 Chaperonin HSP60, mitochondrial precursor 496 
Tb927.8.4970 Paraflagellar rod protein (PFR2) 196 
10 3.57 
Tb927.10.5390 Hypothetical protein 147 
Tb927.4.1080 V-type ATPase A subunit 112 
Table 3-4: Peptides identified in a 2D-DiGE undergoing significant changes after AN5568-treatment. 
Spot number corresponds to those identified in figure 3-30B. Out of the 10 most significant results, 4 
were found to be decreased in AN5568-treated cells, with the rest showing increased abundance. In some 
cases, more than the first significant hit were included in the analysis, if the overall score was relatively 
low compared to the other hits in the peptide sample. Domain analyses were carried out for the 
hypothetical proteins, using the Interpro, Pfam and SMART databases. 
Finally, two more spots with increased volume in AN5568-treated cells were identified as 
mitochondrial chaperonin HSP60 precursor, and a hypothetical protein (spots 9 and 10 
respectively, table 3-4). 
Results from the DiGE experiment, whilst not as conclusive as was initially hoped, do provide 
an interesting insight into the proteomic changes occurring in response to AN5568. 
Interestingly, a knock-down of ATG4.2, a cysteine peptidase in Leishmania major, showed a 
remarkably similar mitochondrial phenotype to T. brucei cells incubated with AN5568 (Williams 
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et al., 2013). In this paper, Williams and colleagues found that the mitochondria exhibited a 
“patchy” phenotype after an RNAi-mediated ATG4.2 knock-down. However, the orthologue of 
this protein in T. brucei is Tb927.6.1690, not the CA cysteine peptidase identified in the DiGE 
experiment. 
Unfortunately, the experiments shown here were carried out late on during this project, and 
hence, more data and planning is necessary in order to follow up on the leads identified with 
the 2D DiGE experiment. This work is currently ongoing in the Barrett group. 
The main hypotheses on AN5568 mode of action, up to this point, were as follows: the 
compound causes significant, yet specific changes in cellular metabolism, characterised by a 
sharp increase in AdoMet, 5’-MTA and adenine. Further significant changes in 8-amino-7-
oxononanoate, AdoHcy, L-cystathionine and lysine methylation support the hypothesis that 
methyl metabolism is targeted. Additional data from sinefungin-treatment showed overlap 
with AN5568. With this knowledge, it was decided to explore the T. brucei complement of 
MTase, in order to obtain a better picture of the repertoire of these enzymes and with it, 
possible ideas on AN5568 targets.   
3.12 Analysis of the T. brucei complement of methyltransferases – 
the “methyltransferome” 
Methyltransferases are a large class of proteins catalysing the methylation of substrates 
including protein targets as well as nucleic acids (Schubert et al., 2003). It is estimated that the 
overwhelming majority of the methyl groups used in these reactions come from AdoMet 
(Fontecave et al., 2004). The substrates of MTases vary widely, and their biological roles have 
generated great interest in a diverse range of biological systems and models, ranging from 
oncology to tropical disease (Schubert et al., 2003, Petrossian & Clarke, 2011, Wlodarski et al., 
2011, Subramaniam et al., 2014, Hamamoto & Nakamura, 2016). To gain a better 
understanding of the MTase repertoire present in T. brucei, we performed a literature search. 
To our surprise, only 22 MTases have been identified and characterised in T. brucei (Table 3-5). 
This is in stark contrast to, for example, kinases, many more of which have been studied in detail 
in recent years (Parsons et al., 2005, Jones et al., 2014b). Furthermore, a search in the TriTrypDB 
database using a key term of “methyltransferase” produced an output of 129 putative genes. 
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GeneID Name Putative function Reference 
Tb927.1.4690 PRMT 1 type I arginine MTase (Pelletier et al., 2005) 
Tb927.10.640 PRMT 5 type II arginine MTase (Pasternack et al., 2007) 
Tb927.7.5490 PRMT 7 type III arginine MTase 
(Pasternack et al., 2007) 
(Fisk et al., 2009) 
(Wang et al., 2014a) 
Tb927.5.3960 PRMT 6 type I arginine MTase 
(Pasternack et al., 2007) 
(Fisk et al., 2010) 
(Wang et al., 2014a) 
Tb927.10.3560 PRMT putative arginine MTase (Pasternack et al., 2007) 
Tb927.10.3560 PRMTs looked at all arginine MTases (Lott et al., 2014) 
Tb927.1.4690 PRMTs looked at all arginine MTases (Goulah et al., 2006) 
Tb927.7.2080 TbCgm1 
cap guanynyltransferase-
methyltransferase 
(Ruan et al., 2007a) 
Tb927.10.4500 TbCmt1 cap methyltransferase (Hall & Ho, 2006a) 
Tb927.10.7940 TbMtr1 2'-O-ribose MTase 
(Zamudio et al., 2007, 
Mittra et al., 2008) 
Tb927.11.4890 TbMtr2 2'-O-ribose MTase 
(Hall & Ho, 2006b) 
(Arhin et al., 2006b) 
Tb927.9.12040 TbMtr3 2'-O-ribose MTase 
(Arhin et al., 2006a) 
(Zamudio et al., 2006) 
Tb927.8.1920 DOT1A Histone MTase (Janzen et al., 2006) 
Tb927.1.570 DOT1B Histone MTase (Figueiredo et al., 2008) 
Tb927.11.3200 DOT1A/B Histone MTase (Janzen et al., 2006) 
Tb927.9.2800 MGMT O6-methylguanine-MTase Genois 
Tb927.10.12600 TbHEN1 HUA enhancer (Shi et al., 2014) 
Tb927.8.5720 TbTRM5 tRNA MTase (Paris et al., 2013) 
Tb11.02.5090 TbTgs 
PRIP interacting protein, 
Trimethylguanosine (TMG) RNA cap 
synthase 
(Benarroch et al., 2010) 
(Ruan et al., 2007b) 
Tb927.10.6910  
N/A sterol 24-c-MTases (Perez-Moreno et al., 2012) 
Tb927.10.6950  
Tb927.8.7120 
Tb927.11.3270 
Tb927.9.12690 N/A 
Prenyl protein specific carboxyl 
MTase 
(Buckner et al., 2002) 
Table 3-5: MTases that have been identified and characterised in T. brucei. A literature search of 
MTases characterised in T. brucei showed publications covering 32 genes, with varying levels of 
characterisation. Unsurprisingly, MTases involved in spliced leader methylation have received by far the 
most attention, followed closely by arginine MTases. Whilst histone MTases such as DOT1A & DOT1B have 
been investigated, it is interesting to note that most lysine MTases in T. brucei have yet to receive similar 
amounts of attention. 
Based on the hypothesis that AN5568 might affect an essential MTase in T. brucei, we sought 
to carry out an in silico study of the entire MTase complement in T. brucei. This type of study 
has been carried out in both Saccharomyces cerevisiae and in the human genome (Petrossian 
& Clarke, 2011, Wlodarski et al., 2011). However, both studies disagreed on the term used to 
describe the MTase complement, with Petrossian & Clarke coining the name 
“methyltransferasome”, whilst Wlodarski and colleagues called it the “methyltransferome”. It 
was decided to use the latter name in this study.  
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The first list, generated through TriTrypDB (v9.0) (Aslett et al., 2010), was analysed and used for 
the subsequent overexpression experiments detailed below. However, more in depth analysis 
of MTases in T. brucei was carried out using domain searches. For this, the pfam, interpro and 
SMART databases (Finn et al., 2014, Jones et al., 2014b, Letunic et al., 2015) were used to 
generate a list of all genes containing MTase domains (table 3-6). The list was refined further 
by including EC number analysis from TriTrypDB with the search term “2.1.1” 
(methyltransferase).  
The final list for the T. brucei MTase complement totalled 145 genes, all predicted to contain 
MTase domains (table 3-6). Most genes contained just one MTase domain, whilst several were 
predicted to contain multiple MTase domains. In addition, many of the predicted MTases also 
possessed other domains related to substrate binding, as well as transmembrane domains. 
We divided the “methyltransferome” into groups depending on the major folds present in the 
MTase domains, as was carried out by Wlodarski and colleagues (Wlodarski et al., 2011). These 
classes have previously been made based on the catalytic domain structure (Schubert et al., 
2003), as explained in section 1.8.5. Rossmann-like folds are the largest class of MTases and 
consist of a seven-stranded beta sheet joined by several alpha helices (Schubert et al., 2003). 
Fold Substrate GeneID (Name) 
Rossmann-like DNA  Tb927.3.1360, Tb927.7.6620 
 RNA mRNA 
Tb11.02.5090 (TbTgs1), Tb927.7.2080 (TbCgm1), 
Tb927.10.4500 (TbCMT1), Tb927.10.7940 (TbMtr1), 
Tb927.11.4890 (TbMtr2), Tb927.9.12040 (TbMtr3), 
Tb927.11.5060, Tb927.11.6720, Tb927.2.2450, 
Tb927.2.4550, Tb927.4.4170, Tb927.5.490, 
Tb927.8.2500, Tb11.02.5090b, Tb11.v5.0219, 
Tb11.v5.0415 
  tRNA 
Tb927.8.5720 (TbTRM5), Tb927.1.3050, 
Tb927.10.3080, Tb927.11.3890, Tb927.11.5240, 
Tb927.4.4030, Tb927.9.9120 
  rRNA Tb927.8.3130, Tb927.6.1610, Tb927.10.3690 
  
sno/ 
snRNA 
Tb927.10.14630, Tb927.10.14750, Tb927.10.7500 
 Protein  
Tb927.8.1920 (TbDOT1A), Tb927.1.570 (TbDOT1B), 
Tb927.11.3200 (TbDOT1A/B), Tb927.1.4690 
(TbPRMT1), Tb927.10.640 (TbPRMT5), Tb927.7.5490 
(TbPRMT7), Tb927.10.3560 (TbPRMTx), 
Tb927.10.12980, Tb927.10.4460, Tb927.10.6680, 
Tb927.10.7850, Tb927.11.15630, Tb927.11.9090, 
Tb927.11.9210, Tb927.3.3230, Tb927.3.4540, 
Tb927.4.3840, Tb927.5.2050, Tb927.5.2420, 
Tb927.6.2270, Tb927.6.2330, Tb927.9.12780, 
Tb927.9.6430, Tb927.9.6720 
 Small molecule 
Tb11.v5.0692, Tb927.10.9390, Tb927.11.10510, 
Tb927.5.3000 
 Lipid  
Tb10.v4.0247, Tb11.v5.0496, Tb927.10.6910, 
Tb927.10.6950 
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Fold Substrate GeneID (Name) 
 Unknown  
Tb927.10.12600 (TbHEN1), Tb11.v5.0775, 
Tb11.v5.0832, Tb927.1.1120, Tb927.10.12270, 
Tb927.10.15420, Tb927.10.1800, Tb927.10.2590, 
Tb927.10.7560, Tb927.10.9860, Tb927.11.15290, 
Tb927.11.9200, Tb927.3.4940, Tb927.4.1900, 
Tb927.5.2600, Tb927.6.2540, Tb927.7.3340, 
Tb927.7.6890, Tb927.8.2670, Tb927.8.5420, 
Tb927.9.10580, Tb927.9.11750, Tb927.9.14200, 
Tb927.9.2320, Tb927.9.7000 
SET domain Protein  
Tb11.v5.0422, Tb11.v5.0590, Tb927.1.4720, 
Tb927.10.11130, Tb927.10.12880, Tb927.10.3730, 
Tb927.10.4600, Tb927.10.8060, Tb927.10.8100, 
Tb927.10.9680, Tb927.11.13560, Tb927.11.5120, 
Tb927.3.1860, Tb927.3.3370, Tb927.3.750, 
Tb927.4.2440, Tb927.4.3310, Tb927.4.4300, 
Tb927.5.2770, Tb927.5.3500, Tb927.6.3610, 
Tb927.6.910, Tb927.7.2040, Tb927.7.5620, 
Tb927.8.2490, Tb927.8.2690, Tb927.8.2710, 
Tb927.8.6470, Tb927.8.6530, Tb927.9.10100, 
Tb927.9.11350, Tb927.9.13470, Tb927.9.1510 
SPOUT RNA tRNA Tb927.6.4420 
  rRNA 
Tb11.v5.0683, Tb927.1.4810, Tb927.11.15830, 
Tb927.2.4980, Tb927.7.5120, Tb927.8.5040, 
Tb927.8.6560, Tb927.9.12850 
Radical SAM Protein  
Tb11.v5.0520, Tb11.v5.0635, Tb927.10.15010, 
Tb927.6.3510, Tb927.7.7130, Tb927.8.3310, 
Tb927.8.5770, Tb927.9.4950 
Tetrapyrrole 
methylase 
Small molecule Tb927.4.4650, Tb927.9.12100 
DNA/RNA-binding 
3-helical bundle 
DNA  Tb927.9.2800 (MGMT) 
Hcy MTase Small molecule Tb927.1.1270 
ICMT Protein  Tb927.9.12690 
Thymidylate 
synthetase 
Small molecule Tb927.7.5480 
TIM beta/alpha-
barrel 
Small molecule Tb927.8.2610 
TYW3 RNA tRNA Tb927.11.12670 
Table 3-6: A comprehensive overview of the T. brucei methyltransferase repertoire. MTases were 
divided into groups based on A) their MTase domain structure, and B) their substrate, if known. 
Identification of MTases was based on their domains that were identified using pfam and interpro (Finn 
et al., 2014, Jones et al., 2014b). These are available on the TriTrypDB website. 
Using the Pfam database, Rossmann-like folds were assigned to the pfam clan CL0063 
(FAD/NAD(P)-binding Rossmann fold superfamily). This was by far the largest group of MTases 
in the T. brucei genome, with 88 representatives (fig. 3-31A). The second largest group was 
MTases belonging to the SET domain class, which is known to include mostly methylases of 
lysine residues in proteins (Wlodarski et al., 2011). 
The most studied group of MTases in T. brucei is the mRNA MTase group (fig. 3-31B). Indeed, 
many of these proteins have been characterised as methylases of the mRNA spliced leader cap, 
which, as mentioned previously, is unique and complex in the kinetoplastids (Gunzl, 2010). 
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However, interestingly, many of these proteins have not been found to be essential to the 
parasite (Zamudio et al., 2006). Indeed, the absence of methylation does not appear to inhibit 
protein synthesis in all cases, although TbCgm1, for which an RNAi knock-down was generated, 
did appear to have reduced mRNA synthesis. This has been shown for three other mRNA 
methylators: TbMtr1, TbMtr2 and TbMtr3 act on the first, second and third bases of the spliced 
leader respectively, but all are non-essential (Zamudio et al., 2006, Zamudio et al., 2009). 
 
Figure 3-31: Overview of MTases in the T. brucei genome. A) MTases were grouped according to the 
catalytic MTase domain they possessed. The most abundant fold is the Rossmann-like fold (Pfam: CL0063), 
most often associated with AdoMet-dependent MTases. Many lysine MTases, which contain a SET domain, 
were also predicted. Several putative MTases were predicted to contain a SPOUT domain, or a radical 
SAM domain. Other classes that have been covered in literature elsewhere were also found here. In most 
cases, only one MTase was predicted for each domain, similar to the MTase complement in Saccharomyces 
cerevisiae. B) Putative MTases encoded in the T. brucei genome were grouped based on their predicted 
substrates, dependent on the domains identified in each gene. The majority of MTases were predicted 
to act on amino acid residues in proteins, especially those containing the SET domain known to interact 
with lysines. In addition, at least 16 predicted MTases are predicted to catalyse mRNA methylation. There 
was also a large group of MTases for which the substrates remain unknown, and must be investigated 
further. 
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Four of the putative MTases (Tb10.v4.0247, Tb11.v5.0496, Tb927.10.6910 & Tb927.10.6950) 
were found to contain sterol MTase C-terminal domains (Pfam: PF08498), and were therefore 
predicted to be sterol MTases. These can be involved in the methylation of sterols, which is an 
essential process in lipid membranes (Perez-Moreno et al., 2012). 
In some cases, proteins previously found to be MTases did not contain pfam domains relating 
to MTase activity. One example is Tb927.8.7120, which was predicted to be a sterol MTase 
(Perez-Moreno et al., 2012). Instead, this protein was found to possess a squalene synthesis 
domain. Similarly, Tb927.11.3270 contained a squalene epoxidase domain, but no MTase 
domain. In another case, we could not find any arginine MTase domains in the PRMT6 gene 
(Tb927.5.3960). 
These cases highlight the need for a more refined study of methyltransferases in the T. brucei 
genome. This type of study of the MTase complement should incorporate two analyses: Firstly, 
domain prediction allows for the identification of signalling peptides that could give clues as to 
the localisation of all the MTases. Indeed, this information can also be gained through the study 
of homologues in other organisms. For example, two distant homologues of a mitochondrial 
MTase that dimethylates 12S rRNA in humans and yeast (TFB1M), Tb927.6.1610 & 
Tb927.10.3690, were found based on their similarity to the yeast and human proteins. Based 
on this finding, many other characteristics of these MTases can potentially be found. 
Secondly, datasets exist that give very detailed information of protein expression as well as 
transcript abundance of thousands of genes throughout the varying life cycle stages of the 
parasite. These datasets could be used to find important MTases involved in the regulation of 
life-cycle-specific genes. 
One interesting findings from this study is the very high number of protein MTases T. brucei 
possesses (fig. 3-31B). Our analyses predict 67 protein MTases, which is much higher compared 
to organisms such as yeast (32) (Wlodarski et al., 2011), but similar to the number in humans 
(at least 57 SET domain proteins humans) (Petrossian & Clarke, 2011). One possible reason for 
this is due to the complex life cycle the parasite undergoes, requiring a significant number of 
changes in morphology, gene expression and metabolism. Protein methylation is well 
established as a posttranslational modification that can induce these necessary changes. Given 
this information, one would hypothesize that this gene set could contain unique proteins and 
therefore, potential drug targets against the parasite.  
Further work to refine the T. brucei methyltransferome, as well as those of the other TriTryps 
would be highly beneficial to the scientific community. Firstly, this dataset will contain 
druggable proteins that can be used to develop novel therapeutics against these parasites. In 
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addition, the kinetoplastidea in particular, are an ancient eukaryote Therefore, a great deal of 
biological understanding can be gained through the study of both Trypanosoma spp., and 
Leishmania spp.  
The human and yeast genomes were shown to contain 208 and 86 MTases respectively 
(Petrossian & Clarke, 2011, Wlodarski et al., 2011), and a good starting point would be to find 
any homologues in the TriTryp genomes. Additional work would include analysis of all genes 
containing MTase domains, especially with regards to any conserved secondary and tertiary 
structure using prediction algorithms such as Hidden Markov Models (HMM) (Katz et al., 2003, 
Petrossian & Clarke, 2009). 
The development of systems such as RITseq have been very useful for the study of T. brucei 
(Alsford et al., 2012). Recently, it was used with great success to investigate the T. brucei kinase 
repertoire, referred to as the “kinome” (Jones et al., 2014a). A similar approach to the 
methyltransferase complement would provide great insight into the varied roles these proteins 
are thought to play, including, but not limited to, differentiation, DNA transcription, protein 
synthesis, and posttranslational modifications (Petrossian & Clarke, 2009, Subramaniam et al., 
2014, Swinehart & Jackman, 2015). Using the RITseq dataset that was previously published 
elsewhere (Alsford et al., 2011), we analysed the first list of 129 MTases to look for enzymes 
that were deemed essential, i.e. their knock-down was lethal.  
3.13 Overexpression of 12 essential methyltransferases in vitro 
does not identify an AN5568 target 
3.13.1 Domain analysis of 12 essential methyltransferases 
Using RITseq analysis datasets available on TriTrypDB (Aslett et al., 2010), we determined 12 
MTases that were shown to be essential in the original dataset of 129 genes found in the initial 
“methyltransferome” scan (Table 3-7). As a proof-of-principle, to confirm that overexpression 
of a target protein could lead to drug resistance, a cell line overexpressing ornithine 
decarboxylase (ID: Tb427tmp.01.5300), the target of eflornithine (Vincent et al., 2012), was 
generated. For each of the MTases, the sequence was run through the SMART database to 
identify any known protein domains (Letunic et al., 2015). The results from this experiment are 
presented in table 3-7. 
 
 
 
 
 
 
122 
Gene – TREU 927 Gene – Lister 427 Given ID Putative description 
Tb927.10.3080 Tb427.10.3080 MT 1 AdoMet-dependent MTase 
Tb927.10.7560 Tb427.10.7560 MT 2 AdoMet-dependent MTase 
Tb927.10.9020 Tb427.10.9020 MT 3 Gcd10p MTase 
Tb927.11.13250 Tb427tmp.01.4830 MT 4 Elongation factor MTase 
Tb927.11.9690 Tb427tmp.01.1460 MT 5 MORN repeat protein 
Tb927.3.2890 Tb427.03.2890 MT 6 MORN repeat protein 
Tb927.4.1900 Tb427.04.1900 MT 7 AdoMet-dependent MTase 
Tb927.5.2050 Tb427.05.2050 MT 8 Lysine MTase 
Tb927.7.4320 Tb427.07.4320 MT 9 mRNA cap triphosphatase 
Tb927.8.5040 Tb427.08.5040 MT 10 Alpha/beta-knot fold MTase 
Tb927.6.2270 Tb427.06.2270 MT 11 
AdoMet-dependent di-
proline MTase 
Tb927.10.7850 Tb427.10.7850 MT 12 Rab-like GTPase 
Tb927.11.13730 Tb427tmp.01.5300 ODC Ornithine decarboxylase 
Table 3-7: Putative essential MTases. The genes chosen for further analysis were deemed to be essential 
using the RITseq datasets generated by Horn & Alsford (Alsford et al., 2011). In total, 12 genes were 
chosen to be overexpressed to test whether they could be potential targets of AN5568. Whilst TriTrypDB 
generated these genes in the search for MTases, some were found to contain unrelated domains. These 
were still treated as putative MTases, and thus included in the subsequent overexpression experiments. 
A predicted MTase previously isolated from the previously discussed DARTS assay (table 3-3) 
(ID: Tb927.10.3080) was shown to contain a methyltransferase domain (pfam: PF02475, IPR: 
003402) thought to be involved in wybutosine biosynthesis. This is a heavily modified 
nucleoside present in PhetRNA, and thus required for protein synthesis (Kalhor et al., 2005, Noma 
et al., 2006). By analysing the RITseq data published by Horn & Alsford, we were able to confirm 
that this protein was essential, and it was selected for downstream analyses. There is no 
literature to suggest the presence of the wybutosine biosynthesis pathway in T. brucei, although 
it is conserved across most eukaryotes (Kalhor et al., 2005, Noma et al., 2006). 
The second gene (ID: Tb927.10.5760) was shown to contain a domain matching 4 different pfam 
domain classes of AdoMet-dependent methyltransferases (pfam: PF13489, PF12847, PF13649 
& PF08241). The third gene (Tb427.10.9020) possesses a predicted domain involved in a 
methyltransferase complex with Gcd14p (pfam: 04189), which is involved with modifying tRNA 
residues. A homologue of this domain has been characterised in S. cerevisiae where it has been 
shown to be an essential 1-methyladenosine MTase (Anderson et al., 2000). The fourth 
methyltransferase, Tb427tmp.01.4830, was predicted to contain an elongation factor domain 
(pfam: PF00009). This domain is part of a family that is involved in GTP-dependent binding of 
aminoacyl tRNAs to ribosomes and aids in the binding of initiation factors such as eIF2 gamma 
(Moller et al., 1987). 
Two genes filtered from this subset (Tb427tmp.01.1460 & Tb427.03.2890) were predicted to 
contain several membrane occupation and recognition nexus (MORN) repeat domains (pfam: 
PF02493). Proteins containing this domain are thought to function as linkers between 
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membrane regions and the cytoskeleton, as has been shown in the apicomplexan parasite 
Toxoplasma gondii, where it is thought the proteins play important roles in cytokinesis (Gubbels 
et al., 2006). In addition, this domain can also be found on a subset of histone-lysine MTases, 
specifically the SETD7 MTase that is found in many eukaryotes (Couture et al., 2006). 
The seventh protein (Tb427.04.1900) contained two predicted MTase domains. The first was an 
AdoMet-dependent MTase domain (pfam: PF012847), as was the second (pfam: PF12589). 
Interestingly, the latter domain has been shown to be deleted in a neurodevelopmental 
disorder in humans known as Williams-Beuren Syndrome (Doll & Grzeschik, 2001). However, it 
is unknown what role, if any, this domain plays in trypanosomatids. Another essential MTase, 
Tb427.5.2050, was shown to contain a lysine MTase domain (pfam: PF10294). Further study 
indicated that this domain is also found in nicotinamide N-MTases (Katz et al., 2003). 
mRNA capping enzymes are vital in trypanosome biology, and one of the proteins found to be 
essential by RITseq, Tb427.07.4320, was predicted to contain a beta domain that codes for an 
mRNA cap triphosphatase (pfam: PF02940). Normally, proteins with this domain also contain a 
catalytic alpha chain that possesses guanylyltransferase activity (Lima et al., 1999). However, 
neither pfam, nor SMART, could predict any alpha chains in the gene examined here. 
A further essential protein, Tb427.8.5040, was predicted to possess an EMG1/NEP1 MTase 
domain (pfam: PF03587). This MTase belongs in the alpha/beta-knot MTases and this domain 
in particular was previously shown to be involved in 40S ribosome biogenesis in S. cerevisiae 
and the domain in question is conserved across most eukaryotes and archaea (Leulliot et al., 
2008). Two other putative MTases were predicted to be essential by RITseq. The first, 
Tb427.6.2270, a predicted AdoMet-dependent di-proline MTase (pfam: PF05891). In other 
organisms such as yeast, this MTase domain is involved in methylation of ribosomal N-terminal 
domains (Webb et al., 2010). This gene also contained a second predicted AdoMet-dependent 
MTase domain, but this domain has not been annotated or characterised. 
Finally, Tb927.10.7850 was found not to contain any domains as predicted by the Pfam 
database, but did contain a Rab-like GTPase domain when analysed using the SMART database. 
The proteins are involved in GTPase activation, an important and conserved signalling 
mechanism. 
In all cases, these T. brucei genes and the proteins they encode had not been characterised 
before, and there was no mention in the literature of any. Indeed, several of the processes or 
pathways they are predicted to be involved in have not been confirmed to exist in the 
trypanosomatids, perhaps highlighting the lack of knowledge regarding MTases in these 
parasites. 
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It must be stressed that further bioinformatics analyses of these 12 proteins carried out later in 
the study, showed that not all of these were purported to be MTases, but instead, were 
enzymes containing domains that might interact directly or indirectly with MTases. It was 
surprising to find that several of the putative MTases filtered out by TriTrypDB did not in fact 
contain recognised MTase domains, and it would be worthwhile to repeat this search for 
essential MTases with the new knowledge gained from the generation of a dataset containing 
every predicted MTase, as shown in table 3-6. However, further work was carried out in order 
to overexpress all genes summarised in table 3-7, initially with the overexpression of each gene 
in the lab-adapted Lister 427 T.b. brucei strain. 
3.13.2 Characterisation of 12 overexpression cell lines 
To determine whether any of the 12 chosen genes could be a potential target of AN5568, we 
chose to overexpress the genes in vitro in Lister 427 wild-type T. brucei cells. This was carried 
out primarily with the ribosomal (r)RNA targeting pURAN plasmid (a gift from S. Hadjuk). As the 
427 Lister strain was used, it was chosen to overexpress the homologues of the corresponding 
427 genes in these cell lines. This also allowed easy amplification of DNA from 427 Lister total 
DNA. All genes were cloned into pURAN after sequencing in the intermediate vector pGEM-T 
easy, as described in the methods (section 2.4.5). 
For two of the chosen genes, (IDs: Tb427.10.7560 & Tb427.05.2050) attempts to transfect a 
pURAN construct into parasites were unsuccessful and, therefore, a different plasmid, pRM482, 
was chosen. This plasmid targets the tubulin array, which is constitutively active, but at a lower 
overall rate of transcription (Trenaman et al., 2013) compared to the rRNA loci. Unsuccessful 
transfection could be due to the detrimental effect resulting from high levels of overexpression 
of a protein usually present in much lower quantities. In addition, high levels of expression could 
also compromise the structure of the endoplasmic reticulum, leading to swollen ERs as well as 
ER stress. This could explain the lack of stable transfected clones for the two aforementioned 
genes. 
Important to note is the lack of tags on the proteins being overexpressed. It is common to 
express proteins with tags such as GFP or HA. This enables localisation of the protein 
intracellularly, and more importantly, to confirm overexpression on a protein level, rather than 
just transcript level, as a qPCR does. However, the tags run the risk of leading to improper 
folding of the protein due to interference with the protein chain’s C- or N-terminal domains. 
For this reason, no tags were transfected along with the proteins of interest. 
Upon transfection of each MTase overexpression construct, two clonal transfectants were 
isolated for each MTase, as well as the transfectant for ODC. To confirm overexpression of each 
MTase, qPCR analysis was carried out on each clone (table 3-8). Changes in mRNA abundance 
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were found to be highly variable in cell lines transfected with pURAN, as well as pRM482 
constructs, with fold changes ranging from <2-fold all the way to >34-fold. This is most likely 
due to the nature of the construct, which is not specifically targeted to one locus in the rRNA or 
tubulin arrays. Instead, the construct can recombine in many places within the same locus, 
leading to the high variability seen in table 3-8. Satisfied that overexpression was achieved, we 
next sought to characterise both cellular growth, as well as changes in drug 
resistance/sensitivity. 
GeneID 
Fold change 
(overexpressor/WT ctrl) 
MT 1 - clone 1 2.01 ± 0.13 
MT 1 - clone 2 2.29 ± 0.05 
MT 2 - clone 1 21.61 ± 5.98 
MT 2 - clone 2 1.49 ± 0.09 
MT 3 - clone 1 10.90 ± 8.15 
MT 3 - clone 2 8.90 ± 3.84 
MT 4 - clone 1 2.89 ± 0.71 
MT 4 - clone 2 2.32 ± 0.19 
MT 5 - clone 1 4.64 ± 2.35 
MT 5 - clone 2 6.90 ± 0.53 
MT 6 - clone 1 1.86 ± 1.86 
MT 6 - clone 2 4.16 ± 1.54 
MT 7 - clone 1 6.58 ± 1.58 
MT 7 - clone 2 2.47 ± 0.41 
MT 8 - clone 1 1.71 ± 0.03 
MT 8 - clone 2 3.14 ± 0.06 
MT 9 - clone 1 4.82 ± 0.56 
MT 9 - clone 2 2.81 ± 0.21 
MT 10 - clone 1 3.41 ± 0.19 
MT 10 - clone 2 3.22 ± 0.05 
MT 11 - clone 1 1.55 ± 0.09 
MT 11 - clone 2 1.71 ± 0.04 
MT 12 - clone 1 16.42 ± 0.37 
MT 12 - clone 2 34.52 ± 0.95 
ODC - clone 1 2.70 ± 0.09 
ODC - clone 2 2.88 ± 0.45 
Table 3-8: qPCR analysis of 12 MTase overexpression lines. RNA was isolated and reverse-transcribed 
from each overexpression line made. Transcript abundance of the gene of interest was then analysed by 
qPCR. Results showed a significant amount of variation in the levels of overexpression, ranging from 2-
fold to as high as 34-fold for one cell line. Two clones were characterised for each construct. Cell lines 
are given by their ID, corresponding full gene IDs are given in table 3-7. 
Mean doubling time was next calculated as described by Sykes & Avery (Sykes & Avery, 2009b), 
and is shown in figure 3-32A. All cell lines were counted every 24 hours during exponential 
growth (between 2 × 104 and 2 × 106 cells/mL) over a period of 5 days, and mean doubling time 
was then calculated for each 24-hour period. Previous studies on the 427 Lister cell line has 
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shown mean doubling time to vary between 6 and 7 hours (Sykes & Avery, 2009a). Every MTase 
overexpression line that was analysed showed a mean doubling time within these limits, 
indicating that none of the protein overexpression was detrimental, nor advantageous, to the 
modified cell lines. 
Previous studies in T. brucei have suggested that overexpression of proteins can cause 
resistance to drugs that target the protein in question (Ranade et al., 2013). To confirm whether 
overexpression of a protein target with the pURAN construct can in fact cause resistance to a 
specific drug, we first analysed the ODC overexpressor (fig. 3-32B & 3-32C). Firstly, qPCR 
analysis of total cDNA showed that for two isolated clones of the overexpressor, there was just 
under 3-fold change in transcript abundance (table 3-8 & fig. 3-32B), suggesting that the 
construct was successfully integrated and overexpressing ODC at the transcript level. Next, an 
alamar blue assay was run for eflornithine (Ornidyl®), using a wild-type Lister 427 T. brucei line 
as a control. Whilst the WT control showed an EC50 of ~5 µM, the combined average of the two 
ODC overexpressors exhibited an EC50 of more than 15 µM, equivalent to a 3-fold increase in 
drug resistance (fig. 3-32C). This result showed that overexpression can change drug resistance, 
and therefore allowed use to proceed with the characterisation of the 12 MTase 
overexpressors. 
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Figure 3-32: Characterisation of an ODC overexpressor as well as 12 putative MTase overexpressors. 
Once successful integration of the constructs, as well as overexpression, had been confirmed, the cell 
lines were characterised with regards to growth and drug sensitivity/resistance. A) Growth curves carried 
out for all 12 lines showed that none exhibited any significant changes in their doubling times, when 
compared to wild-type Lister 427 cells which have been shown to possess a doubling time of 
approximately 6-7 hours (Sykes & Avery, 2009a). B) As a proof-of-concept, a cell line overexpressing 
ornithine decarboxylase (ODC) was generated. C) The ODC overexpressor showed an increased resistance 
to Eflornithine, an ODC inhibitor, by more than 3-fold. D) Subsequent analysis of the 12 putative MTase 
overexpressors showed that none had gained any significant resistance to AN5568 when compared to a 
wild-type cell line, although two cell lines did appear to show increased sensitivity. E) Interestingly, 
several of the putative MTase overexpressors showed increased resistance to sinefungin, a non-specific 
MTase inhibitor. Whilst not entirely unexpected, this result was interesting by itself, and warrants further 
study (* = P<0.05, Student’s t-test). 
To ascertain whether any of the MTase overexpressors had altered resistance or sensitivity to 
the benzoxaborole, alamar blue assays were carried out in 12-well format, as described in the 
methods. For this assay, the same AN5568 sample was used for each cell line, so that the results 
could be compared. The increased AN5568 (250 nM) EC50 for Lister 427 WT cells was likely due 
to the compound degrading over time (fig. 3-32D). However, when compared to the EC50 values 
of all other MTase overexpressors for AN5568, no statistically (Student’s t-test) significant 
differences were found, In addition to investigating changes in AN5568 resistance, and given 
that the proteins being overexpressed were putative MTase, further drug resistance assays 
were carried out with sinefungin, a non-specific AdoMet-dependent MTase inhibitor discussed 
earlier in this chapter. In similar fashion to the AN5568 sensitivity assays, alamar blue 
experiments were carried out for each cell line (fig. 3-32E). Results showed a significant amount 
of variation within cell lines, for unknown reasons. Interestingly, four of the twelve MTase 
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overexpressors showed a significant increase in sinefungin resistance (fig. 3-32E). The MORN-
repeat protein (MT 6, p = 0.0005), putative mRNA cap-triphosphatase (MT 9, p = 0.0250), 
putative alpha/beta-knot MTase (MT 10, p = 0.0008) and rab-like GTPase (MT 12, p = 0.070) all 
showed increased resistance to sinefungin (Gene IDs: Tb427.03.2890, Tb427.07.4320, 
Tb427.05.5040 & Tb427.10.8750 respectively). These differences were not completely 
unexpected, but it is interesting that these genes in particular seem to be involved in dealing 
with sinefungin exposure, whilst other MTases are not. Overexpression of an mRNA cap 
triphosphatase could increase the parasite’s capability for protein expression, thereby 
providing a larger pool of essential proteins, and diminishing the potency/efficacy of the 
compound. In addition, whilst there is no literature on this mRNA cap triphosphatase, others 
have been identified and characterised to a greater extent in T. brucei (Takagi et al., 2007), 
suggesting there might be some redundancy between related genes. 
It was interesting to observe that not every MTase could confer cellular resistance to sinefungin 
when overexpressed. It is likely that high amounts of overexpression would give the parasites 
the ability to “mop” up the sinefungin, without compromising metabolism. This mechanism 
would not be specific to a particular methyltransferase because sinefungin is non-specific. In 
addition, some methyltransferases might be more essential 
Unfortunately, overexpression of these 12 candidate genes did not lead to a potential AN5568 
target. However, it is encouraging to know that overexpression of the correct target should 
provide an idea of the possible targets, as shown in the case of ODC overexpression and 
eflornithine-treatment. The RITseq approach pioneered by David Horn and Sam Alsford has 
recently been applied to the study of drug mode of action, with interesting findings (Alsford et 
al., 2012). However, one of the main disadvantages of this approach is that RNAi-mediated 
knock-down of essential proteins is highly detrimental to the parasite. With this in mind, it is 
likely that RITseq will only identify non-essential proteins involved in drug mode of action. In 
contrast, essential protein targets that are overexpressed do not appear to cause severe growth 
phenotypes given the experiments presented here. Therefore, this approach could in theory, 
identify direct protein drug targets. The main issue associated with this method is that, unlike 
RITseq, the full ORF of the protein must be transfected into the parasite. This means that 
development of a complete overexpression library of the entire proteome, which is thought to 
contain upwards of 9,000 genes, would take a considerable amount of effort and time, and 
would require very elaborate and well-organised experimental set-up. However, several groups 
collaborating in Dundee are currently proceeding with an overexpression library generated with 
a random shotgun approach, which is easier and more efficient to carry out (M. Barrett, 
personal communication). 
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3.14 Discussion 
The novel benzoxaborole, AN5568, has been shown to have a high efficacy both in vivo and in 
vitro, and importantly, is active against both T. b. rhodesiense and T. b. gambiense (Jacobs et 
al., 2011). The drug is currently undergoing clinical trials, and along with another novel 
compound, fexinidazole, could become the first new anti-trypanosomal on the market in a 
generation (Brun et al., 2011). However, the MoA of AN5568 is currently unknown. 
Here, we attempted to utilise a range of omics-based approaches in combination with 
molecular biology techniques, in order to dissect the MoA of this novel benzoxaborole. Firstly, 
we show that the drug retains potency in an in vitro setting, against BSF T. brucei Lister 427 
cells. In contrast, the compound efficacy was drastically reduced in PCF trypanosomes, 
indicating that this drug is better suited to the treatment of the mammalian infective stages. 
Indeed, even after a 30 hour treatment at 10× EC50, live cells were observed in PCF cultures. In 
addition, T. brucei BSF are more sensitive to AN5568 compared to other trypanosomatids such 
as L. mexicana and T. cruzi.  
Several interesting BSF phenotypes were observed during microscopy analyses of AN5568-
treated cells. Firstly, drug-mediated action causes significant complications in cell division. This 
was highlighted by incubating cells for 24 hours with a sub-lethal dosage of the benzoxaborole 
(fig. 3-3), but also occurred in lethal concentrations (fig. 3-4). By 12 hours, cells become rounded 
and mitochondrial morphology was severely compromised, and quantification of nuclei and 
kinetoplasts hinted at defects in cytokinesis, as well as kDNA replication, as shown by the 
increase in 2N1K and MNMK cells subsequent to drug-treatment. These phenomena have 
previously been reported in KO’s or knock-downs of specific targets involved in mitochondrial 
metabolism and nucleotide replication (Ferguson et al., 1994, Liu et al., 2010, Clayton et al., 
2011). For example, knock-down of the mitochondrial acyl carrier protein led to alterations in 
mitochondrial morphology (Clayton et al., 2011), and kinetoplast replication is compromised 
when expression of important maintenance proteins are abolished (Hines & Ray, 2010, Liu et 
al., 2010). 
In order to obtain a better understanding of intracellular metabolism during AN5568 treatment, 
cell pellets were analysed by LC-MS. In BSF cells, upregulation of methionine metabolism was 
by far the most significant change. This result, in addition to the significant antagonism between 
sinefungin and AN5568, suggests that the benzoxaborole potentially affects an MTase reaction 
pathway. Given that PCF cells require a higher dose of the compound, we hypothesize that the 
drug targets a BSF-specific MTase. Several other significant perturbations occurred during 
AN5568-treatment. For example, a general downward trend was observed in lipid metabolism. 
In particular, phospholipids such as PC and PE and other metabolites derived from these 
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phospholipids decreased significantly. Furthermore, modified lysines, such as acetyl-L-lysine 
and methylated lysines, exhibited significant increases in drug-treated cells. We hypothesise 
that cells treated with AN5568 respond through the activation of the oxidative stress response 
pathway. This hypothesis is supported by upregulation of the trypanothione biosynthesis 
pathway that was observed in metabolomics analysis. 
Finally, there were changes in metabolites with unknown roles in the trypanosome, such as 
aminoacetone, 5-guanidino-2-oxopentanoate and 8-amino7-oxononanoate. The changes in 
these metabolites were significant and they warrant further study to understand their role in T. 
brucei metabolism. 
Further metabolomics analysis was carried out using stable-isotope labelled 13C-(U)-L-
methionine, in the hope that changes in isotope labelling distributions would be observed. 
However, only 18 metabolites that incorporated carbon isotopes were observed. There are 
several reasons for this. Firstly, the experiment was carried out over a period of 6 hours. In this 
time, AdoMet and AdoHcy incorporated 13C isotopes, as did methylated L-lysine residues. This 
suggests that methylation was still occurring in the presence of AN5568. However, metabolites 
such as methyl-arginine, which is known to receive a methyl group from AdoMet (Lott et al., 
2014), was not labelled. Therefore, the experiment could be repeated over a longer duration, 
with a lower concentration of AN5568, to ensure that cell cultures survive longer. Secondly, the 
majority of methylation occurs on proteins and nucleic acids. Proteins, apart from short 
peptides (<3 residues), are not detected with the LC-MS platform, or the metabolite extraction 
protocol that was used. Therefore, MS such as MALDI-TOF could be employed to investigate 
patterns of protein distribution, potentially coupled to SILAC for comparative proteomics. This 
has been carried out successfully in trypanosomatids in the context of phosphorylation 
detection (Urbaniak et al., 2013). 
Several of the observed metabolic changes were followed up by comparative metabolomics 
analyses using genetically modified cell lines as well as other drug treatments with known 
targets. For the former, an RNAi construct was generated to knock-down TbCgm1, an essential 
SL MTase that modifies cap0 (Hall & Ho, 2006a, Takagi et al., 2007). This pathway is unique and 
essential in T. brucei, although the cap1, cap2, cap3 and cap4 methylators are currently not 
thought to be essential (Zamudio et al., 2006). Once successful knock-down had been 
confirmed, comparative metabolomics analyses were carried out. These showed that L-
methionine and adenine increased drastically, probably due to a decrease in protein synthesis 
as a result of transcription inhibition. However, there were no changes in AdoMet of 5’-MTA, 
such as those observed in AN5568-treated cells. Interestingly, knock-down of TbCgm1 resulted 
in high levels of nucleotides. This supports the theory that SL methylation inhibition significantly 
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affects the cell’s transcriptional machinery, as well as ability to generate mature mRNAs 
(Zamudio et al., 2009). 
To confirm activation of stress responses in AN5568-treated cells, comparative metabolomics 
analyses were carried out with DTT, a known ER stress inducer. Here, we show that DTT causes 
significant upregulation of the trypanothione biosynthesis pathway, with increases observed in 
glutathione and L-ornithine. There was also a significant decrease in trypanothione disulphide, 
due to the effect of DTT in breaking disulphide bridges (Tiengwe et al., 2015). In addition, the 
increases in modified lysines seen in AN5568-treated cells were also observed in DTT-treated 
cells, suggesting these are involved in the oxidative stress response. This supports the 
hypothesis that AN5568 causes widespread cellular stress responses, and these metabolites 
might not be directly involved in the benzoxaborole target inhibition. In contrast, no changes 
were seen in AdoMet, 5’-MTA or adenine, and we hypothesise that these changes can be 
attributed to the effect of AN5568 target inhibition.  
As described in chapter 1, several methods exist for the identification of drug targets. Prior to 
the study presented here, we were informed that affinity chromatography experiments had 
been carried out unsuccessfully to identify the AN5568 MoA (R. Jacobs, personal 
communication). This was likely due to a lack of knowledge concerning SAR. We therefore 
attempted to carry out drug target identification techniques without the requirement of drug 
immobilisation, in the form of the DARTS assay. This assay was developed several years ago by 
Lomenick and colleagues and has been successfully used in mammalian system as well as 
prokaryotes (Lomenick et al., 2009, Chin et al., 2014). To our knowledge, the data presented 
here is the first description of the DARTS assay in a protozoan parasite.  
Using the DARTS assay, several hits were identified, although none were hypothesised to be 
involved in the AN5568 MoA. Indeed, proteins such as ALD and the branched chain 
aminotransferase identified in both protein samples are reported to be highly abundant in the 
T. brucei proteome (M. Barrett, personal communication). One of the proteins identified was a 
putative methionine biosynthetic protein (table 3-3). Further analyses showed that this protein 
contained a wybutosine MTase domain. Wybutosine, a heavily modified tRNA, has not been 
described in T. brucei and this gene remains to be characterised, although several publications 
have described the yeast homologue (Kalhor et al., 2005, Noma et al., 2006). As part of a small 
overexpression library, this gene (Tb927.1.3080) was overexpressed to look for changes in 
AN5568 sensitivity. However, none was found. The primase 2 identified in the DARTS assay has 
been reported to be localised in the T. brucei mitochondrion (Hines & Ray, 2011). This study 
showed that primase 2 was an essential component in kDNA maintenance (Hines & Ray, 2011). 
It would therefore be of interest to confirm whether or not AN5568 targets this protein. 
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There are several limitations with the DARTS approach. Firstly, it requires a lengthy optimisation 
process for each novel organism and/or compound that is tested, because it is unknown 
whether the unidentified target protein undergoes significant alterations in thermodynamic 
stability when bound to a ligand or drug. Furthermore, the concentrations of pronase, or 
proteolysis agent, required differ for each compound. Indeed, we found that the pronase 
concentration added must be sufficient to degrade most of the proteome, without 
compromising the drug target protein to the same extent. In addition, there are differing results 
depending on whether the drug-lysate incubation is carried out in living cells, or with a protein 
extract. This is especially important if the drug requires activation.  
During the DARTS analysis, we found that running AN5568-treated protein extracts directly on 
a protein generated a band enrichment at ~37 kDa (fig. 3-29). Subsequently, a 2D-DiGE 
experiment was carried out to enable higher resolution of protein differences between WT and 
drug-treated cell lysates (fig. 3-30). Through this experiment, it was found that expression of 
cysteine and serine peptidases, or their precursors, are upregulated in response to AN5568 
treatment (table 3-4). Cysteine peptidases in particular have been studied as a potential drug 
target in T. brucei (Troeberg et al., 1999). Several studies have shown that these enzymes 
influence the ability of the cell to differentiate (Williams et al., 2006, Santos et al., 2007). In T. 
brucei, disruption of the natural inhibitor of cysteine peptidase gene leads to increased clan CA 
cysteine peptidase expression (Santos et al., 2007). Cells possessing increased cysteine 
peptidase expression were found to undergo more efficient VSG surface coat exchange, 
although there was no difference in the cells’ ability to commit to differentiation (Santos et al., 
2007). Whilst further work is required to validate the proteomics findings in AN5568-treated 
cells, the aforementioned studies suggest that increased cysteine peptidase expression could 
result from increased autophagy or activation of differentiation pathways in T. brucei. 
The 2D-DiGE experiment also revealed downregulation of Hsp70 in AN5568-treated T. brucei. 
This gene has been reported to be localised in the glycosome (Guther et al., 2014) and its 
downregulation could be associated with a decrease in energy metabolism due to the effects 
of the benzoxaborole. Furthermore, a putative chaperonin Hsp60 that is targeted to the 
mitochondrion, was upregulated in AN5568-treated cells. These findings again hint at the 
potential stress that T. brucei undergoes upon treatment with AN5568. One note of interest is 
that several of these proteins are regulated by a T. brucei zinc finger protein called ZC3H11 
(Droll et al., 2013, Singh et al., 2014). It is therefore possible that AN5568 inhibits a transcription 
regulator that leads to widespread perturbations in the cell. 
During the course of this study, the decision was made to carry out a more detailed study of the 
T. brucei MTase complement, which has not been done for the trypanosomatids. This 
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complement, known as the “methyltransferome”, identified 145 MTases encoded in the T. 
brucei genome (table 3-6). In similar fashion to both S. cerevisiae and H. sapiens, the MTases 
differed in both type/fold and substrate. There were 33 MTases containing SET domains, which 
are thought to be involved in lysine methylation and in particular, histone methylation (Herz et 
al., 2013). This number was larger than both of the previous MTome studies (Petrossian & 
Clarke, 2011, Wlodarski et al., 2011), and could reflect the requirement of T. brucei to change 
global transcription levels in response to differentiation to different life cycle stages. There were 
also predicted radical SAM MTases, tetrapyrrole methylases, a Hcy MTase, a thymidylate 
synthetase, a TIM beta/alpha barrel MTase and TYW3, none of which have been described in T. 
brucei. Given the importance and conserved roles of MTases in cellular function, an in-depth 
description and characterisation of the MTase complement in the tri-tryps would be beneficial 
to the field. 
The final experiment in this chapter was to overexpress 12 essential putative 
methyltransferases and test the sensitivity of these overexpressors to both AN5568 and the 
MTase inhibitor sinefungin. Using an ornithine decarboxylase overexpressor, we were able to 
show that overexpression of a drug target generates resistance to the specific drug (fig. 3-32). 
This has previously been reported in the context of methionyl-tRNA synthetase inhibitors 
(Ranade et al., 2013). Unfortunately, none of the 12 overexpression lines generated resistance 
against AN5568, although 4 of these were significantly desensitised to sinefungin. This is most 
likely due to higher abundance of a protein “absorbing” or “mopping” excess sinefungin. We 
therefore conclude that none of these 12 proteins are targeted by AN5568. 
The volume of data produced during this study was significant, and several datasets were not 
fully discussed but instead, the results deemed important in the context of AN5568 target 
identification were presented in a way that highlights key findings of each mass spectrometry 
experiment. Each dataset was carefully analysed by looking at individual pathways that were 
hypothesised to have undergone perturbations, and comparative metabolomics analyses 
proved highly beneficial to dissecting the mode of action of AN5568. The next step of the project 
was to generate and characterise an AN5568-resistance cell line with the expectation that this 
could greatly aid in the identification of the benzoxaborole MoA in T. brucei. 
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Chapter 4. Generation and characterisation of 
an AN5568-resistant cell line 
4.1 Introduction 
As described in the chapter 1, several methods exist that can be utilised to investigate drug 
modes of action. Some were employed in chapter 3, with reasonable success. However, when 
there is limited information regarding the SAR of a compound, as often occurs with candidates 
selected from large multi-compound screens, many of these methods are rendered somewhat 
useless. This is especially true with affinity chromatography, which requires docking of 
compounds to affinity beads, before a protein lysate pull-down is performed (Denise et al., 
1999). 
One method that has been used with great success on many occasions is the generation and 
selection of a drug-resistant cell line, and subsequent investigation of the biological and 
molecular changes that have occurred to cause increased drug-resistance. This was the method 
used by Rock and colleagues to elucidate the mechanism by which the anti-fungal AN2690 
inhibits tRNALEU synthetase (Rock et al., 2007). Generating resistant cell lines has also led to 
many significant discoveries in T. brucei and the related tri-tryps, Trypanosoma cruzi and 
Leishmania spp. (Campos et al., 2013, Berg et al., 2015).  
For example, loss of the P2 transporter was associated with resistance against the 
mitochondrial targeting DB75 (Lanteri et al., 2006). Another study by Ranade and colleagues 
found that resistance against methionyl-tRNA targeted drugs was generated by high levels of 
target protein expression (Ranade et al., 2013). Furthermore, both the MacLeod and Barrett 
groups have studied drug resistance in detail in both African trypanosomes and Leishmania, 
especially in the cases of melarsoprol and amphotericin B respectively (A. MacLeod & M. 
Barrett, personal communication). 
It is important to note that especially in the case of T. brucei, resistance is often generated by 
the downregulation, or loss of expression, of uptake transporters specific to the drug, as was 
demonstrated by Vincent and colleagues when they characterised an Eflornithine-resistant T. 
brucei line (Vincent et al., 2010). In these cases, whilst important discoveries are made with 
regards to potential resistance mechanisms in the field, it does not aid in furthering our 
understanding of the drug mode of action, as the drug is no longer taken up by the cell. Whilst 
this method of resistance sometimes has a detrimental effect on growth-rates, it allows the 
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parasite to survive in high concentrations of the drug in question as shown by the 
aforementioned studies. 
Combined with the modernisation of technologies allowing the characterisation of new cell 
lines, generating drug resistance is a simple (albeit painstakingly slow), but effective tool to 
understand drug mode of action. Therefore, we decided to utilise this experimental technique, 
in order to try and gain a better understanding of the mechanisms by which AN5568 kills T. 
brucei, and if and how the parasite could generate resistance against it. Building on the 
knowledge and hypotheses developed in the earlier chapter, we developed a targeted 
approach. Again, we utilised the expertise and specialities of the Barrett and MacLeod groups, 
namely metabolomics, genomics and transcriptomics, to characterise this resistant cell line. 
4.2 Generation of AN5568 in T. brucei cells in vitro 
The project, in keeping with previous work, utilised the Lister 427 strain of T.b. brucei as a 
parental strain. With the knowledge of the EC50, cells were grown in the presence of very low 
concentrations of AN5568 initially. As we did not know how well cells would grow, the 
experiment was initiated by keeping cells in several wells of a 24-well plate at varying 
concentrations of the benzoxaborole. The highest concentration that allowed growth of cells 
initially, was ~170 nM. This was just under the EC50 value reported in Chapter 3 (section 3.2). 
From here on, higher concentrations of AN5568 were added if and when cells were deemed to 
be resistant to the lower concentrations (fig. 4-1A). After a period of ~200 days, cells were stably 
growing in 4.8 µM AN5568, approximately 24-fold the EC50 of wild-type cells. At this point, cells 
were cloned by dilution, and 4 clones were retrieved for further investigation. 
Growth analysis was carried out on the AN5568R cell line, to assess whether there were any 
differences compared to wild-type cells (fig. 4-1B). This experiment showed that all resistant 
clones had a very slow growth rate compared to wild-type Lister 427 T.b. brucei. This suggests 
the resistance comes at a fitness cost, resulting in slower growth and potentially, slower 
metabolism. 
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Figure 4-1: Generation of an AN5568-resistant cell line. A) Resistance was generated in a Lister 427-
derived cell line, by adding increasing increments of the benzoxaborole to cell cultures in vitro. Whilst 
parasites could only grow at very low concentrations (<EC50) and a very slow rate initially, there was a 
significant increase in the concentration they could tolerate, after approximately 46 days, suggesting a 
resistance mechanism was generated at this point. Red line indicates mean wild-type EC50. B) Once cells 
were thought to have a stable resistance phenotype, they were cloned by dilution, and 4 clones were 
assessed for their growth. Whilst separate AN5568R clones grew at similar rates, overall this was much 
slower than WT Lister 427 cells. 
To test whether the observed resistance against AN5568 was indeed quantitative, we carried 
out Alamar blue assays with the AN5568R line and a WT Lister 427 control (fig. 4-2). Overall, the 
AN5568R clones showed a 15-20-fold increase in EC50 value against the benzoxaborole, thereby 
proving the cell lines were resistant, especially compared to wild-type cells (fig. 4-2A). Further 
analyses were also performed with other drugs, to test any cross-resistance that might have 
arisen.  
In Chapter 3 (section 3.4.5), the contrasts and similarities between the modes of action of 
sinefungin and AN5568 were discussed in detail. We were therefore very interested to find that 
the AN5568R lines also exhibited some resistance against sinefungin, albeit at a lesser extreme 
than the benzoxaborole (fig. 4-2B). There was a 4-fold increase in the sinefungin EC50 
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concentrations between wild-type cells and the AN5568R lines, which was significant by t-test 
(P=0.0236). 
 
Figure 4-2: AN5568R undergoes several changes in drug sensitivity. A) As expected, the AN5568R line, 
once cloned and assayed for drug resistance using an alamar blue assay, showed a significantly increased 
EC50 compared to wild-type cells. Indeed, the mean EC50 was 4.88 ± 0.56 µM, approximately 19-fold higher 
than WT cells. B) Interestingly, AN5568R also showed an increased resistance again the AdoMet-dependent 
MTase inhibitor sinefungin, which was shown to act in similar fashion to AN5568 (chapter 3). Three other 
drugs were assayed with the AN5568R line. Whilst pentamidine (C) and diminazene (E) both showed 
increased sensitivity compared to WT cells, there was no significant change in suramin (D) resistance.  
Further analyses were carried out using pentamidine, suramin and diminazene (fig. 4-2). Whilst 
resistant cells showed hypersensitivity to pentamidine (fig. 4-2C) and diminazene (fig. 4-2E), 
there was no significant change in suramin resistance. It was interesting to observe that the 
generation of resistance to AN5568 also resulted in altered sensitivity to several other drugs. In 
the cases of pentamidine and diminazene, resistance has previously been shown to result from 
altered expression of cell surface receptors (de Koning et al., 2004, Bridges et al., 2007). 
Therefore, we were interested to find out whether a similar phenomenon had occurred in the 
case of AN5568-resistance. In addition, it would be interesting to know whether resistance to 
sinefungin could also be due to a loss of transporter, as this has not been investigated before. 
Having established changes in drug sensitivity and in vitro growth of the benzoxaborole-
resistant line, we next sought to characterise the cell line using omics-based approaches, to 
follow up on these objectives, and to generate new hypotheses about the mechanisms involved 
in AN5568 resistance. 
 
 
138 
4.3 RNA-seq analysis of the AN5568R cell line 
The use of RNA-seq, which allows the observation of the transcriptome, has both advantages 
and disadvantages compared to DNA-seq. The transcriptome is known to be significantly more 
dynamic than the genome with regards to environmental responses (Macaulay & Voet, 2014). 
Therefore, to get a more accurate picture of the cellular response to drugs, as well as changes 
that render cells drug-resistant, RNA-seq was judged to be preferable to DNA-seq. However, 
sequencing analysis would be more difficult as only coding regions and their untranslated 
regions could be analysed for polymorphisms and other forms of mutation. RNA-seq was also 
chosen instead of other transcriptome analysis techniques such as microarray or EST/cDNA 
sequencing due to the high resolution offered by this platform, in addition to the fact it enables 
high-throughput analysis with automated bioinformatics pipelines similar to those that are 
already in use for DNA-seq analysis (Mortazavi et al., 2008). 
For this experiment, 6 RNA samples were prepared: Four AN5568R clones, along with an RNA 
sample from the parental line from which the AN5568R line was derived. This sample was 
isolated before generation of resistance was initiated. In addition, another RNA sample was 
prepared from a cell line that underwent a high number of passages without the benzoxaborole. 
This was done in order to rule out false positive mutations that might arise from adaptations to 
long-term in vitro tissue culture. The 6 samples were submitted to Glasgow Polyomics for RNA 
sequencing. Libraries were prepared using the Illumina TruSeq mRNA library prep kit, which 
involves a poly-adenylation targeting step to ensure enrichment of mRNAs. Paired end 
sequencing (2×75 bp) was carried out using the Illumina NextSeq 500 platform (Illumina®). 
The resulting raw data was processed and analysed with the aid of the Wellcome Trust Centre 
for Molecular Parasitology Bioinformatics team. This was done using the bioinformatics pipeline 
described in the methods. Briefly, all reads were trimmed to remove adapters, and a quality 
control was carried out on each sample using FastQC (Andrews, 2010). Once the sequencing 
quality was judged to be satisfactory for each sample, processing was done using the TopHat 
pipeline (Trapnell et al., 2009), and transcriptome analysis was carried out using the cufflinks 
package (Trapnell et al., 2010). Finally, the cummeRbund tool package was used to visualise the 
data (Trapnell et al., 2012). The widely used reference genome as well as transcriptome for the 
TREU 927 strain (v9.0) was used for RNA-seq alignments. This reference genome is commonly 
used as it provides by far the best assembly and annotation, although it does contain some 
differences compared to the Lister 427 cell line (Brems et al., 2005). Therefore, we anticipated 
a high number of polymorphisms (SNPs and indels) arising from this analysis. This is discussed 
in detail in section 4.4. 
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A dendrogram generated using cummeRbund showed that both controls were more closely 
correlated to each other than any of the AN5568R samples, in terms of differential gene 
expression data (fig. 4-3A). Importantly, this meant that long-term in vitro culture had not 
significantly altered the high-passage control, as it still clustered with the parental control. This 
led to the assumption that the genetic or transcriptomic drift caused by drug resistance was 
greater than the effect of long-term culture. 
In addition, dispersion, a measure of the quality of the data, of the two sample groups was 
analysed (fig. 4-3B). Here, deviation from the threshold (dispersion) was plotted against the 
read count in FPKM (fragments per kilobase of transcript per million mapped reads). Thus, with 
high FPKM, a specific fragment, or gene, is hypothesised to show increased dispersion. This is 
what was found from the RNA-seq data generated from the 6 cell lines. Indeed, both sample 
groups showed similar dispersion patterns, and no over-dispersion was observed in either 
sample group. 
 
 
Figure 4-3: RNAseq data quality analysis. A) A dendrogram showed clustering of samples was the same 
as hypothesised. Whilst all four AN5568R clones clustered together, they were found to be dissimilar to 
either control. Similarly, both controls clustered together, suggesting that high passage number had 
minimal effect on gene expression profiles. B) A plot of dispersion against FPKM counts showed the data 
to be of high quality with little over-dispersion observed in either sample group. 
The next step was to analyse the mapping of the sequencing reads (fig. 4-4). In total, just under 
174 million reads were mapped from the 6 samples. Between 25 and 32 million reads were 
mapped to the genome for each sample. Coverage of the reads was calculated using the 
bedtools package which found a median of 100% coverage (measured as percentage of bases 
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for each gene that had non-zero coverage). The mean percentage coverage of the 
transcriptome was 81.33 ± 0.32%, although this included a large number of contigs and 
transcripts corresponding to VSGs, which are not usually mapped. In addition, it was important 
to ensure that reads mapped across the genome in a similar fashion in all samples. Using 
samtools, the numbers of reads mapped on each individual chromosome was assessed (fig. 4-
4A). These data showed that each sample had similar numbers of reads mapped to each 
chromosome. The two largest chromosomes, 10 and 11 (4,144,375 bp and 10,821,667 bp 
respectively) had the highest numbers of mapped reads. Whilst the T. brucei genome is known 
to contain 11 chromosomes, the assembled genome thus far contains numerous extra 
unassembled contigs, which appear in datasets as chromosomes by themselves (Berriman et 
al., 2005). In this experiment, these contigs are presented under the “other” genome 
sequences. As shown in figure 4-4A, these sequences only make up a small portion of the RNA-
seq assembly. It was important to confirm that the number of reads matched to each 
chromosome was similar in each sample. Taken together, we concluded from these analyses 
that the rate of false positives would be limited and differential expression would be due to 
variation between samples, not RNA quality or sequencing errors. 
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Figure 4-4: RNA-seq sequencing data analysis of the AN5568-resistant cell line. A) The samtools 
package was used to observe the numbers of reads mapped to each chromosome in the T. brucei genome. 
For each sample, similar numbers of reads were mapped to each chromosome, with the highest number 
being identified as belonging to chromosomes 10 and 11. The fewest number of reads were mapped to 
extra-chromosomal contigs. B) A density plot of the Log10 FPKM values was plotted for all 6 samples. This 
showed significant overlap of all samples, indicating high quality of reads.  
A density plot, or smooth histogram, was generated using kernel density estimation to map the 
distributions of RNA-seq read counts in FPKM. The resulting figure showed a high amount of 
overlap between samples, indicative that the data were comparable in terms of their quality. 
In addition, the data distribution appeared to be unimodal. 
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The reads obtained by RNAseq mapped to 11,563 genes. Of these, 2422 genes showed a 
significant change in transcript abundance based on the P-value alone, with a threshold of 
P=0.05 (fig. 4-5). This number was more than expected, mainly because this analysis also 
included changes in transcript abundance below 2-fold. Therefore, we set out to refine the 
dataset and identify the significantly changed genes. 
 
Figure 4-5: Volcano plot of changes in transcript abundance in the AN5568R cell line. The RNAseq 
transcriptome dataset was analysed using the R package cummeRbund. Across the transcriptome, 2422 
genes were found to exhibit significant changes in transcript abundance in the AN5568R line (red dots), 
compared to a combination of a parental, and high-passage controls. As can be seen here, many of the 
significant hits did not show large Log2 fold changes. There were 11 genes that had a Log2 fold change 
above 5 or below -5, and therefore these are not shown. 
To refine the data set containing all significant hits further, we selected all genes that showed 
a Log2 fold-change above 1, or below -1, equating to a fold change of 2 or 0.5 respectively. This 
led to datasets of 126 genes showing significant upregulation, and 371 genes showing 
significant down-regulation. These are shown in the supplementary data (S4). The top 15 hits 
for both upregulation and downregulation are presented in tables 4-1 and 4-2 respectively. 
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4.3.1 PCF-associated genes are upregulated 
Strikingly, many of the genes shown to be significantly upregulated (P=<0.05, Log2 fold 
change = >1) in the AN5568R line were PCF-form specific genes. In particular, GPEET and EP 
procyclins, both surface markers of early and late-differentiated PCFs respectively, were found 
at high levels of transcript abundance (table 4-1). The assembled transcriptome was analysed 
in detail to find the reads for these proteins, which were localised on chromosome 6 (fig. 4-6). 
Indeed, almost no reads were mapped to procyclins for the two control samples, whilst all 4 
resistant clones showed a high number of mapped reads in this region. 
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Tb927.6.510 GPEET2 procyclin precursor 112.276 1648.920 3.8764 0.00005 0.00045 
Tb927.5.5530 
Variant Surface Glycoprotein, 
putative 
0.339 2.505 2.8842 0.00575 0.02376 
Tb927.5.4020 hypothetical protein 35.287 222.540 2.6569 0.00005 0.00045 
Tb927.10.10260 EP1 procyclin (EP1) 25.538 138.305 2.4371 0.00005 0.00045 
Tb927.10.10250 EP2 procyclin (EP2) 2.785 14.234 2.3534 0.00375 0.01693 
Tb927.9.7470 
purine nucleoside transporter 
(NT10) 
45.384 172.052 1.9226 0.00005 0.00045 
Tb927.10.10760 hypothetical protein 13.029 48.740 1.9033 0.00010 0.00082 
Tb927.11.2410 hypothetical protein, conserved 43.069 159.920 1.8926 0.00005 0.00045 
Tb927.11.6280 
pyruvate phosphate dikinase 
(PPDK) 
70.542 254.852 1.8531 0.00005 0.00045 
Tb927.3.5790 
expression site-associated gene  
(ESAG, pseudogene), putative,  
36.384 129.655 1.8333 0.00005 0.00045 
Tb927.8.6170 transketolase, putative (TK) 59.517 210.032 1.8192 0.00005 0.00045 
Tb927.10.12780 ZC3H37 6.190 21.829 1.8183 0.00005 0.00045 
Tb927.1.2820 pteridine transporter, putative 12.890 43.965 1.7701 0.00005 0.00045 
Tb927.6.2890 
single strand-specific nuclease, 
putative 
42.781 143.279 1.7438 0.00005 0.00045 
Tb927.4.3500 
Amastin surface glycoprotein, 
putative 
133.087 436.540 1.7137 0.00005 0.00045 
Table 4-1: Top 15 genes significantly upregulated in the AN5568R line. 
Transporter expression levels are known to change over the course of differentiation from BSF 
to stumpy-forms and subsequently to PCFs. Several analyses of transcriptomic changes that 
occur during the differention process have been published (Siegel et al., 2010, Capewell et al., 
2013b). Both these studies reported increased expression of the purine transporter identified 
here (Tb927.9.7470) in SSFs and PCFs. Moreover there was increased expression of the 
pteridine transporter (Tb927.1.2820) in both these differentiated forms, as was found in the 
benzoxaborole-resistant cells. 
A predicted CCCH-domain containing protein (Tb927.10.12780) was identified. Interestingly, 
this protein was not found to be differentially expressed in studies of T. brucei differentiation 
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(Siegel et al., 2010, Capewell et al., 2013b). It is unknown what increased expression of this gene 
could lead to, but its domains suggest it plays an important role in mRNA regulation. 
Further increases that corresponded to differentiation phenotypes were found with a putative 
pyruvate phosphate dikinase (Tb927.11.6280) and a glycosomal transketolase (Tb927.8.6170) 
previously shown to be expressed exclusively in PCF T. brucei (Stoffel et al., 2011). In addition, 
a nuclease (Tb927.6.2890) and an amastin surface glycoprotein (Tb927.4.3500) were also 
upregulated, although these were found not to be differentially expressed in the Siegel study 
(Siegel et al., 2010).  
The upregulated genes also included a VSG, which was in contrast to the main trend of PCF-
specific genes. However, the FPKM values for both sample groups were low for this gene, and 
could be a result of improper alignment, given the high mutation rates in VSG genes. Three 
hypothetical proteins were identified and as such, were not followed up. 
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Figure 4-6: RNAseq coverage of chromosome 6. RNAseq data output from the cufflinks tool suggested increased abundance of both GPEET and EP procyclins, which 
are known to be upregulated in PCF trypanosomes. These genes are found in an array on chromosome 6 in the T. brucei genome. Coverage of the relevant portion of 
chromosome 6 was analysed using the IGV software (Robinson et al., 2011), and is shown here. In this result, which mirrors that of the transcript analysis, coverage 
analysis showed a similar increase in transcript abundance around the procyclin loci (black arrow). Whilst both the controls showed minimal number of reads mapped 
to this portion of the genome, there were similarly high increases in all four AN5568R clones. 
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4.3.2 Downregulation of BSF-specific genes 
A similar table was generated for the 15 genes showing highest amounts of downregulation in the 
AN5568R line (table 4-2). Here, we found widespread downregulation of VSGs and their associated 
expression site associated genes. In addition, a retrotransposon hot spot protein was also found to 
be downregulated. 
Again, there were similarities between these data and the aforementioned transcriptomics 
datasets discussing differentiation in T. brucei. A nucleoside transporter (Tb927.9.15980) was 
shown to exhibit decreased transcript abundance in stumpy forms, but not in PCF trypanosomes. A 
putative potassium voltage-gated channel (Tb11.v5.0396) showed decreased transcript abundance, 
but was not reported in either the Siegel (Siegel et al., 2010), or the Capewell (Capewell et al., 
2013b) study. Furthermore, a leucine-rich repeat protein was found to decrease significantly here, 
but not in stumpy forms, although it did have decrease abundance in PCF cells according to the 
Siegel study. 
Overall, these data indicate significant cell surface remodelling, albeit at the transcript level, with 
the loss of VSG and related expression site genes. In addition, there is a corresponding increase in 
procyclins. In addition there is upregulation of transketolase which could suggest increased PPP 
metabolism. Finally, there are changes in transporters which could have a profound impact of 
uptake of metabolites, as well as drugs. Indeed, changes in these transporters could potentially be 
responsible for the increased sensitivity of the AN5568R line to diamidines such as pentamidine and 
diminazene, as is discussed in more detail in section 4.3.3. 
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Tb09.v4.0136 variant surface glycoprotein  (VSG) 112.834 0.236 -8.8991 0.00975 0.03612 
Tb927.2.1380 leucine-rich repeat protein (LRRP) 30.159 0.424 -6.1539 0.00010 0.00082 
Tb927.9.7400 
expression site-associated gene 11 
(ESAG11) 
35.798 2.416 -3.8892 0.00005 0.00045 
Tb927.9.16010 
expression site-associated gene 4 
(ESAG4) 
29.454 2.117 -3.7987 0.00150 0.00799 
Tb927.2.3330 hypothetical protein 20.694 1.562 -3.7278 0.00435 0.01903 
Tb927.1.520 variant surface glycoprotein (VSG) 9.346 0.733 -3.6720 0.00260 0.01249 
Tb927.5.160 
retrotransposon hot spot protein 
(RHS) 
12.345 0.993 -3.6354 0.00970 0.03595 
Tb927.6.170 
receptor-type adenylate cyclase 
(GRESAG4) 
6.239 0.534 -3.5455 0.00005 0.00045 
Tb11.v5.0396 potassium voltage-gated channel 16.682 1.557 -3.4211 0.00005 0.00045 
Tb927.3.5750 
retrotransposon hot spot protein 
(RHS) 
42.142 4.211 -3.3229 0.00005 0.00045 
Tb927.2.3340 hypothetical protein 138.552 14.271 -3.2793 0.00005 0.00045 
Tb09.v4.0018 
expression site-associated gene 
(ESAG)  
13.292 1.432 -3.2145 0.00015 0.00117 
Tb927.9.7290 variant surface glycoprotein (VSG) 23.027 2.594 -3.1503 0.00005 0.00045 
Tb927.9.15980 nucleoside transporter 1, putative 3.611 0.435 -3.0544 0.00515 0.02174 
Tb05.5K5.290 hypothetical protein 6.141 0.743 -3.0463 0.00930 0.03485 
Table 4-2: Top 15 genes significantly downregulated in the AN5568R cell line. A significant portion of 
downregulated genes were identified as BSF-specific proteins, including VSGs and VSG expression site 
associated genes. 
4.3.3 Differential expression of T. brucei transporters 
As mentioned previously, drug-resistance in T. brucei can be generated due to differential 
expression of transporters. We therefore analysed whether any transporters exhibited altered 
transcript abundance in the AN5568R cell line. The results are shown in table 4-3.  
The gene set was chosen based on a GO-term search of “transport” on the TriTryp database. Genes 
annotated as “hypothetical” were removed from the search results, leaving a gene set comprising 
of 313 genes. Analysis of expression levels for these genes was carried out through manual filtering 
of the data, as well as analysis using the cummeRbund package for R (Trapnell et al., 2012).  
A total of 24 identified and putative transporters underwent significant changes in transcript 
abundance, based on both the P value as well as the fold change (log2 fold change = >1 or <-1). Of 
these, 11 were found to have a higher transcript abundance in the AN5568R line, whilst the 
remaining 13 genes were shown to have decreased transcript abundances (table 4-3). 
The transporter that underwent the highest increase, a purine nucleotide transporter 
(Tb927.9.7470), was previously shown to play a role in nifurtimox efficacy and resistance, as 
detected by RIT-seq analyses (Alsford et al., 2012).  
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Tb927.2.5410 ABC transporter family-like protein 33.7451 13.2269 -1.3512 0.00005 0.00045 
Tb927.2.6150 
adenosine transporter 2 
(TbNT2/927) 
43.8016 17.4699 -1.32611 0.00005 0.00045 
Tb927.2.6200 
adenosine transporter 2, putative 
(TbNT3) 
13.023 5.11097 -1.34939 0.00005 0.00045 
Tb927.2.6220 
adenosine transporter 2, putative 
(TbNT4) 
65.725 10.3236 -2.6705 0.00005 0.00045 
Tb927.2.6320 
adenosine transporter 2, putative 
(TbNT6) 
47.2069 7.01062 -2.75138 0.00005 0.00045 
Tb927.8.7670 amino acid transporter, putative 25.3989 56.7563 1.16001 0.00005 0.00045 
Tb927.8.7740 amino acid transporter, putative 84.4543 226.075 1.42056 0.00005 0.00045 
Tb927.8.8300 amino acid transporter, putative 39.0075 99.0958 1.34507 0.00005 0.00045 
Tb927.4.4730 
amino acid transporter, putative 
(AATP11) 
109.314 314.637 1.52522 0.00005 0.00045 
Tb927.10.14160 Aquaglyceroporin 3 (AQP3) 489.331 155.568 -1.65327 0.00005 0.00045 
Tb927.5.3400 
calcium-translocating P-type 
ATPase, calcium pump 
176.261 78.7892 -1.16164 0.00005 0.00045 
Tb927.6.2200 DJ-1 family protein, putative 237.118 115.203 -1.04142 0.00005 0.00045 
Tb927.10.8460 glucose transporter, putative 56.438 11.3104 -2.31902 0.00005 0.00045 
Tb927.6.440 
haptoglobin-hemoglobin receptor 
(HpHbR) 
160.353 68.9258 -1.21813 0.00005 0.00045 
Tb927.11.3620 
nucleobase/nucleoside transporter 
8.1 (NT8.1) 
19.8014 47.1702 1.25227 0.00005 0.00045 
Tb927.9.15980 nucleoside transporter 1, putative 3.61119 0.434711 -3.05435 0.00515 0.02174 
Tb09.v4.0106 
nucleoside transporter 1, putative, 
chrIX additional, unordered contigs 
4.64334 0.643949 -2.85015 0.00210 0.01052 
Tb927.7.5930 
Protein Associated with 
Differentiation (PAD1) 
68.5347 148.767 1.11815 0.00005 0.00045 
Tb927.7.5940 
Protein Associated with 
Differentiation (PAD2) 
92.4903 256.789 1.47321 0.00005 0.00045 
Tb927.7.5950 
protein associated with 
differentiation 3, putative (PAD3) 
15.9397 31.8947 1.0007 0.00005 0.00045 
Tb927.1.2820 pteridine transporter, putative 12.8901 43.9649 1.77009 0.00005 0.00045 
Tb927.1.2880 pteridine transporter, putative 14.4442 43.9246 1.60453 0.00005 0.00045 
Tb927.9.7470 
purine nucleoside transporter 
(NT10) 
45.3842 172.052 1.92259 0.00005 0.00045 
Tb11.v5.0330 THT1 - hexose transporter, putative 48.3846 7.48095 -2.69326 0.00005 0.00045 
Table 4-3: Transporter proteins that exhibited significant differential expression in AN5568-resistant T. 
brucei cells, shown alphabetically. 
The NT8 nucleobase transporter that was observed to have a higher abundance (table 4-3, gene ID: 
Tb927.11.3620) was also recently shown to be upregulated in late log phase PCF cells (Fernandez-
Moya et al., 2014), thereby supporting the hypothesis that these cells were showing PCF 
phenotypes. 
The most significant finding from the transporter dataset was undoubtedly the increased 
expression levels of 3 PAD proteins, which have been implicated in playing major roles in T. brucei 
differentiation (Dean et al., 2009). Whilst PAD3 was not upregulated to the same degree as the 
other PAD receptors, the increase was still significant statistically. PAD1 and PAD2 showed much 
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higher transcript abundance, thereby concretely supporting our hypotheses that the AN5568R line 
had undergone, or was undergoing, a differentiation event. 
There were several interesting transporters showing decreased abundance in AN5568R cells. An 
ATP-binding cassette (ABC) transporter family-like protein (Tb927.2.5410) was previously shown to 
localise to the outer mitochondrial membrane (Niemann et al., 2013), and was present at lower 
levels in the resistant cell line. In addition, AQP3, a transporter implicated in suramin efficacy 
(Alsford et al., 2012), was also present in decreased abundance. The AN5568R cell line exhibited a 
decrease in mean EC50 against suramin (fig. 4-2), but this was found not to be significant by a t-test. 
Further transcripts with decreased abundance in resistant cells included glucose transporters, as 
well as several other adenosine and nucleotide transporters (table 4-2). The glucose transporters 
in particular were an interesting finding, because they support the hypothesis that these cells are 
similar to PCF cells with regards to their transcriptome. The results were also in agreement with the 
previous studies that carried out comparative analyses of BSF, stumpy and PCF parasite 
transcriptomes (Siegel et al., 2010, Capewell et al., 2013b). 
The data presented here, in addition to the differential expression data in general, indicate that the 
benzoxaborole-resistant cell line possess a transcriptome that resembles a PCF or stumpy T.b. 
brucei phenotype. Investigations into transporter expression in resistant cells requires molecular 
biology to confirm whether they are responsible for the PCF-like phenotype these cells possess, as 
well as whether the differential expression can explain any changes in the parasites’ sensitivity to 
particular trypanocidals (fig. 4-2). In addition, these expression differences also suggest the 
AN5568R cell line might show altered sensitivity to drugs such as nifurtimox, and overexpression of 
the pteridine transporter could compensate for pteridine reductase inhibition by allowing for 
higher levels of uptake. Pteridine reductase is a validated drug target in T. brucei (Sienkiewicz et al., 
2010).  
4.3.4 Pathway analysis of RNA-seq data 
Using genome and transcriptome analyses published elsewhere, further analysis was done on the 
transcriptome dataset. In particular, specific pathways were analysed using the cummeRbund 
package (Trapnell et al., 2012). A recent study from the Keith Matthews group provided many gene 
sets of various essential pathways in T. brucei (Capewell et al., 2013b). Using these gene sets, we 
looked at individual pathways and areas of metabolism in the wild-type and resistant lines by 
plotting the Log10FPKM values for individual pathway components (fig. 4-7, 4-8 & S5) Firstly, 
glycolysis was analysed (fig. 4-7). Whilst there was no significant general trend in glycolysis between 
the sample groups, several genes showed decreased FPKM in the AN5568R lines (fig. 4-7). In 
particular, glucose 6-phosphate isomerase (PGI), phosphoglycerate kinase C (PGKC), pyruvate 
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kinase (PYR1) and the two hexokinases (HK1 & HK2) exhibited decreased Log10FPKM values in the 
resistant clones (fig. 4-7). This is consistent with a switch to a procyclic-like transcriptome. 
Central carbon metabolism in PCF trypanosomes contrasts widely with that in BSFs (Mazet et al., 
2013). In particular, whilst BSF parasites rely solely on glycolysis for ATP production, PCF cells import 
malate and pyruvate into the mitochondrion, and produce succinate, acetate and alanine. PCF 
metabolism involves an incomplete TCA (Krebs) cycle, and therefore, we analysed whether gene 
components of this pathway showed differential expression in the AN5568R line (fig. 4-8). 
Interestingly, there seemed to be a general trend of increased expression in resistant cells, as shown 
by higher Log10FPKM values. Significantly increased transcript abundance was found in 
Tb927.10.2560 (mitochondrial malate dehydrogenase, Log2 fold change=1.04, P=5.0e-5), 
Tb927.3.2230 (succinyl-CoA synthetase, α sub-unit, Log2 fold change=1.45, P=5.0e-5) and 
Tb927.5.940 (fumarate reductase, Log2 fold change=1.09, P=5.0e-5). Whilst significance was 
reported for further genes in this cluster, the change in differential expression was below 2-fold 
and they were therefore omitted from further analyses.  
These transcriptome changes were interesting, because they suggest there is increased activity in 
the mitochondrion in the benzoxaborole-resistant cell line. Combined with the transcriptome 
changes in surface protein expression, these data support the evidence that the AN5568R lines 
possess a PCF-like transcriptome. Whether these changes translated to proteomic or metabolic 
changes in the cell would be analysed later on using mass spectrometry (section 4-6). 
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Figure 4-7: Heat map of abundances of transcripts involved in glycolytic metabolism. Full names and gene 
IDs: cMDH: cytosolic malate dehydrogenase, Tb927.11.11250; PGAM: phosphoglycerate mutase protein, 
Tb927.10.7930; PGI: glucose-6-phosphate isomerase, Tb927.1.3830; galactokinase: Tb927.5.290; TIM: 
triosephosphate isomerase, Tb927.11.5520; glycosidase: Tb927.10.13630; glxII: glyoxalase II, Tb927.6.1080; 
GPDH: glyceraldehyde-3-phosphate dehydrogenase, Tb927.9.9820; phosphoglycerate kinase: 
Tb927.11.2380; aldehyde hydrogenase: Tb927.6.3050; PEPCK: phosphoenolpyruvate carboxykinase, 
Tb927.2.4210; PGAM: Tb927.5.3580; PFK2-FBPase2a: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, 
Tb927.8.1020; aldo/keto reductase: Tb927.11.5360; malate dehydrogenase related: Tb927.10.2550; PFK-
FBPase2b: Tb927.3.2710; ALDH: aldehyde dehydrogenase, Tb927.6.4210; phosphomannose isomerase: 
Tb927.11.14780; FRDg: NADH-dependent fumarate reductase, Tb927.5.930; THT3: trypanosome hexose 
transporter 3, Tb927.4.2290; PGKA: phosphoglycerate kinase A, Tb927.1.720; acylphosphatase: 
Tb927.3.2030; PGAM: phosphoglycerate mutase, Tb927.11.10340; DAT: dihydroxyacetone phosphate 
acyltransferase, Tb927.4.3160; PGAM-like: phosphoglycerate mutase-like protein, Tb927.11.11490; enolase: 
Tb927.11.16410; PFK-FBPase2c: Tb927.7.1610; PFK-FBPase2d: Tb927.10.4520; aldose 1-epimerase: 
Tb927.4.1360; glxII-2: Tb927.4.1350; FHc: fumarate hydratase, Tb927.3.4500; PPDK: pyruvate phosphate 
dikinase, Tb927.11.6280; gMDH: glycosomal malate dehydrogenase, Tb927.10.15410; PGKB: 
phosphoglycerate kinase B, Tb927.1.710; PFK: ATP-dependent phosphofructokinase, Tb927.3.3270; HK2: 
hexokinase 2, Tb927.10.2020; PGKC: phosphoglycerate kinase C, Tb927.1.700; HK1: hexokinase 1, 
Tb927.10.2010; PYK1: pyruvate kinase 1, Tb927.10.14140; glk1: glycerol kinase, Tb927.9.12610; THT2: 
trypanosome hexose transporter 2, Tb927.10.8440; GAPDH: glyceraldehyde 3-phosphate dehydrogenase, 
Tb927.10.6880. 
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Figure 4-8: Heat map of abundances of transcripts involved in carboxylic acid metabolism. Full names and 
gene IDs: KDH-E1: 2-oxoglutarate dehydrogenase E1 complement, Tb927.11.1450; KDH-E2: 2-oxoglutarate 
dehydrogenase E2 complement, Tb927.11.11680; ACO: aconitase, Tb927.10.14000; citrate synthase: 
Tb927.10.13430; KDH-E1: 2-oxoglutarate dehydrogenase E1 complement, Tb927.11.9980; mMDH: 
mitochondrial malate dehydrogenase, Tb927.10.2560; FHm: fumarate hydratase, Tb927.11.5050; GCVL-2: 
dihydrolipoyl dehydrogenase, Tb927.11.16730; SCoAS beta chain: succinyl-CoA ligase, Tb927.10.7410; 
succinate dehydrogenase flavoprotein: Tb927.8.6580; FRDm: NADH-dependent fumarate reductase, 
Tb927.10.3650; IDHm: isocitrate dehydrogenase, mitochondrial precursor, Tb927.8.3690; hypothetical: 
putative 2-oxoglutarate dehydrogenase, Tb927.11.9940; IDHg: isocitrate dehydrogenase, Tb927.11.900. 
Further heat maps were generated to investigate transcript abundance changes in transcripts 
specific to mitochondrial metabolism (S5). This organelle is the site where the respiratory chain is 
located, generating another pool of ATP. In addition, the trypanosome alternative oxidase (AOX) is 
located in this compartment, which has previously been recognised as a potential drug target (Nihei 
et al., 2002).  
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Within the genes that make up the respiratory chain, we could only identify two genes that had 
significant upregulation with a Log2 fold change higher than 1. These were Tb927.3.1380 (ATP 
synthase β sub-unit, Log2 fold change=1.18, P=5.0e-5) and Tb927.3.1940 (TLP18.3, Log2 fold 
change=1.09, P=5.0e-5). All other genes did not show significant changes. There were also no major 
expression differences in mitochondrial carriers, which transport various small molecules across 
the outer and inner membrane. Whilst some genes showed a potential upregulation, these were 
not found to very high fold changes, and were thus disregarded. 
Two components of acetate metabolism were found to be upregulated significantly. One of these, 
Tb927.3.2230, was already found as a component of the TCA cycle, whilst the other was 
Tb927.3.1970 (Log2 fold change=1.13, P=5.0e-5), a putative 4’-phosphopantothenoylcysteine 
synthase. There were decreasing trends in lipid metabolism as well as fatty acid metabolism, 
although none of these data sets contained changes of less than 0.5-fold in the resistant lines (S5).  
One side effect of long-term in vitro culture is the differentiation of T.b. brucei cells into stumpy-
form-like parasites that possess stumpy form characteristics, but still replicate (Breidbach et al., 
2002). Whilst stumpy-form cells do not normally possess the ability to proliferate, there have been 
reports of a “semi-differentiation” phenotype that involves formation of RNA granules containing 
PCF-specific mRNA (Kramer et al., 2008). In the field, this is a natural occurrence, thought to be 
initiated by cascades related to quorum sensing as a result of increased cell density (Mony et al., 
2014). This process enables the parasite to pre-adapt to the environment of the tsetse fly midgut. 
To assess whether the transcriptome observations were due to the effects of long-term culture, we 
analysed expression levels of genes previously shown to be either up or downregulated during BSF 
to stumpy differentiation. These gene sets were previously collated by the Matthews group in 
Edinburgh (Capewell et al., 2013b). Two gene sets were made for upregulated genes and 
downregulated genes, containing 263 and 330 genes respectively, and the FPKM values for these 
gene sets from each sample group were plotted against each other to ascertain the correlation 
between the controls and AN5568-resistant cells (fig. 4-9). 
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Figure 4-9: Comparative analyses of the AN5568R line and “stumpy” expression. The data analysed in the 
RNA-seq experiment was compared to data from a recent publication that investigated differential expression 
in slender BSF and “stumpy” form trypanosomes (Capewell et al., 2013b). Two groups of genes were made: 
One containing all the genes significantly upregulated in stumpy forms (A), and one containing all genes 
significantly downregulated in SSFs, compared to slender form BSF cells (B). The correlations in FPKM values 
were then analysed for these gene sets in the RNA-seq data. A) Genes upregulated in stumpy forms show no 
significant changes between wild-type cells and AN5568R cells (correlation coefficient = 0.9626). B) Similarly, 
there are no significant changes in genes normally downregulated in stumpy-forms, although the correlation 
was lower than that between stumpy upregulated genes (correlation coefficient = 0.9197). Overall, the 
changes in transcript abundance seen in the AN5568R cell line appear to be a direct cause of resistance 
generated against the benzoxaborole, rather than differentiation of cells into stumpy forms. 
In general, there was very good correlation between genes in the wild-type lines and the AN5568R 
lines with the “upregulated” and “downregulated” gene sets showing correlation coefficients of 
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0.9626 and 0.9197 respectively. This correlations suggest the overall expression of the majority of 
genes perceived to exhibit differential expression during differentiation are not altered between 
the Lister 427 wild-type cells and the AN5568R cell line. Hence, there is a real possibility that the 
“semi-differentiated” phenotype these cells possess are a result of their resistance to the 
benzoxaborole compound. However, with the large amount of differential expression occurring, it 
is very challenging to pin-point a single mechanism. 
4.4 SNP and Indel analysis of the AN5568R line 
To further investigate potential genetic alterations in the AN5568-resistant cell line, analysis of 
single nucleotide polymorphisms (SNPs) and insertions or deletions (indels) was undertaken. This 
was carried out on the same RNA-seq assembly that was utilised in transcriptome analysis, and this 
alignment data was further processed using the Genome Analysis Toolkit (McKenna et al., 2010). 
Annotation of the data set was done using the SnpEff and SnpSift packages (Cingolani et al., 2012). 
Results of the SNP and indel counts are summarised in table 4-4. 
Type  of SNP Count % 
DOWNSTREAM  431806 38.31% 
INTERGENIC  66072 5.86% 
INTRAGENIC  2587 0.23% 
INTRON  430 0.04% 
NON_SYNONYMOUS_CODING  47068 4.18% 
NON_SYNONYMOUS_START  4 0.00% 
SPLICE_SITE_ACCEPTOR  1 0.00% 
SPLICE_SITE_REGION  2 0.00% 
START_GAINED  2157 0.19% 
START_LOST  49 0.00% 
STOP_GAINED  396 0.04% 
STOP_LOST  230 0.02% 
SYNONYMOUS_CODING  58364 5.18% 
SYNONYMOUS_STOP  117 0.01% 
UPSTREAM  453228 40.21% 
UTR_3_PRIME  47703 4.23% 
UTR_5_PRIME  16836 1.49% 
Table 4-4: SNP and indel counts for the complete RNA-seq data set. Data was processed using GATK, 
following by SNP and indel annotation using the SnpEff package. Upstream and Downstream mutations 
accounted for the majority of polymorphisms by far, followed by mutations in intergenic and coding regions 
(both synonymous and non-synonymous). 
One of the main challenges associated with SNP/indel analysis was the fact that the sequencing 
data had been aligned to the TREU 927 line, as mentioned previously. Whilst this did aid in more 
accurate alignments and fine read mapping, the result was many SNPs that were found in all 
samples analysed. The likely reasons for these are that they are not true SNPs that can account for 
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phenotypic difference. Instead, these are most likely a result of natural variation between the two 
strains of T. brucei. This was taken into account for the polymorphism analysis. 
Further complications can arise from using RNA-seq to analyse polymorphisms, when compared to 
DNA-seq (Pareek et al., 2011). Some of these problems have been well described (Piskol et al., 
2013). One of the challenges is the complexity of the transcriptome, which often involves processes 
such as splicing, leading to technical complications when calling SNPs (Piskol et al., 2013). This 
challenge is somewhat eliminated in the study of T. brucei, because the only trans-splicing to occur 
is the addition of the spliced leader and poly-A tail to RNA transcripts, rather than intragenic splicing 
(Huang & van der Ploeg, 1991). However, another potential pitfall that does apply to the study of 
T. brucei is that the ability of analysis tools to detect variants such as SNPs and indels often depends 
on the expression levels of the gene in question (Piskol et al., 2013, Quinn et al., 2013). For example, 
if a mutation in a gene causes decreased levels of expression of that variant, it might not be 
detected with RNA-seq. In other words, there is a higher risk of both false positives and false 
negatives. However, given the discoveries that were made from transcript abundance analyses, the 
use of RNA-seq over DNA-seq was warranted. Nevertheless, we set out to analyse some of the 
variants in detail. 
 
Figure 4-10: Number of variants (SNPs and indels) detected on each chromosome. At least 10,000 variants 
were detected on each chromosome using the SnpEff tool. This reflects the inherent differences between the 
Lister 427 and TREU 927 T. brucei strains. Many of the variants called were common to all cell lines that were 
sequenced, suggesting they played no role in benzoxaborole resistance. In addition, many variants were 
identified in only one sample, which suggests a high mutation rate in cell undergoing long-term in vitro 
culture. X = unassembled contigs. 
Due to the high number of downstream and upstream mutations (fig. 4-10), many of which 
overlapped due to the nature of the poly-cistronic arrays that T. brucei possesses (i.e. downstream 
mutations for one gene were the same as upstream mutations for the next gene), these were 
disregarded in the analysis of SNPs. Instead, we focused out attentions on non-synonymous coding 
mutations.  
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Using the SnpSift tool, we filtered both SNPs and indels very strictly, by ensuring both controls 
matched the reference genome, and the polymorphism resulted in a non-synonymous coding 
mutation. In addition we filtered out only SNPs and indels that appeared in all 4 AN5568R clones. 
The result of this filter still led to the calling of 277 SNPs, but no indels. Therefore, we further refined 
this SNP set by only filtering homozygous mutations leading to 90 SNPs in 82 genes. 
The 82 genes found to contain homozygous SNPs were analysed with the TriTryp database. In total, 
42 genes were annotated as hypothetical (including “hypothetical, unlikely”, and “hypothetical, 
conserved”). In addition, 2 genes were annotated as “unspecified product”. Whilst further analyses 
of these genes could be carried out in the form of domain and sequence analysis in the future, this 
was not done due to time constraints. Further genes identified were 7 BARP proteins, 6 VSG genes, 
two expression site-associated genes, a retrotransposon hot spot protein (Tb927.6.5160), a 
receptor-type adenylate cyclase (Tb927.6.780), and a protein of unknown function (Tb927.7.2330). 
These genes were not thought to be responsible for the resistance phenotype, and were therefore 
not studied further. In addition, several surface proteins such as VSGs, receptor adenylate cyclases 
and BARP proteins, are known to have high mutation rates (Saada et al., 2014, Lopez et al., 2015) 
and should be considered as false positives. This left 20 genes, which are shown in table 4-5.  
We were interested to find several SNPs in proteins known to be important in regulation of protein 
expression. This included a SNP in a Zinc finger protein and 2 RNA binding proteins (RBPs). In 
addition, the dataset included a protein associated with differentiation (PAD2). This protein is 
known to be upregulated in stumpy and procyclic form parasites. Indeed, we found the protein to 
be upregulated in the AN5568R cell line as well (Log2 fold change=1.47, P=5.0e-5). However, the 
SNP identified in PAD2 was outside any predicted domains, and thus we could not confirm its 
importance. 
Interestingly, the zinc finger CCCH-domain containing protein, ZC3H37 (Tb927.10.12780), was the 
same protein identified as exhibiting significantly increased transcript abundance in the AN5568-
resistant cell line. Whilst no domains of interest were found using the SMART and Pfam databases, 
this protein was recently shown to contain a CCCH domain by the Carrington group (Kramer et al., 
2010). However, by means of an Interpro search, we were able to conclude that the SNP once again 
did not localise to any predicted domains.  
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Tb11.v5.0807 ribonuclease, putative A G cAg/cGg Q107R 
Tb11.v5.1056 DNA polymerase kappa, putative T C gTc/gCc V13A 
Tb927.1.880 Midasin, putative (MDN1) C A Gcg/Tcg A473S 
Tb927.10.12780 Zinc finger CCCH domain-containing protein 37 (ZC3H37) G C tCt/tGt S136C 
Tb927.10.13930 phosphatidic acid phosphatase, putative G A Ccg/Tcg P206S 
Tb927.10.15290 tubulin binding cofactor c, putative A G cAc/cGc H64R 
Tb927.10.9600 serine/threonine kinase, putative G A Gcc/Acc A538T 
Tb927.11.540 
ABC transporter, mitochondrial, putative, multidrug 
resistance protein, mitochondrial, putative (ABCT) 
A G aTc/aCc I5T 
Tb927.11.980 
Nuclear pore complex protein 158, serine peptidase, 
Clan SP, family S59, putative (Nup158) 
A G Acg/Gcg T227A 
Tb927.2.4230 NUP-1 protein, putative C T Ggt/Agt G3292S 
Tb927.3.710 RING-variant domain containing protein, putative C T gGt/gAt G424D 
Tb927.4.4230 RNA-binding protein, putative (RBP31) C T aGt/aAt S360N 
Tb927.5.1120 Phage tail fibre repeat, putative C G gCt/gGt A3059G 
Tb927.5.4140 ZIP Zinc transporter, putative A G aTc/aCc I310T 
Tb927.7.5940 Protein Associated with Differentiation (PAD2) T A gaT/gaA D312E 
Tb927.8.6650 RNA-binding protein, putative (DRBD12) C T Gta/Ata V147I 
Tb927.8.7600 amino acid transporter, putative A G tAc/tGc Y40C 
Tb927.9.14000 60S ribosomal protein L12, putative C T Gct/Act A12T 
Tb927.9.14660 SLACS reverse transcriptase, putative G A Gac/Aac D356N 
Tb927.9.8250 atypical dual specificity phosphatase, putative T C Aaa/Gaa K23E 
Table 4-5: Homozygous SNPs unique to the AN5568R cell lines. This dataset was generated using the SnpSift 
tool by filtering only SNPs where both controls were found to match the reference genotype. In addition, we 
searched for non-synonymous coding SNPs that were found in all 4 resistant clones. 
Several other genes identified were followed up with domain analysis. For example, a SNP in RBP12 
(Tb927.4.4230) was found to be located far downstream of the RNA recognition motif (RRM) 
domain, and therefore probably did not affect the protein’s interactions with RNA. Another RBP, 
called DRBD12 (Tb927.8.6650), contained 2 RRM domains, but neither were predicted to be in the 
same position as the homozygous SNP identified in the protein. 
Similarly, the SNP found in a serine/threonine kinase (Tb927.10.9600), was predicted to be located 
far downstream of the predicted protein kinase domain (pfam, position 6–311), and was also 
disregarded. Interestingly, the variant identified in a mitochondrial ABC transporter (Tb927.11.540) 
was predicted to lie in a 21-mer signal peptide. Whilst we could not confirm whether the protein 
was targeted to the mitochondrion, a previous study found it to be localised in the mitochondrial 
outer membrane (Niemann et al., 2013). 
Whether the variant discoveries are significant either in terms of the PCF-phenotype, or AN5568-
resistance, would be important to analyse in the future. Due to time-constraints, we were not able 
to analyse these 20 genes in depth. However, domain analyses of the remaining genes to determine 
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where exactly all of these variants lie, would go some distance in determining whether any of the 
SNPs are significant. In addition, this study did not investigate heterozygous SNPs found in the 
AN5568R cell line. Using the same parameters with the SnpSift tool, a search for heterozygous 
instead of homozygous SNPs led to the discovery of 187 variants (100% SNPs, no indels). T. brucei 
is a diploid organism, and therefore, one gain of function or loss of function allele could have a 
significant impact on the cellular response to the benzoxaborole. Indeed, this mechanism has been 
shown to generate resistance in previous studies of other organisms (Anderson et al., 2004). 
There is, however, a possibility that the differentiation phenotype arose due to a loss-of-function 
of a repressor. There are at least two repressor of differentiation kinases, the loss of which leads to 
BSF differentiation (Jones et al., 2014a). Whilst neither of these kinases contained SNPs in the 
benzoxaborole-resistant cell line, there are potentially other candidate genes that cause similar 
effects. Should a loss-of-function mutation occur leading to loss of expression, the variants would 
not be identified using RNA-seq, for reasons described above. 
Whilst this method of searching for SNPs and indels certainly proved useful, we also used a targeted 
approach where subsets of genes were filtered from the datasets. This was done for three subsets 
of interest: a methyltransferase subset first presented in the previous chapter, a kinase subset 
collated by Jones and colleagues (Jones et al., 2014a), and an RNA binding protein set assembled 
by Wurst and colleagues (Wurst et al., 2009). With these searches we again filtered out only SNPs 
that were unique to the AN5568R lines and the results are shown in the supplementary data (S6). 
Currently, no leads have been identified from these 3 data-sets, but more in-depth analysis is 
ongoing. Further analyses could also be carried out on SNPs found in the UTRs, as mutations here 
can disrupt the binding of proteins such as transcription factors, thereby inhibiting, or stimulating 
gene expression. 
4.5 The AN5568R line exhibits BSF morphology 
The transcriptomics results for the AN5568R cell line were quite surprising, especially given the fact 
that all in vitro culture to generate resistant cells was carried out in HMI-9, a culture medium 
designed for BSF parasites. Moreover, the parental Lister 427 cell line is perceived to be 
monomorphic, although recent work has shown that these cells can still exhibit differentiation 
phenotypes (K. Matthews, personal communication). To investigate whether the transcriptomics 
changes caused any differences to the cellular morphology, microscopy analysis was undertaken. 
Similar to the microscopy experiments shown in chapter 3, cells were stained with mitotracker and 
counter-stained with DAPI in order to observe the morphology of the nucleus, kinetoplast and 
mitochondrion. 
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Under direct light microscopy, the benzoxaborole resistant cell line appeared to exhibit normal 
wild-type BSF morphology (fig. 4-11). Cellular length did not appear to be altered, nor was the 
appearance of the flagella and cell body in general (fig. 4-11). Furthermore, the kinetoplasts and 
nuclei showed no adverse morphology. Cell cycle analysis was not carried out at this stage, but this 
should not be ruled out as an experiment in the future. However, for all intents and purposes, the 
drug-resistant parasites appeared to show no defects in cell cycle progression.  
Interestingly, when visualising the mitochondria using Mitotracker Red, we found a mixed 
population of cells. Whilst many cells showed a normal mitochondrion, characterised as a long 
slender organelle that lies alongside the long-axis of the cell, other cells were found to contain a 
mitochondrion that seemed to be composed of several small organelles, rather akin to the “patchy” 
phenotype observed during AN5568 treatment of wild-type cells (chapter 3).  Whilst this phenotype 
only occurred in approximately 50%, it could be a consequence of becoming resistant to the 
benzoxaborole. This phenomenon should be studied in more detail, in addition to quantification of 
wild-type morphology versus “patchy” morphology. 
The RNA-seq analysis hinted at the possibility of the cells having undergone a differentiation event. 
Therefore, it was crucial to understand whether the morphology and localisation of intracellular 
organelles has also been altered. Procyclic trypanosomes are known to have different localisation 
of the kinetoplast and nucleus, compared to BSF parasites (Matthews, 2005). Whilst the 
mammalian form has a kinetoplast very close to the posterior limit of the cell body, it migrates 
during differentiation to a position equidistant between the posterior end and the nucleus 
(Matthews, 2005). To find out whether the AN5568R exhibited PCF-like, or BSF-like positioning of 
the kinetoplast and nuclei, the distance between these organelles was measured in both wild-type 
and resistant cells. The experiment was repeated three times and approximately 30-40 
measurements were taken for each sample (fig. 4-12C). 
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Figure 4-11: Microscopy analysis of the AN5568R cell line. General morphology of the resistant cell line was 
analysed, and localisation of the nucleus, kinetoplast and mitochondria was studied. In general, cellular 
morphology was found to be normal, without significant deviation from that of BSF cells. A) In some cases, 
the mitochondrion showed a “patchy” phenotype. B) In contrast, many cells also exhibited wild-type 
mitochondrial morphology, with the entire mitochondrion running along the long axis of the cell. C) To 
investigate changes in nucleic and kinetoplast localisation, the distance between these two organelles was 
measured. This distance is known to decrease in PCF cells. However, in three separate experiments, no 
significant changes in this distance were found, even though the graphs are suggestive of a decreasing trend. 
The average distance between nucleus and kinetoplast in wild-type cells was between 4 and 4.5 
µm, as calculated using the Fiji software (Schindelin et al., 2012). Similarly, the same distance in 
AN5568R cells showed a mean value of 3.5–4 µm, over three replicates. Whilst this did show a slight 
decrease in distance, this was calculated with a Student’s t-test to bear no significance. Given these 
results, we concluded that the AN5568R cell line exhibits mostly BSF-like morphology.  
4.6 Metabolomics analysis of the AN5568R line 
To assess whether the transcriptome changes seen in the AN5568R line translated to proteomic or 
metabolic changes, we next carried out metabolomics analysis, maintaining the same 
methodologies as previously undertaken experiments. For this experiment, wild-type Lister 427 
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cells were grown in 10× EC50 of the benzoxaborole for 6 hours, to ensure consistency with 
experimental data provided in the earlier chapter. Two AN5568R clones were incubated in the 
absence or presence of 4.8 µM AN5568, equal to the concentration they were cultured in, and they 
were resistant to. Four biological replicates were prepared for each sample group, and metabolites 
were extracted at the 6-hour time-point as described in the methods (section 2.6.1). Samples were 
run on a Q-Exactive orbitrap mass spectrometer, and data was processed using the same 
mzMatch/Ideom pipeline used in all metabolomics analyses. 
4.6.1 The AdoMet/5’-MTA phenotype is abolished in AN5568R cells 
The first metabolites analysed were those that showed major perturbations in earlier experiments 
using the benzoxaborole with wild-type cells (fig. 4-12). As shown previously, wild-type cells showed 
high levels of AdoMet, 5’-MTA, adenine, cystathionine and methylated lysines subsequent to 
AN5568-treatment. In addition there were elevated levels of 8-amino-7-oxononanoate, GDP-
mannose and general decreases in lipid metabolism. However, when the resistant cells were 
analysed, these cells showed almost none of the aforementioned changes (fig. 4-12). 
In particular, AdoMet (m/z: 398.1380, RT: 13.95 mins), 5’-MTA (m/z: 297.0896, RT: 7.73 mins) and 
adenine (m/z: 135.0546, RT: 10.12 mins), which thus far showed very reproducible increases in 
wild-type cells treated with AN5568, remained at normal levels in the AN5568R line when cells were 
treated with the benzoxaborole. In addition, high levels of adenine, characteristic of AN5568-
treatment, had also been abolished, suggesting methionine metabolism in general had been 
completely downregulated in the benzoxaborole-resistant line, when in the presence of AN5568. 
This finding was also intriguing in the context of AN5568-treated PCF parasites. As shown in chapter 
3, these cells showed the same changes in methionine metabolism as BSF cells when treated with 
10× EC50 of the benzoxaborole. The AN5568R line exhibits a procyclic phenotype based on 
transcriptome analyses, yet they are more resistant to AN5568 treatment than wild-type PCF cells. 
Methylation of hydroxyl-glutamate was shown to be carried out in an AdoMet-dependent fashion, 
using 13C-(U)-methionine (chapter 3). However, as mentioned previously, the role of this metabolite 
is currently not understood in T. brucei. There is some indication it provides an alternate substrate 
to 4-hydroxyglutamate transaminase in the production of glutamate (Winter & Dekker, 1989). 
However, such an enzyme is not currently known to exist in T. brucei. The peak corresponding to 4-
ydroxy-4-methylglutamate (m/z: 177.0634, RT: 12.02 mins), was again increased in intensity in 
AN5568-treated wild-type cells (fig. 4-12E). However, levels of this metabolite were decreased in 
AN5568R cells, even in the presence of the benzoxaborole. Indeed, the levels were even low 
compared to untreated wild-type cells. This suggests metabolism in this part of the metabolome 
has been significantly downregulated, potentially by a compensatory mechanism. 
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Figure 4-12: Significant metabolic changes in methionine metabolism seen during AN5568 treatment are 
abolished in AN5568R cells. The three most significant changes that usually occur in AN5568-treated cells 
were found in methionine metabolism. However, these changes were completely abolished in both 
benzoxaborole clones. There was no change in levels of AdoMet (A), 5’-MTA (B) or adenine (C), suggesting 
the resistant cell line had developed a mechanism to control these drug-induced effects. In addition, L-
cystathionine peak intensities were less than half of that detected in WT and drug-treated WT cells (D). A 
similar phenotype was observed for 4-hydroxy-4-methylglutamate (E). Interestingly, AN5568 levels in treated 
cell pellets were still at high levels. Indeed, AN5568 levels were higher in the resistant cell line than WTs, 
possibly due to the fact a higher concentration of the drug was added to cultures during treatment 
incubations. This suggests the parasite was still taking up the benzoxaborole, even though it had managed to 
diminish its potency drastically. Key: WT: wild-type; WT+D: AN5568-treated wild-type; cl1: resistant line 
clone 1; cl1+D: AN5568-treated resistant line clone 1; cl2: resistant line clone 2; cl1+D: AN5568-treated 
resistant line clone 2; 
Previous studies of drug resistance in trypanosomes showed that decreased transporter expression 
is often the cause, resulting in significantly reduced uptake of the active drug (Vincent et al., 2010). 
Indeed, transcriptomics data did indicate differential expression of several transporters, as shown 
in previous sections. A search for the benzoxaborole amongst the mass spectrometry data showed 
that it was still present in the cell pellets at high levels, indicating that uptake was probably 
occurring (fig. 4-12F). Therefore, metabolic phenotypes observed indicated that the resistant line 
had become resistant against drug action, but not through the action of downregulated cell surface 
transporters. Importantly, this does not rule out loss of expression in transporters located on 
organelle membranes. Should the mitochondrion contain the AN5568 target, this could not be 
confirmed by metabolomics of whole cells. Instead, fractionation of cellular compartments 
followed by metabolomics analyses could allow more accurate information as to where the 
benzoxaborole localises. However, given the expression data for mitochondrial transporters, it is 
unlikely that any of the transporters investigated played a role in AN5568 uptake (S5). 
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4.6.2 Lipid and carbohydrate metabolism in the AN5568R line 
Previous experiments showed that levels of metabolites involved in GPI metabolism pathways 
increased in the presence of AN5568. However, we consistently found these changes to be nullified 
in the resistant cell line (fig. 4-13). GDP-mannose (m/z: 605.0754, RT: 14.49 mins) levels were lower 
than those seen in wild-type either treated or untreated, similar to UDP-glucose (m/z:  566.0542, 
RT: 13.56 mins) abundance. Interestingly, N-acetyl-D-glucosamine (m/z: 211.0898, RT: 11.56 mins), 
which was previously thought to increase in response to AN5568, was observed to decrease in this 
experiment, for unknown reasons. In addition, high levels of this metabolite were maintained in 
two resistant clones, both in the presence and absence of the benzoxaborole (fig. 4-13C). 
Two metabolites related to lipid metabolism of interest, glycerol 3-phosphate (m/z: 172.0135, RT: 
12.92) and L-carnitine (m/z: 161.105, RT: 12.49 mins), were again decreased in AN5568-treated 
cells (fig. 4-13D & E respectively).  In contrast, these two metabolites were both present at higher 
levels in the resistant cell line, both in the presence and absence of AN5568. The reason for this is 
unknown, although one could hypothesize it is a requirement in a “PCF-like” cell which possesses 
higher mitochondrial activity compared to BSF cells. This would result in higher levels of fatty acid 
transport across the mitochondrial membranes. 
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Figure 4-13: Further wild-type metabolic signatures that are altered in the AN5568R cell line. Several 
metabolites involved in GPI metabolism were previously shown to be elevated in the presence of AN5568, 
including GDP-mannose (A) and UDP-glucose (B). Both these metabolites did not exhibit any changes in the 
AN5568R line, even in the presence of AN5568. For GDP-mannose in particular, this could indicate reduced 
GPI production in the PCF-like cells. Furthermore, N-acetyl-D-glucosamine (C), which was reduced in AN5568-
treated WT cells, was observed to be at WT levels in the resistant cell line. Interestingly, glycerol 3-phosphate 
(D) and L-carnitine (E), the latter of which exhibits increased abundancy in differentiating cells (J. Anderson, 
unpublished), were both increased more than 2-fold in the resistant cell line. Finally, 5-guanidino-2-
oxopentanoate (F) and 8-amino-7-oxononanoate (G), both shown to increase for unexplained reasons in WT 
AN5568-treated cells, were reduced close to WT levels in benzoxaborole-resistant cells, although the former 
was slightly increased, even in untreated AN5568R cells. Key: WT: wild-type; WT+D: AN5568-treated wild-
type; cl1: resistant line clone 1; cl1+D: AN5568-treated resistant line clone 1; cl2: resistant line clone 2; 
cl1+D: AN5568-treated resistant line clone 2 
Two further metabolites of interest were identified and shown to have abolished the wild-type 
drug-treated metabolic phenotype. 5-guanidino-2-oxopentanoate (m/z: 173.0800, RT: 13.26 mins) 
is also known as 2-ketoarginine. Interestingly, this metabolite has been shown to be involved in an 
AdoMet-dependent MTase reaction (Braun et al., 2010). This reaction results in the production of 
5-guanidino-3-methyl-2-oxopentanoate and is part of the 3-methylarginine biosynthesis pathway. 
The MTase study presented in the previous chapter did not lead to the accurate prediction of a 
potential methyltransferase for this reaction, although its presence should not be ruled out. In 
addition, in all of the metabolomics experiments carried out with AN5568 so far, no significant 
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perturbations in L-arginine, Nγ-monomethyl-L-arginine or Nγ,Nγ-dimethyl-L-arginine have been 
reported. There was a small increase seen in L-arginine phosphate (data not shown), but this was 
not thought to be significant, given the other changes observed. We did find a peak for 
homoarginine, which possesses the same monoisotopic mass as 3-methylarginine, but again, this 
metabolite showed no significant changes with either cell line in the presence or absence of 
AN5568. 
Finally, 8-amino-7-oxononanoate (m/z: 187.1208, RT: 111.77 mins) was again found to increase 
significantly in drug-treated cells. However, this phenotype was again ablated in resistant cells, both 
in the presence or absence of AN5568 (fig. 4-13G), although there did appear to be slight increases 
in the presence of AN5568, even in the resistant cells. However, these increases were still vastly 
reduced compared to the wildtype peaks. As discussed previously, 8-amino-7-oxononanoate has 
been shown in other organisms to be involved in an AdoMet-dependent transaminase reaction, 
resulting in the production of 7,8-diaminononanoate and S-adenosyl-4-methylthio-2-
oxobutanoate. This reaction is part of the biotin synthesis pathway. Unfortunately, we were not 
able to detect either metabolite, leaving the interpretation of this result open to discussion. 
4.6.3 Lysine metabolism in the absence and presence of AN5568 
Changes in lysine metabolism were previously discussed as they were highly reproducible and 
potentially crucial to the mode of action of AN5568 in the context of a stress response. Given the 
transcriptomics changes seen in the benzoxaborole-resistant cell line, changes in lysine metabolism 
and methyl lysine production in particular, could be due to changes in histone methylation, as well 
as protein activation/inhibition. 
Concurrent with previous analyses, intracellular L-lysine (m/z: 146.1056, RT: 19.79 mins) levels did 
not undergo significant changes, either in wild-type cells or benzoxaborole-resistant cells (fig. 4-
14A). An increase in acetyl-L-lysine (m/z: 188.1157, RT: 12.09 mins) was found in the first 
metabolomics experiment presented in chapter 3. interestingly, this metabolite’s abundance was 
increased in the resistant clones in both the absence and presence of AN5568 (fig. 4-14B). In 
contrast, the significant increases first seen in the methylation of lysine were completely abolished 
(fig. 4-14C, D & E). All three methylated lysine metabolites, N6-methyl-L-lysine (m/z: 160.1212, RT: 
19.16 mins), N6,N6-dimethyl-L-lysine (m/z: 174.1368, RT: 17.85 mins) and N6,N6,N6-tryimethyl-L-
lysine (m/z: 188.1527, RT: 18.29 mins), were identified and no increase was observed. 
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Figure 4-14: Modified lysine metabolism in benzoxaborole-resistant cells. As shown in chapter 3, changes 
in lysine metabolism were found in AN5568-treated cells. Whilst there were no changes in L-lysine (A) itself, 
there were again interesting changes in lysine metabolism in the AN5568R cell line. Acetyl-L-lysine (B) was 
found at varying levels in resistant cells ranging from a 1.5-fold increase compared to WT untreated cells, to 
2.3-fold increased. Interestingly, this metabolite was detected at higher levels in differentiating cells (J. 
Anderson, unpublished). In contrast, most methylated lysines were observed at WT levels in the AN5568R 
lines. As shown previously, N6-methyl-L-lysine (C), N6,N6-dimethyl-L-lysine (D) and N6,N6,N6-trimethyl-L-
lysine (E), were increased after AN5568 treatment under WT conditions and whilst the latter still showed a 
slight increase in drug-treated resistant cells, these metabolites were all unchanged, even after AN5568-
treatment. Key: WT: wild-type; WT+D: AN5568-treated wild-type; cl1: resistant line clone 1; cl1+D: AN5568-
treated resistant line clone 1; cl2: resistant line clone 2; cl1+D: AN5568-treated resistant line clone 2 
4.6.4 Differences in metabolism between untreated wild-type and untreated 
AN5568R cells 
Having discovered many metabolites to have reverted to wild-type levels in the benzoxaborole-
resistant cell line, even in the presence of AN5568, we next turned our attention to changes in 
metabolism that were unique to this cell line compared to wild-type parasites. 
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The most significant increase found in the AN5568R line was putatively identified as nonaprenyl-4-
hydroxybenzoate (m/z: 750.5959, RT: 3.65 mins) (fig. 4-15A), a molecule involved in the 
biosynthesis of ubiquinol, which is an important intermediate in the respiratory chain of the inner 
mitochondrial membrane. There was one isomer reported for this metabolite, 2-nonaprenyl-6-
methoxy-1,4-benzoquinone. Interestingly, this molecule is found upstream, in the same ubiquinol 
biosynthesis pathway. Attempts were made to locate a peak corresponding to ubiquinol itself, and 
this led to the putative detection of ubiquinol-7 (m/z: 660.5116, RT: 4.64 mins) (fig. 4-15B). This 
peak was highly variable between individual replicates, but the changes this metabolite underwent 
were interesting because of the localisation of this pathway, in the electron transport chain of the 
mitochondrion.  
Another interesting change that was not seen in wild-type cells was increased levels of L-2-
aminoadipate (m/z: 161.0688, RT: 12.84 mins) (fig. 4-15C). Whilst the presence of the 
benzoxaborole caused a significant decrease of this metabolite back to wild-type levels, there were 
high levels in the absence of drug. This metabolite has been implicated in both the synthesis and 
degradation of lysine (Danhauser et al., 2012). In addition, it has been identified as a marker of 
oxidative stress (Zeitoun-Ghandour et al., 2011). However, its role in metabolism of T. brucei has 
not been discussed. Given the changes occurring in lysine metabolism, the increased levels of L-2-
aminoadipate could be very important in the abolishment of methylated lysine increases. 
Finally, higher levels of ribose (m/z: 150.0530, RT: 1.48 mins) (fig. 4-15E) in AN5568R cells could 
suggest increase pentose-phosphate metabolism. Indeed, the upregulation of transketolase found 
in transcriptome data supports this theory. In addition, resistant cells showed higher levels of 
adenosine (m/z: 267.0967, RT: 9.73 mins) (fig. 4-15F). This result was interesting because the 
transcriptomics data indicated that adenosine transporter mRNA transcripts were present at lower 
abundance in the resistant cell line 
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Figure 4-15: Novel metabolic changes in the benzoxaborole-resistant cell line. A putatively identified 
nonaprenyl-4-hydroxybenzoate (A) was found in high abundance in AN5568R cells. In the same ubiquinol 
biosynthesis pathway, ubiquinol-7 (B) was putatively identified, and shown to be present in high levels in one 
of the resistant clones. Varying levels of L-2-aminoadipate (C) were seen in the resistant line. Whilst drug-
treatment caused a reduction in this metabolite, untreated cells exhibited a higher level of this metabolite 
compared to WT cells. Key: WT: wild-type; WT+D: AN5568-treated wild-type; cl1: resistant line clone 1; 
cl1+D: AN5568-treated resistant line clone 1; cl2: resistant line clone 2; cl1+D: AN5568-treated resistant line 
clone 2 
4.6.5 Lipid metabolism is almost completely restored in AN5568R cells 
Treatment of wild-type T. brucei with AN5568 led to reduced abundance of several essential lipids 
(chapter 3). We therefore attempted to assess whether these lipids were restored to wild-type 
levels in the AN5568R line, and whether lipid metabolism in general was perturbed (fig. 4-16).  
As mentioned previously, glycerol 3-phosphate, levels of which were found to decrease in AN5568-
treated WT T. brucei cells, was observed at far higher abundance in AN5568R cells both treated and 
untreated (fig. 4-16). 
Ethanolamine derivatives were generally decreased in AN5568-treated WT cells, and whilst the case 
was similar in AN5568R cells, the reduction was not as dramatic (fig. 4-16). Ethanolamine is used to 
generate phosphatidylethanolamine (PE) through CDP-ethanolamine branch of the so-called 
Kennedy pathway (Gibellini et al., 2009). This is an essential pathway in both PCF and BSF T. brucei, 
and in general, PE is present at lower abundancy in PCF cells (Richmond et al., 2010). Therefore, the 
metabolomics findings presented here support the transcriptomics data described previously. 
The other branch of the Kennedy pathway uses CDP-choline to generate phosphatidylcholine (PC) 
(Farine et al., 2015). In addition to CDP-choline, several choline derivatives were also observed in 
the metabolomics dataset (fig. 4-16). For unknown reasons, CDP-choline was increased in WT 
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AN5568-treated cells. This contrasted with previous findings (chapter 3) that showed a reduction 
in CDP-choline after treatment. This could be due to a technical fault, or sensitivity of the MS, or 
incorrect annotation (both m/z ratio and RT were found to be equal in the datasets). CDP-glycero-
3-phosphocholine was, like CDP-glycero-3-ethanolamine, decreased in AN5568-treated WT cells, 
and again the extent of these decreases was reduced in AN5568R cells, suggesting that the 
resistance mechanism had reduced the impact of AN5568 on the T. brucei lipidome (fig. 4-16) 
 
Figure 4-16: Lipid metabolism in AN5568-resistant cells. Several putatively identified metabolites involved 
in lipid metabolism were altered in abundance in the different sample groups. A metabolite identified as 
taurine (2), a cysteine derivative, was found to increase in resistant cells in the absence of AN5568. Several 
fatty acids (docosanoic acid & tetracosanoic acid, 4 & 5 respectively) were increased in WT AN5568-treated 
cells, and in contrast, these were reduced in resistant cells, in the presence and absence of drug. As 
mentioned previously, glycerol 3-phosphate (12) was highly abundant in the resistant line, compared to WT 
cells. Furthermore, the extent of reduction in PC- and PE-derived metabolites was diminished in AN5568R 
cells, as exemplified by phosphodimethylethanolamine (14), sn-glycero-3-phosphocholine (15) and sn-glycero-
3-phosphoethanolamine. Metabolites corresponding to each number are shown in table 4-6, below. 
Lipid metabolism 
1 CMP-N-trimethyl-2-aminoethylphosphonate 11 Hexadecanal 
2 Taurine 12 sn-Glycerol 3-phosphate 
3 Glycodeoxycholate 13 Choline phosphate 
4 Docosanoic acid 14 Phosphodimethylethanolamine 
5 Tetracosanoic acid 15 sn-glycero-3-phosphocholine 
6 Dodecanoic acid 16 CDP-choline 
7 Tetradecanoic acid 17 Diethanolamine 
8 Octadecanoic acid 18 sn-glycero-3-phosphoethanolamine 
9 (9Z)-Hexadecenoic acid 19 Acetylcholine 
10 Decanoic acid 20 Triethanolamine 
Table 4-6: Corresponding putative metabolite identifications for figure 4-16. 
For the most part, lipid metabolism was not significantly perturbed either in treated or un-treated 
benzoxaborole-resistant cells, as shown by the abundances of carboxylic acids such as dodecanoic 
acid and tetradecanoic acid (fig. 4-16). However, significant changes in the PE and PC branches of 
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lipid metabolism seen in AN5568-treated cells had been reduced, or as was shown by Richmond 
and colleagues, the lipid composition might have changed somewhat due to the procyclic 
phenotypes of the resistant line. 
4.6.6 Comparison of metabolomics and transcriptomics datasets 
The ability to generate large data sets unravelling a complete biological system at the genome, 
transcriptome, proteome and metabolome levels can provide huge amounts of data.  However, the 
integration of these datasets to give a more complete picture of a biological system is crucial. 
Systems approaches allow the mapping out of entire pathways of interest. Thus, the metabolomics 
data was analysed in the context of the changing transcriptome of benzoxaborole-resistant cells to 
find significant changes in T. brucei upon AN5568-resistance. 
One area of metabolism that showed upregulation on a transcriptome levels was mitochondrial 
metabolism in the form of the TCA cycle. As mentioned previously, mitochondrial malate 
dehydrogenase was shown to be upregulated in the AN5568R. Indeed, the product of this enzyme, 
oxoglutarate, was found to have a higher abundance (fig. 4-15D). 
Another interesting metabolic finding was increased levels of glycerol 3-phosphate (fig. 4-13 & 4-
16). Interestingly, when looking back through the transcriptome dataset we found significantly 
decreased levels of glycerol 3-phosphate dehydrogenase (Tb11.v5.0516, S4). This suggests that 
glycerol 3-phosphate is not utilised at the same rate in the resistant cell line compared to WT cells. 
Furthermore, glycerol 3-phosphoate dehydrogenase is a glycosomal enzyme (Bringaud et al., 2006), 
and the aforementioned data support the theory that the resistant cell line possesses a PCF-like 
transcriptome as well as metabolome. 
In the some cases, transcriptome did not match metabolome. For example, pyruvate, phosphate 
dikinase (PPDK) was shown to have increased transcript abundance in AN5568R cells (S4). However, 
metabolomics data indicated that there was not much change in the levels of substrate (pyruvate), 
nor product (PEP) (S7).  
Unfortunately, time constraints meant that data integration of metabolomics and transcriptomics 
was not completed. There is currently no efficient pipeline for the integration of omics datasets in 
T. brucei, although work to this extent is ongoing at Glasgow Polyomics.  
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4.7 Discussion 
We here report the generation of a 427-Lister derived T. brucei cell line that shows high levels of 
AN5568-resistance, with an EC50 value almost 20-fold higher than WT T. brucei. This cell line also 
exhibited moderate resistance against the MTase inhibitor sinefungin, thereby supporting the 
theory that these two compounds act on similar pathways, or are taken up by similar transporters. 
The resistant line is hypersensitive to diminazene and pentamidine, but the known transporters for 
these compounds, which include TbHAPT1, TbLAPT and the P2 aminopurine transporter, were not 
differentially expressed. Several studies have suggested that pentamidine, like other diamidines, 
targets the mitochondrion (Ludewig et al., 1994). There is a possibility that the mitochondrion is 
more active in the resistant cell line, based on the RNA-seq data discussed below. In theory, this 
could render the parasite hypersensitive to mitochondrion-targeting compounds. 
Interestingly, this study shows that the AN5568R line, whilst exhibiting BSF-morphology, possesses 
a transcriptome that more closely resembles a differentiating, or SSF trypanosome. BSF-specific 
transcripts such as VSG expression sites and proteins involved in glycolysis were present at a lower 
abundance and in contrast, PCF-specific transcripts such as those encoding mitochondrial 
metabolism and EP procyclin proteins, were found at higher levels. Transcripts corresponding to 
three PAD receptors, known to be instrumental in T. brucei differentiation (MacGregor & 
Matthews, 2012), were significantly more abundant in the AN5568R line. Furthermore, there was a 
significant decrease in THT-1 glucose transporter transcription. This transporter is specific to BSF-
stage trypanosomes (Bringaud & Baltz, 1993), and its downregulation supports the aforementioned 
hypothesis. Pathway-specific analyses hinted at a general downward trend in glycolytic component 
transcripts and increased transcription of TCA cycle component transcripts (fig. 4-7). In addition, 
acetate metabolism, which was until recently thought to be carried out in PCF-stage cells only, was 
also upregulated (fig. 4-8). Taken together, the above suggests that the T. brucei AN5568-resistant 
cell line had undergone a differentiation event, which coincided with increased resistance to the 
benzoxaborole. 
The AN5568R RNA-seq data was also analysed for any SNPs of interest. Here, we found an 
unexpectedly high number of SNPs across the transcriptome. However, in this study, the RNA-seq 
data was aligned to the TREU 927 reference genome, as it was judged to have superior annotation. 
It would be beneficial to carry out this analysis by alignment to the updated (v9.0) genome of the 
Lister 427 cell line, from which this resistant cell line was derived. Nonetheless, homozygous SNPs 
were filtered out from the dataset, and whilst no indels of note were discovered, we found 20 SNPs 
that were present in all 4 clones of the AN5568R line. Interestingly, several SNPs were found in 
essential regulatory proteins such as the PAD2 receptor and a zinc-finger protein. However, domain 
analysis predicted these SNPs did not lie in regions of importance. Further analyses of heterozygous 
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SNPs are ongoing and will investigate in particular whether RNA-binding proteins or other master 
regulators of differentiation, such as zinc finger proteins, are mutated, which could lead to 
resistance.  
The AN5568-resistant cell line was also subject to metabolomics analyses both in the presence and 
absence of the benzoxaborole. This dataset showed the resistant cell line to be almost unaffected 
by the presence of the benzoxaborole. In particular, there was a noticeable ablation of the AdoMet, 
5’-MTA and adenine increases seen in WT cells. In addition, L-cystathionine levels were decreased, 
even when compared to WT cells in the absence of AN5568. Similarly, 5-guanidino-2-
oxopentanoate and 8-amino-7oxononanoate levels were comparable to WT cells, as were those of 
methylated lysine residues. These data suggest that the cell line has managed to control the drug 
effects, even though uptake is still occurring. 
Interestingly, there were several metabolic changes that have also been observed in differentiating 
cells. The Barrett group has recently carried out LC-MS analyses of differentiating T. brucei (M. 
Barrett & J. Anderson, unpublished). In this experiment, the most significant metabolites identified 
were increases in acetyl-L-lysine and L-carnitine. Whilst L-carnitine levels were reduced in AN5568-
treated WT cells, levels of this metabolite were increased in both treated and untreated AN5568R 
cells (fig. 4-13). Furthermore, acetyl-L-lysine was also increased in abundance, although only when 
compared to untreated WT cells (fig. 4-14). However, an increase in 5’-MTA, one of the main 
metabolic phenotypes of AN5568 treatment, was not observed in the resistant cell line. Whilst the 
cell line is able to compensate and abolish the severe upregulation of methionine metabolism, the 
metabolome, just like the transcriptome, carries the signature of a differentiating trypanosome. 
One important drawback of the metabolomics experiment was the lack of a control sample group 
incubated with 10× EC50 concentration of AN5568 on the resistant line. Instead, the concentration 
of drug the cells were cultured in (4.8 µM) was used. The EC50 of the drug in resistant cells is close 
to 5 µM. Therefore, further work for this analysis might require a novel time course with addition 
of drug at a concentration closer to 10× EC50 (50 µM), to allow for consistency, and to assess 
whether cells incubated with a high dose of drugs undergo metabolic changes that more closely 
resemble wild-type cells treated at 10× EC50. One problem that might be associated with this 
experiment is the high concentration of AN5568 could potentially lead to non-specific drug-induced 
effects that can drastically alter the resulting metabolic profiles of the parasites. Interestingly, 
previous work by Jacobs and colleagues found that brain exposure to AN5568 is high, with a Cmax of 
>10 µg/mL (equivalent to ~27 µM) and AUC0-24 hr equal to > 100 µg*hr/mL after treatment with 
25 mg/kg of the benzoxaborole (Jacobs et al., 2011). The resistant cell line generated here is unlikely 
to survive in concentrations of that magnitude. 
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Importantly, the metabolomics study presented here did not investigate changes in nutrient uptake 
or waste excretion by the resistant cell line. This can be done by carrying out metabolite extractions 
on spent medium of wild-type cells as well as resistant cells, running these through an LC-MS 
system, and carrying out subsequent analyses through the same bioinformatics pipeline. For 
example, the transcriptomics data indicated increased expression of cystathionine gamma-lyase. 
We therefore expected to see increased abundance of L-cysteine, one of the products of the 
reaction this enzyme catalyses. However, there was no such increase in intracellular L-cysteine 
levels (electronic supplementary data). There is a possibility that excess L-cysteine was excreted 
from the cells, which would be detectable through the analyses of spent medium. 
The logical hypothesis that has arisen from this study, is that the benzoxaborole may target proteins 
involved in the T. brucei differentiation pathway. Indeed, we did investigate whether two recently 
discovered repressors of differentiation kinases could be targeted (Jones et al., 2014a). The 
Mottram group possesses two Lister 427-derived cell lines that overexpress the two kinases, RDK-
1 and RDK-2, individually. Alamar blue assays (two replicates only) were carried out to determine 
whether these cell lines showed increased resistance, but both showed no change when compared 
to a wild-type control. However, there are thought to be many uncharacterised regulators of 
differentiation, as shown by a recent RIT-seq study carried out by the K. Matthews group (Mony et 
al., 2014). 
Of utmost importance for this study is to replicate the generation of resistance multiple times in 
vitro. The data presented here was generated from one replicate which was cloned by dilution 
towards the end of the experiment. In most cases where this process has been successfully 
employed, several independent drug resistance lines are raised to investigate the compound in 
question, a good example being the study that investigated the mode of action of the 
benzoxaborole AN2690 (Rock et al., 2007). Should the PCF phenotype appear in more replicates of 
this resistance generation, only then could we concretely conclude whether this differentiation 
phenotype is involved in the generation of AN5568 resistance. 
It is important to note that several other phenomena could lead to a “semi-differentiating” 
transcriptome profile. Firstly, whilst RNA samples were only taken once cells had reached the end 
of log phase at a density of 2 × 106 cells/mL, no work was done to investigate whether these cells 
were stressed. It has been observed that cells undergoing extreme stress events can alter their 
expression profiles to match those of differentiating cells (K. Matthews, personal communication). 
Furthermore, there are few significant hits that have a fold change higher than 2-fold or lower than 
-2-fold, and critical analysis of the dataset would suggest there is not a large amount of differential 
expression (C. Clayton, personal communication). To this extent, further molecular biology must be 
utilised to follow-up on several of the most significant changes in transcript abundance. For 
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example, western blots and immunofluorescent microscopy could help to understand the extent of 
VSG downregulation and EP as well as GPEET procyclin upregulation. The Lister 427 line exhibits 
stable expression of VSG221 (Lamont et al., 1986). Antibodies for this VSG subtype exist, and were 
in fact successfully used earlier in this study (chapter 3). In addition, antibodies exist for EP 
procyclin. Western blots could indicate whether the changing surface transcripts are consistent at 
a protein level. 
Further analyses should centre on investigating the extent to which the resistant cell-line proteome 
matches its transcriptome, and this work could involve Western blotting for several other proteins 
to analyse whether these also change in abundance. Confirmation of the transcriptome dataset 
findings should include Northern blot or real-time PCR analysis of mRNA transcript abundance, and 
this work would greatly compliment the proteomics analyses. 
There are several major limitations in the genomic analyses of T. brucei. Firstly, whilst recent 
updates in the TriTrypDB database are aiding in the annotations of the complete genomes of several 
African trypanosome strains, the majority of the genome remains in the absence of annotations. 
For example, there were 35 and 134 “hypothetical” proteins identified in the upregulation and 
downregulation datasets respectively. This amounts to approximately one third of genes in either 
case, a significant number. Whilst domain analysis using databases such as pfam, COG, SCOP and 
SMART can help to identify proteins, it remains difficult to implicate hypothetical genes in 
mechanisms of resistance of drug actions, and further work should include selection of several 
important hits and further characterisation of these genes/proteins. This is a challenging task, 
especially if there are a significant number of hypothetical genes to investigate. 
It would be interesting to observe the ability of the AN5568R line to differentiate. This was in fact 
attempted using a differentiating trypanosome medium (DTM) (Overath et al., 1986). The recipe to 
this medium is provided in Appendix A. Unfortunately, the cell doubling time was very slow indeed, 
with passages carried out once every two weeks on average. Live cells were still visible more than 
a month after cis-aconitate-mediated induction of differentiation. In contrast, WT cells subjected 
to the same experiment did not survive past 72 hours. This suggests that the benzoxaborole-
resistant cell line does possess pleomorphic capabilities to some extent. For this reason, these cells 
are interesting not solely from a drug-resistance point of view, but potentially for the study of the 
molecular mechanisms of differentiation. 
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Chapter 5. Loss-of-heterozygosity in African 
trypanosomes 
5.1 Introduction 
Genetic diversity in all organisms is crucial for survival and lack of sexual recombination is known 
to play a vital role in evolution (Diogo et al., 2009, Capewell et al., 2015a, Weir et al., 2016). 
However, organisms that reproduce asexually have been described. These are clonal populations, 
which in theory presents an interesting problem with regards to maintaining genetic diversity in the 
context of species evolution, as explained in chapter 1. 
The human-infective T.b. gambiense possesses a VSG-like gene called TgsGP, which confers 
resistance to human serum (Capewell et al., 2013a). This species of African trypanosome can be 
divided further, based on other mechanisms of human serum resistance (Koffi et al., 2009, Capewell 
et al., 2011). Type I T.b. gambiense are also able to avoid uptake of TLF-1 and thus, Apo-L1, due to 
downregulation of TbHbHbR (Capewell et al., 2011). In contrast, type II T.b. gambiense exhibit 
variable resistance to human serum, and no downregulation of TbHbHbR has been reported 
(Capewell et al., 2011). Instead, type II gambiense still internalize TLF-1, relying solely on the poorly 
understood mechanisms of TgsGP-mediated serum resistance (Capewell et al., 2011, Capewell et 
al., 2013a). 
The majority of T. brucei species so far described have been reported to reproduce sexually with 
Mendelian allelic segregation. This has been shown to occur in the Tsetse fly vector stage of the 
parasite’s life cycle, prior to differentiation to mammalian-infective metacyclics (Turner et al., 1990, 
MacLeod et al., 2005). In contrast, sexual recombination has not been reported in type I T.b. 
gambiense and they are considered a clonal subpopulation of trypanosomes arising from a single 
ancestor (MacLeod et al., 2001, Koffi et al., 2009, Weir et al., 2016). This T. brucei subspecies 
exhibits low genetic diversity within populations, and higher levels of diversity between different 
geographical foci (Morrison et al., 2008, Koffi et al., 2009). 
One of the recently described mechanisms by which T.b. gambiense type I maintains genetic 
diversity is termed loss-of-heterozygosity (LOH) (Weir et al., 2016). Genomic analyses of SNP 
distributions of several isolates showed large areas devoid of SNPs, suggesting LOH plays an 
important role in driving genetic diversity and evolution in this subspecies of African trypanosomes 
(Weir et al., 2016). Interestingly, chromosome 10 appeared to be particularly affected by LOH. Weir 
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and colleagues also showed that SNPs are regained independently through the Meselson effect 
(Weir et al., 2016), as described in chapter 1. 
As well as identifying LOH events occurring in natural populations in T.b. gambiense, the MacLeod 
group, through routine genotyping, uncovered several laboratory adapted T.b. brucei cell lines 
showing significant genomic alterations, mainly on chromosome 10, the second largest of the 11 
classical T. brucei chromosomes (A. MacLeod, personal communication). A combination of 
genotyping studies, as well as Illumina sequencing, showed widespread LOH across the 
chromosome in two TREU 927-derived T. brucei PCF cell lines. In addition, LOH was found in cell 
lines derived from STIB 247 T.b. brucei and STIB 386 T.b. gambiense (Cooper, 2009). This suggests 
that LOH is not a rarity, and can occur independently in vitro.  
Interestingly, in both TREU 927-derived PCF, as well as the STIB 247 BSF cell lines, a growth 
phenotype was observed, where LOH lines exhibited a significantly increased growth rate compared 
to the wild-type strains (Cooper, 2009). Indeed, it was the increased growth rates that first led the 
group to discover the genetic alterations (A. MacLeod, personal communication). 
The reasons these types of mutations could lead to increased growth rates in poorly understood. 
Observations indicate that this process has the same consequences in BSF and PCF trypanosomes, 
suggesting that the underlying metabolic changes are consistent across life cycle stages. However, 
only in vitro, genomics analyses had been carried out up to this point. Therefore, a study was 
initiated to attempt to elucidate the metabolic perturbations that may have occured as a result of 
LOH, and lead to increased growth rates in these mutated lines. The most significant phenotype 
had been observed in two LOH lines derived independently from a TREU 927 PCF wild-type cell line 
in vitro. These lines were chosen for further in vitro studies as well as metabolomics analysis. 
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5.1.1 Aims & Objectives 
The previous work presented in this thesis clearly demonstrates the advantages and potential 
offered by the use of various omics technologies to dissect T. brucei metabolism. We therefore 
attempted to use similar techniques in order to investigate the metabolic changes occurring in cells 
that undergo LOH under in vitro conditions. Whilst this would not necessarily reflect how LOH 
impacts genetic diversity and evolution in the field, it would allow clear demonstration in the ways 
genetic variation can impact cell metabolism. For this study, we decided to utilise two TREU 927 
PCF LOH lines previously characterised by Cooper and colleagues in the MacLeod group, with the 
following objectives in mind: 
• To what extent does LOH affect growth of T. brucei parasites? 
• Can cell culture medium influence these changes? 
• Does cell metabolism change in LOH parasites? 
• Which genes are located in the LOH region and could mutations in these genes explain the 
LOH metabolotype? 
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5.2 Occurrence of LOH on chromosome 10 
To ensure that the lines being used were identified correctly, we carried out genotyping PCRs of 
minisatellite markers using primers designed by the MacLeod group (MacLeod et al., 2000). The 
two primer sets chosen were CRAM (fig. 5-1A), for which both LOH lines were homozygous, and 
3778, for which only LOH 2 was homozygous (fig. 5-1B). In both cases, the resultant DNA bands that 
were seen concurred with previous studies of these cell lines (A. Cooper, personal communication). 
In all cases, the TREU 927 wild-type genome is heterozygous for these loci on chromosome 10 (A. 
MacLeod, personal communication). 
 
Figure 5-1: Genotyping PCRs to identify the LOH 1 and LOH 2 cell lines. A) Both LOH lines were homozygous 
for the CRAM primer set, which is located between positions 1,805,332 and 1,808,751 on chromosome 10. WT 
cells were heterozygous for this primer set. B) The 3778 primer set amplifies a region between position 
2,404,358 and 2,404,930 on chromosome 10. Only the LOH 2 line was homozygous for this region, which shows 
that this line possesses a greater extent of LOH on this chromosome compared to the LOH 1 line. 
5.3 Growth phenotype in LOH lines is glucose-dependent, but not 
related to chromosome 10 glucose transporter arrays 
Growth curves carried out previously by the MacLeod group had shown that several LOH lines, 
including those derived from a TREU 927 line, exhibited significantly increased growth rates 
(Cooper, 2009). Growth assays were repeated to confirm these findings (fig. 5-2). Cells from a wild-
type TREU 927 PCF line and two LOH lines used for this study were seeded in SDM-79 at a 
concentration of 5 × 105 cells/mL. Cell density was monitored every 24 hours and cells were 
passaged back to the starting concentration once they had reached the end of log phase (estimated 
to be ~2 × 107 cells/mL).   
Results showed that the original phenotype of these cells was reproducible in SDM-79, the standard 
PCF T. brucei culture medium. Here, both LOH lines growing at a significantly faster rate compared 
to a wild-type control (fig. 5-2A). Growth curves were subsequently set up in SDM-80, a culture 
medium derived from SDM-79, which allows the user more control over the concentrations of 
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glucose and proline, the main carbon sources used by PCF trypanosomes (Coustou et al., 2008, 
Ebikeme et al., 2008). The growth phenotype was maintained in glucose-rich SDM-80 (fig. 5-2B). 
However, LOH cells grown in proline-rich SDM-80, which contains only 100 µM glucose, did not 
show any growth phenotype compared to wild-type cells. Instead, all three cell lines grew at a 
similar rate, with the LOH 2 line reaching the end of log phase before the end of the time course 
(fig. 5-2C). This suggested that in the absence of abundant sources of glucose, LOH cells returned 
to a wild-type growth phenotype and in addition did not grow to the same densities as those in 
glucose-rich conditions.  
 
Figure 5-2: Growth of WT and LOH T. brucei TREU 927 PCF cells in procyclic culture media. A) LOH cells 
(dotted lines) cultured in the standard PCF medium, SDM-79, showed increased growth rate when compared 
to WT cells (unbroken line). B) In glucose-rich SDM-80, a growth phenotype was still apparent, although to a 
lesser degree than that seen in SDM-79. C) LOH cells grown in proline-rich SDM-80, containing only 100 µM 
glucose, did not exhibit a growth phenotype compared to WT cells grown in the same media. Indeed, the LOH 
2 line (broken line, triangles) reached the end of log phase more than 24 hours before the end of the time 
course. 
These results suggest that the growth phenotype is dependent on the availability of glucose to the 
parasite. L-proline is the preferred source of carbon for PCF trypanosomes, as this is the most 
abundant source available in the tsetse fly haemolymph (Michalkova et al., 2014). However, this 
life cycle stage is routinely cultured in high levels (>10 mM) of glucose, which has been shown to 
induce a metabolic shift that causes the semi-complete citric acid cycle to be inactivated in favour 
of glucose catabolism (Lamour et al., 2005). We therefore hypothesised that the LOH lines had 
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undergone a metabolic alteration to more efficiently utilise the abundant glucose available from its 
extracellular environment in culture. 
Genetic changes occurring due to LOH could result in significant alterations in gene expression, as 
well as leading to the production of mutated proteins. IT was therefore crucial to understand which 
genes were affected by LOH. We hypothesised from genotyping experiments that LOH has occurred 
in laboratory strains from the start of chromosome 10 until approximately the halfway point. 
Specifically, it was determined from analysis of all LOH lines currently in possession by the MacLeod 
group, that the furthest occurrence was at approximately 2,400,00 bp, close to the centre of the 4 
Mb chromosome. We therefore analysed the gene complement present in this locus using the TREU 
927 reference genome (v9.0), which represents the most up-to-date release of this reference 
genome.  
Interestingly, the current version of TriTrypDB predicts a total of 12,094 genes in T. brucei TREU 
927. Of these, 1,762 predicted genes are found on chromosome 10, and a total of 918 genes were 
predicted to lie in the LOH region. This was a surprisingly large fraction (~7.6%) of the genome, and 
included 363 hypothetical proteins. In addition, there were 2 VSG genes (located at the telomeric 
end of the chromosome), 11 proteins of unknown function (which differ from hypotheticals as they 
are known to be expressed) and 27 ribosomal proteins. Genes of interest were filtered out from 
this dataset based on whether they were likely to contribute to energy metabolism. This area of 
metabolism was chosen with the phenotype of altered growth rate in mind. To further condense 
this dataset, we filtered genes with very strict parameters in that they should be directly involved 
in glucose metabolism, given the growth phenotype was glucose dependent, as well mitochondrial 
metabolism. This resulted in a greatly refined list of 40 genes (table 5-1).  
Amongst the genes found in this dataset, were two sequential arrays of glucose transporters and 
two hexokinases. In addition, several genes encoding subunits of the mitochondrial ATP synthase 
were present in this part of the chromosome. Further genes involved in glycolytic metabolism 
included fructose-bisphosphate aldolase, 2-phosphofructo-2-kinase, cytosolic glyceraldehyde 3-
phosphate dehydrogenase, and glucose-6-phosphate 1-dehydrogenase (table 5-1). The 
mitochondrial trypanosome alternative oxidase (TAO) is also located in the LOH region of 
chromosome 10, along with the mitochondrial malate dehydrogenase, pyruvate dehydrogenase 
complex E3 binding protein, cytochrome subunits, and the beta-chain of succinyl-CoA ligase. In the 
scope of this thesis, it was unlikely all of these candidates could be investigated in much detail, but 
combining these findings with genomics and metabolomics data could aid in pinpointing the 
underlying mechanisms for increased growth rate in the LOH lines. 
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GENE ID 
GENOMIC LOCATION 
(STRAND) 
PRODUCT DESCRIPTION 
Tb927.10.180 72,359 - 73,442 (+) ATP synthase F1 subunit gamma protein, putative 
Tb927.10.200 74,489 - 75,381 (+) vacuolar ATP synthase, putative 
Tb927.10.280 83,997 - 84,699 (+) cytochrome oxidase subunit VI (COXVI) 
Tb927.10.730 187,319 - 190,277 (+) ATP synthase, putative 
Tb927.10.1570 432,405 - 433,074 (-) ATPase subunit 9, putative 
Tb927.10.2010 526,631 - 529,526 (+) hexokinase (HK1) 
Tb927.10.2020 529,677 - 531,586 (+) hexokinase (HK2) 
Tb927.10.2230 575,971 - 578,176 (+) NADPH:adrenodoxin oxidoreductase, mitochondrial, putative 
Tb927.10.2350 604,810 - 605,707 (+) pyruvate dehydrogenase complex E3 binding protein, putative 
Tb927.10.2490 647,196 - 651,453 (+) glucose-6-phosphate 1-dehydrogenase (G6PD) 
Tb927.10.2550 661,714 - 663,255 (+) malate dehydrogenase-related 
Tb927.10.2560 663,121 - 664,733 (+) mitochondrial malate dehydrogenase (mMDH) 
Tb927.10.2760 706,132 - 708,326 (+) 
ATPase family associated with various cellular activities (AAA), 
putative 
Tb927.10.3100 810,236 - 812,441 (+) glycerol-3-phosphate acyltransferase, putative 
Tb927.10.3120 815,459 - 816,499 (+) cytochrome c oxidase assembly protein, putative 
Tb927.10.3260 841,483 - 844,883 (+) 
Long-chain-fatty-acid--CoA ligase (Long-chain acyl-CoA synthetase 5) 
(LACS 5), putative 
Tb927.10.3420 884,101 - 884,568 (+) NADH-ubiquinone oxidoreductase c, putative 
Tb927.10.3650 944,892 - 951,041 (-) NADH-dependent fumarate reductase, putative 
Tb927.10.3760 976,594 - 977,949 (-) vacuolar ATP synthase subunit d, putative 
Tb927.10.4520 1,159,602 - 1,161,066 (-) 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, putative 
Tb927.10.5050 1,249,111 - 1,249,681 (+) Mitochondrial ATP synthase epsilon chain, putative 
Tb927.10.5620 1,404,187 - 1,406,027 (+) fructose-bisphosphate aldolase, glycosomal (ALD) 
Tb927.10.5890 1,474,573 - 1,477,290 (-) Galactose oxidase, central domain containing protein, putative 
Tb927.10.6190 1,569,800 - 1,571,566 (-) aldehyde dehydrogenase, putative (ALDH) 
Tb927.10.6880 1,730,060 - 1,731,607 (+) glyceraldehyde 3-phosphate dehydrogenase, cytosolic (GAP) 
Tb927.10.7090 1,783,387 - 1,785,997 (+) 
Alternative oxidase, mitochondrial, Trypanosome alternative 
oxidase, mitochondrial (AOX) 
Tb927.10.7410 1,868,838 - 1,871,292 (-) succinyl-CoA ligase [GDP-forming] beta-chain, putative 
Tb927.10.8070 2,011,046 - 2,012,760 (-) ATPase, putative 
Tb927.10.8320 2,056,893 - 2,057,660 (-) cytochrome oxidase subunit IX (COXIX) 
Tb927.10.8440 2,092,756 - 2,095,694 (+) glucose transporter 1B (THT1-) 
Tb927.10.8450 2,095,852 - 2,098,083 (+) glucose transporter 1E (THT1E) 
Tb927.10.8460 2,098,241 - 2,100,472 (+) glucose transporter, putative 
Tb927.10.8470 2,100,630 - 2,102,861 (+) glucose transporter, putative 
Tb927.10.8480 2,103,019 - 2,105,423 (+) glucose transporter, putative 
Tb927.10.8490 2,105,581 - 2,107,989 (+) glucose transporter, putative 
Tb927.10.8500 2,108,147 - 2,110,554 (+) glucose transporter, putative 
Tb927.10.8510 2,110,665 - 2,113,118 (+) glucose transporter, putative 
Tb927.10.8520 2,113,229 - 2,115,680 (+) glucose transporter, putative 
Tb927.10.8530 2,115,838 - 2,118,125 (+) glucose transporter 2A (THT2A) 
Tb927.10.8640 2,139,619 - 2,140,922 (+) Galactose oxidase, central domain containing protein, putative 
Table 5-1: Genes of interest located in the LOH region of T. brucei TREU 927 chromosome 10. All 
annotated genes on chromosome 10 between position 1 and position 2,200,000 were downloaded from the 
TriTrypDB and filtered depending on the metabolic pathways they were involved with. The 40 genes in this 
table are all involved in glycolytic metabolism, mitochondrial metabolism, or ATP production. 
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One of the candidates we chose to pursue further were the trypanosome hexose transporter (THT)-
1 and THT-2 arrays (table 5-1). These two arrays differ in their expression in a life-cycle dependent 
stage, with THT-1 expression occurring only in BSF trypanosomes, whereas both PCF and BSF cells 
express THT-2 in a glucose-dependent manner (Bringaud & Baltz, 1993). Previous work has shown 
that these arrays can vary widely in copy number in the field (Barrett et al., 1996). Mitotic 
recombination could in theory also affect copy number. Increased expression of these transporters 
could lead to increase glucose uptake, which could lead to the glucose-dependent growth effect 
observed in the LOH lines. 
Due to the poly-cistronic nature of the trypanosome genome, one would hypothesise that 
increased copy numbers will lead to increased expression, allowing quicker uptake of glucose and 
increased flux through the glycolytic pathway. 
To test this theory, real-time PCR (RT-PCR) analysis was performed on both total DNA and cDNA of 
all three cell lines (fig. 5-3). Whilst southern blots are generally used to investigate copy number, 
real-time PCR experiments have been shown to be effective at revealing copy number differences, 
given that increased copy number will lead to a fluorescence detection at a lower Ct value (D'haene 
et al., 2010). Real-time PCRs were run using primer sets for both the THT-1 and THT-2 transporters 
individually. The genetic materials for copy number and expression analyses (total DNA and total 
RNA respectively), were isolated from cells in log phase of growth as described in the methods. 
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Figure 5-3: Comparative Analysis of the THT-1 and THT-2 glucose transporters from total genomic DNA 
and cDNA in WT and LOH T. brucei parasites. Genetic material was isolated from all three cells as described 
in the methods, and real-time PCR analyses were carried out by comparing relative abundance of the THT-1 
and THT-2 transcripts as well as DNA. A) RT-PCR analysis of total genomic DNA suggested that there was a 
lower abundance of THT-1 genes in both LOH cell lines compared to WT cells, which could be consistent with 
a lower copy number. Whilst the same was true for THT-2 transporters in the LOH 1 line, the LOH 2 line 
showed an identical abundancy of THT-2 DNA compared to WT cells. *=P<0.05, **=P<0.001, Student’s t-test. 
Our analyses showed that THT-1 transporters seemed to have a lower copy number in both LOH 
lines. This decrease was significant in both LOH lines (LOH 1, P=2.3×10-6; LOH 2, P=1.8×10-5) using a 
Student’s t-test. Further analysis of RT-PCR data using the THT-2 primer set showed that there was 
again a lower abundance of DNA in the LOH 1 line (P=1.6×10-7). However, the LOH 2 cell line showed 
no variation compared to WT cells (P=0.43).  
Analysis of cDNA isolates from all three cell lines showed no significant changes in THT-1 transcript 
abundance (LOH 1, P=0.06; LOH 2, P=0.24). However, THT-2, a transporter expressed in all life cycle 
stages, was found to exhibit increased abundance in both LOH lines (LOH 1, P=0.03; LOH 2, 
P=0.003). For the LOH 1 line, this increase was almost 3 fold, albeit with a high amount of variability. 
Given these data, it is unlikely that changes in THT-1 glucose transporter were responsible for the 
growth phenotype in both LOH lines. In LOH 1 cells, THT-1 transcript abundance and copy number 
were decreased and unchanged respectively. In contrast, there is a possibility that THT-2 expression 
could have an impact in the LOH lines. Further protein analyses would be needed to confirm this as 
transcript abundance only provides weak correlation to protein expression in trypanosomatids. 
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Given the similarities in both the LOH genomes, and their growth phenotypes, there is a significant 
possibility that the underlying mechanisms are identical.  
Other alterations in glycolysis should by no means be ruled out. As shown in table 5-1, there were 
several other glycolytic proteins of interest found on the LOH region of chromosome 10, including 
two hexokinases, a glucose 6-phosphate 1-dehydrogenase, a 6-phosphofructo-2-kinase and a 
fructose-bisphosphate aldolase. LOH across all these genes could in theory cause significant 
changes in gene regulation or expression, leading to widespread alterations in metabolism not due 
to one protein in particular, but rather, the combination of many. This phenomenon has been 
shown in other organisms such as Candida albicans (Diogo et al., 2009, Forche et al., 2011).  
5.4 Comparative genomics analyses of independent LOH lines 
Previous work by the MacLeod group identified LOH in STIB 247 and TREU 927, two different strains 
of T.b. brucei. In both cases, there were similar increases in growth rate (A. Cooper, personal 
communication). STIB 247 is a strain of T.b. brucei isolated from a Hartebeest in the Serengeti 
(Turner et al., 1990), and in contrast to TREU 927, this strain is predominantly homozygous, with 
up to 94% of commonly used genotyping markers showing homozygosity (Morrison et al., 2009). 
Several analyses have already shown that this strain exhibits differing phenotypes with regards to 
virulence and growth, when compared to TREU 927 (Morrison et al., 2009). Furthermore, genetic 
crosses of the aforementioned T.b. brucei strains have been carried out to generate a library of 
progeny with differing genetics and varied phenotypes, in a bid to uncover quantitative trait loci 
(QTL) associated with common phenotypes. In addition, a cell line of a T.b. gambiense type II strain 
commonly used in laboratory cultures, STIB 386, has been shown to undergo LOH localised to 
chromosome 10, in similar fashion to the aforementioned T.b. brucei strains (A. MacLeod, personal 
communication). 
A collaboration with the Sanger Institute recently investigated SNPs found in all three of these 
strains (A. MacLeod, personal communication). Using this dataset, we set out to analyse SNPs along 
chromosome 10 in both the TREU 927 and STIB 247 strains. Any of these SNPs falling in the LOH 
region are likely to become homozygous, and previous sequencing data analyses of the LOH lines 
have indicated that the homozygous alleles remaining are often non-reference (Cooper, 2009). To 
our surprise, only 27 SNPs were predicted to exist in both strains along the entirety of chromosome 
10 (S8). Moreover, only one of these SNPs fell in the region designated as the LOH region 
responsible for the growth phenotype. Using TriTrypDB, we determined this SNP to lie in a 
predicted mitochondrial malate dehydrogenase (mMDH) gene, Tb927.10.2560. 
This mutation was located at E293, a glutamate residue towards the C-terminal end of mMDH (fig. 
5-4A). Using domain analysis tools SMART and Pfam, two domains characteristic of an MDH were 
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found in the protein. Firstly, a lactate/malate dehydrogenase N-terminal domain (pfam: PF00056, 
start: 9, end: 151, E=1.2e-46), thought to be a Rossmann NAD-binding fold, was present. Secondly, 
a lactate/malate dehydrogenase C-terminal domain (pfam: PF02866, start: 153, end: 315, E=3.9e-
46) was also present, and was the domain thought to harbour the E293G variant present in both 
STIB 247 and TREU 927. 
To further probe the potential effect of this SNP, we attempted to predict the 3-dimensional 
structure of both forms of the mMDH protein. For this, the 3D structure prediction tool Phyre2 was 
utilised (Pettersen et al., 2004). Protein prediction algorithms were run for both versions of the 
mMDH protein sequence, using the default parameters. As expected, the Phyre2 package predicted 
the protein to possess a structure similar to other mMDH proteins. Using the Chimera software 
(Pettersen et al., 2004), the two proteins were superimposed to analyse whether the SNP caused 
any predictable structure changes (fig. 5-4B).  
In general, no significant change was seen in the protein structure, which maintained its 
characteristic Rossmann fold and its C-terminal domain (fig. 5-4 & 5-5). We next looked at several 
residue interactions around the E293G mutation site. The main finding of interest was the presence 
of several predicted hydrogen bonds between the E293 residue and a serine residue found at 
position 193 (fig 5-5A). Hydrogen bonds are integral to the secondary structure of a protein (Martin 
& Derewenda, 1999). In the mutated mMDH protein, 3 of these predicted bonds were absent (fig. 
5-5B). It is unknown what effect this would have on the overall stability and folding of the protein, 
although the Phyre2 software did not predict any significant differences in the two structures when 
overlaid (fig. 5-4).  
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Figure 5-4: Predicted sequence and structure of mitochondrial malate dehydrogenase (mMDH, 
Tb927.10.2560) in the T.b. brucei TREU 927 LOH lines. A) mMDH consists of 319 amino acids. The predicted 
SNP is found on E293, leading to an E293G mutation. B) The Phyre2 software was used to superimpose the 
two mMDH variants on top of one another, with the E293 residue highlighted in red. By superimposing the 
two structures, it was clear that no significant structural alterations are predicted to occur as a result of the 
E293G mutation. 
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Figure 5-5: Hydrogen bonding around residue E293 of mMDH. A) The glutamate residue that harbours the 
SNP was predicted to form 3 stabilising hydrogen bonds with S193, when structural predictions were carried 
out using Phyre2. B) By replacing the glutamate residue with the glycine residue as was predicted in the LOH 
lines removes these hydrogen bonds. However, this did not affect the overall predicted structure of the 
protein as the serine residue (S193) maintained further hydrogen bonds. 
5.5 Metabolomics analyses of the TREU 927 LOH lines  
To further probe differences in metabolism between wild-type TREU 927 cells and the LOH lines, 
we carried out LC-MS-based metabolomics analyses. This experiment was untargeted, without the 
addition of stable isotopes. Samples were cultured in SDM-79 and kept between 1 × 106 and 
2 × 107 cells/mL. The differences in growth rates were taken into account (i.e. wild-type cells were 
seeded at a higher density) and all samples were extracted in triplicate when cells were nearing the 
end of log phase growth at 2 × 107 cells/mL. Metabolite extractions for this LC-MS experiment were 
carried out as described in the methods. The samples were run on a Q-Exactive Orbitrap mass 
spectrometer by Glasgow Polyomics and raw data was processed and analysed using the 
mzMatch/Ideom pipeline described in chapter 2. 
The glycolytic components did not appear to change significantly in the LOH lines, compared to 
wild-type cells (fig. 5-6). Glucose (m/z: 180.0635, RT: 10.58 mins) was found at a lower abundance, 
but not significantly (fig. 5-6A). Pyruvate (m/z: 88.0160, RT: 6.99 mins), the final component of 
classical glycolysis, showed no significant change in either of the LOH samples (fig. 5-6E). 
Interestingly, glucose 6-phosphate (m/z: 260.0297, RT: 10.57 mins) was decreased and increased in 
LOH 1 and LOH 2 respectively compared to WT cells (fig. 5-6B), for reasons we were not able to 
determine. In addition, one replicate of the LOH 2 line exhibited very high levels of both 3-phospho-
D-glycerate (m/z: 185.9929, RT: 10.56 mins) and phosphoenolpyruvate (PEP, m/z: 167.9823, RT: 
10.76 mins), whilst all other replicates for both LOH lines were comparable to the wild-type samples 
for both metabolites (fig. 5-6C & 5-6D).  
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Amongst the metabolites showing a similar level in both LOH lines, malate (m/z: 134.0215, RT: 10.27 
mins) was decreased, albeit not significantly, compared to WT cells. Further work could be carried 
out to identify whether this malate is produced in the glycosome, or in the mitochondrion, as it is 
produced and consumed in both organelles (Creek et al., 2015). This work could include both stable 
isotope labelling of glucose or proline, as well as fractionation experiments prior to sample 
preparation for LC-MS analysis (Fly et al., 2015). 
 
Figure 5-6: Glycolytic metabolism in WT and LOH cells. Whilst the growth phenotype observed in LOH cells 
was glucose-dependent, there were no changes in intracellular glucose (A) levels. Glucose 6-phosphate was 
less abundant in LOH 1 cells compared to WT (B). However, there was an increase in this metabolite’s 
abundance in LOH 2 cells. Levels of 3-phospho-D-glycerate (C) and PEP (D) did not change in the LOH lines, 
although 1 LOH sample exhibited high levels of both these metabolites. Pyruvate (E), the end product of 
glycolysis, was unchanged in LOH cells. However, there was a downward trend in malate (F) levels in both 
LOH lines. 
We next analysed metabolites from other areas of central carbon metabolism (fig. 5-7). Whilst BSF 
cells primarily utilise glucose as a carbon source, PCF cells are able to switch to proline metabolism, 
as explained in chapter 1. In particular, components of the semi-complete citric acid cycle, which 
uses proline to generate ATP, with succinate as an end product (Besteiro et al., 2005), were studied. 
Here, we found succinate (m/z: 118.0266, RT: 9.72 mins) to exhibit lower abundance in both LOH 
lines compared to the wild-type cells (fig. 5-7F). Importantly, this metabolite is produced in varying 
amounts in both glucose-and proline-rich conditions. Whilst it is the major excretory product of the 
semi-complete citric acid cycle, it is one of several excretory products in PCF cells where glycolysis 
is the main central carbon metabolic pathway (Bringaud et al., 2006). 
Alanine is generated by an aminotransferase reaction that utilises pyruvate (Spitznagel et al., 2009), 
and it has been hypothesised that this shunt can function at high rates to remove pyruvate from 
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the intracellular environment (M. Barrett, personal communication). In the LOH metabolomics 
dataset, there was no change in alanine (m/z: 89.0477, RT: 10.63 mins) levels, which suggests this 
pathway is not more active in LOH cells than in WT cells (fig. 5-7A). 
 
 
Figure 5-7: Levels of metabolites involved in PCF central carbon metabolism. Metabolites involved in 
mitochondrial metabolism were identified from the metabolomics dataset. L-alanine, a product of an 
aminotransferase reaction that consumes pyruvate, was unchanged in LOH cells (A). In contrast, L-glutamine 
levels were increased in LOH cells (B), whilst L-glutamate was only increased in the LOH 2 line (C). Proline 
levels were decreased in LOH cells (D), an interesting result when compared to the changes in glutamine 
metabolism. However, this could also reflect the LOH cells’ dependency on glucose, as shown by growth 
analyses. Further changes were seen in L-threonine (E), which was more abundant in LOH cells. Succinate 
(F), an end product in both glycolysis and TCA metabolism, was reduced in the LOH lines. Whilst no drastic 
changes were observed in L-carnitine (G), a metabolite derived from it, O-propanoyl-L-carnitine (H), was 
found only in LOH cells, suggesting it might play a role in generating the growth phenotype seen in LOH cells. 
Glutamine can also be fed into the TCA cycle, where it is converted to glutamate and subsequently, 
α-ketoglutarate (Besteiro et al., 2005). Interestingly, intracellular L-glutamine (m/z: 146.0691, RT: 
10.53 mins) levels were higher in both LOH lines (fig. 5-7B), and whilst L-glutamate (m/z: 147.0532, 
RT: 9.76 mins) levels did not appear to change (fig. 5-7C), there was a decrease observed in L-proline 
(m/z: 115.0633, RT: 9.75 mins) levels. This could suggest that the LOH lines take up more L-
glutamine and less L-proline than the WT counterparts. 
Threonine is an important amino acid that T. brucei incorporates into fatty acids (Millerioux et al., 
2013). This amino acid was shown to be present in higher intracellular levels in the LOH lines (m/z: 
119.0582, RT: 10.30 mins), compared to WT cells (fig. 5-7E), suggesting more uptake. This can be 
understood as a need for higher levels of fatty acid production in a rapidly dividing cell. 
Carnitine, as discussed in chapter 3 and chapter 4, is crucial in the transport of long-chain acyl 
groups from fatty acids across the mitochondrial membrane (Klein et al., 1982). L-carnitine (m/z: 
161.1051, RT: 9.81 mins) levels did not change in the LOH lines (fig. 5-7G), but an acyl carnitine 
derivative, O-propanoyl-L-carnitine (m/z: 217.1314, RT: 8.10 mins), which was not detected in WT 
cells, was present in high abundance in both LOH lines. 
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One of the most significant and surprising findings was observed in the coenzyme A (CoA) 
biosynthesis pathway which involves phosphorylation of pantothenate, a vitamin (Spry et al., 2008). 
Whilst pantothenate (m/z: 219.1107, RT: 7.08 mins) levels were unchanged between the three 
sample groups (fig. 5-8A), D-4’-phosphopantothenate (m/z: 299.0771, RT: 9.46 mins) was almost 
completely absent from either LOH line (fig. 5-8B). 
 
 
Figure 5-8: Phosphorylated pantothenate is absent from the LOH lines. Pantothenate is an essential 
vitamin required for CoA biosynthesis. Whilst levels of this vitamin were unchanged in the LOH lines compared 
to WT cells (A), D-4’-phosphopantothenate, the product of the pantothenate kinase reaction was absent in 
LOH cells (B). Furthermore, CoA levels were reduced in LOH cells compared to WT cells. 
In this pathway, D-4’-phosphopantothenate is converted to 3’-dephospho-CoA through R-4’-
phosphopantothenoyl-L-cysteine and 4’-phosphopantetheine, before CoA is generated (Spry et al., 
2008). Whilst the intermediates of this pathway were not detected by LC-MS, CoA (m/z: 383.5577, 
RT: 8.66 mins) was found to be decreased in the LOH lines. This decrease, although not as dramatic 
as that seen in D-4’-phosphopantothenate, was consistent between the two LOH lines studied. 
These data suggest that the CoA synthesis pathway is much less active in the LOH lines, which could 
have a significant impact on mitochondrial metabolism.  
An attempt was made to search for genes related to pantothenate kinase in the T. brucei genome, 
using the TriTrypDB tool. There is currently one pantothenate kinase subunit (Tb927.11.7290) 
predicted in the genome and there are homologues of this subunit in all the trypanosomatids. In 
addition nothing was found in the literature concerning pantothenate kinase in T. brucei, indicating 
it might not have been characterised in this organism. Therefore, further bioinformatics analyses 
are required to identify other pantothenate kinase subunits in the T. brucei genome. 
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5.6 Discussion 
Recent evidence has emerged suggesting that African trypanosomes can undergo loss-of-
heterozygosity (LOH), both in the field and in a laboratory environment (Weir et al., 2016). During 
routine genotyping experiments, the MacLeod group uncovered significant LOH on chromosome 
10, occurring multiple times independently in laboratory-adapted T.b. brucei and T.b. gambiense 
strains, both BSF and PCF (Cooper, 2009). Interestingly, these lab-adapted LOH cells exhibited 
significantly increased growth rates, as shown by this study (fig. 5.2). 
In this study, further work was carried out on two PCF LOH TREU 927 T.b. brucei cell lines. 
Subsequent to confirmation of both the previously generated genotyping data and differential 
growth rates in SDM-79 culture medium, we sought to understand how the genomic alterations led 
to increased growth rates in vitro. Further growth analyses showed that the increased growth rates 
are glucose-dependent (fig. 5-2), suggesting that the LOH lines had streamlined their metabolism 
to suit the high levels of glucose present in laboratory culture media. Current evidence shows that 
PCF T. brucei can switch between utilising glucose, or L-proline as its primary carbon source. This 
enables it to survive in the tsetse fly haemolymph in the absence of glucose (Michalkova et al., 
2014). However, it can switch to glycolysis during tsetse fly feeding, utilising glucose from the host 
bloodmeal (Besteiro et al., 2005). 
Genomic analyses of chromosome 10 showed the presence of 918 genes in the LOH region. This list 
was refined to include only those genes thought to be involved in energy metabolism, given the 
growth phenotype (table 5-1). This gene set contained the THT-1 and THT-2 glucose transporter 
arrays, and it was hypothesised that differential expression of these transporters could impact 
glycolytic metabolism through increased uptake of glucose. Analysis of gene expression in the 
glucose transporter arrays on chromosome 10 showed increased expression of the THT-2 
transporter, which is known to be expressed in a glucose-dependent fashion in PCF trypanosomes 
in culture (Bringaud & Baltz, 1993). No changes were detected in THT-1 expression in LOH cells 
compared to wild-type cells. This transporter is normally not expressed in PCF trypanosomes 
(Bringaud & Baltz, 1993). We were unable to determine any changes in glycolytic flux. One method 
that could be used is uptake assays involving 2-deoxy-D-glucose (Barrett et al., 1995). This 
experiment could assess whether uptake of glucose from the extracellular environment was 
altered. Indeed, one replicate of this experiment was done, with no change detected. However, at 
least 5 replicates would be required before any conclusions could be drawn from this experiment. 
Other experiments such as overexpression of the THT transporters could also establish whether 
increased expression levels can lead to increased growth rates. 
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Figure 5-9: Putative changes in central carbon metabolism occuring in LOH cell line, based on 
metabolomics data. Lower levels of glycolytic end products such as succinate and malate led us to 
hypothesize that this pathway of metabolism is utilised less in the LOH lines. In PCF cells, and to a lesser 
extent BSF cells, pyruvate is also imported to mitochondria, where it is utilised in acetate production, an 
important pathway for fatty acid biosynthesis in situ. Whilst acetate was not detected by LC-MS, further 
investigations in collaboration with the Bringaud group are ongoing to determine the fate of pyruvate in LOH 
cells. 
The MacLeod group has utilised F1 progeny from several T. brucei crosses to investigate the genetic 
determinants of several phenotypes including virulence and growth (Morrison et al., 2009, 
Capewell et al., 2015b). Analysis of the latter phenotype uncovered several QTLs, with the most 
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significant one located on chromosome 10 (MacLeod, unpublished). This finding supports the 
theory that loci on this chromosome can influence growth. Further work combining data from the 
QTL study with the data presented here could lead to novel candidate genes and loci underlying T. 
brucei growth. 
Analysis of SNPs on chromosome 10 in both TREU 927 and STIB 247 led to the discovery of one 
shared SNP located towards the 3’ end of the mMDH gene (supp. fig. 8). Bioinformatics approaches 
were employed in order to investigate the effect of this SNP on the mMDH structure. However, we 
were unable to conclude whether the SNP could impede enzyme function (fig. 5-4 & 5-5). Molecular 
biology approaches such as allele replacement strategies could ultimately determine whether this 
SNP can impact T. brucei growth. The hypothesis that a SNP possessed by both strains might be 
responsible for the growth phenotype is questionable, and it is perhaps more likely that several 
SNPs in similar regions of chromosome 10 might determine the LOH phenotype. 
Metabolomics experiments were carried out on the two LOH lines, using a wild-type TREU 927 line 
as a control. This experiment, carried out in SDM-79, showed several interesting metabolic 
phenotypes in the LOH lines. Whilst glycolytic metabolism was not altered to a great extent, a 
reduction in malate and succinate was found (fig. 5-6 & 5-7). Given that SDM-79 contains high levels 
of glucose, and the growth phenotype is glucose-dependent, we hypothesise that glycolysis is 
carried out in these cells in favour of L-proline uptake and TCA metabolism. Therefore, it is likely 
that the succinate and malate detected in this experiment were formed through glycolytic 
intermediates. Indeed, stable isotope labelling experiments could allow us to confirm this 
hypothesis. Reduced malate and succinate could suggest reduced production of these metabolites 
during glycolysis, with pyruvate instead being transported into the mitochondria for acetate 
production (fig. 5-9). 
Interestingly, a previous study found that pyruvate kinase activity is stimulated by the presence of 
L-carnitine (Klein et al., 1982). This enzyme presents a key metabolic step as it generates ATP 
(Coustou et al., 2003). Gilbert and Klein argued in their paper that L-carnitine removes acetyl-CoA, 
an inhibitory modulator, through the action of carnitine acyl transferases (Klein et al., 1982). 
Production of acyl carnitines could therefore indicate elevated production of ATP in the cell. Indeed, 
our metabolomics analyses showed high levels of O-propanoylcarnitine, which was not detected in 
WT cells. In addition downregulation of the CoA biosynthesis pathway could also impact the 
generation of inhibitory acetyl-CoA, and our findings regarding D-4’-phosphopantothenate and CoA 
levels suggest downregulation has occurred in the LOH lines. More work must be carried out to 
confirm whether perturbations in acyl carnitine production could lead to increased growth rates. A 
collaboration with the Bringaud group in Bordeaux will determine the fate of pyruvate through the 
use of NMR, which can detect acetate and succinate (Ebikeme et al., 2010). Further work involving 
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the use of pantothenate kinase inhibitors is also ongoing, in an attempt to replicate the LOH growth 
phenotype through downregulation of the CoA synthesis pathway. 
Further experiments can also be carried out regarding the genomics of the LOH lines. In particular, 
RNA-seq analysis could help to narrow down genes of interest on chromosome 10. Lower or higher 
expression levels of particular genes could implicate them in the altered growth observed in the 
LOH cells. Due to time constraints, this analysis was not carried out during the study, although 
previous transcriptome work in the form of digital SAGE has been done on a melarsoprol-resistant 
STIB 247 line that was retrospectively shown to have undergone LOH in the same area of 
chromosome 10 as the LOH PCF cell lines used in this study (MacLeod, personal communication). 
Combining these data could enable the identification of further candidate genes. In particular, 
genes involved in the regulation of protein synthesis, such as RNA-binding proteins, could be 
investigated. 
The underlying mechanisms leading to LOH remain poorly understood, although current data 
indicates that mitotic recombination is likely to be responsible (Cooper, 2009). There are several 
mechanisms of mitotic recombination, including reciprocal exchange and non-reciprocal break-
induced repair, both of which have been observedin T. brucei in the context of VSG switching 
(Boothroyd et al., 2009). As discussed in the introduction to this chapter, the occurrence of LOH has 
implications for the field. Whilst the cell lines studied here are thought to have undergone LOH 
during in vitro culture, recent genomics analyses by the MacLeod group have shown that LOH 
occurs in T.b. gambiense group 1 isolates. Here, it is hypothesised that LOH provides a crucial 
mechanism to maintain genetic diversity in a clonal population of parasites (Weir et al., 2016). In 
addition, whilst chromosome 10 in particular undergoes significant amounts of LOH, all 
chromosomes are affected. This raises the intriguing possibility that LOH occurs across the T. brucei 
genome, even when cultured in vitro. Increased growth rates led to the identification of the LOH 
lines analysed here, but in theory, LOH could occur in the absence of visible phenotypes. 
Routine genotyping is important to ensure consistency in the cell lines used for biological research. 
However, this requires much time, and normally only several markers are used during genotyping 
assays. In addition, studies in other organisms such as Candida albicans, have found that 
environmental stresses such as oxidative stress, drug pressure and even temperature alterations 
can influence the formation of DNA strand breakage that leads to LOH (Diogo et al., 2009, Forche 
et al., 2011). This is important, because if the same is true in T. brucei and related kinetoplastids, it 
highlights the crucial need for standard practices during in vitro culturing, in order to maintain 
genetically identical cell lines. Furthermore, it could implicate LOH as an important driver of drug 
resistance. 
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Chapter 6. Discussion & final thoughts 
6.1 The mode of action of AN5568 – Where do we stand? 
This study used multiple omics-based approaches combined with generation of resistant cell lines 
to attempt to elucidate the mechanism of action of AN5568, a novel benzoxaborole compound 
currently in clinical trials as a therapeutic against HAT. Many of the findings from chapter 3 and 4 
were described in detail in the respective discussions. Here, I discuss the current hypotheses on the 
MoA taking into account this study as well as other research published or carried out since this 
project was initiated. There are several hypotheses which should be studied in further detail: 
1. AN5568 targets the mitochondrion 
2. AN5568 causes defects in cytokinesis 
3. AN5568 inhibits an essential methyltransferase 
4. AN5568 targets repressors of T. brucei differentiation 
5. AN5568 targets a protein that is more essential in BSF T. brucei than PCF 
A collaboration with several groups at the University of Dundee that pioneered the high-throughput 
RITseq approach has led to several interesting findings regarding AN5568 (M. Barrett, personal 
communication). One of the proteins found to influence drug resistance was a hypothetical protein 
(Tb927.9.9030). Further sequence analysis showed this protein to be a predicted mitochondrial 
transporter with similarities to TIM54. This supports the hypothesis that the mitochondrion could 
be targeted.  
Further work by the Barrett group also investigated drug-drug interactions between AN5568 and 
drugs known to target the mitochondrion. An isobologram with DB-75, a fluorescent diamidine that 
localises to the mitochondrion (Lanteri et al., 2006), showed significant antagonism, suggesting 
similarities between the two MoAs. Work is underway to repeat this experiment (F. Giordani, 
personal communication). Investigations of AN5568 treatment on akinetoplast trypanosomes, of 
which several species exist (Carnes et al., 2015), could also provide useful information as to the 
MoA of AN5568. 
There have been many reports of mitochondrial defects resulting in arrest of cytokinesis. For 
example, depletion of the mitochondrial acyl carrier protein was shown to lead to defects in 
kinetoplast segregation (Clayton et al., 2011). In addition, RNAi-mediated knock-down of the serine 
palmitoyltransferase enzyme involved in sphingolipid synthesis also leads to aberrant kinetoplast 
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division (Fridberg et al., 2008). T. brucei possess a single dynamin-like protein (DLP) which is 
involved in mitochondrial fission (Chanez et al., 2006). One study has shown that a DLP KO leads to 
arrest of cytokinesis in the 2N2K stage of cell division (Chanez et al., 2006). In contrast, AN5568 led 
to enrichment of 2N1K and MNMK cells. However, the aforementioned studies do confirm the 
involvement of mitochondrial proteins in cell division. 
During the final writing stages of this thesis, a paper was published on the investigation of the 
AN5568 target (Jones et al., 2015). This study used omics approaches, in particular genomic and 
proteomics, to attempt to unravel the mode of action of AN5568. Interestingly, this study observed 
the same cell cycle inhibition phenotype that was observed in this study. In addition, Jones and 
colleagues study generated an AN5568-resistant cell line, although no transcriptomic studies of this 
cell line were undertaken. The resistance phenotype was found to be reversible, similar to our 
observations (Jones et al., 2015). 
The comparative metabolomics analyses between AN5568 and various other drugs, provided a 
detailed insight into the mechanisms of benzoxaborole action. In particular, the similarities 
observed between AN5568 and sinefungin led to a hypothesis that a methyltransferase is targeted. 
There is further work that could be done with these datasets. For example, in their 2007 study on 
AN2690, Rock and colleagues noted that the leucyl-tRNA synthetase-targeting anti-fungal formed 
an adduct with AMP, which was mediated by the boronic acid binding hydroxide groups on the 
adenosine (Rock et al., 2007). We did not discover any adducts in the metabolomics analyses, and 
work should be carried out to identify whether this phenomenon occurs during AN5568 treatment 
with, for example, the hydroxide groups on AdoMet, which is highly increased in drug-treated cells. 
AdoMet is the second most utilised substrate, after ATP (Fontecave et al., 2004). Whilst its 
importance as a methyl group donor has long been established, it has been reported as a donor for 
several other reactions. In one of these, known as a radical SAM reaction, AdoMet acts as a source 
of 5’-deoxyadenosyl radicals (Sofia et al., 2001, Fontecave et al., 2004). This reaction is catalysed by 
enzymes with an iron-sulphur (Fe-S) cluster and generates a highly reactive radical as well as L-
methionine. Interestingly, our metabolomics analyses showed high levels of deoxyadenosine (S1), 
which could result from the formation of radicals. In addition, adenosine is highly increased in the 
AN5568R cell line (S7), which could be a compensatory mechanism of some sort. Finally, the 
mitochondrial enzyme identified by collaborators in Dundee was also thought to contain a radical 
SAM domain. Therefore, other processes that involve AdoMet as a substrate should not be 
excluded from hypotheses regarding the AN5568 MoA. 
There are 145 MTases predicted in the T. brucei genome and a RIT-seq approach similar to that 
carried out with the kinome (Jones et al., 2014a) could provide a significant insight into the roles 
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these enzymes play in the biology of T. brucei, as well as whether any of these are targeted by 
AN5568. Indeed, MTases that regulate differentiation could exist, but are as-of-yet unidentified. 
Histone methylases with important roles in antigenic variation have already been described 
(Figueiredo et al., 2008). Furthermore, the DOT1 MTases, of which T. brucei possesses two, have 
been implicated in differentiation and cell cycle regulation in other organisms (Kim et al., 2014). 
Finally, there are several further predicted mRNA capping MTases in the T. brucei genome, as 
evidenced in chapter 3. Therefore, the hypothesis that AN5568 targets the spliced leader should 
not be completely ruled out. 
The generation of an AN5568-resistant cell line led to the hypothesis that the benzoxaborole targets 
repressors, or regulators, of differentiation. The procyclic phenotype observed in the 
transcriptomic and metabolomics datasets allows the parasite to “escape” sensitivity to the 
compound. This process was reversible, although the parameters of unstable resistance were not 
quantified in this study. Interestingly, a collaboration with the Clayton group led to the finding that 
the PCF-specific PIP39 protein was upregulated in WT BSF T. brucei treated with another 
benzoxaborole (D. Begolo, personal communication). This finding supports the theory that 
differentiation is targeted. To further explore this hypothesis, a cell line expressing GFP with the 3’-
UTR of a differentiation marker such as EP procyclic or PAD could be utilised to look for activation 
of differentiation cascades during benzoxaborole treatment. In addition, transcript and protein 
analyses such as real-time PCR and western blotting respectively, could further probe upregulation 
of SSF or PCF specific proteins. 
One of the top priorities is to assess the infectivity of the AN5568R cell line in vivo. Given the 
downregulation of VSG transcripts, it is likely this cell line would quickly succumb to the host 
immune response. In addition, further studies of the differentiation phenotype are planned to 
identify abnormal regulation of RBPs and other master regulators that could activate 
differentiation, whilst simultaneously repress morphological changes such as those normally 
occurring in the transformation of long slender BSF cells to SSF and PCF. 
Work on other benzoxaborole scaffolds has shown that the targets of these compounds vary 
widely. Aside from AN2690 (Tavaborole), which is undergoing FDA review as a cream to treat 
onychomycosis (FDA, 2014, Markham, 2014), several other benzoxaborole drug targets have been 
identified, mostly through work carried out by researchers at Anacor Pharmaceuticals Inc. One 
study developed a novel hinge-motif in the oxaborole scaffold which allowed strong inhibition of 
rho kinases (Akama et al., 2013b). Further work on 6-(benzoylamino)benzoxaboroles has shown 
these modified scaffolds can also act as anti-inflammatories and might specifically target Toll-like 
receptor-mediated inflammation (Akama et al., 2013a, Dong et al., 2013). Optimisation of 
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benzoxaboroles targeting tRNA synthetases has also continued since the discovery of AN2690 
(Baker et al., 2011, Goldstein et al., 2013). 
These publications, in addition to the knowledge that benzoxaboroles form strong –diol entities 
with their target (Liu et al., 2014), suggest that these compounds could bind to more than one 
protein in their host system. Whilst Rock and colleagues identified the oxaborole tRNA trapping 
(OBORT) mechanism, this might not apply to all benzoxaboroles, and additional mechanisms of 
action might exist. 
Unfortunately, this study did not pinpoint a mechanism by which AN5568 targets the T. brucei 
parasite. However, significant strides have been made to identify this mechanism, and with follow-
up work planned, as well as plenty of scientifically valid hypotheses to explore, it is expected that 
the MoA of this exciting new drug against HAT will not remain elusive for long. 
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6.2 The relationship between metabolism and its genetic 
determinants – LOH as a case study 
The integration of genomics and metabolomics, which has been referred to as genetical 
metabolomics (Keurentjes, 2009), enables a very detailed insight into the mechanisms by which 
genomic alterations can impact metabolic traits. This concept is well established and has been 
explored through the use of genetically modified cell lines and subsequent metabolomics analysis 
(Creek et al., 2015). However, the study described here has important implications for the field, 
given the LOH phenotype is a natural phenomenon that can impact cellular growth and metabolism.  
With recently emerged high-throughput technologies, one can now phenotype metabolic traits 
across a species in a similar way to genotypic traits, where instead of QTLs, the metabolomic 
(m)QTLs are investigated, with regards to phenotypes of interest such as growth and drug 
resistance (Nicholson et al., 2011, Lewis et al., 2014, Hill et al., 2015, Kraus et al., 2015). This 
approach has proved highly successful in recent years, in particular in the field of plant biology, 
where large scale crosses are relatively simple to carry out (Carreno-Quintero et al., 2013). With 
the T. brucei genetic crosses carried out by the MacLeod group several years ago (MacLeod et al., 
2005, Cooper et al., 2008), this type of approach could give rise to valuable insights into 
trypanosome metabolism. 
One significant question that remains for the LOH study presented here is whether the natural 
infectivity of LOH cell lines is altered subsequent to the chromosomal alteration. In PCF lines, we 
were able to show that increased growth was glucose-dependent. However, PCF cells naturally 
reside in the midgut of the tsetse fly where, aside from bloodmeal contents, the major carbon 
sources are proline and glutamine, both components of the tsetse haemolymph (Besteiro et al., 
2005, Michalkova et al., 2014). It is not known whether LOH cells would outcompete WT cells in 
this situation. However, in the bloodstream, where glucose is the primary carbon source, LOH lines 
could in theory maintain a growth advantage over WT cells, should the phenotype be identical to 
that observed in PCF strains in vitro. The priority is therefore to carry out in vivo experiments with 
LOH lines, to determine whether genetic determinants of metabolism can influence natural 
infections. 
The recent genomics study carried out on the clonal T.b. gambiense type 1 highlights the 
mechanisms by which genetic diversity can be generated, even in clonal trypanosomes (Weir et al., 
2016). This knowledge is valuable as it will aid in the prediction of drug resistance and potentially 
affect vaccine efficacy, should these become available in the future (Weir et al., 2016). It also 
underlines the fact that trypanosome genetics might be far more complex than thought. 
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6.3 Omics in the study of biological organisms – final thoughts 
Biological research has increasingly profited from rapidly modernising computer science which has 
enabled the generation, as well as analyses, of large datasets (Berger et al., 2013). Metabolomics 
alone is supported by a myriad of computer tools designed specifically for the analysis of these 
types of data (Misra & van der Hooft, 2016). The integration of laboratory science and 
bioinformatics, especially with regards to building and developing computer models, has aided in 
many areas of science, including drug discovery (Haanstra & Bakker, 2015). 
One aspect of omics studies that was not covered during this project is the study of individual 
organelles in biological systems. Metabolomics studies of fractionated cells have been carried out 
in plant biology, with particular emphasis on the chloroplast (Geigenberger et al., 2011, Kueger et 
al., 2012). Cellular fractionation could be used to further understand the biology of the 
trypanosome, both in the context of general metabolism (e.g. mitochondrial malate and succinate 
versus that present in the glycosome), and in the study of drug target deconvolution (e.g. 
confirmation that reduced transporter expression is correlated to decreased uptake of 
trypanocidals). Whilst these techniques are in early developmental stages, they will provide new 
opportunities to investigate metabolism. 
Although the benefits (and some disadvantages) of omics research have been openly discussed 
throughout this thesis, there are caveats associated with these techniques. For the MoA study 
presented here, 7 metabolomics, 3 proteomics and a transcriptomic dataset were generated, each 
containing vast amounts of information. For the purpose of this study, data was mined to search 
for clues relating to the MoA of AN5568. However, there were also further discoveries that are of 
great interest in their own right. For example, knock-down of the TbCgm1 cap MTase leads to a 
build-up of free nucleotides, which might be expected during arrest in translation, but also suggests 
high levels of mRNA degradation. The point being made, is that the inferences made from these 
datasets must be well-informed, and researchers must be well equipped to deal with, and 
understand the generation of, the datasets in question.  
It is fundamental to piece together the biologically relevant information from omics datasets, and 
to interpret and present them in a logical manner, as this enables the generation of new hypotheses 
that can be explored. In his book “La Science et l’Hypothèse”, the French philosopher Henri 
Poincaré wrote “Science is built up with facts, as a house is with stones. But a collection of facts is 
no more a science than a heap of stones is a house” (Poincaré, 1905). As long as omics research 
adheres to this principle, scientists will benefit from it for generations to come.  
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Appendix A. Differentiating trypanosome medium 
(DTM) 
Component Molarity (mM) 
KCl 5.40 
CaCl2 1.80 
NaH2PO4.H2O 1.00 
MgSO4.7H2O 0.80 
Sodium pyruvate 1.00 
Phenol red 0.03 
Hypoxanthine 0.10 
Alanine 0.10 
Arginine.HCl 0.60 
Asparagine 0.11 
Aspartic acid 0.11 
Cysteine 0.20 
Glutamic acid 1.70 
Glutamine 11.00 
Glycine 0.11 
Histidine.HCl.H2O 0.20 
Isoleucine 0.40 
Leucine 0.40 
Lycine.HCl 0.40 
Methionine 0.10 
Phenylalanine 0.19 
Proline 5.60 
Serine 0.11 
Threonine 0.40 
Tryptophan 0.05 
Tyrosine 0.20 
Valine 0.39 
NaCl 116.00 
Hepes 32.00 
NaHCO3 26.00 
Hemin 0.01 
β-mercaptoethanol 0.20 
Sodium citrate 3.00 
Cis-aconitate 3.00 
Glycerol 0.08% 
Vitamin solution (Sigma) 1% 
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Appendix B. SDM-80  
Component Molarity (mM) 
NaH2PO4 1.00 
NaCl 116.00 
MgSO4 0.80 
KCl 5.40 
CaCl2 1.80 
NaHCO3 26.20 
HEPES 30.70 
MOPS 23.90 
Pyruvate 4.00 
L-Arginine 1.10 
Glycine 0.10 
L-Alanine 2.25 
L-Asparagine 0.10 
L-Aspartate 0.10 
L-Cystine 0.10 
L-Glutamate 0.09 
L-Glutamine 0.46 
L-Histidine 0.20 
L-Isoleucine 0.40 
L-Leucine 0.76 
L-Lysine 0.40 
L-Methionine 0.58 
L-Phenylalanine 0.68 
L-Serine 0.49 
L-tryptophan 0.05 
L-Tyrosine 0.75 
L-Valine 0.40 
Taurine 1.28 
Mercaptoethanol 0.20 
Hypoxanthine 0.10 
Thymidine 0.02 
Kanamycin 0.10 
Hemin 0.01 
Glucose 0.15 
Proline 5.20 
Threonine 5.90 
Vitamins 100 X (Invitrogen) 1% 
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Appendix C. Creek’s minimal medium (CMM) 
Component Molarity (mM) 
D-glucose 10.000 
L-glutamine 1.000 
L-cysteine 1.000 
NaCl 77.590 
CaCl2∙2H2O 1.490 
KCl 4.400 
MgSO4∙7H2O 0.814 
NaHCO3 35.950 
HEPES 25.032 
Phenol Red 0.042 
Bathocuproinedisulfonic acid 0.052 
β-mercaptoethanol 0.192 
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Appendix D. Buffers and reagents 
TAE buffer, 50× 
• 2 M Tris 
• 6% Acetic acid 
• 50 mM EDTA 
PBS, 20× 
• 2.74 M NaCl 
• 200 mM Na2HPO4 
• 54 mM KCl 
• 36 mM KH2PO4 
PBS-T 
• 1× PBS 
• 0.05% Tween 
T. brucei transfection buffer 
• 90 mM Sodium phosphate 
• 5 mM Potassium chloride 
• 0.15 mM Calcium chloride 
• 50 mM HEPES 
• pH = 7.3 
Protein extraction lysis buffer 
• 2% SDS 
• 50 mM Tris, pH 7.5 
• 1 mM EDTA 
• cOmpleteTM ULTRA protease inhibitor cocktail (Roche) 
Hypotonic lysis buffer 
• 10 mM Tris base, pH 7.5 
Protein sample loading buffer, 4× 
• 200 mM Tris-HCl, pH 6.8 
• 8% SDS 
• 40% glycerol 
• 4% β-mercaptoethanol 
• 50 mM EDTA 
• 0.08% bromophenol blue 
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SDS-PAGE gel for 2D-DiGE 
• 12.5% acrylamide 
• 0.4 M Tris, pH 8.8 
• 0.1 SDS 
• 0.04% APS 
• 0.05% TEMED 
DiGE lysis buffer 
• 6 M Urea 
• 2 M Thiourea 
• 4% CHAPS 
• 25 mM Tris-base 
DiGE rehydration buffer 
• 6 M Urea 
• 2 M Thiourea 
• 4% CHAPS 
• 0.5% IPG buffer 
• 65 mM DTT 
• 0.001% bromophenol blue 
DARTS lysis buffer 
• 150 mM NaCl 
• 0.5% Triton X-100 
• 1× PBS 
Coomassie staining solution 
• 1 mM Coomassie brilliant blue 
• 50% methanol 
• 10% glacial acetic acid 
• 40% ddH2O 
Colloidal Coomassie staining solution 
• 10% ammonium sulfate 
• 0.1% Coomassie G-250 
• 3% ortho-phosphoric acid 
• 20% ethanol 
Protein gel destaining solution 
• 50% methanol 
• 10% glacial acetic acid 
• 40% ddH2O 
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SDS running buffer, 20× (Life Technologies) 
• 50 mM MOPS 
• 50 mM Tris-base 
• 0.1% SDS 
• 1 mM EDTA 
• pH 7.7 
Western blot transfer buffer, 10× 
• 1.92 M Glycine 
• 250 mM Tris-Base 
Western blot transfer buffer, 1× 
• 192 mM Glycine 
• 25 mM Tris-base 
• 10% methanol 
Western blot blocking solution 
• PBS-T 
• 5% powdered milk 
Metabolite extraction solvent 
• 60% methanol 
• 20% chloroform 
• 20% ddH2O 
DEPC-treated H2O 
• 0.1% diethylpyrocarbonate in ddH2O 
• Overnight incubation, followed by autoclaving 
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Appendix E. Primers & Plasmids 
GeneID Description Sequence Restriction sites Identifier 
Tb427.10.3080 pURAN overexpression, fwd GCGAATTCATGGGGATAGTCCGAGTACA EcoRI MB0867 
“ pURAN overexpression, rev GCGAATTCTTATTCCGGCTCCTGTAAAC EcoRI MB0931 
Tb427.10.7560 pURAN overexpression, fwd GCGAATTCATGAGTGCCCCTACTGAAAG EcoRI MB0869 
“ pURAN overexpression, rev GCGAATTCTCACTGTTCACCCCTCTTAC EcoRI MB0870 
Tb927.10.9020 pURAN overexpression, fwd GCGAATTCATGATGGGTGATGCTGGTAG EcoRI MB0871 
“ pURAN overexpression, rev GCGAATTCCTACGAGTCTGAAAGATTTC EcoRI MB0872 
Tb427tmp.01.4830 pURAN overexpression, fwd GCGAATTCATGAGCGAGAATGACATTGC EcoRI MB0873 
“ pURAN overexpression, rev GCGAATTCTTAATTCAGTTTCACTGGCA EcoRI MB0874 
Tb427tmp.01.1460 pURAN overexpression, fwd GCGAATTCATGCTAGACAAAGTTGTAGG EcoRI MB0875 
“ pURAN overexpression, rev GCGAATTCTCACCGGACAGTAAGAGGAA EcoRI MB0876 
Tb427.03.2890 pURAN overexpression, fwd GCGAATTCATGTCGAAGCAAAAGAATGT EcoRI MB0877 
“ pURAN overexpression, rev GCGAATTCCTAATCGGTCCACGTCATGC EcoRI MB0878 
Tb427.04.1900 pURAN overexpression, fwd GCGAATTCATGCCGCCAACACGTCCCGA EcoRI MB0879 
“ pURAN overexpression, rev GCGAATTCCTAAAAACGGGGTCGCCGCC EcoRI MB0880 
Table E-1: Primers used in this study 
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GeneID Description Sequence Restriction sites Identifier 
Tb427.05.2050 pURAN overexpression, fwd GCGAATTCATGCTCCAATGGGTCGTGAA EcoRI MB0881 
“ pURAN overexpression, rev GCGAATTCCTATCGAGTCCGCTCTCGCT EcoRI MB0882 
“ Mutagenesis primer, fwd GAATATTGAGTTAAATAAGGAGAGGATACTCTCACGAAGCAATGG n/a n/a 
“ Mutagenesis primer, rev CCATTGCTTCGTGAGAGTATCCTCTCCTTATTTAACTCAATATTC n/a n/a 
Tb427.07.4320 pURAN overexpression, fwd GCGAATTCATGCTGCAACGTATTCCACC EcoRI MB0883 
“ pURAN overexpression, rev GCGAATTCTCACTTCACCGTCAGGAACT EcoRI MB0884 
Tb427.08.5040 pURAN overexpression, fwd GCGAATTCATGGATTACCGACAGAAAGC EcoRI MB0885 
“ pURAN overexpression, rev GCGAATTCCTAACACGCCTCGTTATCCT EcoRI MB0886 
Tb427.06.2270 pURAN overexpression, fwd GCGAATTCATGCCCGCACGTGGCTGTGC EcoRI MB0887 
“ pURAN overexpression, rev GCGAATTCTTAGCGTAGTGCGTACATCT EcoRI MB0888 
Tb427.10.7850 pURAN overexpression, fwd GCGAATTCATGGCATGGACATGTTCCGG EcoRI MB0927 
“ pURAN overexpression, rev GCGAATTCCTAAATACCTCCCCTTTGGT EcoRI MB0928 
Tb427tmp.01.5300 
(ODC) 
pURAN overexpression, fwd GCGAATTCATGACCACCAAATCAACCCC EcoRI MB0929 
“ pURAN overexpression, rev GCGAATTCTTATGATTTTTGACTTTTCA EcoRI MB0930 
n/a pURAN construct integration 5’ GTCAATACAACACACAATAGG n/a n/a 
n/a pRM482 construct integration 5’ GAGCTAGTGAGATCAACAGTAC n/a MB0925 
Table E-1: (continued) 
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GeneID Description Sequence 
Restriction 
sites 
Identifier 
Tb927.7.2080 
RNAi fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTCCAGTTCCCTCAGAAGCAAG n/a MB0783 
(TbCgm1) 
“ RNAi rev GGGGACCACTTTGTACAAGAAAGCTGGGTGCGAAGTGACCGAAAGAAAG n/a MB0784 
Tb927.10.7940 
 RNAi fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTAGGGCACCTTTACGTTTGTG n/a MB0785 
(TbMtr1) 
“ RNAi rev GGGGACCACTTTGTACAAGAAAGCTGGGTGGCGAGAAGCAGTCGAATAG n/a MB0786 
Table E-2: RNAi primers used in this study 
 
 
Marker Name Sequence Chromosome location (TREU 927 v5.1) PCR product size 
TB10/14 
CRAM, fwd AACTCCCTCCCGATCGATCACAAC 1,805,332 – 1,805,355 
3,319 bp 
CRAM, rev CTGCTGATGCCGTACATGATGATTTC 1,808,726 – 1,808,751 
TB10/28 
3778, fwd CAACAGTGCCCGGAGGAGGTACG 2,404,358 – 2,404,380 
509 bp 
3778, rev GCGGTGACTCGTCCGTCTTCTTGC 2,404,907 – 2,404,930 
Table E-3: Genotyping primers used in chapter 5 in this study 
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GeneID Description Sequence Identifier 
Tb927.7.2080 TbCgm1 – Fwd primer AGCAAGACGCAGCTCAAGTG n/a 
“ TbCgm 1 – Rev primer GGCTCCAGTCGACGGAAA n/a 
Tb427.10.3080 MT 1 – Fwd primer GCTGTTGGGTGCCGTGTT  n/a 
“ MT 1 – Rev primer CTGCATCGGCGCTGTCT  n/a 
Tb427.10.7560 MT 2 – Fwd primer CGGTCGCACCGAACTTCT MB 0992 
“ MT 2 – Rev primer CCGTTGCGAAACGCTGTA MB 0993 
Tb927.10.9020 MT 3 – Fwd primer CGGCGCAACCCAACAT MB 0994 
“ MT 3 – Rev primer TTCCCGGACGTTCTCTATGC  MB 0995 
Tb427tmp.01.4830 MT 4 – Fwd primer CCGGGCGTTAACGTTGAA MB 0996 
“ MT 4 – Rev primer CCACCTGGTATTGCGTATTGC MB 0997 
Tb427tmp.01.1460 MT 5 – Fwd primer ACCCCGAGGGTGACTGGTA  MB 0998 
“ MT 5 – Rev primer CCCCAGCCGTGGTGTTT MB 0999 
Tb427.03.2890 MT 6 – Fwd primer GACTACGTGCGCGGTAAGC  MB 1000 
“ MT 6 – Rev primer ACACCGTACCGTCTTTGTTCTTC MB 1001 
Tb427.04.1900 MT 7 – Fwd primer TTGCGAGAGTGTGGCCATAC  MB 1002 
“ MT 7 – Rev primer TGCCATTCCGAGCATATCC  MB 1003 
Tb427.05.2050 MT 8 – Fwd primer GGGACCAGAGGGAAACGAA  MB 1004 
“ MT 8 – Rev primer CCCCGCATCCGCAAT MB 1005 
Tb427.07.4320 MT 9 – Fwd primer CCCTTCGCCACCAATACG MB 1006 
“ MT 9 – Rev primer TGCCGACGCTGCTGTGT MB 1007 
Tb427.08.5040 MT 10 – Fwd primer CAGGATCCCGCGGAATG MB 1008 
“ MT 10 – Rev primer TCAAGTGAAGCAACGCTTGGT MB 1009 
Tb427.06.2270 MT 11 – Fwd primer AATGGGCGGCGATCTATCT  MB 1010 
“ MT 11 – Rev primer TGCAGCGTACCAAGAAAGCA  MB 1011 
Tb427.10.7850 MT 12 – Fwd primer GGCCTTTCGTCGTGTTGATC  MB 1012 
“ MT 12 – Rev primer TTCGGGTGGCGAATGC MB 1013 
Tb427tmp.01.5300 TbODC – Fwd primer TCTCGGCACGGGATTTGA MB 1014 
“ TbODC – Rev primer CCAATGCCTCTCACACGTTGT MB 1015 
Tb927.10.8440 THT-1 – Fwd primer TCGAGAATCCCAAATGTAGTGAAG MB 913 
“ THT-1 – Rev primer GGCCACCTCGTTTTTGCA MB 914 
Tb927.10.8490 THT-2 – Fwd primer ACGGATTTTCCATCGGCTTT MB 917 
“ THT-2 – Rev primer TGAACAATTCGTCGCCACTTC MB 918 
TERT Endogenous ctrl, fwd GAGCGTGTGACTTCCGAAGG MB 0864 
“ Endogenous ctrl, rev AGGAACTGTCACGGAGTTTGC MB 0865 
Table E-4: real-time (RT) PCR primers used in this study. 
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GeneID Description Parent 
Tb427.10.3080 Over-expressor for Δ3080::NEO pURAN 
Tb427.10.7560 Re-expressor for Δ7560::NEO pRM482 
Tb927.10.9020 Over-expressor for Δ9020::NEO pURAN 
Tb427tmp.01.4830 Over-expressor for Δ4830::NEO pURAN 
Tb427tmp.01.1460 Over-expressor for Δ1460::NEO pURAN 
Tb427.03.2890 Over-expressor for Δ2890::NEO pURAN 
Tb427.04.1900 Over-expressor for Δ1900::NEO pURAN 
Tb427.05.2050 Re-expressor for Δ2050::NEO pRM482 
Tb427.07.4320 Over-expressor for Δ4320::NEO pURAN 
Tb427.08.5040 Over-expressor for Δ5040::NEO pURAN 
Tb427.06.2270 Over-expressor for Δ2270::NEO pURAN 
Tb427.10.7850 Over-expressor for Δ7850::NEO pURAN 
Tb427tmp.01.5300 Over-expressor for ΔODC::NEO pURAN 
Tb927.7.2080 - TbCgm1 TbCgm1RNAi pGL2084 
Tb927.10.7940 - TbMtr1 TbMtr1RNAi pGL2084 
Table E-5: Plasmids used in this study 
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Appendix F. PCR and IEF cycling conditions 
High-fidelity polymerase PCR (HF Phusion, New England Biolabs) 
 Temp. Time  
1 98ºC 0:30  
2 98ºC 0:15 
34x  65ºC 0:30 
 72ºC 1:00 per kb 
3 72ºC 5:00  
4 10ºC HOLD  
 
Colony screen/construct integration PCR (GoTaq polymerase, promega) 
 Temp. Time  
1 95ºC 2:00  
2 95ºC 0:30 
32x  55ºC 0:30 
 72ºC 1:00 per kb 
3 72ºC 5:00  
4 10ºC HOLD  
 
Genotyping PCR – 3778/CRAM 
 Temp. Time  
1 95ºC 0:50 
30x 
 64ºC 0:50 
 
65ºC 
0:50 - 3778 
 3:00 - CRAM 
 
Real-time PCR (ABI 7500 system) 
 Temp. Time  
1 95ºC 10:00  
2 95ºC 0:15 
40x 
 60ºC 1:00 
 
IEF cycling conditions 
 Voltage (V) Time (hours) Notes 
1 30 10 Step ‘n’ hold 
2 300 2 Step ‘n’ hold 
3 600 2 Gradient 
4 1000 2 Gradient 
5 8000 1 Gradient 
6 8000 9 Step ‘n’ hold 
7 1000 ∞ Step ‘n’ hold 
 
 
